ticker,rpa_date_utc,rpa_time_utc,rp_entity_id,entity_name,relevance,event_sentiment_score,group,sub_type,event_text,news_type,source_name,headline
REGN,2024-01-02,21:15:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Zoghbi Registers 1,117 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Zoghbi Registers 1,117 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-01-02,21:36:51,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Yancopoulos Registers 4,212 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Chmn Yancopoulos Registers 4,212 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-01-02,22:10:41,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp McCourt Registers 274 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,VP McCourt Registers 274 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-01-03,16:33:25,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bassler Registers 826 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Bassler Registers 826 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-01-04,12:31:06,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Kiniksa Pharmaceuticals Sees 2024 ARCALYST Pdt Rev,NEWS-FLASH,Dow Jones Newswires,Kiniksa Pharmaceuticals Sees 2024 ARCALYST Pdt Rev $360 M - $380 M
REGN,2024-01-04,21:13:22,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bassler Sells 826 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bassler Sells 826 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-01-04,21:13:53,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Zoghbi Sells 1,117 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Zoghbi Sells 1,117 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-01-04,21:14:26,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-01-04,21:25:57,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Yancopoulos Sells 16,848 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Yancopoulos Sells 16,848 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-01-04,21:30:59,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp McCourt Sells 274 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP McCourt Sells 274 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-01-04,21:36:22,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,Cfo Landry Acquires 641 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Acquires 641 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-01-04,21:36:50,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Vp Larosa Acquires 9,507 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Larosa Acquires 9,507 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-01-04,21:37:21,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Vp Fenimore Acquires 2,488 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Fenimore Acquires 2,488 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-01-05,17:53:33,589803,Regeneron Pharmaceuticals Inc.,100,0.03,credit-ratings,stable,Moody's Upgrades Regeneron To Baa1; Outlook Stable,NEWS-FLASH,Dow Jones Newswires,Moody's Upgrades Regeneron To Baa1; Outlook Stable
REGN,2024-01-05,21:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024"
REGN,2024-01-05,21:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024"
REGN,2024-01-08,08:02:16,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Eylea Treatment Approved in EU,NEWS-FLASH,Dow Jones Newswires,Bayer: New Eylea Treatment Approved in EU
REGN,2024-01-08,08:06:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Bayer: Eylea Gets EU Approval,NEWS-FLASH,Dow Jones Newswires,Bayer: Eylea Gets EU Approval for Neovascular Age-Related Macular Degeneration
REGN,2024-01-08,12:30:05,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to,PRESS-RELEASE,Canadian News Wire,Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
REGN,2024-01-08,12:30:05,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
REGN,2024-01-08,12:30:06,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to,PRESS-RELEASE,PR Newswire,Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo(R) (cemiplimab) in Multiple Countries
REGN,2024-01-08,12:30:43,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to,PRESS-RELEASE,PR Newswire,Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
REGN,2024-01-08,12:30:53,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo(R) (cemiplimab) in Multiple Countries
REGN,2024-01-08,12:30:56,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Medison Pharma Announces Agreement With Regeneron Pharmaceuticals to,NEWS-FLASH,Dow Jones Newswires,Medison Pharma Announces Agreement With Regeneron Pharmaceuticals to Commercialize Libtayo in Multiple Countries
REGN,2024-01-08,14:51:19,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals preannounced disappointing fourth-quarter sales,FULL-ARTICLE,Dow Jones Newswires,Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes -- IBD
REGN,2024-01-08,17:16:42,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron announced $1.34 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Regeneron Slumps As Its Biggest Moneymaker Flops Amid Ongoing Roche Rivalry -- IBD
REGN,2024-01-08,21:02:49,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,Cfo Landry Acquires 158 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Acquires 158 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-01-08,21:41:34,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron announced $1.34 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Regeneron Slumps As Its Biggest Moneymaker Flops Amid Ongoing Roche Rivalry -- IBD
REGN,2024-01-12,11:55:03,589803,Regeneron Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Regeneron Pharma Raised to Outperform From Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Raised to Outperform From Sector Perform by RBC Capital
REGN,2024-01-12,11:55:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $1076.00/Share by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $1076.00/Share by RBC Capital
REGN,2024-01-12,18:23:07,589803,Regeneron Pharmaceuticals Inc.,99,0.54,revenues,up,Dupixent sales grew 41%,FULL-ARTICLE,Dow Jones Newswires,Here's Why Regeneron Pharmaceuticals Just Hit A Record High -- Again -- IBD
REGN,2024-01-12,18:23:07,589803,Regeneron Pharmaceuticals Inc.,99,0.41,products-services,start,Regeneron Pharmaceuticals Inc.: The company hopes to begin a Phase 2 study in mid-2024,FULL-ARTICLE,Dow Jones Newswires,Here's Why Regeneron Pharmaceuticals Just Hit A Record High -- Again -- IBD
REGN,2024-01-12,18:23:07,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Regeneron is also partnered with Alnylam Pharmaceuticals and AstraZeneca on,FULL-ARTICLE,Dow Jones Newswires,Here's Why Regeneron Pharmaceuticals Just Hit A Record High -- Again -- IBD
REGN,2024-01-12,21:04:48,589803,Regeneron Pharmaceuticals Inc.,99,0.54,revenues,up,Dupixent sales grew 41%,FULL-ARTICLE,Dow Jones Newswires,Here's Why Regeneron Pharmaceuticals Just Hit A Record High -- Again -- IBD
REGN,2024-01-12,21:04:48,589803,Regeneron Pharmaceuticals Inc.,99,0.41,products-services,start,Regeneron Pharmaceuticals Inc.: The company hopes to begin a Phase 2 study in mid-2024,FULL-ARTICLE,Dow Jones Newswires,Here's Why Regeneron Pharmaceuticals Just Hit A Record High -- Again -- IBD
REGN,2024-01-12,21:04:48,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Regeneron is also partnered with Alnylam Pharmaceuticals and AstraZeneca on,FULL-ARTICLE,Dow Jones Newswires,Here's Why Regeneron Pharmaceuticals Just Hit A Record High -- Again -- IBD
REGN,2024-01-16,12:00:54,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharma Phase 3 Trial Showed,NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharma Phase 3 Trial Showed More Than Twice as Many Patients Treated With Dupixent Achieved Clear or Almost Clear Skin and Nearly Four Times as Many Had Improvement in Itch, Compared With Placebo >REGN"
REGN,2024-01-17,21:05:33,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,Cfo Landry Acquires 232 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Acquires 232 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-01-18,07:34:28,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Japan Granted Market Authorization for Eylea,NEWS-FLASH,Dow Jones Newswires,Bayer: Japan Granted Market Authorization for Eylea 8 Mg for Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
REGN,2024-01-18,21:03:51,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,Cfo Landry Acquires 146 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Acquires 146 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-01-23,13:32:28,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Barclays
REGN,2024-01-23,13:32:28,589803,Regeneron Pharmaceuticals Inc.,100,0.74,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1020.00/Share From $935.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1020.00/Share From $935.00 by Barclays
REGN,2024-01-23,21:18:40,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Goldstein Registers 2,707 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Goldstein Registers 2,707 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-01-24,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,GlobeNewswire,Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards
REGN,2024-01-24,17:00:01,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,Dow Jones Newswires,Press Release: Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards
REGN,2024-01-24,17:05:04,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,PR Newswire,Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards
REGN,2024-01-25,19:32:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron and Sanofi: Dupixent Gets FDA Approval,NEWS-FLASH,Dow Jones Newswires,Regeneron and Sanofi: Dupixent Gets FDA Approval for Children Aged 1 Yr and Older With Eosinophilic Esophagitis
REGN,2024-01-25,19:32:59,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi: Dupixent Gets Expanded FDA Approval,NEWS-FLASH,Dow Jones Newswires,Regeneron and Sanofi: Dupixent Gets Expanded FDA Approval Under Priority Review
REGN,2024-01-25,19:49:22,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals and Sanofi's Dupilumab received approval from the U.S. Food and Drug Administration,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Get FDA OK for Esophagus Inflammation Treatment in Younger Children"
REGN,2024-01-25,20:04:21,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals and Sanofi's Dupilumab received approval from the U.S. Food and Drug Administration,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Get FDA OK for Esophagus Inflammation Treatment in Younger Children"
REGN,2024-01-25,21:18:32,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,Cfo Landry Acquires 472 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Acquires 472 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-01-25,21:20:59,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Goldstein Sells 2,707 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Goldstein Sells 2,707 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-01-25,21:22:08,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Vp Fenimore Acquires 2,431 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Fenimore Acquires 2,431 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-01-30,12:00:41,589803,Regeneron Pharmaceuticals Inc.,99,0.53,labor-issues,,Be appointed Senior Vice President and Head of Regeneron,PRESS-RELEASE,GlobeNewswire,Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
REGN,2024-01-30,12:00:41,589803,Regeneron Pharmaceuticals Inc.,99,0.53,labor-issues,,Be appointed Senior Vice President and Head of Regeneron,PRESS-RELEASE,GlobeNewswire,Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
REGN,2024-01-30,12:00:42,589803,Regeneron Pharmaceuticals Inc.,99,0.53,labor-issues,,Be appointed Senior Vice President and Head of Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
REGN,2024-01-30,12:00:42,589803,Regeneron Pharmaceuticals Inc.,99,0.53,labor-issues,,Be appointed Senior Vice President and Head of Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
REGN,2024-01-30,22:06:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bassler Registers 827 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Bassler Registers 827 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-01-31,21:54:30,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bassler Sells 827 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bassler Sells 827 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-02-01,21:12:32,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp McCourt Registers 273 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,VP McCourt Registers 273 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-02-01,21:52:29,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Ryan Registers 300 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Ryan Registers 300 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2023",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2023",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Fourth quarter 2023 revenues increased 1% to $3.43 billion,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Full year 2023 revenues increased 8% to $13.12 billion,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 4Q EPS $10.19,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q EPS $10.19 >REGN
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Fourth quarter 2023 U.S. net sales,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: full year 2023 U.S. net sales,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Fourth quarter 2023 GAAP diluted EPS of $10.19,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $3,434 $ 3,414",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,The FDA approved Dupixent for the treatment,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,filed,Regeneron Pharmaceuticals Inc.: A BLA for linvoseltamab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,filed,Regeneron Pharmaceuticals Inc.: A BLA for odronextamab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,equity-actions,listing,"Regeneron Pharmaceuticals Inc.: The Company presented, at European",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: The EC approved Evkeeza(R) (evinacumab),PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.7,products-services,,Regeneron Pharmaceuticals Inc.: The FDA granted Breakthrough Therapy designation to mibavademab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,legal,,Regeneron Pharmaceuticals Inc.: In the Company's ongoing patent infringement lawsuit against Mylan Pharmaceuticals,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Mylan's filing for FDA approval of an aflibercept,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,"Regeneron Pharmaceuticals Inc.: In January 2024, the Company entered into an agreement with 2seventy bio, Inc.",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,96,0.51,products-services,complete,Dupixent) (2024) - Complete enrollment of Phase 3 studies of itepekimab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,96,0.41,products-services,start,Initiate Phase 1 study of linvoseltamab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,96,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Obesity - Initiate Phase 2 study of semaglutide in combination with trevogrumab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,96,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Obesity - Initiate Phase 2 study of semaglutide in combination with trevogrumab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,96,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Fourth Quarter 2023 Financial Results,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,96,-0.68,revenues,down,"Regeneron Pharmaceuticals Inc.: Total revenues $3,434 $3,414",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,96,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA in the U.S. decreased in the fourth quarter,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,96,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the fourth quarter,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 4Q Rev $3.43B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q Rev $3.43B >REGN
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Other revenue for the fourth quarter,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.65,revenues,up,Regeneron Pharmaceuticals Inc.: The increase in other revenue in 2023,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D for the full year 2023,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $10.19 in the fourth quarter of 2023,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $34.77 for the full year 2023,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $11.86 in the fourth quarter of 2023,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $43.79 for the full year 2023,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,Regeneron Pharmaceuticals Inc.: the Company repurchased shares of its common stock,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2024 Financial Guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2024 financial guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -4-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: Conference Call Information,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -4-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: Total assets $33,080.2 $29,214.5",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Net income $1,159.6 $1,197.1",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 10.88 $ 11.19 $,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,97,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $1,159.6 $1,197.1",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -6-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,97,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,366.3 $1,449.0",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -6-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,97,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 12.82 $ 13.54 $,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -6-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,97,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -6-
REGN,2024-02-02,11:30:00,589803,Regeneron Pharmaceuticals Inc.,91,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Fourth Quarter 2023 Financial Results",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -7-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Fourth quarter 2023 revenues increased 1% to $3.43 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Full year 2023 revenues increased 8% to $13.12 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Fourth quarter 2023 U.S. net sales,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: full year 2023 U.S. net sales,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Fourth quarter 2023 GAAP diluted EPS of $10.19,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $3,434 $ 3,414",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,The FDA approved Dupixent for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,filed,Regeneron Pharmaceuticals Inc.: A BLA for linvoseltamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,filed,Regeneron Pharmaceuticals Inc.: A BLA for odronextamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,equity-actions,listing,"Regeneron Pharmaceuticals Inc.: The Company presented, at European",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: The EC approved Evkeeza(R) (evinacumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.7,products-services,,Regeneron Pharmaceuticals Inc.: The FDA granted Breakthrough Therapy designation to mibavademab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,legal,,Regeneron Pharmaceuticals Inc.: In the Company's ongoing patent infringement lawsuit against Mylan Pharmaceuticals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Mylan's filing for FDA approval of an aflibercept,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,"Regeneron Pharmaceuticals Inc.: In January 2024, the Company entered into an agreement with 2seventy bio, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,96,0.51,products-services,complete,Dupixent) (2024) - Complete enrollment of Phase 3 studies of itepekimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,96,0.41,products-services,start,Initiate Phase 1 study of linvoseltamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,96,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Obesity - Initiate Phase 2 study of semaglutide in combination with trevogrumab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,96,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Obesity - Initiate Phase 2 study of semaglutide in combination with trevogrumab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,96,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Fourth Quarter 2023 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,96,-0.68,revenues,down,"Regeneron Pharmaceuticals Inc.: Total revenues $3,434 $3,414",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,96,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA in the U.S. decreased in the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,96,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Other revenue for the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.65,revenues,up,Regeneron Pharmaceuticals Inc.: The increase in other revenue in 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D for the full year 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $10.19 in the fourth quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $34.77 for the full year 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $11.86 in the fourth quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $43.79 for the full year 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,Regeneron Pharmaceuticals Inc.: the Company repurchased shares of its common stock,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2024 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -4-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: Conference Call Information,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -4-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: Total assets $33,080.2 $29,214.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Net income $1,159.6 $1,197.1",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 10.88 $ 11.19 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,97,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $1,159.6 $1,197.1",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -6-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,97,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,366.3 $1,449.0",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -6-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,97,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 12.82 $ 13.54 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -6-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,97,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -6-
REGN,2024-02-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,91,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Fourth Quarter 2023 Financial Results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -7-
REGN,2024-02-02,11:31:41,589803,Regeneron Pharmaceuticals Inc.,100,0.48,revenues,up,"Regeneron Pharma: 4Q Dupixent Global Sales, Recorded by Sanofi, Rose 31%",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharma: 4Q Dupixent Global Sales, Recorded by Sanofi, Rose 31% to $3.22B >REGN"
REGN,2024-02-02,11:36:56,589803,Regeneron Pharmaceuticals Inc.,100,0.0,equity-actions,,Regeneron Pharma Sees 2024 Capital Spending $825M-$950M >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Sees 2024 Capital Spending $825M-$950M >REGN
REGN,2024-02-02,11:44:12,589803,Regeneron Pharmaceuticals Inc.,100,0.65,revenues,up,Regeneron's 4Q Sales Edge Higher,FULL-ARTICLE,Dow Jones Newswires,"Regeneron's 4Q Sales Edge Higher, Despite Softening Demand for Covid Products"
REGN,2024-02-02,11:59:12,589803,Regeneron Pharmaceuticals Inc.,100,0.65,revenues,up,Regeneron's 4Q Sales Edge Higher,FULL-ARTICLE,Dow Jones Newswires,"Regeneron's 4Q Sales Edge Higher, Despite Softening Demand for Covid Products"
REGN,2024-02-02,14:13:44,589803,Regeneron Pharmaceuticals Inc.,92,0.61,earnings,positive,Regeneron earned $11.86 per share,FULL-ARTICLE,Dow Jones Newswires,The Surprising Sources Of Regeneron's Fourth-Quarter Beat As Shares Hit Another Record High -- IBD
REGN,2024-02-02,17:05:22,589803,Regeneron Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Regeneron Earnings Beat Forecasts,FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Beat Forecasts as Sales of Updated Eye Drug Raise Hopes -- Barrons.com
REGN,2024-02-02,17:05:22,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron reported Dupixent sales of $3.2 billion for the quarter,FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Beat Forecasts as Sales of Updated Eye Drug Raise Hopes -- Barrons.com
REGN,2024-02-02,21:04:04,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp McCourt Sells 273 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP McCourt Sells 273 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-02-02,21:04:16,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,Cfo Landry Acquires 118 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Acquires 118 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-02-05,14:25:40,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by BMO Capital
REGN,2024-02-05,14:25:40,589803,Regeneron Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1082.00/Share From $1055.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1082.00/Share From $1055.00 by BMO Capital
REGN,2024-02-05,15:44:40,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by RBC Capital
REGN,2024-02-05,15:44:40,589803,Regeneron Pharmaceuticals Inc.,100,0.46,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1110.00/Share From $1076.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1110.00/Share From $1076.00 by RBC Capital
REGN,2024-02-05,21:09:20,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-02-05,22:20:09,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-06,14:48:52,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Neutral by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Neutral by Cantor Fitzgerald
REGN,2024-02-06,14:48:52,589803,Regeneron Pharmaceuticals Inc.,100,0.74,price-targets,upgrade,Regeneron Pharma Price Target Raised to $925.00/Share From $850.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $925.00/Share From $850.00 by Cantor Fitzgerald
REGN,2024-02-06,21:09:02,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-06,21:14:00,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Vp Stahl Acquires 8,037 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stahl Acquires 8,037 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-06,21:18:16,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,Cfo Landry Acquires 119 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Acquires 119 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-02-07,21:42:44,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Stahl Registers 8,037 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Stahl Registers 8,037 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-07,22:09:29,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Larosa Registers 2,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Larosa Registers 2,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-08,20:17:57,589803,Regeneron Pharmaceuticals Inc.,95,0.52,products-services,,"Regeneron very recently introduced Eylea HD, a higher-dose formulation",PRESS-RELEASE,GlobeNewswire,"Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights"
REGN,2024-02-08,21:03:49,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Stahl Sells 8,037 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stahl Sells 8,037 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-08,21:30:47,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Sing Registers 500 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Sing Registers 500 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-02-09,17:24:26,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Fenimore Registers 4,919 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Fenimore Registers 4,919 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-09,21:06:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Sing Registers 500 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Sing Registers 500 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-02-09,21:13:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Larosa Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Larosa Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-12,21:03:52,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Fenimore Sells 4,919 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Fenimore Sells 4,919 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-12,21:04:43,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sing Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sing Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-13,21:05:58,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Vp van Plew Acquires 10,434 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP van Plew Acquires 10,434 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-14,22:12:29,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp van Plew Registers 10,434 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP van Plew Registers 10,434 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-16,06:05:15,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Japan Is First Country to Approve Dupixent,NEWS-FLASH,Dow Jones Newswires,Sanofi: Japan Is First Country to Approve Dupixent for CSU
REGN,2024-02-16,06:19:23,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi's Dupixent Urticaria Treatment Approved in Japan,FULL-ARTICLE,Dow Jones Newswires,Sanofi's Dupixent Urticaria Treatment Approved in Japan
REGN,2024-02-16,06:34:23,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi's Dupixent Urticaria Treatment Approved in Japan,FULL-ARTICLE,Dow Jones Newswires,Sanofi's Dupixent Urticaria Treatment Approved in Japan
REGN,2024-02-16,21:17:16,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp van Plew Sells 10,434 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP van Plew Sells 10,434 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-19,08:03:17,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Decibel THERAPEUTICS INC COM, Inst Holders, 4Q 2023 (DBTX)",RNS-SEC13F,Dow Jones Newswires,"DECIBEL THERAPEUTICS INC  COM, Inst Holders, 4Q 2023 (DBTX)"
REGN,2024-02-19,08:09:34,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals Inc, Inst Holders, 4Q 2023 (REGN)",RNS-SEC13F,Dow Jones Newswires,"Regeneron Pharmaceuticals  Inc, Inst Holders, 4Q 2023 (REGN)"
REGN,2024-02-20,21:17:28,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Chmn Yancopoulos Acquires 49,122 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Yancopoulos Acquires 49,122 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-21,12:01:12,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda Accepted for Priority Review BLA for Linvoseltamab,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma : FDA Accepted for Priority Review BLA for Linvoseltamab in Adults With Relapsed/refractory Multiple Myeloma That Progressed After at Least 3 Prior Therapies >REGN
REGN,2024-02-21,12:41:21,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Gets FDA Priority Review of Linvoseltamab,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets FDA Priority Review of Linvoseltamab in Multiple Myeloma
REGN,2024-02-21,12:56:21,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Gets FDA Priority Review of Linvoseltamab,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets FDA Priority Review of Linvoseltamab in Multiple Myeloma
REGN,2024-02-22,21:09:45,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sing Registers 3,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Sing Registers 3,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-23,06:05:30,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda Accepts for Priority Review Supplemental Biologics License Application for Dupixent,NEWS-FLASH,Dow Jones Newswires,Sanofi: FDA Accepts for Priority Review Supplemental Biologics License Application for Dupixent
REGN,2024-02-23,06:08:46,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupixent Is Being Jointly Developed by Sanofi and Regeneron,NEWS-FLASH,Dow Jones Newswires,Sanofi: Dupixent Is Being Jointly Developed by Sanofi and Regeneron
REGN,2024-02-23,21:09:40,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Sing Registers 500 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Sing Registers 500 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-02-26,20:27:50,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bassler Registers 854 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Bassler Registers 854 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-02-26,21:08:55,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sing Sells 3,500 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sing Sells 3,500 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-26,21:09:07,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Larosa Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Larosa Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-26,21:09:47,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sing Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Sing Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-26,21:09:57,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bassler Sells 854 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bassler Sells 854 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-02-26,21:39:34,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Larosa Registers 3,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Larosa Registers 3,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-27,15:06:40,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by RBC Capital
REGN,2024-02-27,15:06:40,589803,Regeneron Pharmaceuticals Inc.,100,0.7,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1184.00/Share From $1096.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1184.00/Share From $1096.00 by RBC Capital
REGN,2024-02-28,21:06:44,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Larosa Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Larosa Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-28,21:07:18,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sing Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sing Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-02-28,21:10:13,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Stahl Gifts 1,020 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stahl Gifts 1,020 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-03-01,21:18:57,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp McCourt Registers 358 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,VP McCourt Registers 358 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-03-05,21:03:20,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp McCourt Sells 358 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP McCourt Sells 358 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-03-05,21:03:43,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-03-11,11:00:23,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Praluent(R) (alirocumab) Injection Receives FDA Approval,PRESS-RELEASE,GlobeNewswire,Praluent(R) (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
REGN,2024-03-11,11:00:23,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Praluent was developed by Regeneron and Sanofi,PRESS-RELEASE,GlobeNewswire,Praluent(R) (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
REGN,2024-03-11,11:00:24,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Praluent(R) (alirocumab) Injection Receives FDA Approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Praluent(R) (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
REGN,2024-03-11,11:00:24,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Praluent was developed by Regeneron and Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Praluent(R) (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
REGN,2024-03-11,11:00:42,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron: Praluent Injection Receives FDA Approval,NEWS-FLASH,Dow Jones Newswires,Regeneron: Praluent Injection Receives FDA Approval to Treat Children With Genetic Form of High Cholesterol
REGN,2024-03-11,20:54:30,589803,Regeneron Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Regeneron Pharma Initiated at Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Initiated at Outperform by Bernstein
REGN,2024-03-11,20:54:30,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $1125.00/Share by Bernstein,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $1125.00/Share by Bernstein
REGN,2024-03-12,09:45:22,589803,Regeneron Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Regeneron Pharma Initiated at Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Initiated at Outperform by Bernstein
REGN,2024-03-12,09:45:22,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $1125.00/Share by Bernstein,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $1125.00/Share by Bernstein
REGN,2024-03-13,01:30:22,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,GlobeNewswire,High School Seniors Win $1.8 Million at Regeneron -2-
REGN,2024-03-13,03:55:46,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,PR Newswire,High School Seniors Win $1.8 Million at Regeneron -2-
REGN,2024-03-13,12:11:14,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley
REGN,2024-03-13,12:11:14,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1115.00/Share From $1104.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1115.00/Share From $1104.00 by Morgan Stanley
REGN,2024-03-14,20:44:05,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Murphy Registers 5,783 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Murphy Registers 5,783 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-03-15,20:02:25,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Murphy Sells 5,783 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Murphy Sells 5,783 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-03-18,11:31:42,589803,Regeneron Pharmaceuticals Inc.,100,0.41,products-services,start,Intellia Therapeutics Doses First Patient in Phase 3 MAGNITUDE Trial of NTLA-2001,NEWS-FLASH,Dow Jones Newswires,Intellia Therapeutics Doses First Patient in Phase 3 MAGNITUDE Trial of NTLA-2001 to Treat Transthyretin Amyloidosis >NTLA
REGN,2024-03-22,14:08:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.43,products-services,terminated,Intellia Therapeutics Ends Co-Development Agreement With Regeneron,RNS-SEC8K,Dow Jones Newswires,Intellia Therapeutics Ends Co-Development Agreement With Regeneron
REGN,2024-03-22,14:23:38,589803,Regeneron Pharmaceuticals Inc.,100,-0.43,products-services,terminated,Intellia Therapeutics Ends Co-Development Agreement With Regeneron,RNS-SEC8K,Dow Jones Newswires,Intellia Therapeutics Ends Co-Development Agreement With Regeneron
REGN,2024-03-25,11:00:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron has been actively enrolling patients in multiple Phase 3,PRESS-RELEASE,GlobeNewswire,Regeneron Provides Update on Biologics License Application for Odronextamab
REGN,2024-03-25,11:00:03,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron has been actively enrolling patients in multiple Phase 3,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Provides Update on Biologics License Application for Odronextamab
REGN,2024-03-25,11:18:23,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,products-services,denied,Fda Rejects Regeneron's Odronextamab,FULL-ARTICLE,Dow Jones Newswires,"FDA Rejects Regeneron's Odronextamab in Follicular, Diffuse Large B-cell Lymphoma"
REGN,2024-03-25,11:33:23,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,products-services,denied,Fda Rejects Regeneron's Odronextamab,FULL-ARTICLE,Dow Jones Newswires,"FDA Rejects Regeneron's Odronextamab in Follicular, Diffuse Large B-cell Lymphoma"
REGN,2024-03-26,13:45:44,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Truist Securities
REGN,2024-04-01,20:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report First Quarter 2024 Financial and Operating Results,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024"
REGN,2024-04-01,20:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024"
REGN,2024-04-01,20:33:45,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp McCourt Registers 250 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,VP McCourt Registers 250 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-04-03,13:50:23,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Truist Securities
REGN,2024-04-03,20:07:19,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-04-03,20:07:24,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp McCourt Sells 250 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP McCourt Sells 250 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-04-10,20:29:13,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Doj: U.S. Files Complaint Against Regeneron Pharmaceuticals Under,NEWS-FLASH,Dow Jones Newswires,DOJ: U.S. Files Complaint Against Regeneron Pharmaceuticals Under False Claims Act
REGN,2024-04-12,12:14:13,589803,Regeneron Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Underperform by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Underperform by B of A Securities
REGN,2024-04-12,12:14:13,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $720.00/Share From $710.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $720.00/Share From $710.00 by B of A Securities
REGN,2024-04-17,18:15:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,Business Wire,"The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-04-18,01:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm"
REGN,2024-04-18,11:43:05,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by UBS
REGN,2024-04-18,11:43:06,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1099.00/Share From $1090.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1099.00/Share From $1090.00 by UBS
REGN,2024-04-18,21:03:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Llp Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,GlobeNewswire,"Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)"
REGN,2024-04-18,21:03:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Llp is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)"
REGN,2024-04-22,21:54:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Oral presentations include updated results from clinical study,PRESS-RELEASE,GlobeNewswire,Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
REGN,2024-04-22,21:54:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Oral presentations include updated results from clinical study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
REGN,2024-04-22,21:55:51,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron to Present Updated Results From Clinical Study,NEWS-FLASH,Dow Jones Newswires,Regeneron to Present Updated Results From Clinical Study of Otoferlin Gene Therapy DB-OTO Demonstrating Restoration in Children With Profound Genetic Hearing Loss
REGN,2024-04-24,14:05:18,589803,Regeneron Pharmaceuticals Inc.,99,0.84,products-services,positive,"Regeneron Pharmaceuticals Inc.: Notably, new safety and efficacy results from a Phase 1/2 trial",PRESS-RELEASE,GlobeNewswire,Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
REGN,2024-04-24,14:05:18,589803,Regeneron Pharmaceuticals Inc.,99,0.52,products-services,,Regeneron Pharmaceuticals Inc.: with cemiplimab in 12:00 p.m.,PRESS-RELEASE,GlobeNewswire,Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
REGN,2024-04-24,14:05:18,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Odronextamab Phase 3 trial,PRESS-RELEASE,GlobeNewswire,Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
REGN,2024-04-24,14:05:18,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,"Regeneron Pharmaceuticals Inc.: Fianlimab, A Phase 3 trial of",PRESS-RELEASE,GlobeNewswire,Regeneron to Showcase Progress in Advancing Novel -2-
REGN,2024-04-24,14:05:18,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The extensive clinical program for Libtayo,PRESS-RELEASE,GlobeNewswire,Regeneron to Showcase Progress in Advancing Novel -2-
REGN,2024-04-24,14:05:18,589803,Regeneron Pharmaceuticals Inc.,99,0.84,products-services,positive,"Regeneron Pharmaceuticals Inc.: Notably, new safety and efficacy results from a Phase 1/2 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
REGN,2024-04-24,14:05:18,589803,Regeneron Pharmaceuticals Inc.,99,0.52,products-services,,Regeneron Pharmaceuticals Inc.: with cemiplimab in 12:00 p.m.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
REGN,2024-04-24,14:05:18,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Odronextamab Phase 3 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
REGN,2024-04-24,14:05:19,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,"Regeneron Pharmaceuticals Inc.: Fianlimab, A Phase 3 trial of",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron to Showcase Progress in -2-
REGN,2024-04-24,14:05:19,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The extensive clinical program for Libtayo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron to Showcase Progress in -2-
REGN,2024-04-24,17:49:19,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by TD Cowen
REGN,2024-04-24,17:49:19,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1030.00/Share From $1020.00 by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1030.00/Share From $1020.00 by TD Cowen
REGN,2024-04-25,11:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Mammoth Biosciences Collaborate to,PRESS-RELEASE,GlobeNewswire,Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
REGN,2024-04-25,11:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Mammoth Biosciences Collaborate to,PRESS-RELEASE,GlobeNewswire,Regeneron and Mammoth Biosciences Collaborate to -2-
REGN,2024-04-25,11:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Mammoth Biosciences, Inc., today announced a collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
REGN,2024-04-25,11:00:13,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Mammoth Biosciences Collaborate to,NEWS-FLASH,Dow Jones Newswires,Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
REGN,2024-04-25,11:49:52,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences,FULL-ARTICLE,Dow Jones Newswires,Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences
REGN,2024-04-25,11:49:52,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Pharmaceuticals has inked a deal with privately held Mammoth Biosciences,FULL-ARTICLE,Dow Jones Newswires,Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences
REGN,2024-04-25,12:04:52,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences,FULL-ARTICLE,Dow Jones Newswires,Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences
REGN,2024-04-25,12:04:52,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Pharmaceuticals has inked a deal with privately held Mammoth Biosciences,FULL-ARTICLE,Dow Jones Newswires,Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences
REGN,2024-05-01,20:01:58,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Yancopoulos Sells 16,848 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Yancopoulos Sells 16,848 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-05-01,20:05:18,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Yancopoulos Gifts 36,296 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Yancopoulos Gifts 36,296 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-05-01,21:06:49,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp McCourt Registers 250 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,VP McCourt Registers 250 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-05-01,21:36:30,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Ryan Registers 300 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Ryan Registers 300 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: First Quarter 2024 Financial Results,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.02,revenues,,Regeneron Pharmaceuticals Inc.: First quarter 2024 revenues decreased 1% to $3.15 billion,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: First quarter 2024 U.S. net sales,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: First quarter 2024 GAAP diluted EPS of $6.27,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Regeneron Pharmaceuticals Inc.: New $3.0 billion share repurchase program authorized,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,The U.S. Food and Drug Administration (FDA) accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 3 study for Dupixent,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Japan approved Dupixent for the treatment of chronic spontaneous urticaria,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 3 confirmatory trial,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: the Company presented positive pivotal data from the Phase 1/2 trial of linvoseltamab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: The FDA has extended the approval of Praluent(R) (alirocumab),PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 2 study for itepekimab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 2 study for ALN-APP,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Regeneron Pharmaceuticals Inc.: In April 2024, the Company and Mammoth Biosciences, Inc. entered into a collaboration",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,145 $ 3,162",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA in the U.S. decreased in the first quarter of 2024,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the first quarter,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,-0.68,revenues,down,"Regeneron Pharmaceuticals Inc.: The decrease in other collaboration revenue in the first quarter of 2024, compared to the first quarter of 2023",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D for first quarter of 2023,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,"Regeneron Pharmaceuticals Inc.: the Company's collaboration agreement with Sonoma Biotherapeutics, Inc.",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Regeneron Pharmaceuticals Inc.: the Company's 2023 acquisition of Decibel Therapeutics, Inc.",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $6.27 in the first quarter of 2024,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $9.55 in the first quarter of 2024,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the first quarter of 2024, the Company repurchased shares of its common stock",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2024 Financial Guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2024 financial guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -3-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its first quarter 2024 financial and operating results on Thursday, May 2, 2024, at 8:30 AM Eastern Time",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -3-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: March 31, December 31, 2024 2023 Assets",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -4-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -4-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income $ 722.0 $ 817.8,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -4-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 6.70 $ 7.64,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -4-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,97,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income $ 722.0 $ 817.8,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -5-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,97,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,115.9 $1,167.5",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -5-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,97,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 10.35 $ 10.90,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -5-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,97,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -5-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,97,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""First Quarter 2024 Financial Results",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -5-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,97,0.0,revenues,,Regeneron Pharmaceuticals Inc.: net product sales of ARCALYST were $71 million,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2024 Financial -5-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 1Q EPS $6.27,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q EPS $6.27 >REGN
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 1Q Adj EPS $9.55,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q Adj EPS $9.55 >REGN
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 1Q Net $722M,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q Net $722M >REGN
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 1Q Rev $3.15B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q Rev $3.15B >REGN
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: First Quarter 2024 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.02,revenues,,Regeneron Pharmaceuticals Inc.: First quarter 2024 revenues decreased 1% to $3.15 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: First quarter 2024 U.S. net sales,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: First quarter 2024 GAAP diluted EPS of $6.27,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Regeneron Pharmaceuticals Inc.: New $3.0 billion share repurchase program authorized,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,The U.S. Food and Drug Administration (FDA) accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 3 study for Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Japan approved Dupixent for the treatment of chronic spontaneous urticaria,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 3 confirmatory trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: the Company presented positive pivotal data from the Phase 1/2 trial of linvoseltamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: The FDA has extended the approval of Praluent(R) (alirocumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 2 study for itepekimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 2 study for ALN-APP,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Regeneron Pharmaceuticals Inc.: In April 2024, the Company and Mammoth Biosciences, Inc. entered into a collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,145 $ 3,162",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA in the U.S. decreased in the first quarter of 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the first quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,-0.68,revenues,down,"Regeneron Pharmaceuticals Inc.: The decrease in other collaboration revenue in the first quarter of 2024, compared to the first quarter of 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D for first quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,"Regeneron Pharmaceuticals Inc.: the Company's collaboration agreement with Sonoma Biotherapeutics, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Regeneron Pharmaceuticals Inc.: the Company's 2023 acquisition of Decibel Therapeutics, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $6.27 in the first quarter of 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $9.55 in the first quarter of 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the first quarter of 2024, the Company repurchased shares of its common stock",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2024 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -3-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its first quarter 2024 financial and operating results on Thursday, May 2, 2024, at 8:30 AM Eastern Time",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -3-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: March 31, December 31, 2024 2023 Assets",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income $ 722.0 $ 817.8,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 6.70 $ 7.64,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,97,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income $ 722.0 $ 817.8,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -5-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,97,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,115.9 $1,167.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -5-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,97,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 10.35 $ 10.90,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -5-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,97,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -5-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,97,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""First Quarter 2024 Financial Results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -5-
REGN,2024-05-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,97,0.0,revenues,,Regeneron Pharmaceuticals Inc.: net product sales of ARCALYST were $71 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -5-
REGN,2024-05-02,10:31:14,589803,Regeneron Pharmaceuticals Inc.,100,0.59,equity-actions,,Regeneron Pharma Sets New $3 Billion Share-Repurchase Program,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Sets New $3 Billion Share-Repurchase Program >REGN
REGN,2024-05-02,10:32:43,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,equity-actions,down,Regeneron Pharma Cuts 2024 Capital Spending View to $780M-$880M From $825M-$950M,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Cuts 2024 Capital Spending View to $780M-$880M From $825M-$950M >REGN
REGN,2024-05-02,10:45:23,589803,Regeneron Pharmaceuticals Inc.,100,-0.74,earnings,below-expectations,Regeneron Pharmaceuticals Inc.: the company's first-quarter earnings fell short of estimates,FULL-ARTICLE,MarketWatch,MW Regeneron's stock dips after earnings fall short of estimates
REGN,2024-05-02,10:45:23,589803,Regeneron Pharmaceuticals Inc.,100,-0.74,earnings,below-expectations,Regeneron Pharmaceuticals Inc.: the company's first-quarter earnings fell short of estimates,FULL-ARTICLE,Dow Jones Newswires,Regeneron's Stock Dips After Earnings Fall Short Of Estimates -- MarketWatch
REGN,2024-05-02,10:45:39,589803,Regeneron Pharmaceuticals Inc.,100,-0.74,earnings,below-expectations,Regeneron Earnings Miss,FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Miss; Biotech Giant's Stock Falls -- IBD
REGN,2024-05-02,10:45:39,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Factset expected Regeneron Pharmaceuticals to earn $10.18 per share,FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Miss; Biotech Giant's Stock Falls -- IBD
REGN,2024-05-02,10:45:39,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron earned $10.09 per share,FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Miss; Biotech Giant's Stock Falls -- IBD
REGN,2024-05-02,10:47:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.68,revenues,down,Regeneron Pharmaceuticals 1Q Revenue Declines,FULL-ARTICLE,Dow Jones Newswires,Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales
REGN,2024-05-02,10:47:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.75,revenues,below-expectations,Regeneron Pharmaceuticals posted lower-than-expected revenue,FULL-ARTICLE,Dow Jones Newswires,Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales
REGN,2024-05-02,11:02:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.68,revenues,down,Regeneron Pharmaceuticals 1Q Revenue Declines,FULL-ARTICLE,Dow Jones Newswires,Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales
REGN,2024-05-02,11:02:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.75,revenues,below-expectations,Regeneron Pharmaceuticals posted lower-than-expected revenue,FULL-ARTICLE,Dow Jones Newswires,Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales
REGN,2024-05-02,11:10:38,589803,Regeneron Pharmaceuticals Inc.,100,-0.24,revenues,down,Eylea sales fell 2% to $1.402 billion,FULL-ARTICLE,MarketWatch,MW Regeneron's stock dips after earnings fall short of estimates
REGN,2024-05-02,11:10:38,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,The U.S. Food and Drug Administration has accepted for priority review the supplemental Biologics License Application for Dupixent,FULL-ARTICLE,MarketWatch,MW Regeneron's stock dips after earnings fall short of estimates
REGN,2024-05-02,15:53:09,589803,Regeneron Pharmaceuticals Inc.,100,-0.47,assets,expired,Eylea Sales As Patent Expiration Looms,FULL-ARTICLE,Dow Jones Newswires,Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms -- IBD
REGN,2024-05-02,15:53:09,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron also partners with Sanofi and Bayer on,FULL-ARTICLE,Dow Jones Newswires,Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms -- IBD
REGN,2024-05-02,20:03:40,589803,Regeneron Pharmaceuticals Inc.,100,-0.47,assets,expired,Eylea Sales As Patent Expiration Looms,FULL-ARTICLE,Dow Jones Newswires,Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms -- IBD
REGN,2024-05-02,20:03:40,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron also partners with Sanofi and Bayer on,FULL-ARTICLE,Dow Jones Newswires,Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms -- IBD
REGN,2024-05-03,20:03:14,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-05-03,20:03:25,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp McCourt Sells 250 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP McCourt Sells 250 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-05-06,20:21:06,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Dir Sing Acquires 1,123 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sing Acquires 1,123 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-05-14,09:24:13,589803,Regeneron Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Regeneron Pharma Initiated at Outperform by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Initiated at Outperform by Evercore ISI Group
REGN,2024-05-14,09:24:13,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $1150.00/Share by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $1150.00/Share by Evercore ISI Group
REGN,2024-05-14,20:27:27,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Schleifer Registers 58,771 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Chmn Schleifer Registers 58,771 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-05-15,20:27:31,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Chmn Yancopoulos Registers 100,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Chmn Yancopoulos Registers 100,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-05-15,22:12:17,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Schleifer Sells 35,941 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Schleifer Sells 35,941 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-05-16,19:54:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Complaint filed against Regeneron,PRESS-RELEASE,Business Wire,"Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)"
REGN,2024-05-16,19:54:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Regeneron Pharmaceuticals Inc.: the firm is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,Business Wire,"Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)"
REGN,2024-05-17,17:45:49,589803,Regeneron Pharmaceuticals Inc.,99,0.52,products-services,,Regeneron Pharmaceuticals Inc.: His new software,PRESS-RELEASE,GlobeNewswire,More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
REGN,2024-05-17,17:45:50,589803,Regeneron Pharmaceuticals Inc.,99,0.52,products-services,,Regeneron Pharmaceuticals Inc.: His new software,PRESS-RELEASE,Dow Jones Newswires,Press Release: More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
REGN,2024-05-17,20:05:56,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Yancopoulos Sells 50,000 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Yancopoulos Sells 50,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-05-17,20:07:54,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Yancopoulos Sells 50,000 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Yancopoulos Sells 50,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-05-17,20:24:01,589803,Regeneron Pharmaceuticals Inc.,99,0.52,products-services,,Regeneron Pharmaceuticals Inc.: His new software,PRESS-RELEASE,Canadian News Wire,More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
REGN,2024-05-17,20:24:02,589803,Regeneron Pharmaceuticals Inc.,99,0.52,products-services,,Regeneron Pharmaceuticals Inc.: His new software,PRESS-RELEASE,PR Newswire,(PR) More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
REGN,2024-05-17,20:50:54,589803,Regeneron Pharmaceuticals Inc.,99,0.52,products-services,,Regeneron Pharmaceuticals Inc.: His new software,PRESS-RELEASE,PR Newswire,More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
REGN,2024-05-17,21:59:04,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Schleifer Sells 22,830 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Schleifer Sells 22,830 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-05-19,07:03:10,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Decibel THERAPEUTICS INC COM, Inst Holders, 1Q 2024 (DBTX)",RNS-SEC13F,Dow Jones Newswires,"DECIBEL THERAPEUTICS INC  COM, Inst Holders, 1Q 2024 (DBTX)"
REGN,2024-05-19,07:09:19,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals Inc, Inst Holders, 1Q 2024 (REGN)",RNS-SEC13F,Dow Jones Newswires,"Regeneron Pharmaceuticals  Inc, Inst Holders, 1Q 2024 (REGN)"
REGN,2024-05-20,21:30:24,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-05-21,20:18:49,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Larosa Registers 3,731 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Larosa Registers 3,731 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-05-22,20:05:33,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Larosa Sells 1,865 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Larosa Sells 1,865 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-05-22,20:50:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-05-26,14:14:07,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-05-28,19:02:20,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-05-28,20:37:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Brown Registers 1,172 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Brown Registers 1,172 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-05-29,20:02:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Brown Sells 1,172 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Brown Sells 1,172 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-05-30,21:40:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Recommended for EU Approval,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,The U.S. Food and Drug Administration (FDA) accepted for Priority Review the supplemental Biologics License Application for Dupixent,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent recommended for EU approval,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,The U.S. Food and Drug Administration (FDA) accepted for Priority Review the supplemental Biologics License Application for Dupixent,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent recommended for EU approval,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,The U.S. Food and Drug Administration (FDA) accepted for Priority Review the supplemental Biologics License Application for Dupixent,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Recommended for EU Approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,The U.S. Food and Drug Administration (FDA) accepted for Priority Review the supplemental Biologics License Application for Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent recommended for EU approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,The U.S. Food and Drug Administration (FDA) accepted for Priority Review the supplemental Biologics License Application for Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN,2024-05-31,05:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN,2024-05-31,05:05:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent recommended for EU approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN,2024-05-31,05:05:01,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,The U.S. Food and Drug Administration (FDA) accepted for Priority Review the supplemental Biologics License Application for Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN,2024-05-31,05:05:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN,2024-05-31,05:05:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN,2024-05-31,05:10:15,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent Recommended for EU Approval,NEWS-FLASH,Dow Jones Newswires,Sanofi: Dupixent Recommended for EU Approval by CHMP to Treat Patients With COPD
REGN,2024-05-31,05:34:34,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Sanofi's Dupixent Drug Review,FULL-ARTICLE,Dow Jones Newswires,Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S.
REGN,2024-05-31,05:34:34,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Sanofi and Regeneron are jointly developing Dupixent,FULL-ARTICLE,Dow Jones Newswires,Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S.
REGN,2024-05-31,05:49:34,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Sanofi's Dupixent Drug Review,FULL-ARTICLE,Dow Jones Newswires,Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S.
REGN,2024-05-31,05:49:34,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Sanofi and Regeneron are jointly developing Dupixent,FULL-ARTICLE,Dow Jones Newswires,Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S.
REGN,2024-06-01,16:09:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-06-03,20:05:01,589803,Regeneron Pharmaceuticals Inc.,96,0.49,partnerships,,Excited to collaborate with Regeneron Pharmaceuticals to,PRESS-RELEASE,GlobeNewswire,"FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO(R) in Upcoming Clinical Trials"
REGN,2024-06-03,20:05:01,589803,Regeneron Pharmaceuticals Inc.,96,0.49,partnerships,,Excited to collaborate with Regeneron Pharmaceuticals to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO(R) in Upcoming Clinical Trials"
REGN,2024-06-03,20:42:53,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,138 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,138 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-06-03,20:56:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-06-04,14:02:20,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by RBC Capital
REGN,2024-06-04,14:02:20,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1200.00/Share From $1185.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1200.00/Share From $1185.00 by RBC Capital
REGN,2024-06-05,18:27:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bassler Registers 827 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Bassler Registers 827 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-06-05,19:25:49,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-06-05,20:08:26,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,138 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,138 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-06-05,20:09:27,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-06-07,20:08:34,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bassler Sells 827 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bassler Sells 827 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-06-09,16:11:47,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-06-10,20:04:34,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Chmn Schleifer Sells 787 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,Chmn Schleifer Sells 787 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-06-11,11:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi today announced that the U.S. Food and Drug Administration has approved Kevzara(R) (sarilumab),PRESS-RELEASE,GlobeNewswire,Kevzara(R) (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
REGN,2024-06-11,11:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Sarilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,GlobeNewswire,Kevzara(R) (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
REGN,2024-06-11,11:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Kevzara(R) (sarilumab) Approved by FDA,PRESS-RELEASE,GlobeNewswire,Kevzara(R) (sarilumab) Approved by FDA for the -2-
REGN,2024-06-11,11:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Kevzara(R) (sarilumab) Approved by FDA,PRESS-RELEASE,GlobeNewswire,Kevzara(R) (sarilumab) Approved by FDA for the -3-
REGN,2024-06-11,11:00:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi today announced that the U.S. Food and Drug Administration has approved Kevzara(R) (sarilumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Kevzara(R) (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
REGN,2024-06-11,11:00:04,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Sarilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Kevzara(R) (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
REGN,2024-06-11,11:00:26,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi: Kevzara Approved by FDA,NEWS-FLASH,Dow Jones Newswires,"Regeneron, Sanofi: Kevzara Approved by FDA for Treatment of Active Polyarticular Juvenile Idiopathic Arthritis"
REGN,2024-06-11,11:20:14,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi Get Expanded FDA OK for Kevzara,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Get Expanded FDA OK for Kevzara in Polyarticular Juvenile Idiopathic Arthritis"
REGN,2024-06-11,11:35:14,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi Get Expanded FDA OK for Kevzara,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Get Expanded FDA OK for Kevzara in Polyarticular Juvenile Idiopathic Arthritis"
REGN,2024-06-11,20:29:45,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-06-12,12:03:18,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by RBC Capital
REGN,2024-06-12,12:03:18,589803,Regeneron Pharmaceuticals Inc.,100,0.4,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1229.00/Share From $1200.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1229.00/Share From $1200.00 by RBC Capital
REGN,2024-06-12,20:15:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Larosa Gifts 1,608 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Larosa Gifts 1,608 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-06-12,20:16:40,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Yancopoulos Gifts 75,799 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Yancopoulos Gifts 75,799 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-06-13,12:00:37,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron and Sanofi tested Dupixent,FULL-ARTICLE,Dow Jones Newswires,"Why It's A New Day For COPD Patients -- And Regeneron, Sanofi, Verona Stocks -- IBD"
REGN,2024-06-13,12:00:37,589803,Regeneron Pharmaceuticals Inc.,99,0.72,revenues,up,Regeneron STOCK: EXPECTED REVENUE BOOST,FULL-ARTICLE,Dow Jones Newswires,"Why It's A New Day For COPD Patients -- And Regeneron, Sanofi, Verona Stocks -- IBD"
REGN,2024-06-13,20:02:51,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Schleifer Sells 25,213 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Schleifer Sells 25,213 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-06-13,20:24:35,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-06-14,20:33:55,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Brown Registers 1,535 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Brown Registers 1,535 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-06-15,12:15:04,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-06-17,14:29:39,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by JP Morgan
REGN,2024-06-17,14:29:39,589803,Regeneron Pharmaceuticals Inc.,100,0.76,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1150.00/Share From $1050.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1150.00/Share From $1050.00 by JP Morgan
REGN,2024-06-17,20:03:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Brown Sells 1,535 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Brown Sells 1,535 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-06-17,23:50:29,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-06-18,08:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.51,products-services,,Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea(R) LD/HD in Europe
REGN,2024-06-18,08:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.51,products-services,,Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea(R),PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea(R) LD/HD in Europe
REGN,2024-06-18,08:01:00,589803,Regeneron Pharmaceuticals Inc.,100,0.51,products-services,,Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea(R),PRESS-RELEASE,GlobeNewswire,Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea(R) LD/HD in Europe
REGN,2024-06-18,08:01:01,589803,Regeneron Pharmaceuticals Inc.,100,0.51,products-services,,Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea(R) LD/HD in Europe
REGN,2024-06-18,08:11:26,589803,Regeneron Pharmaceuticals Inc.,100,0.51,products-services,,Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea(R),NEWS-FLASH,Dow Jones Newswires,"Alvotech, Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea(R) LD/HD in Europe >ALVO"
REGN,2024-06-20,20:55:09,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-06-22,20:47:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-06-24,18:48:32,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bassler Registers 756 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Bassler Registers 756 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-06-24,23:10:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-06-25,12:38:26,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Argus Research
REGN,2024-06-25,12:38:26,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1170.00/Share From $1060.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1170.00/Share From $1060.00 by Argus Research
REGN,2024-06-25,20:40:42,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Vp Larosa Acquires 3,366 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Larosa Acquires 3,366 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-06-25,20:41:44,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bassler Sells 756 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bassler Sells 756 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-06-27,01:40:48,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-06-27,13:50:59,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Canaccord Genuity
REGN,2024-06-27,20:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report Second Quarter 2024 Financial and Operating Results,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024"
REGN,2024-06-27,20:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024"
REGN,2024-06-28,11:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Odronextamab Recommended for EU Approval,PRESS-RELEASE,GlobeNewswire,Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
REGN,2024-06-28,11:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.63,products-services,,Ema previously granted odronextamab Orphan Designation,PRESS-RELEASE,GlobeNewswire,Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
REGN,2024-06-28,11:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Odronextamab Recommended for EU Approval,PRESS-RELEASE,GlobeNewswire,Odronextamab Recommended for EU Approval by the -2-
REGN,2024-06-28,11:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Odronextamab Recommended for EU Approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
REGN,2024-06-28,11:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.63,products-services,,Ema previously granted odronextamab Orphan Designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
REGN,2024-06-28,11:00:20,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Odronextamab Recommended for EU Approval,NEWS-FLASH,Dow Jones Newswires,Regeneron: Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
REGN,2024-06-28,11:29:50,589803,Regeneron Pharmaceuticals Inc.,92,0.57,products-services,granted,Regeneron Pharmaceuticals on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of odronextamab,FULL-ARTICLE,Dow Jones Newswires,Regeneron Wins CHMP Backing of Lymphoma Drug Odronextamab
REGN,2024-06-28,11:29:50,589803,Regeneron Pharmaceuticals Inc.,92,0.57,products-services,granted,Regeneron Pharmaceuticals on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of odronextamab,FULL-ARTICLE,Dow Jones Newswires,Regeneron Wins CHMP Backing of Lymphoma Drug Odronextamab
REGN,2024-06-28,11:29:50,589803,Regeneron Pharmaceuticals Inc.,92,0.0,products-services,,Regeneron's application seeking approval of odronextamab,FULL-ARTICLE,Dow Jones Newswires,Regeneron Wins CHMP Backing of Lymphoma Drug Odronextamab
REGN,2024-06-28,11:44:49,589803,Regeneron Pharmaceuticals Inc.,92,0.57,products-services,granted,Regeneron Pharmaceuticals on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of odronextamab,FULL-ARTICLE,Dow Jones Newswires,Regeneron Wins CHMP Backing of Lymphoma Drug Odronextamab
REGN,2024-06-28,11:44:49,589803,Regeneron Pharmaceuticals Inc.,92,0.57,products-services,granted,Regeneron Pharmaceuticals on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of odronextamab,FULL-ARTICLE,Dow Jones Newswires,Regeneron Wins CHMP Backing of Lymphoma Drug Odronextamab
REGN,2024-06-28,11:44:49,589803,Regeneron Pharmaceuticals Inc.,92,0.0,products-services,,Regeneron's application seeking approval of odronextamab,FULL-ARTICLE,Dow Jones Newswires,Regeneron Wins CHMP Backing of Lymphoma Drug Odronextamab
REGN,2024-06-28,16:34:23,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-06-28,21:51:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda grants approval for Eylea®,PRESS-RELEASE,Dow Jones Newswires,EQS-Adhoc: FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
REGN,2024-06-28,21:51:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda grants approval for Eylea®,PRESS-RELEASE,DGAP News,EQS-Adhoc: FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
REGN,2024-06-28,21:52:07,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda grants approval for Eylea®,PRESS-RELEASE,DGAP News,EQS-Adhoc: FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
REGN,2024-06-28,21:52:07,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda grants approval for Eylea®,PRESS-RELEASE,Dow Jones Newswires,EQS-Adhoc: FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
REGN,2024-06-29,16:40:06,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-06-30,15:51:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. -- REGN"
REGN,2024-07-01,21:27:33,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,137 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,137 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-07-02,14:15:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-07-02,20:02:49,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,137 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,137 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-07-02,20:03:25,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-07-03,05:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in the EU as the first-ever targeted therapy,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
REGN,2024-07-03,05:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
REGN,2024-07-03,05:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi today announced that the European Commission (EC) has approved Dupixent(R) (dupilumab),PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
REGN,2024-07-03,05:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in the EU as the first-ever targeted therapy,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
REGN,2024-07-03,05:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
REGN,2024-07-03,05:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in the EU as the first-ever targeted therapy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
REGN,2024-07-03,05:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
REGN,2024-07-03,05:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in the EU as the first-ever targeted therapy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
REGN,2024-07-03,05:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
REGN,2024-07-03,05:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi today announced that the European Commission (EC) has approved Dupixent(R) (dupilumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
REGN,2024-07-03,05:02:13,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Say Dupixent Approved in EU,NEWS-FLASH,Dow Jones Newswires,"Sanofi, Regeneron Say Dupixent Approved in EU as COPD Therapy"
REGN,2024-07-03,05:03:46,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,First Regulatory Authority to Approve Dupixent,NEWS-FLASH,Dow Jones Newswires,"Sanofi, Regeneron: EMA Is First Regulatory Authority to Approve Dupixent for COPD Patients"
REGN,2024-07-03,05:23:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Sanofi, Regeneron Get EU Approval for Dupixent",FULL-ARTICLE,Dow Jones Newswires,"Sanofi, Regeneron Get EU Approval for Dupixent to Treat Respiratory Disease"
REGN,2024-07-03,05:23:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Sanofi and Regeneron are jointly developing Dupixent,FULL-ARTICLE,Dow Jones Newswires,"Sanofi, Regeneron Get EU Approval for Dupixent to Treat Respiratory Disease"
REGN,2024-07-03,05:38:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Sanofi, Regeneron Get EU Approval for Dupixent",FULL-ARTICLE,Dow Jones Newswires,"Sanofi, Regeneron Get EU Approval for Dupixent to Treat Respiratory Disease"
REGN,2024-07-03,05:38:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Sanofi and Regeneron are jointly developing Dupixent,FULL-ARTICLE,Dow Jones Newswires,"Sanofi, Regeneron Get EU Approval for Dupixent to Treat Respiratory Disease"
REGN,2024-07-05,16:08:41,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-07-07,18:59:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-07-08,21:04:27,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-07-09,18:46:08,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals Inc.: Investigation Into Claims Against Regeneron Pharmaceuticals Inc,PRESS-RELEASE,DJ Global Press Release Wire,Investigation Into Claims Against Regeneron Pharmaceuticals Inc Is Initiated By The Schall Law Firm And Investors Who Have Incurred Losses Are Encouraged To Contact
REGN,2024-07-10,19:27:19,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm"
REGN,2024-07-10,23:28:04,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2024-07-10,23:31:09,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Barclays
REGN,2024-07-10,23:31:09,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1200.00/Share From $1050.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1200.00/Share From $1050.00 by Barclays
REGN,2024-07-11,17:18:51,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley
REGN,2024-07-11,17:18:51,589803,Regeneron Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1182.00/Share From $1183.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1182.00/Share From $1183.00 by Morgan Stanley
REGN,2024-07-12,20:01:13,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Larosa Sells 1,866 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Larosa Sells 1,866 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-07-18,15:51:21,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Guggenheim
REGN,2024-07-18,15:51:21,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1180.00/Share From $1040.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1180.00/Share From $1040.00 by Guggenheim
REGN,2024-07-19,12:27:43,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Piper Sandler
REGN,2024-07-19,12:27:43,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1166.00/Share From $1000.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1166.00/Share From $1000.00 by Piper Sandler
REGN,2024-07-22,15:43:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Neutral by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Neutral by Cantor Fitzgerald
REGN,2024-07-22,15:43:00,589803,Regeneron Pharmaceuticals Inc.,100,0.7,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1000.00/Share From $925.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1000.00/Share From $925.00 by Cantor Fitzgerald
REGN,2024-07-23,17:06:02,589803,Regeneron Pharmaceuticals Inc.,100,0.72,revenues,up,Arcalyst Sales Guidance Increase,FULL-ARTICLE,Dow Jones Newswires,"Kiniksa Pharma Shares Rise 27% After 2Q Earnings, Arcalyst Sales Guidance Increase"
REGN,2024-07-23,17:11:22,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by TD Cowen
REGN,2024-07-23,17:11:22,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1200.00/Share From $1030.00 by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1200.00/Share From $1030.00 by TD Cowen
REGN,2024-07-31,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,GlobeNewswire,Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 2Q EPS $12.41,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q EPS $12.41 >REGN
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 2Q Net $1.43B,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q Net $1.43B >REGN
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 2Q Rev $3.55B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q Rev $3.55B >REGN
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2024",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Second quarter 2024 revenues increased 12% to $3.55 billion,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Second quarter 2024 U.S. net sales,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.58,earnings,up,Regeneron Pharmaceuticals Inc.: Second quarter 2024 GAAP diluted EPS increased 46%,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: European Commission approved Dupixent,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda accepted for priority review the sBLA for Dupixent,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Nejm published results from a positive Phase 3 trial for Dupixent,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.62,products-services,positive,Regeneron Pharmaceuticals Inc.: The Company announced positive updated results from an ongoing Phase 1/2 trial,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,The FDA approved Kevzara(R) (sarilumab) for the treatment,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The Company presented updated data from the Phase 1/2 trial of DB-OTO,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2024 financial guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial -3-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its second quarter 2024 financial and operating results on Thursday, August 1, 2024, at 8:30 AM Eastern Time",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial -3-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: Total assets $36,086.8 $ 33,080.2",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial -4-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial -4-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Net income $1,432.3 $ 968.4",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial -4-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 13.25 $ 9.05 $,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial -4-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $1,432.3 $ 968.4",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial -5-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,351.2 $1,181.6",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial -5-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 12.50 $ 11.04 $,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial -5-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,98,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial -5-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,98,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Second Quarter 2024 Financial Results",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial -5-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,90,0.0,revenues,,Regeneron Pharmaceuticals Inc.: net product sales of ARCALYST were $79 million,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2024 Financial -6-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Second quarter 2024 revenues increased 12% to $3.55 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Second quarter 2024 U.S. net sales,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.58,earnings,up,Regeneron Pharmaceuticals Inc.: Second quarter 2024 GAAP diluted EPS increased 46%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: European Commission approved Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda accepted for priority review the sBLA for Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Nejm published results from a positive Phase 3 trial for Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.62,products-services,positive,Regeneron Pharmaceuticals Inc.: The Company announced positive updated results from an ongoing Phase 1/2 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,The FDA approved Kevzara(R) (sarilumab) for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The Company presented updated data from the Phase 1/2 trial of DB-OTO,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2024 Financial and Operating Results
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,547 $3,158",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Eylea HD was approved by the FDA in August 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA decreased in the second quarter of 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the second quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D for the second quarter of 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Regeneron Pharmaceuticals Inc.: the Company's 2023 acquisition of Decibel Therapeutics, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.58,earnings,up,"Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $12.41 in the second quarter of 2024, compared to $8.50 in the second quarter of 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.4,earnings,up,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $11.56 in the second quarter of 2024, compared to $10.24 in the second quarter of 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,approved,Regeneron Pharmaceuticals Inc.: the Company's board of directors authorized a new share repurchase program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the second quarter of 2024, the Company repurchased shares of its common stock",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2024 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -3-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its second quarter 2024 financial and operating results on Thursday, August 1, 2024, at 8:30 AM Eastern Time",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -3-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: Total assets $36,086.8 $ 33,080.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Net income $1,432.3 $ 968.4",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 13.25 $ 9.05 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $1,432.3 $ 968.4",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -5-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,351.2 $1,181.6",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -5-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 12.50 $ 11.04 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -5-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,98,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -5-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,98,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Second Quarter 2024 Financial Results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -5-
REGN,2024-08-01,10:30:01,589803,Regeneron Pharmaceuticals Inc.,90,0.0,revenues,,Regeneron Pharmaceuticals Inc.: net product sales of ARCALYST were $79 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -6-
REGN,2024-08-01,10:37:28,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 2Q Adj EPS $11.56,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q Adj EPS $11.56 >REGN
REGN,2024-08-01,11:50:04,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals to earn $10.62 a share,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD
REGN,2024-08-01,20:07:29,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Ryan Registers 300 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Ryan Registers 300 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-08-01,20:22:14,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,137 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,137 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-08-02,13:32:24,589803,Regeneron Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1200.00/Share From $1135.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1200.00/Share From $1135.00 by Truist Securities
REGN,2024-08-02,14:45:29,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bassler Registers 756 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Bassler Registers 756 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-08-02,15:42:14,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Barclays
REGN,2024-08-02,15:42:14,589803,Regeneron Pharmaceuticals Inc.,100,0.32,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1220.00/Share From $1200.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1220.00/Share From $1200.00 by Barclays
REGN,2024-08-02,18:40:35,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Wells Fargo
REGN,2024-08-02,18:40:35,589803,Regeneron Pharmaceuticals Inc.,100,0.64,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1200.00/Share From $1125.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1200.00/Share From $1125.00 by Wells Fargo
REGN,2024-08-02,19:25:15,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Guggenheim
REGN,2024-08-02,19:25:15,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1300.00/Share From $1180.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1300.00/Share From $1180.00 by Guggenheim
REGN,2024-08-02,20:46:15,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by RBC Capital
REGN,2024-08-02,20:46:15,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1240.00/Share From $1232.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1240.00/Share From $1232.00 by RBC Capital
REGN,2024-08-02,20:58:05,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by JP Morgan
REGN,2024-08-02,20:58:05,589803,Regeneron Pharmaceuticals Inc.,100,0.52,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1200.00/Share From $1150.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1200.00/Share From $1150.00 by JP Morgan
REGN,2024-08-05,20:02:33,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 1 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 1 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-08-05,20:02:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 99 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 99 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-08-05,20:06:06,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,137 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,137 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-08-05,20:07:32,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bassler Sells 756 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bassler Sells 756 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-08-06,20:06:33,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Vp Stahl Acquires 5,197 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stahl Acquires 5,197 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-08-07,20:05:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron will host a conference call and simultaneous webcast,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
REGN,2024-08-07,20:05:03,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron will host a conference call and simultaneous webcast,PRESS-RELEASE,GlobeNewswire,Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
REGN,2024-08-07,20:39:48,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp Pitofsky Registers 487 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,VP Pitofsky Registers 487 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-08-07,20:46:05,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp Pitofsky Sells 487 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP Pitofsky Sells 487 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-08-08,20:57:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Stahl Registers 5,197 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Stahl Registers 5,197 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-08-12,05:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,The US Food and Drug Administration (FDA) has approved Enzeevu(TM) (aflibercept-abzv) 2 mg vial kit and pre-filled,PRESS-RELEASE,GlobeNewswire,"Sandoz receives FDA approval for Enzeevu(TM) (aflibercept-abzv), further strengthening US biosimilar position"
REGN,2024-08-12,05:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,The US Food and Drug Administration (FDA) has approved Enzeevu(TM) (aflibercept-abzv) 2 mg vial kit and pre-filled,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Sandoz receives FDA approval for Enzeevu(TM) (aflibercept-abzv), further strengthening US biosimilar position"
REGN,2024-08-12,05:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,The US Food and Drug Administration (FDA) has approved Enzeevu(TM) (aflibercept-abzv) 2 mg vial kit and pre-filled,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Sandoz receives FDA approval for Enzeevu(TM) (aflibercept-abzv), further strengthening US biosimilar position"
REGN,2024-08-12,05:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,The US Food and Drug Administration (FDA) has approved Enzeevu(TM) (aflibercept-abzv) 2 mg vial kit and pre-filled,PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: Sandoz receives FDA approval for Enzeevu(TM) (aflibercept-abzv), further strengthening US biosimilar position"
REGN,2024-08-12,20:06:44,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Stahl Sells 5,197 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stahl Sells 5,197 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-08-14,20:02:32,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Stahl Gifts 500 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP Stahl Gifts 500 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-08-14,20:12:50,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Murphy Registers 6,363 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Murphy Registers 6,363 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-08-15,15:48:26,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bassler Registers 756 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Bassler Registers 756 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-08-15,20:02:29,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Murphy Sells 6,363 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Murphy Sells 6,363 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-08-15,22:00:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Poon Registers 10,838 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Poon Registers 10,838 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-08-19,07:08:57,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals Inc, Inst Holders, 2Q 2024 (REGN)",RNS-SEC13F,Dow Jones Newswires,"Regeneron Pharmaceuticals  Inc, Inst Holders, 2Q 2024 (REGN)"
REGN,2024-08-19,20:02:21,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Poon Sells 10,838 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Poon Sells 10,838 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-08-19,20:02:55,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bassler Sells 756 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bassler Sells 756 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-08-20,22:45:05,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron's second quarter 2024 earnings call,PRESS-RELEASE,GlobeNewswire,Regeneron Provides Update on Biologics License Application for Linvoseltamab
REGN,2024-08-20,22:45:06,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron's second quarter 2024 earnings call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Provides Update on Biologics License Application for Linvoseltamab
REGN,2024-08-23,14:36:52,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Piper Sandler
REGN,2024-08-23,14:36:52,589803,Regeneron Pharmaceuticals Inc.,100,0.64,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1242.00/Share From $1166.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1242.00/Share From $1166.00 by Piper Sandler
REGN,2024-08-26,11:18:19,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Gets European OK of Lymphoma Drug,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets European OK of Lymphoma Drug Ordspono
REGN,2024-08-28,01:00:21,589803,Regeneron Pharmaceuticals Inc.,100,0.44,products-services,,Regeneron to bring Libtayo® (cemiplimab) to South Korea,PRESS-RELEASE,DGAP News,Zuellig Pharma enters into an agreement with Regeneron to bring Libtayo® (cemiplimab) to South Korea and Taiwan markets
REGN,2024-08-28,01:00:21,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,"Regeneron Pharmaceuticals, Inc. to launch and commercialise Libtayo® (cemiplimab)",PRESS-RELEASE,DGAP News,Zuellig Pharma enters into an agreement with Regeneron to bring Libtayo® (cemiplimab) to South Korea and Taiwan markets
REGN,2024-08-28,01:00:21,589803,Regeneron Pharmaceuticals Inc.,100,0.44,products-services,,Regeneron to bring Libtayo® (cemiplimab) to South Korea,PRESS-RELEASE,Dow Jones Newswires,Zuellig Pharma enters into an agreement with Regeneron to bring Libtayo® (cemiplimab) to South Korea and Taiwan markets
REGN,2024-08-28,01:00:21,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,"Regeneron Pharmaceuticals, Inc. to launch and commercialise Libtayo® (cemiplimab)",PRESS-RELEASE,Dow Jones Newswires,Zuellig Pharma enters into an agreement with Regeneron to bring Libtayo® (cemiplimab) to South Korea and Taiwan markets
REGN,2024-08-28,01:00:45,589803,Regeneron Pharmaceuticals Inc.,100,0.44,products-services,,Regeneron to bring Libtayo® (cemiplimab) to South Korea,PRESS-RELEASE,Dow Jones Newswires,Zuellig Pharma enters into an agreement with Regeneron to bring Libtayo® (cemiplimab) to South Korea and Taiwan markets
REGN,2024-08-28,01:00:45,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,"Regeneron Pharmaceuticals, Inc. to launch and commercialise Libtayo® (cemiplimab)",PRESS-RELEASE,Dow Jones Newswires,Zuellig Pharma enters into an agreement with Regeneron to bring Libtayo® (cemiplimab) to South Korea and Taiwan markets
REGN,2024-08-28,01:00:45,589803,Regeneron Pharmaceuticals Inc.,100,0.44,products-services,,Regeneron to bring Libtayo® (cemiplimab) to South Korea,PRESS-RELEASE,DGAP News,Zuellig Pharma enters into an agreement with Regeneron to bring Libtayo® (cemiplimab) to South Korea and Taiwan markets
REGN,2024-08-28,01:00:45,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,"Regeneron Pharmaceuticals, Inc. to launch and commercialise Libtayo® (cemiplimab)",PRESS-RELEASE,DGAP News,Zuellig Pharma enters into an agreement with Regeneron to bring Libtayo® (cemiplimab) to South Korea and Taiwan markets
REGN,2024-08-29,20:29:05,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Fenimore Sells 5,680 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Fenimore Sells 5,680 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-09-03,20:06:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-09-04,12:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.34,products-services,,Sonoma Biotherapeutics Receives $45 Million Milestone Payment from Regeneron,PRESS-RELEASE,Business Wire,Sonoma Biotherapeutics Receives $45 Million Milestone Payment from Regeneron under Ongoing Collaboration
REGN,2024-09-04,12:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Sonoma Bio entered into a collaboration and license agreement with Regeneron,PRESS-RELEASE,Business Wire,Sonoma Biotherapeutics Receives $45 Million Milestone Payment from Regeneron under Ongoing Collaboration
REGN,2024-09-05,20:03:19,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-09-05,20:04:25,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-09-05,20:04:39,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Dir Sing Gifts 1,200 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sing Gifts 1,200 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-09-09,08:31:12,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Bayer: Eylea 8 Mg Pre-Filled Syringe Approved in the EU,NEWS-FLASH,Dow Jones Newswires,Bayer: Eylea 8 Mg Pre-Filled Syringe Approved in the EU
REGN,2024-09-09,11:00:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,marketing,,Regeneron to host virtual investor event,PRESS-RELEASE,GlobeNewswire,Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
REGN,2024-09-09,11:00:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Clinical Trials in,PRESS-RELEASE,GlobeNewswire,Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
REGN,2024-09-09,11:00:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The extensive clinical program for Libtayo,PRESS-RELEASE,GlobeNewswire,Regeneron to Highlight Progress Across Its -2-
REGN,2024-09-09,14:06:10,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by RBC Capital
REGN,2024-09-09,14:06:10,589803,Regeneron Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1282.00/Share From $1250.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1282.00/Share From $1250.00 by RBC Capital
REGN,2024-09-11,05:08:23,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron: Dupixent Phase 3 Study for Chronic Spontaneous Urticaria,NEWS-FLASH,Dow Jones Newswires,"Sanofi, Regeneron: Dupixent Phase 3 Study for Chronic Spontaneous Urticaria Also Met Key Goals"
REGN,2024-09-12,11:30:05,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent® (dupilumab injection) approved in Canada,PRESS-RELEASE,Canadian News Wire,DUPIXENT® (dupilumab injection) approved in Canada for the treatment of children aged 1 year and older with eosinophilic esophagitis (EoE)
REGN,2024-09-12,11:30:05,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupixent(R) is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Canadian News Wire,DUPIXENT® (dupilumab injection) approved in Canada for the treatment of children aged 1 year and older with eosinophilic esophagitis (EoE)
REGN,2024-09-13,16:15:28,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent(R) (dupilumab),PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
REGN,2024-09-13,16:15:28,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
REGN,2024-09-13,16:15:28,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent(R) (dupilumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
REGN,2024-09-13,16:15:28,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
REGN,2024-09-13,16:17:11,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi: FDA Approves Dupixent,NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Sanofi: FDA Approves Dupixent for Adolescents With Chronic Rhinosinusitis With Nasal Polyps"
REGN,2024-09-13,16:49:18,589803,Regeneron Pharmaceuticals Inc.,93,0.57,products-services,granted,Regeneron Pharmaceuticals and Sanofi have received Food and Drug Administration approval for their treatment,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Get FDA Approval for Upper Airway Disease Treatment"
REGN,2024-09-13,17:04:18,589803,Regeneron Pharmaceuticals Inc.,93,0.57,products-services,granted,Regeneron Pharmaceuticals and Sanofi have received Food and Drug Administration approval for their treatment,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Get FDA Approval for Upper Airway Disease Treatment"
REGN,2024-09-20,11:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent recommended for EU approval,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
REGN,2024-09-20,11:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is already approved in the EU,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
REGN,2024-09-20,11:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
REGN,2024-09-20,11:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Recommended for EU Approval,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
REGN,2024-09-20,11:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is already approved in the EU,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
REGN,2024-09-20,11:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
REGN,2024-09-20,11:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent recommended for EU approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
REGN,2024-09-20,11:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
REGN,2024-09-20,11:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
REGN,2024-09-20,11:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent recommended for EU approval,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
REGN,2024-09-20,11:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
REGN,2024-09-20,11:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
REGN,2024-09-20,11:45:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent recommended for EU approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
REGN,2024-09-20,11:45:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is already approved in the EU,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
REGN,2024-09-20,11:45:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
REGN,2024-09-20,11:45:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Recommended for EU Approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
REGN,2024-09-20,11:45:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is already approved in the EU,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
REGN,2024-09-20,11:45:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
REGN,2024-09-20,11:46:12,589803,Regeneron Pharmaceuticals Inc.,100,0.82,products-services,positive,Sanofi Get CHMP Positive Opinion for Dupixent,NEWS-FLASH,Dow Jones Newswires,"Regeneron, Sanofi Get CHMP Positive Opinion for Dupixent to Treat Eosinophilic Esophagitis in Children as Young as 1"
REGN,2024-09-20,12:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.82,products-services,positive,Biogen Receive Positive CHMP Opinion for Aflibercept,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ(TM)"
REGN,2024-09-20,12:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.82,products-services,positive,Biogen Receive Positive CHMP Opinion for Aflibercept,PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ(TM)"
REGN,2024-09-23,20:06:09,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,The Food and Drug Administration signed off on Amgen's version of Eylea,FULL-ARTICLE,Dow Jones Newswires,Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea -- IBD
REGN,2024-09-23,20:13:39,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,The Food and Drug Administration signed off on Amgen's version of Eylea,FULL-ARTICLE,Dow Jones Newswires,Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea -- IBD
REGN,2024-09-24,10:59:54,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Regeneron Pharma Cut to Market Perform From Outperform by Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Cut to Market Perform From Outperform by Leerink Partners
REGN,2024-09-24,10:59:54,589803,Regeneron Pharmaceuticals Inc.,100,-0.74,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1077.00/Share From $1175.00 by Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1077.00/Share From $1175.00 by Leerink Partners
REGN,2024-09-24,17:10:04,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by RBC Capital
REGN,2024-09-24,17:10:04,589803,Regeneron Pharmaceuticals Inc.,100,-0.4,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1252.00/Share From $1282.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1252.00/Share From $1282.00 by RBC Capital
REGN,2024-09-26,20:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report Third Quarter 2024 Financial and Operating Results,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024"
REGN,2024-09-26,20:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024"
REGN,2024-09-26,20:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report Third Quarter 2024 Financial and Operating Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024"
REGN,2024-09-26,20:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024"
REGN,2024-09-27,11:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in China as the first-ever biologic medicine,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,11:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Dupixent is available in China,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,11:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,11:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in China as the first-ever biologic medicine,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,11:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Dupixent is available in China,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,11:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,11:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in China as the first-ever biologic medicine,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,11:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Dupixent is available in China,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,11:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,11:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in China as the first-ever biologic medicine,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,11:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Dupixent is available in China,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,11:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,11:00:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved in China as the First-ever Biologic Medicine,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
REGN,2024-09-27,11:00:04,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Dupixent is available in China,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
REGN,2024-09-27,11:00:04,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
REGN,2024-09-27,11:00:05,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved in China as the First-ever Biologic Medicine,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
REGN,2024-09-27,11:00:05,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Dupixent is available in China,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
REGN,2024-09-27,11:00:05,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
REGN,2024-09-27,11:01:10,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi Get China OK for Dupixent,NEWS-FLASH,Dow Jones Newswires,"Regenerin, Sanofi Get China OK for Dupixent for Chronic Obstructive Pulmonary Disease"
REGN,2024-09-27,11:04:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent Approved in China as the First-Ever Biologic Medicine,NEWS-FLASH,Dow Jones Newswires,Sanofi: Dupixent Approved in China as the First-Ever Biologic Medicine for Patients With COPD
REGN,2024-09-27,13:35:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in the US as the first-ever biologic medicine,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,13:35:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron announced that the European Medicines Agency approved Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,13:35:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in the US as the first-ever biologic medicine,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,13:35:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron announced that the European Medicines Agency approved Dupixent,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,13:35:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in the US as the first-ever biologic medicine,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,13:35:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron announced that the European Medicines Agency approved Dupixent,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,13:35:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in the US as the first-ever biologic medicine,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,13:35:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron announced that the European Medicines Agency approved Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
REGN,2024-09-27,13:35:08,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent(R) (dupilumab),PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
REGN,2024-09-27,13:35:08,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron and Sanofi announced the European Commission approved Dupixent,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
REGN,2024-09-27,13:35:09,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent(R) (dupilumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
REGN,2024-09-27,13:35:09,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron and Sanofi announced the European Commission approved Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
REGN,2024-09-27,13:36:14,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Regeneron, Sanofi Get FDA OK of Dupixent",NEWS-FLASH,Dow Jones Newswires,"Regeneron, Sanofi Get FDA OK of Dupixent for COPD >REGN"
REGN,2024-09-27,13:36:39,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: the company won Food and Drug Administration approval for Dupixent,FULL-ARTICLE,Dow Jones Newswires,Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent -- IBD
REGN,2024-09-27,13:36:39,589803,Regeneron Pharmaceuticals Inc.,99,0.34,analyst-ratings,neutral,Abrahams has an outperform rating on Regeneron,FULL-ARTICLE,Dow Jones Newswires,Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent -- IBD
REGN,2024-09-27,13:54:08,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Regeneron, Sanofi Get FDA OK for Dupixent",FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD"
REGN,2024-09-27,14:09:08,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Regeneron, Sanofi Get FDA OK for Dupixent",FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD"
REGN,2024-09-27,17:05:43,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Regeneron, Sanofi Get FDA OK of Dupixent",FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Get FDA OK of Dupixent for COPD -- Update"
REGN,2024-09-27,17:20:43,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Regeneron, Sanofi Get FDA OK of Dupixent",FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Get FDA OK of Dupixent for COPD -- Update"
REGN,2024-10-01,20:18:47,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-10-03,20:03:10,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-10-03,20:03:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-10-04,15:21:55,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by RBC Capital
REGN,2024-10-04,15:21:55,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1260.00/Share From $1252.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1260.00/Share From $1252.00 by RBC Capital
REGN,2024-10-07,11:10:39,589803,Regeneron Pharmaceuticals Inc.,100,-0.45,equity-actions,charge,Regeneron Pharma Expects 3Q Acquired In-Process R&D Charge of $56M,RNS-SEC8K,Dow Jones Newswires,Regeneron Pharma Expects 3Q Acquired In-Process R&D Charge of $56M on Pre-Term Basis >REGN
REGN,2024-10-07,11:54:10,589803,Regeneron Pharmaceuticals Inc.,100,-0.45,equity-actions,charge,Regeneron Sees $56M Pretax Charge,FULL-ARTICLE,Dow Jones Newswires,Regeneron Sees $56M Pretax Charge Hitting 3Q Earnings
REGN,2024-10-07,12:09:10,589803,Regeneron Pharmaceuticals Inc.,100,-0.45,equity-actions,charge,Regeneron Sees $56 Million Pretax Charge,FULL-ARTICLE,Dow Jones Newswires,Regeneron Sees $56 Million Pretax Charge Hitting 3Q Earnings
REGN,2024-10-16,14:53:12,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Truist Securities
REGN,2024-10-16,14:53:12,589803,Regeneron Pharmaceuticals Inc.,100,-0.62,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1137.00/Share From $1200.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1137.00/Share From $1200.00 by Truist Securities
REGN,2024-10-22,21:59:17,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Wells Fargo
REGN,2024-10-22,21:59:17,589803,Regeneron Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1050.00/Share From $1200.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1050.00/Share From $1200.00 by Wells Fargo
REGN,2024-10-23,13:16:58,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Barclays
REGN,2024-10-23,13:16:58,589803,Regeneron Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1080.00/Share From $1220.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1080.00/Share From $1220.00 by Barclays
REGN,2024-10-24,12:36:00,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by JP Morgan
REGN,2024-10-24,12:36:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1150.00/Share From $1200.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1150.00/Share From $1200.00 by JP Morgan
REGN,2024-10-24,15:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by Evercore ISI Group
REGN,2024-10-24,15:30:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1175.00/Share From $1250.00 by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1175.00/Share From $1250.00 by Evercore ISI Group
REGN,2024-10-31,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 3Q EPS $11.54,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q EPS $11.54 >REGN
REGN,2024-10-31,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 3Q Net $1.34B,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q Net $1.34B >REGN
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Third Quarter 2024 Financial Results,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Third quarter 2024 revenues increased 11% to $3.72 billion,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Third quarter 2024 U.S. net sales,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.46,earnings,up,Regeneron Pharmaceuticals Inc.: Third quarter 2024 GAAP diluted EPS increased 30%,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: FDA approved Dupixent,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,721 $ 3,363",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: This positive trial confirms results from the first Phase 3 trial,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company announced five-year results,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 2 study for Libtayo,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,720 $3,363",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -2-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Eylea HD was approved by the FDA in August 2023,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -2-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA in the third quarter of 2024,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -2-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the third quarter,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -2-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -2-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D for the third quarter of 2024,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -2-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,"Regeneron Pharmaceuticals Inc.: the Company's collaboration agreement with Sonoma Biotherapeutics, Inc.",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -2-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.46,earnings,up,"Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $11.54 in the third quarter of 2024, compared to $8.89 in the third quarter of 2023",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -2-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.4,earnings,up,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $12.46 in the third quarter of 2024, compared to $11.59 in the third quarter of 2023",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -2-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the third quarter of 2024, the Company repurchased shares of its common stock",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -2-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2024 Financial Guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -2-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2024 financial guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -3-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its third quarter 2024 financial and operating results on Thursday, October 31, 2024, at 8:30 AM Eastern Time",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -3-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: September 30, December 31, 2024 2023 Assets",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -4-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -4-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $1,340.6 $1,007.8",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -4-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 12.40 $ 9.48 $,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -4-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,462.4 $1,329.1",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -5-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 13.53 $ 12.50 $,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -5-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -5-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Third Quarter 2024 Financial Results",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -5-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.0,revenues,,Regeneron Pharmaceuticals Inc.: net product sales of ARCALYST were $103 million,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2024 Financial -5-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Third Quarter 2024 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Third quarter 2024 revenues increased 11% to $3.72 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Third quarter 2024 U.S. net sales,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.46,earnings,up,Regeneron Pharmaceuticals Inc.: Third quarter 2024 GAAP diluted EPS increased 30%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: FDA approved Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,721 $ 3,363",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: This positive trial confirms results from the first Phase 3 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company announced five-year results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 2 study for Libtayo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2024 Financial and Operating Results
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2024 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -3-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its third quarter 2024 financial and operating results on Thursday, October 31, 2024, at 8:30 AM Eastern Time",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -3-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: September 30, December 31, 2024 2023 Assets",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $1,340.6 $1,007.8",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 12.40 $ 9.48 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,462.4 $1,329.1",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -5-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 13.53 $ 12.50 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -5-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -5-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Third Quarter 2024 Financial Results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -5-
REGN,2024-10-31,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.0,revenues,,Regeneron Pharmaceuticals Inc.: net product sales of ARCALYST were $103 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -5-
REGN,2024-10-31,10:30:24,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 3Q Rev $3.72B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q Rev $3.72B >REGN
REGN,2024-10-31,10:32:37,589803,Regeneron Pharmaceuticals Inc.,100,0.42,revenues,up,Regeneron Pharma: 3Q Dupixent Global Net Sales Recorded by Sanofi Rose 23%,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma: 3Q Dupixent Global Net Sales Recorded by Sanofi Rose 23% to $3.82B >REGN
REGN,2024-10-31,10:33:11,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,"Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3%",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3% to $1.54B >REGN"
REGN,2024-10-31,10:33:41,589803,Regeneron Pharmaceuticals Inc.,100,-0.67,earnings,down,Regeneron Pharma 3Q EPS Cut 43c,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q EPS Cut 43c by Acquired IPR&D Charge >REGN
REGN,2024-10-31,10:34:08,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 3Q Adj EPS $12.46,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q Adj EPS $12.46 >REGN
REGN,2024-10-31,10:52:36,589803,Regeneron Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Regeneron Earnings Top Views,FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Top Views For Biotech Giant -- IBD
REGN,2024-10-31,10:52:36,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals to earn $11.70 per share,FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Top Views For Biotech Giant -- IBD
REGN,2024-10-31,10:52:36,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: the company reported $3.36 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Top Views For Biotech Giant -- IBD
REGN,2024-10-31,13:58:07,589803,Regeneron Pharmaceuticals Inc.,99,0.41,products-services,,Limited discount to Eylea,FULL-ARTICLE,Dow Jones Newswires,Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD
REGN,2024-10-31,13:58:07,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Regeneron and Bayer partner on Eylea,FULL-ARTICLE,Dow Jones Newswires,Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD
REGN,2024-10-31,20:12:09,589803,Regeneron Pharmaceuticals Inc.,99,0.41,products-services,,Limited discount to Eylea,FULL-ARTICLE,Dow Jones Newswires,Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD
REGN,2024-10-31,20:12:09,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Regeneron and Bayer partner on Eylea,FULL-ARTICLE,Dow Jones Newswires,Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD
REGN,2024-10-31,21:58:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.75,revenues,below-expectations,Regeneron Pharmaceuticals Inc.: the company reported lower-than-expected sales,FULL-ARTICLE,Dow Jones Newswires,Regeneron Shares Drop After Sales of Higher-Dose Eylea Miss Expectations
REGN,2024-10-31,21:58:37,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron also expects Eylea's fourth-quarter sales,FULL-ARTICLE,Dow Jones Newswires,Regeneron Shares Drop After Sales of Higher-Dose Eylea Miss Expectations
REGN,2024-10-31,22:13:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.75,revenues,below-expectations,Regeneron Pharmaceuticals Inc.: the company reported lower-than-expected sales,FULL-ARTICLE,Dow Jones Newswires,Regeneron Shares Drop After Sales of Higher-Dose Eylea Miss Expectations
REGN,2024-10-31,22:13:37,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron also expects Eylea's fourth-quarter sales,FULL-ARTICLE,Dow Jones Newswires,Regeneron Shares Drop After Sales of Higher-Dose Eylea Miss Expectations
REGN,2024-11-01,12:32:19,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Piper Sandler
REGN,2024-11-01,12:32:19,589803,Regeneron Pharmaceuticals Inc.,100,-0.5,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1195.00/Share From $1242.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1195.00/Share From $1242.00 by Piper Sandler
REGN,2024-11-01,15:04:09,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Truist Securities
REGN,2024-11-01,15:04:09,589803,Regeneron Pharmaceuticals Inc.,100,-0.2,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1126.00/Share From $1137.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1126.00/Share From $1137.00 by Truist Securities
REGN,2024-11-01,16:24:29,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by BMO Capital
REGN,2024-11-01,16:24:29,589803,Regeneron Pharmaceuticals Inc.,100,-0.74,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1190.00/Share From $1300.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1190.00/Share From $1300.00 by BMO Capital
REGN,2024-11-01,17:43:59,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Barclays
REGN,2024-11-01,17:43:59,589803,Regeneron Pharmaceuticals Inc.,100,-0.28,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1065.00/Share From $1080.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1065.00/Share From $1080.00 by Barclays
REGN,2024-11-01,18:01:29,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by RBC Capital
REGN,2024-11-01,18:01:29,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1215.00/Share From $1260.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1215.00/Share From $1260.00 by RBC Capital
REGN,2024-11-01,18:07:59,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley
REGN,2024-11-01,18:07:59,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1184.00/Share From $1235.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1184.00/Share From $1235.00 by Morgan Stanley
REGN,2024-11-01,19:44:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,The United States had filed a complaint against Regeneron,PRESS-RELEASE,Business Wire,"The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-11-01,19:44:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron released its third quarter 2024 financial results",PRESS-RELEASE,Business Wire,"The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-11-01,20:39:30,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-11-04,18:24:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,The United States had filed a complaint against Regeneron,PRESS-RELEASE,Business Wire,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-11-04,18:24:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron released its third quarter 2024 financial results",PRESS-RELEASE,Business Wire,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-11-04,20:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,The United States had filed a complaint against Regeneron,PRESS-RELEASE,Business Wire,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-11-04,20:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,Business Wire,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-11-05,21:24:17,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-11-06,06:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in the EU as the first and only medicine,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
REGN,2024-11-06,06:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
REGN,2024-11-06,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi today announced that the European Commission (EC) has approved Dupixent(R) (dupilumab),PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
REGN,2024-11-06,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
REGN,2024-11-06,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in the EU as the first and only medicine,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
REGN,2024-11-06,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
REGN,2024-11-06,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi today announced that the European Commission (EC) has approved Dupixent(R) (dupilumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
REGN,2024-11-06,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
REGN,2024-11-06,06:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in the EU as the first and only medicine,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
REGN,2024-11-06,06:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
REGN,2024-11-06,06:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in the EU as the first and only medicine,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
REGN,2024-11-06,06:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
REGN,2024-11-06,06:01:50,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Sanofi, Regeneron Get EU Approval for Dupixent",NEWS-FLASH,Dow Jones Newswires,"Sanofi, Regeneron Get EU Approval for Dupixent in Eosinophilic Esophagitis"
REGN,2024-11-06,14:04:30,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by Oppenheimer
REGN,2024-11-06,14:04:31,589803,Regeneron Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1000.00/Share From $1150.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1000.00/Share From $1150.00 by Oppenheimer
REGN,2024-11-12,21:04:51,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Murphy Gifts 1,185 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Murphy Gifts 1,185 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-11-12,22:31:04,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Collaboration between Regeneron and Sanofi,PRESS-RELEASE,PR Newswire,Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight
REGN,2024-11-12,22:31:25,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Collaboration between Regeneron and Sanofi,PRESS-RELEASE,PR Newswire,Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight
REGN,2024-11-13,12:00:25,589803,Regeneron Pharmaceuticals Inc.,99,0.39,products-services,,"Regeneron Pharmaceuticals Inc.: Agreement with Alnylam Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,Regeneron to Highlight Pioneering Pipeline -2-
REGN,2024-11-13,12:00:25,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Odronextamab is approved in the European Union,PRESS-RELEASE,GlobeNewswire,Regeneron to Highlight Pioneering Pipeline -2-
REGN,2024-11-14,13:06:53,589803,Regeneron Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Regeneron Pharma Initiated at Neutral by Citigroup,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Initiated at Neutral by Citigroup
REGN,2024-11-14,13:06:53,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $895.00/Share by Citigroup,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $895.00/Share by Citigroup
REGN,2024-11-15,06:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sandoz receives European Commission approval for Afqlir(R) (aflibercept,PRESS-RELEASE,GlobeNewswire,"Sandoz receives European Commission approval for Afqlir(R) (aflibercept), further strengthening leading biosimilar portfolio"
REGN,2024-11-15,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sandoz receives European Commission approval for Afqlir(R) (aflibercept,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Sandoz receives European Commission approval for Afqlir(R) (aflibercept), further strengthening leading biosimilar portfolio"
REGN,2024-11-15,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sandoz receives European Commission approval for Afqlir(R) (aflibercept,PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: Sandoz receives European Commission approval for Afqlir(R) (aflibercept), further strengthening leading biosimilar portfolio"
REGN,2024-11-15,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sandoz receives European Commission approval for Afqlir(R) (aflibercept,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Sandoz receives European Commission approval for Afqlir(R) (aflibercept), further strengthening leading biosimilar portfolio"
REGN,2024-11-15,11:07:55,589803,Regeneron Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Regeneron Pharma Initiated at Outperform by Wolfe Research,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Initiated at Outperform by Wolfe Research
REGN,2024-11-15,11:07:55,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $1150.00/Share by Wolfe Research,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $1150.00/Share by Wolfe Research
REGN,2024-11-15,11:12:48,589803,Regeneron Pharmaceuticals Inc.,100,-0.47,regulatory,,Fda Review of Dupixent for,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Get New FDA Review of Dupixent for CSU"
REGN,2024-11-15,11:12:48,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Get New FDA Review of Dupixent for CSU"
REGN,2024-11-15,11:27:47,589803,Regeneron Pharmaceuticals Inc.,100,-0.47,regulatory,,Fda Review of Dupixent for,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Get New FDA Review of Dupixent for CSU"
REGN,2024-11-15,11:27:47,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Get New FDA Review of Dupixent for CSU"
REGN,2024-11-19,08:08:38,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals Inc, Inst Holders, 3Q 2024 (REGN)",RNS-SEC13F,Dow Jones Newswires,"Regeneron Pharmaceuticals  Inc, Inst Holders, 3Q 2024 (REGN)"
REGN,2024-11-25,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,The United States had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-11-25,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron released its third quarter 2024 financial results",PRESS-RELEASE,GlobeNewswire,"The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-11-26,17:00:01,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,The United States had filed a complaint against Regeneron,PRESS-RELEASE,Business Wire,"INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-11-26,17:00:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron released its third quarter 2024 financial results",PRESS-RELEASE,Business Wire,"INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-11-26,18:01:19,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"ATTENTION Regeneron Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights"
REGN,2024-11-27,21:00:01,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,The United States had filed a complaint against Regeneron,PRESS-RELEASE,Business Wire,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-11-27,21:00:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,Business Wire,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-11-29,13:01:39,589803,Regeneron Pharmaceuticals Inc.,98,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholder Rights Advocates at Levi & Korsinsky Investigate Regeneron Pharmaceuticals, Inc. (REGN) Regarding Possible Securities Fraud Violations"
REGN,2024-12-02,12:32:23,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - REGN"
REGN,2024-12-02,17:00:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,The United States had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-12-02,17:00:03,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron released its third quarter 2024 financial results",PRESS-RELEASE,PR Newswire,"The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-12-02,17:00:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,The United States had filed a complaint against Regeneron,PRESS-RELEASE,Dow Jones Newswires,"Press Release: The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-12-02,17:00:03,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron released its third quarter 2024 financial results",PRESS-RELEASE,Dow Jones Newswires,"Press Release: The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-12-02,22:00:21,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky"
REGN,2024-12-03,13:17:00,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Maia Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron,PRESS-RELEASE,Business Wire,MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
REGN,2024-12-03,13:17:00,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Our collaboration with Regeneron to,PRESS-RELEASE,Business Wire,MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
REGN,2024-12-03,13:17:01,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Maia Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
REGN,2024-12-03,13:17:01,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Our collaboration with Regeneron to,PRESS-RELEASE,Dow Jones Newswires,Press Release: MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
REGN,2024-12-03,17:33:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,The United States had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-12-03,17:33:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron released its third quarter 2024 financial results",PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-12-03,18:01:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - REGN"
REGN,2024-12-04,18:00:01,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,The United States had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-12-04,18:00:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-12-04,18:17:23,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"REGN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Regeneron Pharmaceuticals, Inc. Shareholders Who Lost Money"
REGN,2024-12-06,12:25:28,589803,Regeneron Pharmaceuticals Inc.,98,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of an Investigation into Regeneron Pharmaceuticals, Inc. (REGN) Regarding Potential Securities Fraud Allegations"
REGN,2024-12-06,17:00:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,The United States had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-12-06,17:00:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron released its third quarter 2024 financial results",PRESS-RELEASE,PR Newswire,"INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors"
REGN,2024-12-06,17:30:50,589803,Regeneron Pharmaceuticals Inc.,98,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation"
REGN,2024-12-09,12:29:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Being Investigated on Behalf of Regeneron Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details."
REGN,2024-12-10,12:28:39,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky"
REGN,2024-12-10,12:43:27,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $565.00/Share by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $565.00/Share by B of A Securities
REGN,2024-12-10,21:04:20,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Larosa Surrenders 492 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP Larosa Surrenders 492 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-12-10,21:04:37,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Murphy Surrenders 492 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP Murphy Surrenders 492 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-12-10,21:04:45,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp McCourt Surrenders 274 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP McCourt Surrenders 274 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-12-10,21:04:50,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp van Plew Surrenders 492 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP van Plew Surrenders 492 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-12-10,21:05:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Stahl Surrenders 466 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP Stahl Surrenders 466 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-12-10,21:06:22,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Pitofsky Surrenders 149 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP Pitofsky Surrenders 149 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-12-10,21:08:27,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Fenimore Surrenders 1,140 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Fenimore Surrenders 1,140 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-12-16,21:30:25,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included in the Dow Jones Sustainability World Index,PRESS-RELEASE,GlobeNewswire,Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
REGN,2024-12-16,21:30:25,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included in the Dow Jones Sustainability World Index,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
REGN,2024-12-17,11:31:53,589803,Regeneron Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Regeneron Pharma Initiated at Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Initiated at Hold by Canaccord Genuity
REGN,2024-12-17,11:31:53,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $165.00/Share by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $165.00/Share by Canaccord Genuity
REGN,2024-12-17,12:01:34,589803,Regeneron Pharmaceuticals Inc.,100,0.62,products-services,positive,Regeneron: Eylea HD Phase 3 Trial Meets Primary Endpoint,NEWS-FLASH,Dow Jones Newswires,Regeneron: Eylea HD Phase 3 Trial Meets Primary Endpoint Showing Improved Vision With Extended Dosing Intervals in Patients With Macular Edema Following Retinal Vein Occlusion
REGN,2024-12-18,21:02:51,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Cfo Fenimore Surrenders 491 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,CFO Fenimore Surrenders 491 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-12-18,21:03:43,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Pitofsky Surrenders 298 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP Pitofsky Surrenders 298 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-12-18,21:04:27,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Larosa Surrenders 702 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP Larosa Surrenders 702 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-12-18,21:04:36,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Murphy Surrenders 1,054 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Murphy Surrenders 1,054 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2024-12-18,21:05:47,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp McCourt Surrenders 759 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP McCourt Surrenders 759 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-12-18,21:07:53,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Stahl Surrenders 304 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP Stahl Surrenders 304 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-12-18,21:08:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp van Plew Surrenders 969 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP van Plew Surrenders 969 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2024-12-19,12:00:01,589803,Regeneron Pharmaceuticals Inc.,99,0.62,products-services,positive,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive Phase 2 results",PRESS-RELEASE,GlobeNewswire,Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
REGN,2024-12-19,12:00:01,589803,Regeneron Pharmaceuticals Inc.,99,0.62,products-services,positive,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive Phase 2 results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
REGN,2021-01-05,21:11:03,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-01-05,23:11:02,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Ryan Registers 200 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Ryan Registers 200 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-01-08,14:11:55,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Regeneron (ticker: REGN) in partnership with Sanofi (SNY),FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Has Fallen. Why It Could Be Time to Buy. -- Barrons.com
REGN,2021-01-08,14:11:55,589803,Regeneron Pharmaceuticals Inc.,99,-0.47,assets,expired,Regeneron Pharmaceuticals Inc.: the company's patent expires,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Has Fallen. Why It Could Be Time to Buy. -- Barrons.com
REGN,2021-01-08,14:11:55,589803,Regeneron Pharmaceuticals Inc.,99,0.94,analyst-ratings,positive,Bansal upgraded Regeneron to Buy from Neutral,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Has Fallen. Why It Could Be Time to Buy. -- Barrons.com
REGN,2021-01-08,14:11:55,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: the Food and Drug Administration's authorization of the company's Covid-19 antibody cocktail,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Has Fallen. Why It Could Be Time to Buy. -- Barrons.com
REGN,2021-01-08,14:11:55,589803,Regeneron Pharmaceuticals Inc.,99,0.65,revenues,up,Dupixent sales are growing,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Has Fallen. Why It Could Be Time to Buy. -- Barrons.com
REGN,2021-01-12,22:45:03,589803,Regeneron Pharmaceuticals Inc.,99,0.39,products-services,,Regeneron Pharmaceuticals Inc.: New agreement,PRESS-RELEASE,PR Newswire,Regeneron Announces U.S. Government Agreement to Purchase Additional COVID-19 Antibody Cocktail Doses
REGN,2021-01-12,22:45:03,589803,Regeneron Pharmaceuticals Inc.,99,0.39,products-services,,Regeneron Pharmaceuticals Inc.: New agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces U.S. Government Agreement to Purchase Additional COVID-19 Antibody Cocktail Doses
REGN,2021-01-12,22:55:00,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Roche and Regeneron are collaborating on developing,PRESS-RELEASE,Dow Jones Newswires,Press Release: Roche confirms US government agreement to purchase additional doses of Regeneron's casirivimab and imdevimab
REGN,2021-01-12,22:55:00,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Roche and Regeneron are collaborating on developing,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Roche confirms US government agreement to purchase additional doses of Regeneron's casirivimab and imdevimab
REGN,2021-01-13,12:23:03,589803,Regeneron Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Regeneron Pharma Raised to Buy From Hold by Benchmark,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Raised to Buy From Hold by Benchmark
REGN,2021-01-13,12:23:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $590.00,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $590.00/Share by Benchmark
REGN,2021-01-13,13:47:30,589803,Regeneron Pharmaceuticals Inc.,100,0.58,products-services,,Regeneron Inks Deal to Sell Covid-19 Treatment to U.S.,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Inks Deal to Sell Covid-19 Treatment to U.S., Even as Usage Lags -- Barrons.com"
REGN,2021-01-13,13:47:30,589803,Regeneron Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,"Huseynov upgraded Regeneron to Buy, from Hold",FULL-ARTICLE,Dow Jones Newswires,"Regeneron Inks Deal to Sell Covid-19 Treatment to U.S., Even as Usage Lags -- Barrons.com"
REGN,2021-01-14,16:52:50,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Citigroup
REGN,2021-01-14,16:52:50,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $584.00/Share From $575.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $584.00/Share From $575.00 by Citigroup
REGN,2021-01-19,14:58:26,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley
REGN,2021-01-19,14:58:26,589803,Regeneron Pharmaceuticals Inc.,100,0.56,price-targets,upgrade,Regeneron Pharma Price Target Raised to $553.00/Share From $527.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $553.00/Share From $527.00 by Morgan Stanley
REGN,2021-01-19,21:15:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast,PRESS-RELEASE,PR Newswire,"Regeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast on February 5, 2021"
REGN,2021-01-19,21:15:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast,PRESS-RELEASE,PR Newswire,"Regeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast on February 5, 2021"
REGN,2021-01-19,21:15:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast on February 5, 2021"
REGN,2021-01-19,21:15:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast on February 5, 2021"
REGN,2021-01-21,17:00:05,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,PR Newswire,Forty of the Nation's Most Talented Young Scientists Named Finalists in Regeneron Science Talent Search 2021
REGN,2021-01-21,17:01:02,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,PR Newswire,Forty of the Nation's Most Talented Young Scientists Named Finalists in Regeneron Science Talent Search 2021
REGN,2021-01-21,17:01:02,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,Dow Jones Newswires,Press Release: Forty of the Nation's Most Talented Young Scientists Named Finalists in Regeneron Science Talent Search 2021
REGN,2021-01-23,08:38:40,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals Inc, Inst Holders, 4Q 2020 (REGN)",RNS-SEC13F,Dow Jones Newswires,"Regeneron Pharmaceuticals Inc, Inst Holders, 4Q 2020 (REGN)"
REGN,2021-01-25,11:47:48,589803,Regeneron Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Regeneron Pharma Raised to Outperform From Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Raised to Outperform From Market Perform by BMO Capital
REGN,2021-01-25,11:47:48,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $630.00/Share by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $630.00/Share by BMO Capital
REGN,2021-01-25,14:19:55,589803,Regeneron Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Regeneron Pharmaceuticals upgraded to outperform at BMO Capital,NEWS-FLASH,MarketWatch,MW Regeneron Pharmaceuticals upgraded to outperform at BMO Capital
REGN,2021-01-26,12:00:21,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive initial results from an ongoing Phase 3 clinical trial",PRESS-RELEASE,PR Newswire,Regeneron Reports Positive Interim Data with REGEN-COV(TM) Antibody Cocktail used as Passive Vaccine to Prevent COVID-19
REGN,2021-01-26,12:48:45,589803,Regeneron Pharmaceuticals Inc.,96,0.0,earnings,,Regeneron Pharmaceuticals Inc. said Tuesday initial results,FULL-ARTICLE,Dow Jones Newswires,Regeneron: Interim Data Positive With REGEN-COV as Passive Vaccine to Prevent Covid-19
REGN,2021-01-26,13:03:45,589803,Regeneron Pharmaceuticals Inc.,96,0.0,earnings,,Regeneron Pharmaceuticals Inc. said Tuesday initial results,FULL-ARTICLE,Dow Jones Newswires,Regeneron: Interim Data Positive With REGEN-COV as Passive Vaccine to Prevent Covid-19
REGN,2021-01-26,13:24:59,589803,Regeneron Pharmaceuticals Inc.,96,0.57,products-services,granted,Regeneron's antibody cocktail already received emergency use authorization,FULL-ARTICLE,MarketWatch,"MW Regeneron says its COVID-19 antibody cocktail can prevent infections, based on late-stage study"
REGN,2021-01-26,13:24:59,589803,Regeneron Pharmaceuticals Inc.,96,0.57,products-services,granted,Regeneron's antibody cocktail already received emergency use authorization,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Says Its COVID-19 Antibody Cocktail Can Prevent Infections, Based On Late-stage Study -- MarketWatch"
REGN,2021-01-26,13:47:49,589803,Regeneron Pharmaceuticals Inc.,96,0.57,products-services,granted,Regeneron's antibody cocktail already received emergency use authorization,FULL-ARTICLE,MarketWatch,"MW UPDATE: Regeneron says its COVID-19 antibody cocktail can prevent infections, based on late-stage study"
REGN,2021-01-26,13:47:49,589803,Regeneron Pharmaceuticals Inc.,96,0.57,products-services,granted,Regeneron's antibody cocktail already received emergency use authorization,FULL-ARTICLE,Dow Jones Newswires,"Update: Regeneron Says Its COVID-19 Antibody Cocktail Can Prevent Infections, Based On Late-stage Study -- MarketWatch"
REGN,2021-01-26,13:48:16,589803,Regeneron Pharmaceuticals Inc.,96,0.57,products-services,granted,Regeneron's antibody cocktail already received emergency use authorization,FULL-ARTICLE,MarketWatch,"MW UPDATE: Regeneron says its COVID-19 antibody cocktail can prevent infections, based on late-stage study"
REGN,2021-01-26,13:48:16,589803,Regeneron Pharmaceuticals Inc.,96,0.57,products-services,granted,Regeneron's antibody cocktail already received emergency use authorization,FULL-ARTICLE,Dow Jones Newswires,"Update: Regeneron Says Its COVID-19 Antibody Cocktail Can Prevent Infections, Based On Late-stage Study -- MarketWatch"
REGN,2021-01-26,15:10:37,589803,Regeneron Pharmaceuticals Inc.,96,0.0,products-services,,Regeneron Pharmaceuticals (REGN) said initial results from a Phase 3 trial,FULL-ARTICLE,Dow Jones Newswires,Eli Lilly and Regeneron Report More Positive Data on Covid-19 Antibody Cocktails -- Barrons.com
REGN,2021-01-26,19:38:26,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Brown Registers 2,480 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Brown Registers 2,480 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-01-27,12:35:40,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Regeneron said it is collaborating with Roche Holding AG,FULL-ARTICLE,Dow Jones Newswires,"Regeneron: REGEN-COV Is Active Against U.K., South Africa SARS-CoV-2 Variants"
REGN,2021-01-27,12:50:40,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Regeneron said it is collaborating with Roche Holding AG,FULL-ARTICLE,Dow Jones Newswires,"Regeneron: REGEN-COV Is Active Against U.K., South Africa SARS-CoV-2 Variants"
REGN,2021-01-27,21:08:16,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Brown Sells 2,480 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Brown Sells 2,480 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-02-02,13:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,"Maia Biotechnology, Inc. Announces Clinical Supply Agreement with Regeneron",PRESS-RELEASE,Business Wire,"MAIA Biotechnology, Inc. Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating THIO in Sequential Administration with Libtayo(R) (cemiplimab) in Advanced Non-Small Cell Lung Cancer"
REGN,2021-02-02,13:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Opportunity to partner with Regeneron on,PRESS-RELEASE,Business Wire,"MAIA Biotechnology, Inc. Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating THIO in Sequential Administration with Libtayo(R) (cemiplimab) in Advanced Non-Small Cell Lung Cancer"
REGN,2021-02-02,13:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: our planned clinical trial of,PRESS-RELEASE,Business Wire,"MAIA Biotechnology, Inc. Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating THIO in Sequential Administration with Libtayo(R) (cemiplimab) in Advanced Non-Small Cell Lung Cancer"
REGN,2021-02-02,21:08:13,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 4Q EPS $10.24,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q EPS $10.24 >REGN
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 4Q Net $1.15B,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q Net $1.15B >REGN
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 4Q Rev $2.42B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q Rev $2.42B >REGN
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2020",PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2020",PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.46,revenues,up,Regeneron Pharmaceuticals Inc.: Fourth quarter 2020 revenues increased 30% to $2.42 billion,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.72,revenues,up,Dupixent global net sales increased 75%,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Fourth quarter 2020 GAAP diluted EPS was $10.24,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Pharmaceuticals Inc.: new agreement,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: the Company announced initial encouraging data from an ongoing Phase 1/2/3 trial,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: the Company announced updated data from the Phase 1 portion of a Phase 1/2 trial,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Fourth Quarter and Full Year 2020 Financial Results,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Fourth Quarter and Full Year 2020 Financial Results,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.46,revenues,up,Regeneron Pharmaceuticals Inc.: Total revenues increased by 30% to $2.423 billion in the fourth quarter of 2020,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.46,revenues,up,"Regeneron Pharmaceuticals Inc.: Full year 2020 total revenues increased 30% to $8.497 billion, compared to $6.558 billion for the full year 2019",PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of REGEN-COV were $146 million in the fourth quarter of 2020,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Other revenues in the fourth quarter,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Other revenues for the full year,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: GAAP income tax expense was $297 million,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $10.24 in the fourth quarter of 2020,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $30.52 for the full year 2020,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $9.53 in the fourth quarter of 2020,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $31.47 for the full year 2020,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During 2020, the Company repurchased 1.6 million shares of its common stock",PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,approved,Regeneron Pharmaceuticals Inc.: the Company's board of directors authorized a new share repurchase program,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2021 Financial Guidance,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -4-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: Conference Call Information,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -4-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: December 31, 2020 2019(*) Assets",PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -6-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $ 1,080.2 $ 857.6 $",PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -6-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $10.90 $7.25,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -6-
REGN,2021-02-05,11:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 10.25 $ 7.85 $,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -6-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,100,0.46,revenues,up,Regeneron Pharmaceuticals Inc.: Fourth quarter 2020 revenues increased 30% to $2.42 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,100,0.72,revenues,up,Dupixent global net sales increased 75%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Fourth quarter 2020 GAAP diluted EPS was $10.24,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Pharmaceuticals Inc.: new agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: the Company announced initial encouraging data from an ongoing Phase 1/2/3 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: the Company announced updated data from the Phase 1 portion of a Phase 1/2 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Fourth Quarter and Full Year 2020 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Fourth Quarter and Full Year 2020 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.46,revenues,up,Regeneron Pharmaceuticals Inc.: Total revenues increased by 30% to $2.423 billion in the fourth quarter of 2020,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.46,revenues,up,"Regeneron Pharmaceuticals Inc.: Full year 2020 total revenues increased 30% to $8.497 billion, compared to $6.558 billion for the full year 2019",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of REGEN-COV were $146 million in the fourth quarter of 2020,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Other revenues in the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Other revenues for the full year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: GAAP income tax expense was $297 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $10.24 in the fourth quarter of 2020,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $30.52 for the full year 2020,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $9.53 in the fourth quarter of 2020,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $31.47 for the full year 2020,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During 2020, the Company repurchased 1.6 million shares of its common stock",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,approved,Regeneron Pharmaceuticals Inc.: the Company's board of directors authorized a new share repurchase program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -4-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: Conference Call Information,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -4-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: December 31, 2020 2019(*) Assets",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -6-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $ 1,080.2 $ 857.6 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -6-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $10.90 $7.25,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -6-
REGN,2021-02-05,11:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 10.25 $ 7.85 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -6-
REGN,2021-02-05,11:30:57,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharma 4Q Eylea U.S. Net Sales Rose 10% to $1.34B,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q Eylea U.S. Net Sales Rose 10% to $1.34B >REGN
REGN,2021-02-05,11:31:35,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 4Q Adj EPS $9.53,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q Adj EPS $9.53 >REGN
REGN,2021-02-05,11:32:04,589803,Regeneron Pharmaceuticals Inc.,100,0.58,earnings,up,Regeneron Q4 EPS $10.24 vs. $6.93 a year ago,NEWS-FLASH,MarketWatch,MW Regeneron Q4 EPS $10.24 vs. $6.93 a year ago
REGN,2021-02-05,11:32:25,589803,Regeneron Pharmaceuticals Inc.,100,0.46,earnings,above-expectations,Regeneron Q4 adj. EPS $9.53; FactSet consensus $8.38,NEWS-FLASH,MarketWatch,MW Regeneron Q4 adj. EPS $9.53; FactSet consensus $8.38
REGN,2021-02-05,11:32:53,589803,Regeneron Pharmaceuticals Inc.,100,0.46,revenues,up,Regeneron Q4 revenue $2.42 bln vs. $1.86 bln a year ago,NEWS-FLASH,MarketWatch,MW Regeneron Q4 revenue $2.42 bln vs. $1.86 bln a year ago; FactSet consensus $2.42 bln
REGN,2021-02-05,11:33:31,589803,Regeneron Pharmaceuticals Inc.,100,0.44,revenues,up,Regeneron Q4 net product sales $1.62 bln vs. $1.29 bln a year ago,NEWS-FLASH,MarketWatch,MW Regeneron Q4 net product sales $1.62 bln vs. $1.29 bln a year ago; FactSet consensus $1.60 bln
REGN,2021-02-05,11:34:44,589803,Regeneron Pharmaceuticals Inc.,100,0.0,equity-actions,,Regeneron Pharma Sees 2021 Capital Spending $600M-$680M >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Sees 2021 Capital Spending $600M-$680M >REGN
REGN,2021-02-05,14:08:03,589803,Regeneron Pharmaceuticals Inc.,100,0.65,revenues,up,Dupixent Sales Jump,FULL-ARTICLE,Dow Jones Newswires,"Sanofi Raises Cost-Savings, Margin Targets as Dupixent Sales Jump -- Earnings Review"
REGN,2021-02-05,14:23:03,589803,Regeneron Pharmaceuticals Inc.,100,0.65,revenues,up,Dupixent Sales Jump,FULL-ARTICLE,Dow Jones Newswires,"Sanofi Raises Cost-Savings, Margin Targets as Dupixent Sales Jump -- Earnings Review"
REGN,2021-02-05,15:00:53,589803,Regeneron Pharmaceuticals Inc.,93,0.0,investor-relations,,Leonard Schleifer on 4Q earnings call,FULL-ARTICLE,Dow Jones Newswires,Regeneron Says Barriers for Covid-19 Drug Persist -- Market Talk
REGN,2021-02-05,15:00:53,589803,Regeneron Pharmaceuticals Inc.,93,0.0,investor-relations,,Leonard Schleifer on 4Q earnings call,FULL-ARTICLE,Dow Jones Newswires,Regeneron Says Barriers for Covid-19 Drug Persist -- Market Talk
REGN,2021-02-05,15:04:48,589803,Regeneron Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Regeneron Earnings Crushed Expectations,FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Crushed Expectations and the Stock Is Rising -- Barrons.com
REGN,2021-02-05,15:04:48,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: the company reported fourth-quarter earnings,FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Crushed Expectations and the Stock Is Rising -- Barrons.com
REGN,2021-02-05,15:04:48,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: The company reported non-GAAP diluted earnings of $9.53 per share for the quarter,FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Crushed Expectations and the Stock Is Rising -- Barrons.com
REGN,2021-02-05,15:04:48,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron markets in collaboration with Sanofi (ticker: SNY),FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Crushed Expectations and the Stock Is Rising -- Barrons.com
REGN,2021-02-05,17:15:39,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals, Inc. CEO Leonard Schleifer on Q4 2020 Results -- Earnings Call",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc. CEO Leonard Schleifer on Q4 2020 Results -- Earnings Call Transcript >REGN"
REGN,2021-02-05,17:15:39,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron-pharmaceuticals-inc-regn-ceo-leonard-schleifer-on-q4-2020-results-earnings,NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc. CEO Leonard Schleifer on Q4 2020 Results -- Earnings Call Transcript >REGN"
REGN,2021-02-08,11:50:53,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by SVB Leerink
REGN,2021-02-08,11:50:53,589803,Regeneron Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Regeneron Pharma Price Target Raised to $640.00/Share From $623.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $640.00/Share From $623.00 by SVB Leerink
REGN,2021-02-08,14:09:13,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley
REGN,2021-02-08,14:09:13,589803,Regeneron Pharmaceuticals Inc.,100,-0.6,price-targets,downgrade,Regeneron Pharma Price Target Cut to $525.00/Share From $553.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $525.00/Share From $553.00 by Morgan Stanley
REGN,2021-02-08,17:10:04,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by Credit Suisse
REGN,2021-02-08,17:10:04,589803,Regeneron Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Regeneron Pharma Price Target Cut to $753.00/Share From $758.00 by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $753.00/Share From $758.00 by Credit Suisse
REGN,2021-02-08,17:19:04,589803,Regeneron Pharmaceuticals Inc.,100,0.2,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by Cowen & Co.
REGN,2021-02-08,17:19:04,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Regeneron Pharma Price Target Cut to $565.00/Share From $684.00 by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $565.00/Share From $684.00 by Cowen & Co.
REGN,2021-02-09,22:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Libtayo(R) (Cemiplimab-rwlc),PRESS-RELEASE,Hugin GlobeNewswire,Press Release: FDA approves Libtayo(R) (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
REGN,2021-02-09,22:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Libtayo(R),PRESS-RELEASE,Hugin GlobeNewswire,Press Release: FDA approves Libtayo(R) -2-
REGN,2021-02-09,22:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Libtayo(R),PRESS-RELEASE,Hugin GlobeNewswire,Press Release: FDA approves Libtayo(R) -3-
REGN,2021-02-09,22:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Libtayo(R) (Cemiplimab-rwlc),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA approves Libtayo(R) (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
REGN,2021-02-09,22:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Libtayo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA approves Libtayo(R) -2-
REGN,2021-02-09,22:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Libtayo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA approves Libtayo(R) -3-
REGN,2021-02-09,22:15:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Libtayo(R) (Cemiplimab-rwlc),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA approves Libtayo(R) (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
REGN,2021-02-09,22:15:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Libtayo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA approves Libtayo(R) -2-
REGN,2021-02-09,22:15:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Libtayo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA approves Libtayo(R) -3-
REGN,2021-02-09,22:23:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA Approves Libtayo(R) (cemiplimab-rwlc),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Approves Libtayo(R) (cemiplimab-rwlc) as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
REGN,2021-02-09,22:23:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA Approves Libtayo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Approves Libtayo(R) -2-
REGN,2021-02-16,15:01:47,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Cantor Fitzgerald
REGN,2021-02-16,15:01:47,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Regeneron Pharma Price Target Cut to $656.00/Share From $696.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $656.00/Share From $696.00 by Cantor Fitzgerald
REGN,2021-02-22,18:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Libtayo(R) (cemiplimab-rwlc),PRESS-RELEASE,Hugin GlobeNewswire,Press Release: FDA approves Libtayo(R) (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of >=50%
REGN,2021-02-22,18:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Libtayo(R) (cemiplimab-rwlc),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA approves Libtayo(R) (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of >=50%
REGN,2021-02-22,18:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Libtayo(R),PRESS-RELEASE,Hugin GlobeNewswire,Press Release: FDA approves Libtayo(R) -2-
REGN,2021-02-22,18:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Libtayo(R),PRESS-RELEASE,Hugin GlobeNewswire,Press Release: FDA approves Libtayo(R) -3-
REGN,2021-02-22,18:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Libtayo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA approves Libtayo(R) -2-
REGN,2021-02-22,18:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Libtayo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA approves Libtayo(R) -3-
REGN,2021-02-22,18:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Libtayo(R) (cemiplimab-rwlc),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA approves Libtayo(R) (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of >=50%
REGN,2021-02-22,18:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Libtayo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA approves Libtayo(R) -2-
REGN,2021-02-22,18:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Libtayo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA approves Libtayo(R) -3-
REGN,2021-02-22,18:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA Approves Libtayo(R) (cemiplimab-rwlc),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Approves Libtayo(R) (cemiplimab-rwlc) Monotherapy for Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of >=50%
REGN,2021-02-22,18:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA Approves Libtayo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Approves Libtayo(R) -3-
REGN,2021-02-22,18:02:22,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Approves Libtayo Cemiplimab,NEWS-FLASH,Dow Jones Newswires,Sanofi: FDA Approves Libtayo Cemiplimab-Rwlc Monotherapy for Patients With First-Line Advanced Non-Small Cell Lung Cancer
REGN,2021-02-22,18:15:42,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi Gets FDA OK of Libtayo,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Gets FDA OK of Libtayo in Advanced Non-Small Cell Lung Cancer"
REGN,2021-02-22,18:30:42,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi Gets FDA OK of Libtayo,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Gets FDA OK of Libtayo in Advanced Non-Small Cell Lung Cancer"
REGN,2021-02-23,13:10:25,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by Credit Suisse
REGN,2021-02-23,13:10:25,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $760.00/Share From $753.00 by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $760.00/Share From $753.00 by Credit Suisse
REGN,2021-02-23,15:00:06,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada approves DUPIXENT® (dupilumab,PRESS-RELEASE,Canadian News Wire,Health Canada approves DUPIXENT® (dupilumab injection) as the first biologic for the treatment of moderate-to-severe atopic dermatitis in children aged 6 to 11 years
REGN,2021-02-24,21:03:51,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Chmn Vagelos Acquires 112,002 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Vagelos Acquires 112,002 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-02-26,11:46:55,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron has collaborated with Roche to develop and manufacture the antibody cocktail,PRESS-RELEASE,PR Newswire,EMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients
REGN,2021-02-26,11:46:55,589803,Regeneron Pharmaceuticals Inc.,99,-0.47,regulatory,,Regeneron Pharmaceuticals Inc.: The CHMP's review,PRESS-RELEASE,PR Newswire,EMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients
REGN,2021-02-26,11:46:55,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,"Regeneron Pharmaceuticals Inc.: In November 2020, REGEN-COV received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment",PRESS-RELEASE,PR Newswire,EMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients
REGN,2021-02-26,11:46:56,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron has collaborated with Roche to develop and manufacture the antibody cocktail,PRESS-RELEASE,Dow Jones Newswires,Press Release: EMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients
REGN,2021-02-26,11:46:56,589803,Regeneron Pharmaceuticals Inc.,99,-0.47,regulatory,,Regeneron Pharmaceuticals Inc.: The CHMP's review,PRESS-RELEASE,Dow Jones Newswires,Press Release: EMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients
REGN,2021-02-26,11:46:56,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,"Regeneron Pharmaceuticals Inc.: In November 2020, REGEN-COV received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment",PRESS-RELEASE,Dow Jones Newswires,Press Release: EMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients
REGN,2021-02-26,12:25:37,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Roche, Regeneron Collaborate to",NEWS-FLASH,Dow Jones Newswires,"Roche, Regeneron Collaborate to Develop, Manufacture, Distribute Casirivimab and Imdevimab"
REGN,2021-02-27,23:25:04,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Announces Positive Phase 2 Data,PRESS-RELEASE,PR Newswire,Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma
REGN,2021-02-27,23:25:04,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Announces Positive Phase 2 Data,PRESS-RELEASE,PR Newswire,Regeneron Announces Positive Phase 2 Data -2-
REGN,2021-02-27,23:25:04,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Announces Positive Phase 2 Data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma
REGN,2021-03-04,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA accepts Dupixent(R) (dupilumab),PRESS-RELEASE,Hugin GlobeNewswire,Press Release: FDA accepts Dupixent(R) (dupilumab) for review in children with moderate-to-severe asthma
REGN,2021-03-04,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA accepts Dupixent(R) (dupilumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA accepts Dupixent(R) (dupilumab) for review in children with moderate-to-severe asthma
REGN,2021-03-04,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA accepts Dupixent(R),PRESS-RELEASE,Hugin GlobeNewswire,Press Release: FDA accepts Dupixent(R) -2-
REGN,2021-03-04,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA accepts Dupixent(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA accepts Dupixent(R) -2-
REGN,2021-03-04,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA accepts Dupixent(R) (dupilumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA accepts Dupixent(R) (dupilumab) for review in children with moderate-to-severe asthma
REGN,2021-03-04,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA accepts Dupixent(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA accepts Dupixent(R) -2-
REGN,2021-03-04,10:39:42,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA Accepts Dupixent(R) (dupilumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Dupixent(R) (dupilumab) for Review in Children with Moderate-to-severe Asthma
REGN,2021-03-04,10:39:42,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA Accepts Dupixent(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Dupixent(R) -2-
REGN,2021-03-04,10:56:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.47,regulatory,,Fda to Review Dupixent for,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi: FDA to Review Dupixent for Asthma Attacks in Children"
REGN,2021-03-04,11:11:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.47,regulatory,,Fda to Review Dupixent for,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi: FDA to Review Dupixent for Asthma Attacks in Children"
REGN,2021-03-16,16:28:35,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals, Inc. (REGN) Presents at Oppenheimer Healthcare Broker Conference Call",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc. (REGN) Presents at Oppenheimer Healthcare Broker Conference Call - (Transcript) >REGN"
REGN,2021-03-18,00:57:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: In clinical tests of,PRESS-RELEASE,PR Newswire,"Teen Scientists Win $1.8 Million at Virtual Regeneron Science Talent Search 2021 for Remarkable Research on Infinite Matching Algorithms, Machine Learning to Evaluate New Medicines and Water Filtration"
REGN,2021-03-18,04:00:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: In clinical tests of,PRESS-RELEASE,PR Newswire,"Teen Scientists Win $1.8 Million at Virtual Regeneron Science Talent Search 2021 for Remarkable Research on Infinite Matching Algorithms, Machine Learning to Evaluate New Medicines and Water Filtration"
REGN,2021-03-23,06:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,"In November, the U.S. Food and Drug Administration cleared Regeneron's drug",FULL-ARTICLE,Dow Jones Newswires,"Regeneron Covid-19 Antibody Drug Reduced Risk of Hospitalization, Death by 70% in Late-Stage Trial"
REGN,2021-03-23,06:10:03,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,"In November, the U.S. Food and Drug Administration cleared Regeneron's drug",FULL-ARTICLE,Dow Jones Newswires,"Regeneron Covid-19 Antibody Drug Reduced Risk of Hospitalization, Death by 70% in Late-Stage Trial"
REGN,2021-03-23,06:14:40,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,"In November, the U.S. Food and Drug Administration cleared Regeneron's drug",FULL-ARTICLE,Dow Jones Newswires,"Regeneron Covid-19 Antibody Drug Reduced Risk of Hospitalization, Death by 70% in Late-Stage Trial"
REGN,2021-03-24,13:46:31,589803,Regeneron Pharmaceuticals Inc.,97,0.84,products-services,positive,Positive results from Regeneron Pharmaceuticals' Phase 3 trial,FULL-ARTICLE,Dow Jones Newswires,Regeneron's Covid-19 Antibody Could See Substantially Higher Sales This Year. Here's Why. -- Barrons.com
REGN,2021-03-24,13:46:31,589803,Regeneron Pharmaceuticals Inc.,97,0.0,products-services,,Regeneron now says it will be able to supply 1.25 million doses of the therapy,FULL-ARTICLE,Dow Jones Newswires,Regeneron's Covid-19 Antibody Could See Substantially Higher Sales This Year. Here's Why. -- Barrons.com
REGN,2021-03-26,11:11:03,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by SVB Leerink
REGN,2021-03-26,11:11:03,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $657.00/Share From $655.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $657.00/Share From $655.00 by SVB Leerink
REGN,2021-03-30,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.63,products-services,,Ntla-2001 Receives European Union Orphan Drug Designation for,PRESS-RELEASE,GlobeNewswire,Intellia Therapeutics' Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
REGN,2021-03-30,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.63,products-services,,European Commission (EC) has granted orphan drug designation to NTLA-2001,PRESS-RELEASE,GlobeNewswire,Intellia Therapeutics' Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
REGN,2021-03-30,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.63,products-services,,Ntla-2001 Receives European Union Orphan Drug Designation for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Intellia Therapeutics' Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
REGN,2021-03-30,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.63,products-services,,European Commission (EC) has granted orphan drug designation to NTLA-2001,PRESS-RELEASE,Dow Jones Newswires,Press Release: Intellia Therapeutics' Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
REGN,2021-03-30,11:31:50,589803,Regeneron Pharmaceuticals Inc.,100,0.63,products-services,,Ntla-2001 Receives European Union Orphan Drug Designation for,NEWS-FLASH,Dow Jones Newswires,Intellia Therapeutics: Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
REGN,2021-04-06,20:05:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report First Quarter 2021 Financial and Operating Results,PRESS-RELEASE,PR Newswire,"Regeneron to Report First Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2021"
REGN,2021-04-06,20:05:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM,PRESS-RELEASE,PR Newswire,"Regeneron to Report First Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2021"
REGN,2021-04-06,20:05:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report First Quarter 2021 Financial and Operating Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report First Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2021"
REGN,2021-04-06,20:05:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report First Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2021"
REGN,2021-04-09,12:50:53,589803,Regeneron Pharmaceuticals Inc.,96,0.49,partnerships,,Regeneron said it is collaborating with Roche Holding AG,FULL-ARTICLE,Dow Jones Newswires,Regeneron Pharma Covid-19 Treatment Recommended by National Institutes of Health
REGN,2021-04-09,13:05:52,589803,Regeneron Pharmaceuticals Inc.,96,0.49,partnerships,,Regeneron said it is collaborating with Roche Holding AG,FULL-ARTICLE,Dow Jones Newswires,Regeneron Pharma Covid-19 Treatment Recommended by National Institutes of Health
REGN,2021-04-12,06:10:23,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron issued the Phase 3 data,FULL-ARTICLE,Dow Jones Newswires,U.S. News:  Regeneron  Drug Curbs  Risk of  Infection  ----  By Joseph Walker
REGN,2021-04-12,06:32:25,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron issued the Phase 3 data,FULL-ARTICLE,Wall Street Journal,Regeneron Drug Curbs Risk of Infection -- WSJ
REGN,2021-04-12,08:18:20,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron issued the Phase 3 data,FULL-ARTICLE,Dow Jones Newswires,"Covid-19 Drug Prevents Symptomatic Disease in Study, Regeneron Says"
REGN,2021-04-12,08:30:03,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron issued the Phase 3 data,FULL-ARTICLE,Dow Jones Newswires,Regeneron Drug Prevents Symptomatic Covid-19 in Study
REGN,2021-04-12,08:33:20,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron issued the Phase 3 data,FULL-ARTICLE,Dow Jones Newswires,"Covid-19 Drug Prevents Symptomatic Disease in Study, Regeneron Says"
REGN,2021-04-12,12:33:16,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron also on Monday announced the results of another Phase 3 trial,FULL-ARTICLE,Dow Jones Newswires,Regeneron's Covid-19 Antibody Protects Household Contacts From Infection -- Barrons.com
REGN,2021-04-19,15:16:26,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley
REGN,2021-04-19,15:16:26,589803,Regeneron Pharmaceuticals Inc.,100,-0.76,price-targets,downgrade,Regeneron Pharma Price Target Cut to $477.00/Share From $525.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $477.00/Share From $525.00 by Morgan Stanley
REGN,2021-04-23,08:10:17,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals Inc, Inst Holders, 1Q 2021 (REGN)",RNS-SEC13F,Dow Jones Newswires,"Regeneron Pharmaceuticals Inc, Inst Holders, 1Q 2021 (REGN)"
REGN,2021-05-03,12:06:43,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Positive Phase 3 Results From REGEN-COV,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma: Positive Phase 3 Results From REGEN-COV Trial in High-Risk Non-Hospitalized Patients With COVID-19 to Be Presented >REGN
REGN,2021-05-03,12:06:57,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Positive Phase 3 Results From Dupixent,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma: Session to Also Include Presentation of Positive Phase 3 Results From Dupixent Trial in Children With Moderate-To-Severe Asthma >REGN
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2021",PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial and Operating Results
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.52,revenues,up,Regeneron Pharmaceuticals Inc.: First quarter 2021 revenues increased 38% to $2.53 billion,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial and Operating Results
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: First quarter 2021 GAAP diluted EPS was $10.09,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial and Operating Results
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Positive Phase 3 results for REGEN-COV,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial and Operating Results
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Regeneron Pharmaceuticals Inc.: EYLEA(R) (aflibercept) Injection,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial and Operating Results
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The Company plans to submit a supplemental Biologics License Application (sBLA),PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial and Operating Results
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: the Company and Sanofi announced positive results from the Phase 3 trial,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial and Operating Results
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.41,products-services,start,Regeneron Pharmaceuticals Inc.: The Company plans to initiate a Phase 3 study,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial and Operating Results
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial and Operating Results
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial -2-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial -2-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $10.09 in the first quarter of 2021,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial -2-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 1Q Rev $2.53B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q Rev $2.53B >REGN
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $9.89 in the first quarter of 2021,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial -2-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,approved,Regeneron Pharmaceuticals Inc.: the Company's board of directors authorized a new share repurchase program,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial -2-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2021 Financial Guidance,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial -2-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 1Q EPS $10.09,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q EPS $10.09 >REGN
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2021 financial guidance,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial -3-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: Conference Call Information,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial -3-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: March 31, December 31, 2021 2020 Assets",PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial -4-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Three Months Ended March 31, 2021 2020 Revenues",PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial -4-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial -4-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $ 1,115.2 $624.6",PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial -4-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 10.58 $5.69,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial -4-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 10.52 $7.02,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2021 Financial -4-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 1Q Net $1.12B,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q Net $1.12B >REGN
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2021 Financial and Operating Results
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.52,revenues,up,Regeneron Pharmaceuticals Inc.: First quarter 2021 revenues increased 38% to $2.53 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2021 Financial and Operating Results
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: First quarter 2021 GAAP diluted EPS was $10.09,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2021 Financial and Operating Results
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Positive Phase 3 results for REGEN-COV,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2021 Financial and Operating Results
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Regeneron Pharmaceuticals Inc.: EYLEA(R) (aflibercept) Injection,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2021 Financial and Operating Results
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The Company plans to submit a supplemental Biologics License Application (sBLA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2021 Financial and Operating Results
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: the Company and Sanofi announced positive results from the Phase 3 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2021 Financial and Operating Results
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.41,products-services,start,Regeneron Pharmaceuticals Inc.: The Company plans to initiate a Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2021 Financial and Operating Results
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2021 Financial and Operating Results
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $10.09 in the first quarter of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $9.89 in the first quarter of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,approved,Regeneron Pharmaceuticals Inc.: the Company's board of directors authorized a new share repurchase program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2021 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -3-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: Conference Call Information,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -3-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: March 31, December 31, 2021 2020 Assets",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Three Months Ended March 31, 2021 2020 Revenues",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $ 1,115.2 $624.6",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 10.58 $5.69,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2021-05-06,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 10.52 $7.02,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2021-05-06,10:30:54,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharma 1Q Eylea U.S. Net Sales Rose 15% to $1.35B,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q Eylea U.S. Net Sales Rose 15% to $1.35B >REGN
REGN,2021-05-06,10:31:25,589803,Regeneron Pharmaceuticals Inc.,100,0.58,revenues,up,Regeneron Pharma: 1Q Dupixent Global Net Sales Recorded by Sanofi Rose 48%,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma: 1Q Dupixent Global Net Sales Recorded by Sanofi Rose 48% to $1.26B >REGN
REGN,2021-05-06,10:31:37,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 1Q Adj EPS $9.89,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q Adj EPS $9.89 >REGN
REGN,2021-05-06,10:32:06,589803,Regeneron Pharmaceuticals Inc.,100,0.76,earnings,up,Regeneron Q1 EPS $10.09 vs. $5.43 a year ago,NEWS-FLASH,MarketWatch,MW Regeneron Q1 EPS $10.09 vs. $5.43 a year ago
REGN,2021-05-06,10:32:29,589803,Regeneron Pharmaceuticals Inc.,100,0.62,earnings,up,Regeneron Q1 adj. EPS $9.89 vs. $6.60 a year ago,NEWS-FLASH,MarketWatch,MW Regeneron Q1 adj. EPS $9.89 vs. $6.60 a year ago; FactSet consensus $8.68
REGN,2021-05-06,10:32:51,589803,Regeneron Pharmaceuticals Inc.,100,0.48,revenues,above-expectations,Regeneron Q1 revenue $2.53 bln vs. $1.83 bln a year ago; FactSet consensus $2.50 bln,NEWS-FLASH,MarketWatch,MW Regeneron Q1 revenue $2.53 bln vs. $1.83 bln a year ago; FactSet consensus $2.50 bln
REGN,2021-05-06,10:32:58,589803,Regeneron Pharmaceuticals Inc.,100,0.56,revenues,,Regeneron Pharma Sees 2021 Adjusted Gross Margin on Net Product Sales 87%-89%,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Sees 2021 Adjusted Gross Margin on Net Product Sales 87%-89% >REGN
REGN,2021-05-06,10:33:33,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharma 1Q Revenue Excluding REGEN-COVTM Rose 20%,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q Revenue Excluding REGEN-COVTM Rose 20% >REGN
REGN,2021-05-06,10:44:04,589803,Regeneron Pharmaceuticals Inc.,100,0.65,revenues,up,Regeneron posted $262 million of revenue for the quarter,FULL-ARTICLE,Dow Jones Newswires,"Regeneron 1Q Rev Increases, With Gain From Covid-19 Antibody Cocktail"
REGN,2021-05-06,10:59:04,589803,Regeneron Pharmaceuticals Inc.,100,0.65,revenues,up,Regeneron posted $262 million of revenue for the quarter,FULL-ARTICLE,Dow Jones Newswires,"Regeneron 1Q Revenue Increases, With Gain From Covid-19 Antibody Cocktail"
REGN,2021-05-06,11:34:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals reported financial results,FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Lift Stock. Here's Why. -- Barrons.com
REGN,2021-05-06,11:34:10,589803,Regeneron Pharmaceuticals Inc.,99,0.52,revenues,up,"Regeneron (ticker: REGN) reported first-quarter revenues of $2.5 billion, up 38% from the first quarter of 2020",FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Lift Stock. Here's Why. -- Barrons.com
REGN,2021-05-06,11:34:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron is hosting a conference call for investors at 8:30 a.m.,FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Lift Stock. Here's Why. -- Barrons.com
REGN,2021-05-06,20:03:16,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals, Inc. CEO Leonard Schleifer on Q1 2021 Results -- Earnings Call",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc. CEO Leonard Schleifer on Q1 2021 Results -- Earnings Call Transcript >REGN"
REGN,2021-05-06,20:03:16,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron-pharmaceuticals-inc-regn-ceo-leonard-schleifer-on-q1-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc. CEO Leonard Schleifer on Q1 2021 Results -- Earnings Call Transcript >REGN"
REGN,2021-05-07,11:30:45,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by SVB Leerink
REGN,2021-05-07,11:30:45,589803,Regeneron Pharmaceuticals Inc.,100,-0.4,price-targets,downgrade,Regeneron Pharma Price Target Cut to $641.00/Share From $657.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $641.00/Share From $657.00 by SVB Leerink
REGN,2021-05-07,12:40:06,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley
REGN,2021-05-07,12:40:06,589803,Regeneron Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Regeneron Pharma Price Target Raised to $495.00/Share From $477.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $495.00/Share From $477.00 by Morgan Stanley
REGN,2021-05-10,10:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron,PRESS-RELEASE,GlobeNewswire,Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron to Evaluate Vidutolimod (CMP-001) in Combination with Libtayo(R) (cemiplimab)
REGN,2021-05-10,10:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Checkmate and Regeneron will collaborate on,PRESS-RELEASE,GlobeNewswire,Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron to Evaluate Vidutolimod (CMP-001) in Combination with Libtayo(R) (cemiplimab)
REGN,2021-05-10,10:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron to Evaluate Vidutolimod (CMP-001) in Combination with Libtayo(R) (cemiplimab)
REGN,2021-05-10,10:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Checkmate and Regeneron will collaborate on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron to Evaluate Vidutolimod (CMP-001) in Combination with Libtayo(R) (cemiplimab)
REGN,2021-05-10,20:03:21,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-05-10,23:05:52,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-05-18,20:05:44,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Stahl Sells 17,521 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stahl Sells 17,521 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-05-18,22:37:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Stahl Registers 17,521 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Stahl Registers 17,521 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-05-20,16:56:58,589803,Regeneron Pharmaceuticals Inc.,99,-0.4,earnings,negative,"Regeneron Pharmaceuticals Inc.: Fortunately, vision loss",PRESS-RELEASE,PR Newswire,"American Diabetes Association, with Visionary Partners VSP Vision Care and Regeneron Launch ""The Next Step Eye Challenge"" Campaign for Healthy Vision Month in May"
REGN,2021-05-24,05:02:03,589803,Regeneron Pharmaceuticals Inc.,100,0.82,products-services,positive,Libtayo(R) (cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe,PRESS-RELEASE,PR Newswire,Libtayo(R) (cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers
REGN,2021-05-24,05:02:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Libtayo is currently approved in the European Union (EU),PRESS-RELEASE,PR Newswire,Libtayo(R) (cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers
REGN,2021-05-24,05:02:03,589803,Regeneron Pharmaceuticals Inc.,100,0.82,products-services,positive,Libtayo(R) (cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe,PRESS-RELEASE,Dow Jones Newswires,Press Release: Libtayo(R) (cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers
REGN,2021-05-24,05:02:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Libtayo is currently approved in the European Union (EU),PRESS-RELEASE,Dow Jones Newswires,Press Release: Libtayo(R) (cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers
REGN,2021-05-26,14:49:37,589803,Regeneron Pharmaceuticals Inc.,99,0.58,products-services,,Regeneron Pharmaceuticals Inc.: the company signed a deal with the U.S. government to,FULL-ARTICLE,Dow Jones Newswires,How Regeneron Could Score Big From an FDA Call -- Barrons.com
REGN,2021-06-04,11:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Permits Lower Dose of Regeneron's Covid-19 Antibody Drug,NEWS-FLASH,Dow Jones Newswires,FDA Permits Lower Dose of Regeneron's Covid-19 Antibody Drug
REGN,2021-06-08,19:27:59,589803,Regeneron Pharmaceuticals Inc.,100,0.0,marketing,,"Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Goldman Sachs 42nd Annual Global Healthcare Conference",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript) >REGN"
REGN,2021-06-08,20:04:05,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"VP McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-06-08,20:04:25,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Goldstein Sells 1,930 Of Regeneron Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"Dir Goldstein Sells 1,930 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-06-08,21:48:17,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-06-14,12:01:00,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Twist Bioscience Collaborates with Regeneron for,PRESS-RELEASE,Business Wire,Twist Bioscience Collaborates with Regeneron for Production of Genotyping by Sequencing Panel to Enable Diverse Genome-wide Screening
REGN,2021-06-14,12:01:01,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Twist Bioscience Collaborates with Regeneron for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Twist Bioscience Collaborates with Regeneron for Production of Genotyping by Sequencing Panel to Enable Diverse Genome-wide Screening
REGN,2021-06-14,12:03:09,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Twist Bioscience Collaborates With Regeneron for,NEWS-FLASH,Dow Jones Newswires,Twist Bioscience Collaborates With Regeneron for Production of Genotyping by Sequencing Panel to Enable Diverse Genome-wide Screening
REGN,2021-06-15,19:26:40,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Brown Registers 3,784 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Brown Registers 3,784 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-06-15,21:32:48,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Ryan Registers 400 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Ryan Registers 400 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-06-16,20:03:51,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Brown Sells 1,700 Of Regeneron Pharmaceuticals Inc",FULL-ARTICLE,Dow Jones Newswires,"Dir Brown Sells 1,700 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-06-16,20:05:24,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-06-22,20:15:03,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: A replay of the conference call,PRESS-RELEASE,PR Newswire,Regeneron to Participate in Guggenheim Biopharma Strategy Series
REGN,2021-06-22,20:15:03,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: A replay of the conference call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron to Participate in Guggenheim Biopharma Strategy Series
REGN,2021-06-23,20:04:54,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Yancopoulos Sells 80,000 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Officer/Dir Yancopoulos Sells 80,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-06-28,20:03:56,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Brown Sells 2,084 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Brown Sells 2,084 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-06-29,11:49:44,589803,Regeneron Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Regeneron Pharma Initiated at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Initiated at Buy by HC Wainwright & Co.
REGN,2021-06-29,11:49:44,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $703.00/Share by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $703.00/Share by HC Wainwright & Co.
REGN,2021-07-01,18:05:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.4,earnings,negative,Regeneron Pharmaceuticals Inc.: Protective 'loss,PRESS-RELEASE,PR Newswire,Regeneron Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity
REGN,2021-07-02,20:03:15,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Bassler Sells 2,558 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Bassler Sells 2,558 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-07-02,20:04:46,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-07-02,20:05:05,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-07-02,21:17:32,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-07-07,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron,PRESS-RELEASE,Business Wire,"Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate SBT6050 in Combination with Libtayo(R) (cemiplimab), initially in HER2-expressing Non-Small Cell Lung and Gastric Cancers"
REGN,2021-07-07,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate SBT6050 in Combination with Libtayo(R) (cemiplimab), initially in HER2-expressing Non-Small Cell Lung and Gastric Cancers"
REGN,2021-07-07,20:02:53,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Larosa Sells 3,398 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Larosa Sells 3,398 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-07-07,20:05:30,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Larosa Registers 3,398 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Larosa Registers 3,398 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-07-07,20:15:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report Second Quarter 2021 Financial and Operating Results,PRESS-RELEASE,PR Newswire,"Regeneron to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2021"
REGN,2021-07-07,20:15:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM,PRESS-RELEASE,PR Newswire,"Regeneron to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2021"
REGN,2021-07-07,20:15:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report Second Quarter 2021 Financial and Operating Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2021"
REGN,2021-07-07,20:15:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2021"
REGN,2021-07-08,10:24:36,589803,Regeneron Pharmaceuticals Inc.,100,0.7,price-targets,upgrade,Regeneron stock price target raised to $636 from $590,NEWS-FLASH,MarketWatch,MW Regeneron stock price target raised to $636 from $590 at Benchmark
REGN,2021-07-08,12:55:00,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Benchmark,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Benchmark
REGN,2021-07-08,12:55:00,589803,Regeneron Pharmaceuticals Inc.,100,0.7,price-targets,upgrade,Regeneron Pharma Price Target Raised to $636.00/Share From $590.00 by Benchmark,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $636.00/Share From $590.00 by Benchmark
REGN,2021-07-20,05:00:03,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Mhlw) has approved Regeneron's casirivimab and imdevimab antibody cocktail,PRESS-RELEASE,PR Newswire,Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19
REGN,2021-07-20,05:00:03,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The approval was based on results from a Phase 3 trial,PRESS-RELEASE,PR Newswire,Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19
REGN,2021-07-20,05:00:04,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Mhlw) has approved Regeneron's casirivimab and imdevimab antibody cocktail,PRESS-RELEASE,Dow Jones Newswires,Press Release: Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19
REGN,2021-07-20,05:00:04,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The approval was based on results from a Phase 3 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19
REGN,2021-07-20,10:39:21,589803,Regeneron Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Regeneron stock price target raised to $559 from $540 at J.P. Morgan,NEWS-FLASH,MarketWatch,MW Regeneron stock price target raised to $559 from $540 at J.P. Morgan
REGN,2021-07-23,08:33:29,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals Inc, Inst Holders, 2Q 2021 (REGN)",RNS-SEC13F,Dow Jones Newswires,"Regeneron Pharmaceuticals Inc, Inst Holders, 2Q 2021 (REGN)"
REGN,2021-07-27,11:00:05,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and AstraZeneca today announced that the companies have entered into a collaboration",PRESS-RELEASE,PR Newswire,"Regeneron and AstraZeneca to Research, Develop and Commercialize New Small Molecule Medicines for Obesity"
REGN,2021-07-27,11:00:05,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and AstraZeneca today announced that the companies have entered into a collaboration",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron and AstraZeneca to Research, Develop and Commercialize New Small Molecule Medicines for Obesity"
REGN,2021-07-27,11:53:12,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,"Regeneron, AstraZeneca to develop obesity treatment",FULL-ARTICLE,MarketWatch,"MW Regeneron, AstraZeneca to develop obesity treatment"
REGN,2021-07-27,11:53:12,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Pharmaceuticals Inc.: the company announced a deal with AstraZeneca (AZN.LN) to develop and commercialize obesity treatments,FULL-ARTICLE,MarketWatch,"MW Regeneron, AstraZeneca to develop obesity treatment"
REGN,2021-07-27,11:53:12,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,"Regeneron, AstraZeneca To Develop Obesity Treatment",FULL-ARTICLE,Dow Jones Newswires,"Regeneron, AstraZeneca To Develop Obesity Treatment -- MarketWatch"
REGN,2021-07-27,11:53:12,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Pharmaceuticals Inc.: the company announced a deal with AstraZeneca (AZN.LN) to develop and commercialize obesity treatments,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, AstraZeneca To Develop Obesity Treatment -- MarketWatch"
REGN,2021-07-30,17:45:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Expands Authorized Use of REGEN-COV(TM),PRESS-RELEASE,PR Newswire,FDA Expands Authorized Use of REGEN-COV(TM) (casirivimab and imdevimab)
REGN,2021-07-30,17:45:03,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron is collaborating with Roche to increase global,PRESS-RELEASE,PR Newswire,FDA Expands Authorized Use of REGEN-COV(TM) (casirivimab and imdevimab)
REGN,2021-07-30,17:45:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Expands Authorized Use of REGEN-COV(TM),PRESS-RELEASE,PR Newswire,FDA Expands Authorized Use of REGEN-COV(TM) -2-
REGN,2021-07-30,17:45:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Expands Authorized Use of REGEN-COV(TM),PRESS-RELEASE,PR Newswire,FDA Expands Authorized Use of REGEN-COV(TM) -3-
REGN,2021-07-30,17:45:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Expands Authorized Use of REGEN-COV(TM),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Expands Authorized Use of REGEN-COV(TM) (casirivimab and imdevimab)
REGN,2021-07-30,17:45:03,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron is collaborating with Roche to increase global,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Expands Authorized Use of REGEN-COV(TM) (casirivimab and imdevimab)
REGN,2021-07-30,17:46:25,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Expands Authorized Use of REGEN-COV(TM),HOT-NEWS-FLASH,Dow Jones Newswires,FDA Expands Authorized Use of REGEN-COV(TM) (casirivimab and Imdevimab)
REGN,2021-07-30,17:58:54,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Gets Expanded EUA for Covid-19 Antibody Cocktail,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets Expanded EUA for Covid-19 Antibody Cocktail
REGN,2021-07-30,18:13:54,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Gets Expanded EUA for Covid-19 Antibody Cocktail,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets Expanded EUA for Covid-19 Antibody Cocktail
REGN,2021-07-30,18:24:23,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Gets Expanded EUA for Covid-19 Antibody Cocktail,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets Expanded EUA for Covid-19 Antibody Cocktail -- Update
REGN,2021-07-30,18:39:23,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Gets Expanded EUA for Covid-19 Antibody Cocktail,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets Expanded EUA for Covid-19 Antibody Cocktail -- Update
REGN,2021-08-02,10:19:03,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by HC Wainwright & Co.
REGN,2021-08-02,10:19:03,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $741.00/Share From $729.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $741.00/Share From $729.00 by HC Wainwright & Co.
REGN,2021-08-03,21:33:06,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-04,20:05:16,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-04,20:06:54,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-08-04,21:05:50,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Positive Phase 3 Trial Results for REGEN-COV(TM),PRESS-RELEASE,PR Newswire,New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV(TM) (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection
REGN,2021-08-04,21:05:50,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron previously announced initial results from the Phase 3 trial,PRESS-RELEASE,PR Newswire,New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV(TM) (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection
REGN,2021-08-04,21:05:50,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron is collaborating with Roche to increase global,PRESS-RELEASE,PR Newswire,New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV(TM) (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection
REGN,2021-08-04,21:05:50,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Positive Phase 3 Trial Results for REGEN-COV(TM),PRESS-RELEASE,Dow Jones Newswires,Press Release: New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV(TM) (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection
REGN,2021-08-04,21:05:50,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron previously announced initial results from the Phase 3 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV(TM) (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection
REGN,2021-08-04,21:05:50,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron is collaborating with Roche to increase global,PRESS-RELEASE,Dow Jones Newswires,Press Release: New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV(TM) (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection
REGN,2021-08-04,21:08:14,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Positive Phase 3 Trial Results for REGEN-COV,NEWS-FLASH,Dow Jones Newswires,Regeneron: New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV to Prevent SARS-CoV-2 Infection
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 2Q EPS $27.97,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q EPS $27.97 >REGN
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2021",PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,100,0.84,revenues,up,Regeneron Pharmaceuticals Inc.: Second quarter 2021 revenues increased 163% to $5.14 billion,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Second quarter 2021 GAAP diluted EPS was $27.97,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: With today's positive Phase 3 results,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: order for our COVID-19 antibody cocktail,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,100,0.22,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: we invest in our,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Regeneron Pharmaceuticals Inc.: EYLEA(R) (aflibercept) Injection,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,100,0.4,products-services,start,Regeneron Pharmaceuticals Inc.: Enrollment in the Phase 3 studies,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,100,0.46,equity-actions,,Regeneron Pharmaceuticals Inc.: The Company intends to invest approximately $1.8 billion over six years,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 2Q Net $3.1B,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q Net $3.1B >REGN
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: U.S. net product sales,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial -2-
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial -2-
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,99,-0.68,revenues,down,Regeneron Pharmaceuticals Inc.: Other revenue decreased in the second quarter of 2021,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial -2-
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial -2-
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $27.97 in the second quarter of 2021,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial -2-
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $25.80 in the second quarter of 2021,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial -2-
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2021 Financial Guidance,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial -2-
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 2Q Rev $5.14B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q Rev $5.14B >REGN
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2021 financial guidance,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial -3-
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: Conference Call Information,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial -3-
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: June 30, December 31, 2021 2020 Assets",PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial -4-
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial -4-
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $3,098.9 $ 897.3",PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial -4-
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $29.51 $8.19,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial -4-
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $27.57 $ 7.80,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial -4-
REGN,2021-08-05,10:30:16,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total collaboration revenue,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2021 Financial -4-
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,100,0.84,revenues,up,Regeneron Pharmaceuticals Inc.: Second quarter 2021 revenues increased 163% to $5.14 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Second quarter 2021 GAAP diluted EPS was $27.97,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: With today's positive Phase 3 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: order for our COVID-19 antibody cocktail,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,100,0.22,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: we invest in our,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Regeneron Pharmaceuticals Inc.: EYLEA(R) (aflibercept) Injection,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,100,0.4,products-services,start,Regeneron Pharmaceuticals Inc.: Enrollment in the Phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,100,0.46,equity-actions,,Regeneron Pharmaceuticals Inc.: The Company intends to invest approximately $1.8 billion over six years,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2021 Financial and Operating Results
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: U.S. net product sales,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,99,-0.68,revenues,down,Regeneron Pharmaceuticals Inc.: Other revenue decreased in the second quarter of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $27.97 in the second quarter of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $25.80 in the second quarter of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2021 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -3-
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: Conference Call Information,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -3-
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: June 30, December 31, 2021 2020 Assets",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $3,098.9 $ 897.3",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $29.51 $8.19,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $27.57 $ 7.80,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2021-08-05,10:30:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total collaboration revenue,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2021-08-05,10:36:29,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 2Q Adj EPS $25.80,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q Adj EPS $25.80 >REGN
REGN,2021-08-05,10:37:48,589803,Regeneron Pharmaceuticals Inc.,100,0.66,revenues,up,Regeneron Pharma 2Q Dupixent Global Net Sales Rose 59% to $1.5B,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q Dupixent Global Net Sales Rose 59% to $1.5B >REGN
REGN,2021-08-05,10:38:11,589803,Regeneron Pharmaceuticals Inc.,100,0.46,revenues,up,Regeneron Pharma 2Q Eylea U.S. Net Sales Rose 28% to $1.42B,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q Eylea U.S. Net Sales Rose 28% to $1.42B >REGN
REGN,2021-08-05,10:40:34,589803,Regeneron Pharmaceuticals Inc.,100,0.86,earnings,up,Regeneron Q2 EPS $27.97 vs. $7.61 a year ago,NEWS-FLASH,MarketWatch,MW Regeneron Q2 EPS $27.97 vs. $7.61 a year ago
REGN,2021-08-05,10:40:52,589803,Regeneron Pharmaceuticals Inc.,100,0.56,earnings,above-expectations,Regeneron Q2 adj. EPS $25.80; FactSet consensus $17.90,NEWS-FLASH,MarketWatch,MW Regeneron Q2 adj. EPS $25.80; FactSet consensus $17.90
REGN,2021-08-05,10:41:15,589803,Regeneron Pharmaceuticals Inc.,100,0.48,revenues,above-expectations,Regeneron Q2 revenue $5.139 bln vs. $1.952 bln a year ago; FactSet consensus $3.963 bln,NEWS-FLASH,MarketWatch,MW Regeneron Q2 revenue $5.139 bln vs. $1.952 bln a year ago; FactSet consensus $3.963 bln
REGN,2021-08-05,10:44:59,589803,Regeneron Pharmaceuticals Inc.,100,0.46,equity-actions,,Regeneron to invest $1.8 bln over 6 years,NEWS-FLASH,MarketWatch,MW Regeneron to invest $1.8 bln over 6 years to expand R&D and manufacturing at Tarrytown campus
REGN,2021-08-05,11:44:03,589803,Regeneron Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Regeneron Earnings Top Estimates,FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Top Estimates. Its Stock May Be Breaking Out. -- Barrons.com
REGN,2021-08-05,11:44:03,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron reported a profit of $25.80,FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Top Estimates. Its Stock May Be Breaking Out. -- Barrons.com
REGN,2021-08-05,18:33:31,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc. CEO Leonard Schleifer on Q2 2021 Results -- Earnings Call,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharmaceuticals Inc. CEO Leonard Schleifer on Q2 2021 Results -- Earnings Call Transcript >REGN
REGN,2021-08-05,18:33:31,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron-pharmaceuticals-inc-regn-ceo-leonard-schleifer-on-q2-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharmaceuticals Inc. CEO Leonard Schleifer on Q2 2021 Results -- Earnings Call Transcript >REGN
REGN,2021-08-05,20:01:01,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,The Collaboration with Regeneron to,PRESS-RELEASE,Business Wire,Ocular Therapeutix(TM) Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases
REGN,2021-08-05,20:01:02,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,The Collaboration with Regeneron to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Ocular Therapeutix(TM) Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases
REGN,2021-08-05,20:01:14,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,The Collaboration With Regeneron to,NEWS-FLASH,Dow Jones Newswires,Ocular Therapeutix(TM) Announces Termination of the Collaboration With Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases
REGN,2021-08-06,12:17:10,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by SVB Leerink
REGN,2021-08-06,12:17:10,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $725.00/Share From $641.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $725.00/Share From $641.00 by SVB Leerink
REGN,2021-08-06,13:20:40,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Barclays
REGN,2021-08-06,13:20:40,589803,Regeneron Pharmaceuticals Inc.,100,0.52,price-targets,upgrade,Regeneron Pharma Price Target Raised to $705.00/Share From $675.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $705.00/Share From $675.00 by Barclays
REGN,2021-08-06,13:37:00,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by Oppenheimer
REGN,2021-08-06,13:37:00,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $825.00/Share From $725.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $825.00/Share From $725.00 by Oppenheimer
REGN,2021-08-06,20:03:58,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Bassler Sells 2,559 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Bassler Sells 2,559 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-06,20:05:09,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Pres Yancopoulos Sells 50,000 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Pres Yancopoulos Sells 50,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-06,20:26:41,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Pres Yancopoulos Registers 50,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Pres Yancopoulos Registers 50,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-09,20:23:34,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sing Registers 19,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Sing Registers 19,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-09,21:11:46,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Chi Nellie Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Chi Nellie Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-10,18:32:46,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Cfo Landry Registers 364 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,CFO Landry Registers 364 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-08-10,21:01:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sing Sells 6,950 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sing Sells 6,950 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-10,21:01:58,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Brown Sells 1,687 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Brown Sells 1,687 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-10,21:07:50,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Ceo Schleifer Acquires 171,425 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Schleifer Acquires 171,425 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-10,21:55:40,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp van Plew Sells 6,603 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP van Plew Sells 6,603 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-10,21:56:53,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Cfo Landry Sells 901 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Sells 901 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-08-11,19:05:27,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp van Plew Registers 6,603 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP van Plew Registers 6,603 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-11,19:56:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Cfo Landry Registers 537 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,CFO Landry Registers 537 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-08-13,21:20:27,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sing Sells 3,800 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sing Sells 3,800 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-16,19:26:26,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Coles Registers 2,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Coles Registers 2,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-16,19:47:52,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Pres Yancopoulos Registers 50,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Pres Yancopoulos Registers 50,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-16,20:07:56,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Coles Sells 2,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Coles Sells 2,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-17,20:14:32,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Pres Yancopoulos Sells 50,000 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Pres Yancopoulos Sells 50,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-17,20:17:52,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Bassler Sells 1,219 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Bassler Sells 1,219 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-17,20:18:13,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sing Sells 1,705 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sing Sells 1,705 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-17,20:44:27,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Schleifer Sells 10,000 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Schleifer Sells 10,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-18,18:36:04,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Coles Registers 900 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Coles Registers 900 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-08-19,18:14:27,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Coles Registers 5,100 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Coles Registers 5,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-19,19:05:57,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Ceo Schleifer Registers 200,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"CEO Schleifer Registers 200,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-19,20:05:15,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Coles Sells 6,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Coles Sells 6,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-19,20:06:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Vagelos Sells 10,039 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Vagelos Sells 10,039 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-20,11:00:06,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,granted,Regeneron Pharmaceuticals Inc.: UK Authorizes Regeneron Antibody Cocktail,PRESS-RELEASE,PR Newswire,UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection
REGN,2021-08-20,11:00:06,589803,Regeneron Pharmaceuticals Inc.,99,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: The robust REGEN-COV development program has reported positive Phase 3 trial results,PRESS-RELEASE,PR Newswire,UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection
REGN,2021-08-20,11:00:06,589803,Regeneron Pharmaceuticals Inc.,90,0.0,products-services,granted,Regeneron Pharmaceuticals Inc.: UK Authorizes Regeneron Antibody Cocktail,PRESS-RELEASE,PR Newswire,UK Authorizes Regeneron Antibody Cocktail to -2-
REGN,2021-08-20,11:00:06,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,granted,Regeneron Pharmaceuticals Inc.: UK Authorizes Regeneron Antibody Cocktail,PRESS-RELEASE,PR Newswire,UK Authorizes Regeneron Antibody Cocktail to -3-
REGN,2021-08-20,11:00:06,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Uk Authorizes Regeneron Antibody Cocktail,PRESS-RELEASE,Dow Jones Newswires,Press Release: UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection
REGN,2021-08-20,11:00:06,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,granted,Regeneron Pharmaceuticals Inc.: UK Authorizes Regeneron Antibody Cocktail,PRESS-RELEASE,Dow Jones Newswires,Press Release: UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection
REGN,2021-08-20,11:00:06,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: The robust REGEN-COV development program has reported positive Phase 3 trial results,PRESS-RELEASE,Dow Jones Newswires,Press Release: UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection
REGN,2021-08-20,11:00:06,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Uk Authorizes Regeneron Antibody,PRESS-RELEASE,Dow Jones Newswires,Press Release: UK Authorizes Regeneron Antibody -2-
REGN,2021-08-20,11:00:06,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Uk Authorizes Regeneron Antibody,PRESS-RELEASE,Dow Jones Newswires,Press Release: UK Authorizes Regeneron Antibody -3-
REGN,2021-08-20,11:17:49,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Gets U.K. Authorization for Covid-19 Antibody Cocktail,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets U.K. Authorization for Covid-19 Antibody Cocktail
REGN,2021-08-20,11:32:49,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Gets U.K. Authorization for Covid-19 Antibody Cocktail,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets U.K. Authorization for Covid-19 Antibody Cocktail
REGN,2021-08-20,20:03:58,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Schleifer Sells 210,000 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Schleifer Sells 210,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-23,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron stock price target raised to $727 from $636,NEWS-FLASH,MarketWatch,MW Regeneron stock price target raised to $727 from $636 at Benchmark
REGN,2021-08-24,11:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Announces Encouraging Topline Phase 2 Data,PRESS-RELEASE,PR Newswire,Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration
REGN,2021-08-24,11:00:08,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Announces Encouraging Topline Phase 2 Data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration
REGN,2021-08-24,11:00:11,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Announces Encouraging Topline Phase 2 Data,NEWS-FLASH,Dow Jones Newswires,Regeneron Announces Encouraging Topline Phase 2 Data of High-dose Aflibercept in Wet Age-related Macular Degeneration
REGN,2021-08-24,18:41:33,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Fenimore Registers 4,781 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Fenimore Registers 4,781 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-24,18:44:55,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Larosa Registers 3,425 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Larosa Registers 3,425 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-24,20:06:52,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Fenimore Sells 4,781 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Fenimore Sells 4,781 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-24,20:07:06,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Larosa Sells 3,425 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Larosa Sells 3,425 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-25,20:08:37,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Fenimore Surrenders 8,719 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Fenimore Surrenders 8,719 Of Regeneron Pharmaceuticals Inc >REGN-Amended"
REGN,2021-08-27,20:13:34,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Chmn Vagelos Acquires 25,718 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Vagelos Acquires 25,718 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-30,20:27:28,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sing Sells 1,700 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sing Sells 1,700 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-30,21:54:43,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Poon Christine Registers 15,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Poon Christine Registers 15,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-31,14:46:16,589803,Regeneron Pharmaceuticals Inc.,96,0.49,partnerships,,Regeneron (ticker: REGN) offers in partnership with Sanofi (SNY),FULL-ARTICLE,Dow Jones Newswires,Regeneron Is More Than a Covid Play. This Drug Could Be the World's Biggest Selling by 2030. -- Barrons.com
REGN,2021-08-31,18:56:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sing Registers 9,295 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Sing Registers 9,295 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-08-31,20:05:09,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Poon Sells 15,000 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Poon Sells 15,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-09-01,20:07:57,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,Cfo Landry Acquires 83 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Acquires 83 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-09-02,21:56:38,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-09-03,20:04:21,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-09-03,20:06:05,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-09-07,12:31:05,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley
REGN,2021-09-07,12:31:05,589803,Regeneron Pharmaceuticals Inc.,100,0.58,price-targets,upgrade,Regeneron Pharma Price Target Raised to $606.00/Share From $576.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $606.00/Share From $576.00 by Morgan Stanley
REGN,2021-09-09,15:39:15,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron started at buy with $763 stock price target at UBS,NEWS-FLASH,MarketWatch,MW Regeneron started at buy with $763 stock price target at UBS
REGN,2021-09-13,19:12:04,589803,Regeneron Pharmaceuticals Inc.,100,0.0,marketing,,"Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Morgan Stanley 19th Annual Global Healthcare Conference",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript) >REGN"
REGN,2021-09-14,19:14:46,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Zoghbi Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Zoghbi Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-09-14,19:23:26,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Tessier-Lavigne Registers 12,750 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Tessier-Lavigne Registers 12,750 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-09-14,21:33:51,589803,Regeneron Pharmaceuticals Inc.,99,-0.58,products-services,denied,Regen-COV has not been approved by the FDA,PRESS-RELEASE,PR Newswire,Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV(TM) (casirivimab and imdevimab) Antibody Cocktail
REGN,2021-09-14,21:33:51,589803,Regeneron Pharmaceuticals Inc.,99,-0.58,products-services,denied,Regen-COV has not been approved by the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV(TM) (casirivimab and imdevimab) Antibody Cocktail
REGN,2021-09-15,10:20:56,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by HC Wainwright & Co.
REGN,2021-09-15,10:20:56,589803,Regeneron Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Regeneron Pharma Price Target Raised to $831.00/Share From $787.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $831.00/Share From $787.00 by HC Wainwright & Co.
REGN,2021-09-15,20:04:10,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Tessier-Lavigne Sells 12,750 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Tessier-Lavigne Sells 12,750 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-09-15,20:04:31,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Zoghbi Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Zoghbi Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-09-15,20:06:17,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Brown Sells 9,704 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Brown Sells 9,704 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-09-16,20:23:28,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Coles Registers 11,948 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Coles Registers 11,948 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-09-17,20:03:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Coles Sells 11,948 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Coles Sells 11,948 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-09-20,17:52:16,589803,Regeneron Pharmaceuticals Inc.,100,0.0,marketing,,Management Presents at Regeneron Oncology Investor Event,NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Regeneron Oncology Investor Event, ESMO 2021 Conference (Transcript) >REGN"
REGN,2021-09-21,16:13:21,589803,Regeneron Pharmaceuticals Inc.,100,0.0,marketing,,Management Presents at Regeneron Oncology Investor Event,NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc.'s (REGN) Management Presents at Regeneron Oncology Investor Event, ESMO 2021 Conference (Transcript) >REGN"
REGN,2021-09-28,11:00:10,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda Accepts Libtayo(R) (cemiplimab-rwlc) for Priority Review,PRESS-RELEASE,PR Newswire,FDA Accepts Libtayo(R) (cemiplimab-rwlc) for Priority Review for Advanced Cervical Cancer
REGN,2021-09-28,11:00:10,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Accepts Libtayo(R) (cemiplimab-rwlc),PRESS-RELEASE,PR Newswire,FDA Accepts Libtayo(R) (cemiplimab-rwlc) for -2-
REGN,2021-09-28,11:00:10,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Accepts Libtayo(R) (cemiplimab-rwlc),PRESS-RELEASE,PR Newswire,FDA Accepts Libtayo(R) (cemiplimab-rwlc) for -3-
REGN,2021-09-28,11:00:10,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA Accepts Libtayo(R) (cemiplimab-rwlc),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Libtayo(R) (cemiplimab-rwlc) for Priority Review for Advanced Cervical Cancer
REGN,2021-09-28,11:00:10,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda Accepts Libtayo(R) (cemiplimab-rwlc) for Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Libtayo(R) (cemiplimab-rwlc) for Priority Review for Advanced Cervical Cancer
REGN,2021-09-28,11:00:10,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA Accepts Libtayo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Libtayo(R) -2-
REGN,2021-09-28,11:00:10,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Accepts Libtayo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Libtayo(R) -3-
REGN,2021-09-28,11:00:48,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Accepts Libtayo,NEWS-FLASH,Dow Jones Newswires,Regeneron: FDA Accepts Libtayo for Priority Review for Advanced Cervical Cancer
REGN,2021-09-28,11:20:23,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Gets FDA Priority Review of Libtayo,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets FDA Priority Review of Libtayo in Advanced Cervical Cancer
REGN,2021-09-28,11:20:23,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets FDA Priority Review of Libtayo in Advanced Cervical Cancer
REGN,2021-09-28,11:35:23,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Gets FDA Priority Review of Libtayo,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets FDA Priority Review of Libtayo in Advanced Cervical Cancer
REGN,2021-09-28,11:35:23,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets FDA Priority Review of Libtayo in Advanced Cervical Cancer
REGN,2021-09-29,21:00:04,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Positive Phase 3 Trial Results for REGEN-COV(TM),PRESS-RELEASE,PR Newswire,New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV(TM) (casirivimab and imdevimab) to Treat COVID-19
REGN,2021-09-29,21:00:04,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron previously presented initial results from the Phase 3 trial at the 2021,PRESS-RELEASE,PR Newswire,New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV(TM) (casirivimab and imdevimab) to Treat COVID-19
REGN,2021-09-29,21:00:04,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,products-services,denied,Regen-COV has not been approved by the FDA,PRESS-RELEASE,PR Newswire,New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV(TM) (casirivimab and imdevimab) to Treat COVID-19
REGN,2021-09-29,21:00:04,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Positive Phase 3 Trial Results for REGEN-COV(TM),PRESS-RELEASE,Dow Jones Newswires,Press Release: New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV(TM) (casirivimab and imdevimab) to Treat COVID-19
REGN,2021-09-29,21:00:04,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron previously presented initial results from the Phase 3 trial at the 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV(TM) (casirivimab and imdevimab) to Treat COVID-19
REGN,2021-09-29,21:00:04,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,products-services,denied,Regen-COV has not been approved by the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV(TM) (casirivimab and imdevimab) to Treat COVID-19
REGN,2021-09-29,21:01:16,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Positive Phase 3 Trial Results for REGEN-COV,NEWS-FLASH,Dow Jones Newswires,New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV to Treat COVID-19
REGN,2021-10-04,20:10:14,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-10-04,20:12:03,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-10-04,22:06:05,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-10-04,22:08:46,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Ryan Registers 300 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Ryan Registers 300 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-10-11,20:15:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report Third Quarter 2021 Financial and Operating Results,PRESS-RELEASE,PR Newswire,"Regeneron to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2021"
REGN,2021-10-11,20:15:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM,PRESS-RELEASE,PR Newswire,"Regeneron to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2021"
REGN,2021-10-11,20:15:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report Third Quarter 2021 Financial and Operating Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2021"
REGN,2021-10-11,20:15:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2021"
REGN,2021-10-12,12:53:38,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley
REGN,2021-10-12,12:53:38,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Regeneron Pharma Price Target Cut to $571.00/Share From $606.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $571.00/Share From $606.00 by Morgan Stanley
REGN,2021-10-14,11:21:19,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Accepts REGEN-COV,PRESS-RELEASE,PR Newswire,FDA Accepts REGEN-COV(R) (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19
REGN,2021-10-14,11:21:19,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Accepts REGEN-COV,PRESS-RELEASE,PR Newswire,FDA Accepts REGEN-COV(R) (casirivimab and -2-
REGN,2021-10-14,11:21:19,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Accepts REGEN-COV,PRESS-RELEASE,PR Newswire,FDA Accepts REGEN-COV(R) (casirivimab and -3-
REGN,2021-10-14,11:21:19,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA Accepts REGEN-COV,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts REGEN-COV(R) (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19
REGN,2021-10-14,11:21:19,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA Accepts REGEN-COV,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts REGEN-COV(R) -2-
REGN,2021-10-14,11:21:19,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA Accepts REGEN-COV,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts REGEN-COV(R) -3-
REGN,2021-10-14,11:22:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals: FDA Accepts REGEN-COV,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharmaceuticals: FDA Accepts REGEN-COV for Priority Review for Treatment and Prophylaxis of Covid-19
REGN,2021-10-14,11:42:14,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Pharmaceuticals Inc. on Thursday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Cocktail Gets FDA Priority Review for Covid-19 Treatment, Prevention"
REGN,2021-10-14,11:51:00,589803,Regeneron Pharmaceuticals Inc.,94,0.0,products-services,granted,Regeneron Pharmaceuticals Inc.: the company said the Food and Drug Administration accepted its application,FULL-ARTICLE,MarketWatch,MW Regeneron is seeking full FDA approval for its monoclonal antibody for two types of COVID-19 patients
REGN,2021-10-14,11:51:00,589803,Regeneron Pharmaceuticals Inc.,94,0.0,products-services,granted,Regeneron Pharmaceuticals Inc.: the company said the Food and Drug Administration accepted its application,FULL-ARTICLE,Dow Jones Newswires,Regeneron Is Seeking Full FDA Approval For Its Monoclonal Antibody For Two Types Of COVID-19 Patients -- MarketWatch
REGN,2021-10-14,11:57:14,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Pharmaceuticals Inc. on Thursday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Cocktail Gets FDA Priority Review for Covid-19 Treatment, Prevention"
REGN,2021-10-14,14:39:11,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Analysts expect Regeneron to report $2.9 billion in sales,FULL-ARTICLE,Dow Jones Newswires,FDA Will Consider Regeneron's Covid-19 Antibody for Full Approval -- Barrons.com
REGN,2021-10-21,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.63,products-services,,Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001,PRESS-RELEASE,GlobeNewswire,"Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis"
REGN,2021-10-21,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.62,products-services,positive,Regeneron announced positive interim clinical results,PRESS-RELEASE,GlobeNewswire,"Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis"
REGN,2021-10-21,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Discovery, development and commercialization collaboration with Regeneron",PRESS-RELEASE,GlobeNewswire,"Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis"
REGN,2021-10-21,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.63,products-services,,Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis"
REGN,2021-10-21,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.62,products-services,positive,Regeneron announced positive interim clinical results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis"
REGN,2021-10-21,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Discovery, development and commercialization collaboration with Regeneron",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis"
REGN,2021-10-21,11:30:20,589803,Regeneron Pharmaceuticals Inc.,100,0.63,products-services,,Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001,NEWS-FLASH,Dow Jones Newswires,"Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis"
REGN,2021-10-21,11:43:24,589803,Regeneron Pharmaceuticals Inc.,100,0.63,products-services,,Intellia Gets FDA Orphan Designation for NTLA-2001,FULL-ARTICLE,Dow Jones Newswires,Intellia Gets FDA Orphan Designation for NTLA-2001 in ATTR Amyloidosis >NTLA
REGN,2021-10-21,11:58:24,589803,Regeneron Pharmaceuticals Inc.,100,0.63,products-services,,Intellia Gets FDA Orphan Designation for NTLA-2001,FULL-ARTICLE,Dow Jones Newswires,Intellia Gets FDA Orphan Designation for NTLA-2001 in ATTR Amyloidosis
REGN,2021-10-22,05:03:08,589803,Regeneron Pharmaceuticals Inc.,100,0.62,products-services,positive,Sanofi: Phase 3 Trial for Dupixent in Prurigo Nodularis Met Primary and Key Secondary Endpoints,NEWS-FLASH,Dow Jones Newswires,Sanofi: Phase 3 Trial for Dupixent in Prurigo Nodularis Met Primary and Key Secondary Endpoints
REGN,2021-10-22,10:09:13,589803,Regeneron Pharmaceuticals Inc.,93,0.84,products-services,positive,Dupixent has shown positive Phase 3 results,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi: Dupixent Hits Main Endpoints in Prurigo Nodularis Trial"
REGN,2021-10-22,10:24:13,589803,Regeneron Pharmaceuticals Inc.,93,0.84,products-services,positive,Dupixent has shown positive Phase 3 results,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi: Dupixent Hits Main Endpoints in Prurigo Nodularis Trial"
REGN,2021-10-22,16:51:00,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by HC Wainwright & Co.
REGN,2021-10-22,16:51:00,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $842.00/Share From $831.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $842.00/Share From $831.00 by HC Wainwright & Co.
REGN,2021-10-26,11:00:33,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by SVB Leerink
REGN,2021-10-26,11:00:33,589803,Regeneron Pharmaceuticals Inc.,100,0.32,price-targets,upgrade,Regeneron Pharma Price Target Raised to $798.00/Share From $785.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $798.00/Share From $785.00 by SVB Leerink
REGN,2021-10-29,11:00:05,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Libtayo(R) (cemiplimab) is now approved in Canada for the first,PRESS-RELEASE,Canadian News Wire,"Libtayo® (cemiplimab) approved in Canada for the first-line treatment of adult patients with non-small cell lung cancer expressing PD-L1 in 50% of tumour cells with no EGFR, ALK or ROS1 aberrations"
REGN,2021-10-29,11:00:05,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Libtayo is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Canadian News Wire,"Libtayo® (cemiplimab) approved in Canada for the first-line treatment of adult patients with non-small cell lung cancer expressing PD-L1 in 50% of tumour cells with no EGFR, ALK or ROS1 aberrations"
REGN,2021-10-29,11:06:39,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi: Libtayo Approved in Canada,NEWS-FLASH,Dow Jones Newswires,Sanofi: Libtayo Approved in Canada for Locally Advanced Basal Cell Carcinoma Patients
REGN,2021-11-03,20:12:25,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-11-03,20:15:45,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2021",PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.62,revenues,up,Regeneron Pharmaceuticals Inc.: Third quarter 2021 revenues increased 51% to $3.45 billion,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Third quarter 2021 GAAP diluted EPS was $14.33,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: FDA expanded approval of Dupixent,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: we announced positive data from Phase 3 trials of Dupixent,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.62,products-services,positive,Regeneron Pharmaceuticals Inc.: We also recently announced positive data from Phase 3 trials,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Regeneron Pharmaceuticals Inc.: EYLEA(R) (aflibercept) Injection,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Results from an additional Phase 3 trial,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,"Regen-COV doses delivered by January 31, 2022",PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,To Regeneron to fulfill Regeneron's agreement with,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,-0.47,regulatory,,Regeneron Pharmaceuticals Inc.: The FDA is currently reviewing the Company's,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: the Company plans to submit a BLA,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: Positive data from the Phase 3 trial of Libtayo,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 3 study of pozelimab,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial -2-
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,-0.68,revenues,down,Regeneron Pharmaceuticals Inc.: Other revenue decreased in the third quarter of 2021,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial -2-
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: The increase in SG&A expenses in the third quarter of 2021,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial -2-
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $14.33 in the third quarter of 2021,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial -2-
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $15.37 in the third quarter of 2021,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial -2-
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2021 Financial Guidance,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial -2-
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2021 financial guidance,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial -3-
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: Conference Call Information,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial -3-
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: fiscal year ended December 31, 2020 and its Form 10-Q for the quarterly",PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial -4-
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: September 30, December 31, 2021 2020 Assets",PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial -4-
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial -4-
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Net income $1,632.2 $842.1",PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial -4-
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $15.37 $7.98,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial -4-
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $16.69 $9.11,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial -4-
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total collaboration revenue,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2021 Financial -4-
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 3Q EPS $14.33,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q EPS $14.33 >REGN
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 3Q Net $1.63B,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q Net $1.63B >REGN
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 3Q Rev $3.45B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q Rev $3.45B >REGN
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.62,revenues,up,Regeneron Pharmaceuticals Inc.: Third quarter 2021 revenues increased 51% to $3.45 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Third quarter 2021 GAAP diluted EPS was $14.33,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: FDA expanded approval of Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: we announced positive data from Phase 3 trials of Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.62,products-services,positive,Regeneron Pharmaceuticals Inc.: We also recently announced positive data from Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Regeneron Pharmaceuticals Inc.: EYLEA(R) (aflibercept) Injection,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Results from an additional Phase 3 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,"Regen-COV doses delivered by January 31, 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,To Regeneron to fulfill Regeneron's agreement with,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,-0.47,regulatory,,Regeneron Pharmaceuticals Inc.: The FDA is currently reviewing the Company's,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: the Company plans to submit a BLA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: Positive data from the Phase 3 trial of Libtayo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 3 study of pozelimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2021 Financial and Operating Results
REGN,2021-11-04,10:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2021-11-04,10:30:10,589803,Regeneron Pharmaceuticals Inc.,99,-0.68,revenues,down,Regeneron Pharmaceuticals Inc.: Other revenue decreased in the third quarter of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2021-11-04,10:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: The increase in SG&A expenses in the third quarter of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2021-11-04,10:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $14.33 in the third quarter of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2021-11-04,10:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $15.37 in the third quarter of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2021-11-04,10:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2021-11-04,10:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2021 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -3-
REGN,2021-11-04,10:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: Conference Call Information,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -3-
REGN,2021-11-04,10:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: fiscal year ended December 31, 2020 and its Form 10-Q for the quarterly",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2021-11-04,10:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: September 30, December 31, 2021 2020 Assets",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2021-11-04,10:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2021-11-04,10:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Net income $1,632.2 $842.1",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2021-11-04,10:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $15.37 $7.98,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2021-11-04,10:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $16.69 $9.11,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2021-11-04,10:30:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total collaboration revenue,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2021-11-04,10:31:24,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharma 3Q Eylea U.S. Net Sales Rose 12% to $1.47B,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q Eylea U.S. Net Sales Rose 12% to $1.47B >REGN
REGN,2021-11-04,10:31:42,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 3Q Adj EPS $15.37,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q Adj EPS $15.37 >REGN
REGN,2021-11-04,10:34:54,589803,Regeneron Pharmaceuticals Inc.,100,0.8,earnings,up,Regeneron Q3 EPS $14.33 vs. $7.39 a year ago,NEWS-FLASH,MarketWatch,MW Regeneron Q3 EPS $14.33 vs. $7.39 a year ago
REGN,2021-11-04,10:35:10,589803,Regeneron Pharmaceuticals Inc.,100,0.62,earnings,above-expectations,Regeneron Q3 adj. EPS $15.37; FactSet consensus $10.20,NEWS-FLASH,MarketWatch,MW Regeneron Q3 adj. EPS $15.37; FactSet consensus $10.20
REGN,2021-11-04,10:35:33,589803,Regeneron Pharmaceuticals Inc.,100,0.48,revenues,above-expectations,Regeneron Q3 revenue $3.453 bln vs. $2.294 bln a year ago; FactSet consensus $2.746 bln,NEWS-FLASH,MarketWatch,MW Regeneron Q3 revenue $3.453 bln vs. $2.294 bln a year ago; FactSet consensus $2.746 bln
REGN,2021-11-04,10:46:54,589803,Regeneron Pharmaceuticals Inc.,100,0.64,earnings,up,Regeneron earnings boosted by,FULL-ARTICLE,MarketWatch,MW Regeneron earnings boosted by $804 million in sales of COVID antibody treatment
REGN,2021-11-04,10:46:54,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: The company posted net income of $1.632 billion,FULL-ARTICLE,MarketWatch,MW Regeneron earnings boosted by $804 million in sales of COVID antibody treatment
REGN,2021-11-04,10:46:54,589803,Regeneron Pharmaceuticals Inc.,100,0.64,earnings,up,Regeneron Earnings Boosted By,FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Boosted By $804 Million In Sales Of COVID Antibody Treatment -- MarketWatch
REGN,2021-11-04,10:46:54,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: The company posted net income of $1.632 billion,FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Boosted By $804 Million In Sales Of COVID Antibody Treatment -- MarketWatch
REGN,2021-11-04,10:50:51,589803,Regeneron Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Regeneron earnings top estimates,NEWS-FLASH,MarketWatch,MW Regeneron earnings top estimates on strong sales of COVID antibody treatment
REGN,2021-11-04,13:53:53,589803,Regeneron Pharmaceuticals Inc.,100,0.6,earnings,above-expectations,Regeneron Earnings Blow Past Estimates,FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Blow Past Estimates on Strong Covid-19 Antibody Sales -- Barrons.com
REGN,2021-11-04,13:53:53,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals reported third-quarter earnings,FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Blow Past Estimates on Strong Covid-19 Antibody Sales -- Barrons.com
REGN,2021-11-04,13:53:53,589803,Regeneron Pharmaceuticals Inc.,100,0.62,revenues,up,"Regeneron reported revenue for the quarter of $3.5 billion, up 51% since the same quarter",FULL-ARTICLE,Dow Jones Newswires,Regeneron Earnings Blow Past Estimates on Strong Covid-19 Antibody Sales -- Barrons.com
REGN,2021-11-04,14:00:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron will host a conference call,PRESS-RELEASE,PR Newswire,Regeneron Presentations at ASH Highlight Expanding Clinical Research in Blood Cancers and Disorders
REGN,2021-11-04,14:00:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron will host a conference call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Presentations at ASH Highlight Expanding Clinical Research in Blood Cancers and Disorders
REGN,2021-11-04,17:51:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals, Inc. CEO Leonard Schleifer on Q3 2021 Results -- Earnings Call",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc. CEO Leonard Schleifer on Q3 2021 Results -- Earnings Call Transcript >REGN"
REGN,2021-11-04,17:51:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron-pharmaceuticals-inc-regn-ceo-leonard-schleifer-on-q3-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc. CEO Leonard Schleifer on Q3 2021 Results -- Earnings Call Transcript >REGN"
REGN,2021-11-05,10:41:36,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by HC Wainwright & Co.
REGN,2021-11-05,10:41:36,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $844.00/Share From $842.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $844.00/Share From $842.00 by HC Wainwright & Co.
REGN,2021-11-05,15:05:48,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by SVB Leerink
REGN,2021-11-05,15:05:48,589803,Regeneron Pharmaceuticals Inc.,100,0.64,price-targets,upgrade,Regeneron Pharma Price Target Raised to $850.00/Share From $798.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $850.00/Share From $798.00 by SVB Leerink
REGN,2021-11-08,12:04:15,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron says data from Phase 3 trial,NEWS-FLASH,MarketWatch,MW Regeneron says data from Phase 3 trial shows its antibody treatment reduces risk of COVID by 81.6% after 8 months
REGN,2021-11-08,15:31:00,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,The Food and Drug Administration has authorized the use of REGEN-COV,FULL-ARTICLE,Dow Jones Newswires,"Regeneron's Antibody Drug Cut Risk of Covid-19 by 82%, Company Says"
REGN,2021-11-08,15:50:04,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,The Food and Drug Administration has authorized the use of REGEN-COV,FULL-ARTICLE,Dow Jones Newswires,"Regeneron's Antibody Drug Cut Risk of Covid-19 by 82%, Company Says"
REGN,2021-11-09,07:32:32,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,The Food and Drug Administration has authorized the use of REGEN-COV,FULL-ARTICLE,Wall Street Journal,"Treatment Cut Covid Risk, Says Regeneron -- WSJ"
REGN,2021-11-09,14:46:23,589803,Regeneron Pharmaceuticals Inc.,100,0.0,credit-ratings,action,"Moody's Announces Completion Of A Periodic Review Of Ratings Of Regeneron Pharmaceuticals, Inc.",NEWS-FLASH,Dow Jones Newswires,"Moody's Announces Completion Of A Periodic Review Of Ratings Of Regeneron Pharmaceuticals, Inc."
REGN,2021-11-10,08:04:47,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Bayer Submits Aflibercept for Approval in EU,NEWS-FLASH,Dow Jones Newswires,"Bayer Submits Aflibercept for Approval in EU, Japan for Retinopathy of Prematurity in Premature Babies"
REGN,2021-11-11,16:03:08,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Eu Approval of Regeneron Antibody Cocktail,PRESS-RELEASE,PR Newswire,CHMP Recommends EU Approval of Regeneron Antibody Cocktail to Treat and Prevent COVID-19
REGN,2021-11-11,16:03:08,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: The positive opinion is based on two positive Phase 3 trials,PRESS-RELEASE,PR Newswire,CHMP Recommends EU Approval of Regeneron Antibody Cocktail to Treat and Prevent COVID-19
REGN,2021-11-11,16:03:08,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,products-services,denied,Regen-COV has not been approved by the FDA,PRESS-RELEASE,PR Newswire,CHMP Recommends EU Approval of Regeneron Antibody Cocktail to Treat and Prevent COVID-19
REGN,2021-11-11,16:03:08,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Eu Approval of Regeneron Antibody,PRESS-RELEASE,PR Newswire,CHMP Recommends EU Approval of Regeneron Antibody -2-
REGN,2021-11-11,16:03:08,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Eu Approval of Regeneron Antibody,PRESS-RELEASE,PR Newswire,CHMP Recommends EU Approval of Regeneron Antibody -3-
REGN,2021-11-11,16:03:08,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Eu Approval of Regeneron Antibody Cocktail,PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP Recommends EU Approval of Regeneron Antibody Cocktail to Treat and Prevent COVID-19
REGN,2021-11-11,16:03:08,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: The positive opinion is based on two positive Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP Recommends EU Approval of Regeneron Antibody Cocktail to Treat and Prevent COVID-19
REGN,2021-11-11,16:03:08,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,products-services,denied,Regen-COV has not been approved by the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP Recommends EU Approval of Regeneron Antibody Cocktail to Treat and Prevent COVID-19
REGN,2021-11-11,16:27:54,589803,Regeneron Pharmaceuticals Inc.,97,0.57,products-services,granted,The U.S. Food and Drug Administration previously granted emergency-use authorization for REGEN-COV,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets CHMP Backing for Covid-19 Cocktail >REGN
REGN,2021-11-11,16:42:54,589803,Regeneron Pharmaceuticals Inc.,96,0.57,products-services,granted,The U.S. Food and Drug Administration previously granted emergency-use authorization for REGEN-COV,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets CHMP Backing for Covid-19 Cocktail
REGN,2021-11-12,15:20:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Antibody Cocktail Approved by European Commission,PRESS-RELEASE,PR Newswire,Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19
REGN,2021-11-12,15:20:03,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: The EC approval is based on two positive Phase 3 trials,PRESS-RELEASE,PR Newswire,Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19
REGN,2021-11-12,15:20:03,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,products-services,denied,Regen-COV has not been approved by the FDA,PRESS-RELEASE,PR Newswire,Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19
REGN,2021-11-12,15:20:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Antibody Cocktail Approved by European,PRESS-RELEASE,PR Newswire,Regeneron Antibody Cocktail Approved by European -2-
REGN,2021-11-12,15:20:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Antibody Cocktail Approved by European,PRESS-RELEASE,PR Newswire,Regeneron Antibody Cocktail Approved by European -3-
REGN,2021-11-12,15:20:12,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Antibody Cocktail Approved by European Commission,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19
REGN,2021-11-12,15:20:12,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: The EC approval is based on two positive Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19
REGN,2021-11-12,15:20:12,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,products-services,denied,Regen-COV has not been approved by the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19
REGN,2021-11-12,15:20:20,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Antibody Cocktail Approved by European Commission,NEWS-FLASH,Dow Jones Newswires,Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent Covid-19
REGN,2021-11-12,21:11:28,589803,Regeneron Pharmaceuticals Inc.,100,0.59,equity-actions,approved,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that its Board of Directors authorized a share repurchase program",PRESS-RELEASE,PR Newswire,Regeneron Announces $3 Billion Share Repurchase Program
REGN,2021-11-12,21:11:28,589803,Regeneron Pharmaceuticals Inc.,100,0.59,equity-actions,,Regeneron Announces $3 Billion Share Repurchase Program,NEWS-FLASH,Dow Jones Newswires,Regeneron Announces $3 Billion Share Repurchase Program >REGN
REGN,2021-11-12,21:11:28,589803,Regeneron Pharmaceuticals Inc.,100,0.59,equity-actions,approved,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that its Board of Directors authorized a share repurchase program",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces $3 Billion Share Repurchase Program
REGN,2021-11-12,21:18:37,589803,Regeneron Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Regeneron's board OKs $3 billion share buyback program,FULL-ARTICLE,MarketWatch,MW Regeneron's board OKs $3 billion share buyback program
REGN,2021-11-12,21:18:37,589803,Regeneron Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Regeneron's Board OKs $3 Billion Share Buyback Program,FULL-ARTICLE,Dow Jones Newswires,Regeneron's Board OKs $3 Billion Share Buyback Program -- MarketWatch
REGN,2021-11-12,21:23:42,589803,Regeneron Pharmaceuticals Inc.,100,0.59,equity-actions,,Regeneron Announces $3 Billion Share Repurchase Program,FULL-ARTICLE,Dow Jones Newswires,Regeneron Announces $3 Billion Share Repurchase Program >REGN
REGN,2021-11-12,21:23:42,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron reported a profit of $5.85 billion,FULL-ARTICLE,Dow Jones Newswires,Regeneron Announces $3 Billion Share Repurchase Program >REGN
REGN,2021-11-12,21:38:42,589803,Regeneron Pharmaceuticals Inc.,100,0.59,equity-actions,,Regeneron Announces $3 Billion Share Repurchase Program,FULL-ARTICLE,Dow Jones Newswires,Regeneron Announces $3 Billion Share Repurchase Program
REGN,2021-11-12,21:38:42,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron reported a profit of $5.85 billion,FULL-ARTICLE,Dow Jones Newswires,Regeneron Announces $3 Billion Share Repurchase Program
REGN,2021-11-15,12:00:18,589803,Regeneron Pharmaceuticals Inc.,100,0.57,equity-actions,listing,Regeneron Listed on Dow Jones Sustainability World Index for Third,PRESS-RELEASE,PR Newswire,Regeneron Listed on Dow Jones Sustainability World Index for Third Consecutive Year
REGN,2021-11-15,12:00:18,589803,Regeneron Pharmaceuticals Inc.,100,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,PR Newswire,Regeneron Listed on Dow Jones Sustainability World Index for Third Consecutive Year
REGN,2021-11-15,12:00:18,589803,Regeneron Pharmaceuticals Inc.,100,0.57,equity-actions,listing,Regeneron Listed on Dow Jones Sustainability World Index for Third,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Listed on Dow Jones Sustainability World Index for Third Consecutive Year
REGN,2021-11-15,12:00:18,589803,Regeneron Pharmaceuticals Inc.,100,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Listed on Dow Jones Sustainability World Index for Third Consecutive Year
REGN,2021-11-17,20:05:30,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp van Plew Registers 6,778 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP van Plew Registers 6,778 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-11-17,20:14:44,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Murphy Registers 7,167 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Murphy Registers 7,167 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-11-17,20:47:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sing Registers 20,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Sing Registers 20,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-11-17,21:04:45,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp van Plew Sells 6,778 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP van Plew Sells 6,778 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-11-18,21:03:18,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Cfo Landry Registers 681 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,CFO Landry Registers 681 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-11-18,21:24:19,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Cfo Landry Sells 681 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Sells 681 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-11-19,22:51:39,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Ceo Schleifer Acquires 161,176 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Schleifer Acquires 161,176 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-11-22,12:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Under Strategic Collaboration with Regeneron to,PRESS-RELEASE,GlobeNewswire,Decibel Therapeutics Announces Extension of Research Term under Strategic Collaboration with Regeneron to Discover and Develop Gene Therapies for Hearing Loss
REGN,2021-11-22,12:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Under Strategic Collaboration with Regeneron to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Decibel Therapeutics Announces Extension of Research Term under Strategic Collaboration with Regeneron to Discover and Develop Gene Therapies for Hearing Loss
REGN,2021-11-22,12:30:13,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Under Strategic Collaboration With Regeneron to,NEWS-FLASH,Dow Jones Newswires,Decibel Therapeutics Announces Extension of Research Term Under Strategic Collaboration With Regeneron to Discover and Develop Gene Therapies for Hearing Loss
REGN,2021-11-23,05:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.28,products-services,,Regeneron to Develop Innovative Vaccines,PRESS-RELEASE,Business Wire,Nykode Therapeutics (Formerly Vaccibody(*) ) Enters Into Multi-target License and Collaboration Agreement With Regeneron to Develop Innovative Vaccines Against Cancer and Infectious Diseases
REGN,2021-11-23,05:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Regeneron said: ""Collaborating with Nykode Therapeutics will bring another dimension to",PRESS-RELEASE,Business Wire,Nykode Therapeutics (Formerly Vaccibody(*) ) Enters Into Multi-target License and Collaboration Agreement With Regeneron to Develop Innovative Vaccines Against Cancer and Infectious Diseases
REGN,2021-11-23,05:45:01,589803,Regeneron Pharmaceuticals Inc.,100,0.28,products-services,,Regeneron to Develop Innovative Vaccines,PRESS-RELEASE,Dow Jones Newswires,Press Release: Nykode Therapeutics (Formerly Vaccibody*)) Enters Into Multi-target License and Collaboration Agreement With Regeneron to Develop Innovative Vaccines Against Cancer and Infectious Diseases
REGN,2021-11-23,05:45:01,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Regeneron said: ""Collaborating with Nykode Therapeutics will bring another dimension to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Nykode Therapeutics (Formerly Vaccibody*)) Enters Into Multi-target License and Collaboration Agreement With Regeneron to Develop Innovative Vaccines Against Cancer and Infectious Diseases
REGN,2021-11-23,06:05:27,589803,Regeneron Pharmaceuticals Inc.,100,0.28,products-services,,Regeneron To Develop Innovative Vaccines,PRESS-RELEASE,Oslo Bors News,VACCIBODY: Nykode Therapeutics (Formerly Vaccibody*)) Enters Into Multi-Target License And Collaboration Agreement With Regeneron To Develop Innovative Vaccines Against Cancer And Infectious Diseases
REGN,2021-11-23,06:05:27,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Regeneron said: ""Collaborating with Nykode Therapeutics will bring another dimension to",PRESS-RELEASE,Oslo Bors News,VACCIBODY: Nykode Therapeutics (Formerly Vaccibody*)) Enters Into Multi-Target License And Collaboration Agreement With Regeneron To Develop Innovative Vaccines Against Cancer And Infectious Diseases
REGN,2021-11-23,07:25:44,589803,Regeneron Pharmaceuticals Inc.,93,0.39,products-services,,"Vaccibody AS, said it has signed a deal with Regeneron Pharmaceuticals Inc.",FULL-ARTICLE,Dow Jones Newswires,Nykode Therapeutics in Vaccine Deal With Regeneron Worth Up to $925 Mln
REGN,2021-11-23,07:40:44,589803,Regeneron Pharmaceuticals Inc.,93,0.39,products-services,,"Vaccibody AS, said it has signed a deal with Regeneron Pharmaceuticals Inc.",FULL-ARTICLE,Dow Jones Newswires,Nykode Therapeutics in Vaccine Deal With Regeneron Worth Up to $925 Million
REGN,2021-11-23,21:30:27,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sing Sells 3,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sing Sells 3,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-11-30,10:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Confo Therapeutics Enters Collaborative Agreement with Regeneron,PRESS-RELEASE,Business Wire,Confo Therapeutics Enters Collaborative Agreement with Regeneron
REGN,2021-11-30,10:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Confo will work together with Regeneron to,PRESS-RELEASE,Business Wire,Confo Therapeutics Enters Collaborative Agreement with Regeneron
REGN,2021-12-01,19:12:05,589803,Regeneron Pharmaceuticals Inc.,100,0.0,marketing,,"Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Piper Sandler 33rd Annual Healthcare Conference",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Piper Sandler 33rd Annual Healthcare Conference Call (Transcript) >REGN"
REGN,2021-12-02,20:35:41,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-12-02,21:05:03,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-12-02,21:10:58,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-12-03,15:00:06,589803,Regeneron Pharmaceuticals Inc.,100,0.0,marketing,,Regeneron to Participate in H.C. Wainwright & Co. Virtual Event,PRESS-RELEASE,PR Newswire,Regeneron to Participate in H.C. Wainwright & Co. Virtual Event
REGN,2021-12-03,15:04:40,589803,Regeneron Pharmaceuticals Inc.,100,0.0,marketing,,Regeneron to Participate in H.C. Wainwright & Co. Virtual Event,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron to Participate in H.C. Wainwright & Co. Virtual Event
REGN,2021-12-06,12:20:24,589803,Regeneron Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Regeneron Pharma Initiated at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Initiated at Buy by Goldman Sachs
REGN,2021-12-06,12:20:24,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $824.00/Share by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $824.00/Share by Goldman Sachs
REGN,2021-12-06,21:10:58,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Vp Stahl Acquires 22,148 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stahl Acquires 22,148 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-12-09,13:40:13,589803,Regeneron Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Regeneron Pharma Initiated at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Initiated at Overweight by Wells Fargo
REGN,2021-12-09,13:40:13,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $750.00/Share by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $750.00/Share by Wells Fargo
REGN,2021-12-10,21:05:41,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Tessier-Lavigne Registers 3,784 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Tessier-Lavigne Registers 3,784 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-12-10,22:32:18,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Vp Larosa Acquires 10,228 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Larosa Acquires 10,228 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-12-10,22:39:41,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Cfo Landry Sells 781 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Sells 781 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-12-10,23:43:44,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Murphy Sells 7,122 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Murphy Sells 7,122 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-12-11,17:00:04,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron will host a conference call,PRESS-RELEASE,PR Newswire,New REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose Levels Studied in Patients with Heavily Pretreated Multiple Myeloma
REGN,2021-12-13,06:10:26,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Sanofi's Dupixent Shows Good Results in Phase-3 Trial,NEWS-FLASH,Dow Jones Newswires,Sanofi's Dupixent Shows Good Results in Phase-3 Trial
REGN,2021-12-13,21:50:52,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Murphy Registers 7,122 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Murphy Registers 7,122 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2021-12-13,22:39:14,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Cfo Landry Registers 781 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,CFO Landry Registers 781 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-12-14,19:41:39,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp McCourt Registers 344 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,VP McCourt Registers 344 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-12-14,19:44:41,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Cfo Landry Registers 116 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,CFO Landry Registers 116 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-12-14,21:05:24,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Cfo Landry Sells 116 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Sells 116 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-12-14,21:06:43,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp van Plew Surrenders 697 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP van Plew Surrenders 697 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-12-14,21:07:43,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp McCourt Sells 344 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP McCourt Sells 344 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-12-14,21:09:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Larosa Surrenders 697 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP Larosa Surrenders 697 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-12-14,21:09:23,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Stahl Surrenders 753 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP Stahl Surrenders 753 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-12-14,21:10:35,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Murphy Surrenders 697 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP Murphy Surrenders 697 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-12-14,21:11:48,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Fenimore Surrenders 270 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP Fenimore Surrenders 270 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2021-12-15,11:24:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Regeneron Pharma Cut to Market Perform From Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Cut to Market Perform From Outperform by Bernstein
REGN,2021-12-15,11:24:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $660.00/Share by Bernstein,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $660.00/Share by Bernstein
REGN,2021-12-16,13:49:23,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regen-Cov treatment is currently authorized for emergency use by the Food and Drug Administration,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Slips Because Its Antibody Doesn't Work as Well Against Omicron -- Barrons.com
REGN,2021-12-23,21:31:38,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Pres Yancopoulos Acquires 132,170 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Pres Yancopoulos Acquires 132,170 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-01-04,22:24:24,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-01-04,22:32:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Ryan Registers 300 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Ryan Registers 300 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-01-05,12:24:39,589803,Regeneron Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Regeneron Pharma Cut to Underperform From Neutral,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Cut to Underperform From Neutral by B of A Securities
REGN,2022-01-05,12:24:39,589803,Regeneron Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Regeneron Pharma Price Target Cut to $575.00/Share From $675.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $575.00/Share From $675.00 by B of A Securities
REGN,2022-01-05,16:26:41,589803,Regeneron Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Regeneron Pharmaceuticals downgraded to underperform from neutral at BofA Securities,NEWS-FLASH,MarketWatch,MW Regeneron Pharmaceuticals downgraded to underperform from neutral at BofA Securities
REGN,2022-01-05,21:23:56,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-01-05,21:26:59,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-01-07,12:00:06,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Ultragenyx Collaborate to,PRESS-RELEASE,PR Newswire,Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza(R) (evinacumab) Outside the United States
REGN,2022-01-07,12:00:06,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Ultragenyx Collaborate to,PRESS-RELEASE,PR Newswire,Regeneron and Ultragenyx Collaborate to -2-
REGN,2022-01-07,12:00:06,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Ultragenyx Collaborate to,PRESS-RELEASE,PR Newswire,Regeneron and Ultragenyx Collaborate to -3-
REGN,2022-01-07,12:00:06,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Ultragenyx Collaborate to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza(R) (evinacumab) Outside the United States
REGN,2022-01-07,12:01:08,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Ultragenyx Collaborate to,NEWS-FLASH,Dow Jones Newswires,Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza Outside the United States
REGN,2022-01-07,12:01:40,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Regeneron Pharma, Ultragenyx in License and Collaboration",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharma, Ultragenyx in License and Collaboration Agreement >REGN"
REGN,2022-01-07,12:19:56,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,"Regeneron, Ultragenyx Ink International Deal",FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Ultragenyx Ink International Deal on Cholesterol Drug Evkeeza"
REGN,2022-01-07,12:34:57,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,"Regeneron, Ultragenyx Ink International Deal",FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Ultragenyx Ink International Deal on Cholesterol Drug Evkeeza"
REGN,2022-01-10,19:30:04,589803,Regeneron Pharmaceuticals Inc.,100,0.0,marketing,,Schleifer Presents at 40th Annual JPMorgan Virtual Healthcare Conference,NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc. (REGN) CEO Len Schleifer Presents at 40th Annual JPMorgan Virtual Healthcare Conference (Transcript) >REGN"
REGN,2022-01-13,21:05:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast,PRESS-RELEASE,PR Newswire,Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast on
REGN,2022-01-13,21:05:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast,PRESS-RELEASE,PR Newswire,Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast on
REGN,2022-01-13,21:05:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast on
REGN,2022-01-13,21:05:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast on
REGN,2022-01-18,15:48:35,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley
REGN,2022-01-18,15:48:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.6,price-targets,downgrade,Regeneron Pharma Price Target Cut to $585.00/Share From $617.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $585.00/Share From $617.00 by Morgan Stanley
REGN,2022-01-19,12:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Accepts for Review Libtayo(R) -2,PRESS-RELEASE,PR Newswire,FDA Accepts for Review Libtayo(R) -2-
REGN,2022-01-19,12:00:08,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Accepts for Review Libtayo(R) -2,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts for Review Libtayo(R) -2-
REGN,2022-01-19,12:01:32,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals: FDA Accepts for Review Libtayo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharmaceuticals: FDA Accepts for Review Libtayo in Combination With Chemotherapy for First-line Treatment of Advanced NSCLC >REGN
REGN,2022-01-19,12:22:09,589803,Regeneron Pharmaceuticals Inc.,93,0.0,products-services,,"Regeneron said the application is supported by results from a randomized, multicenter Phase 3 study",FULL-ARTICLE,Dow Jones Newswires,Regeneron Says FDA to Review Libtayo/Chemotherapy Combo in First-Line NSCLC Treatment
REGN,2022-01-19,12:37:08,589803,Regeneron Pharmaceuticals Inc.,93,0.0,products-services,,"Regeneron said the application is supported by results from a randomized, multicenter Phase 3 study",FULL-ARTICLE,Dow Jones Newswires,Regeneron Says FDA to Review Libtayo/Chemotherapy Combo in First-Line NSCLC Treatment
REGN,2022-01-20,17:00:03,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,PR Newswire,Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent Search
REGN,2022-01-20,17:00:05,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,PR Newswire,Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent Search
REGN,2022-01-24,08:21:27,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals Inc, Inst Holders, 4Q 2021 (REGN)",RNS-SEC13F,Dow Jones Newswires,"Regeneron Pharmaceuticals Inc, Inst Holders, 4Q 2021 (REGN)"
REGN,2022-01-24,22:02:24,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Revises Authorization for Regeneron's REGEN-COV,NEWS-FLASH,Dow Jones Newswires,FDA Revises Authorization for Regeneron's REGEN-COV
REGN,2022-01-28,12:01:07,589803,Regeneron Pharmaceuticals Inc.,100,-0.45,products-services,withdrawn,Sanofi Withdraw FDA Application for Libtayo,NEWS-FLASH,Dow Jones Newswires,"Regeneron, Sanofi Withdraw FDA Application for Libtayo as Second-Line Treatment for Advanced Cervical Cancer >REGN"
REGN,2022-01-28,12:24:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,U.S. approval of the cancer drug Libtayo,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Pull FDA Application for Libtayo in Advanced Cervical Cancer >REGN"
REGN,2022-01-28,12:32:45,589803,Regeneron Pharmaceuticals Inc.,100,-0.61,products-services,,"Regeneron, Sanofi withdraw application",FULL-ARTICLE,MarketWatch,"MW Regeneron, Sanofi withdraw application for Libtaya as a cervical cancer treatment in the U.S."
REGN,2022-01-28,12:32:45,589803,Regeneron Pharmaceuticals Inc.,100,-0.45,products-services,,"Regeneron, Sanofi Withdraw Application",FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Withdraw Application For Libtaya As A Cervical Cancer Treatment In The U.S. -- MarketWatch"
REGN,2022-01-28,12:39:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,U.S. approval of the cancer drug Libtayo,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Pull FDA Application for Libtayo in Advanced Cervical Cancer"
REGN,2022-01-31,05:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Chmp Recommends Approval of Dupixent(R) (dupilumab),PRESS-RELEASE,PR Newswire,CHMP Recommends Approval of Dupixent(R) (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
REGN,2022-01-31,05:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent was approved by the FDA,PRESS-RELEASE,PR Newswire,CHMP Recommends Approval of Dupixent(R) (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
REGN,2022-01-31,05:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is currently approved in Europe,PRESS-RELEASE,PR Newswire,CHMP Recommends Approval of Dupixent(R) (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
REGN,2022-01-31,05:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,PR Newswire,CHMP Recommends Approval of Dupixent(R) (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
REGN,2022-01-31,05:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Chmp Recommends Approval of Dupixent(R),PRESS-RELEASE,PR Newswire,CHMP Recommends Approval of Dupixent(R) -2-
REGN,2022-01-31,05:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Chmp Recommends Approval of Dupixent(R),PRESS-RELEASE,PR Newswire,CHMP Recommends Approval of Dupixent(R) -3-
REGN,2022-01-31,05:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Chmp Recommends Approval of Dupixent(R) (dupilumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP Recommends Approval of Dupixent(R) (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
REGN,2022-01-31,05:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent was approved by the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP Recommends Approval of Dupixent(R) (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
REGN,2022-01-31,05:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is currently approved in Europe,PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP Recommends Approval of Dupixent(R) (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
REGN,2022-01-31,05:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP Recommends Approval of Dupixent(R) (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
REGN,2022-01-31,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Chmp recommends approval of Dupixent(R) (dupilumab),PRESS-RELEASE,GlobeNewswire,CHMP recommends approval of Dupixent(R) (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
REGN,2022-01-31,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent was approved by the FDA,PRESS-RELEASE,GlobeNewswire,CHMP recommends approval of Dupixent(R) (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
REGN,2022-01-31,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is currently approved in Europe,PRESS-RELEASE,GlobeNewswire,CHMP recommends approval of Dupixent(R) (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
REGN,2022-01-31,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,GlobeNewswire,CHMP recommends approval of Dupixent(R) (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
REGN,2022-01-31,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Chmp recommends approval of Dupixent(R),PRESS-RELEASE,GlobeNewswire,CHMP recommends approval of Dupixent(R) -2-
REGN,2022-01-31,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Chmp recommends approval of Dupixent(R) (dupilumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP recommends approval of Dupixent(R) (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
REGN,2022-01-31,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent was approved by the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP recommends approval of Dupixent(R) (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
REGN,2022-01-31,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is currently approved in Europe,PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP recommends approval of Dupixent(R) (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
REGN,2022-01-31,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP recommends approval of Dupixent(R) (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
REGN,2022-01-31,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Chmp recommends approval of Dupixent(R) (dupilumab),PRESS-RELEASE,Hugin GlobeNewswire,Press Release: CHMP recommends approval of Dupixent(R) (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
REGN,2022-01-31,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent was approved by the FDA,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: CHMP recommends approval of Dupixent(R) (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
REGN,2022-01-31,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is currently approved in Europe,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: CHMP recommends approval of Dupixent(R) (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
REGN,2022-01-31,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: CHMP recommends approval of Dupixent(R) (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
REGN,2022-01-31,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Chmp recommends approval of Dupixent(R) (dupilumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP recommends approval of Dupixent(R) (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
REGN,2022-01-31,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent was approved by the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP recommends approval of Dupixent(R) (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
REGN,2022-01-31,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is currently approved in Europe,PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP recommends approval of Dupixent(R) (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
REGN,2022-01-31,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP recommends approval of Dupixent(R) (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
REGN,2022-01-31,06:01:46,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi: European Medicines Agency Recommends Approval of Dupixent,NEWS-FLASH,Dow Jones Newswires,Sanofi: European Medicines Agency Recommends Approval of Dupixent for Children Aged 6 to 11 Years
REGN,2022-01-31,13:41:23,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Truist Securities
REGN,2022-01-31,13:41:23,589803,Regeneron Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Regeneron Pharma Price Target Cut to $754.00/Share From $756.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $754.00/Share From $756.00 by Truist Securities
REGN,2022-02-02,19:41:51,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-02-02,21:18:56,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2021",PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2021",PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.82,revenues,up,Regeneron Pharmaceuticals Inc.: Fourth quarter 2021 revenues increased 104% to $4.95 billion,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.78,revenues,up,Regeneron Pharmaceuticals Inc.: Full year 2021 revenues increased 89% to $16.07 billion,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Fourth quarter 2021 GAAP diluted EPS was $19.69,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: we remain focused on building on EYLEA,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved Dupixent for children,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: The New England Journal of Medicine published positive results from the Phase 3 trial,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: The FDA accepted the sBLA for Libtayo(R) (cemiplimab),PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: the Company and Sanofi announced the voluntary withdrawal of the sBLA for Libtayo as a second-line treatment for patients,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The Company expects to complete enrollment in a potentially pivotal Phase 2 trial in multiple myeloma in the first quarter of 2022,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 3 study of pozelimab,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,98,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Programs Milestones Aflibercept 8 mg - Report results from Phase 3 studies,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,98,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Fourth Quarter and Full Year 2021 Financial Results,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,98,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Fourth Quarter and Full Year 2021 Financial Results,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,98,0.54,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues increased by 104% to $4.952 billion in the fourth quarter of 2021,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,98,0.78,revenues,up,"Regeneron Pharmaceuticals Inc.: Full year 2021 total revenues increased 89% to $16.072 billion, compared to $8.497 billion for the full year 2020",PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,98,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Non-GAAP SG&A expenses in the fourth quarter,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Regeneron Pharmaceuticals Inc.: the Company's collaboration agreement,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.78,earnings,up,"Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $19.69 in the fourth quarter of 2021, compared to $10.24 in the fourth quarter of 2020",PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.82,earnings,up,"Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $71.97 for the full year 2021, compared to $30.52 for full year 2020",PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.82,earnings,up,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $23.72 in the fourth quarter of 2021, compared to $9.53 in the fourth quarter of 2020",PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.82,earnings,up,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $74.66 for the full year 2021, compared to $31.47 for the full year 2020",PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,approved,Regeneron Pharmaceuticals Inc.: the Company's board of directors authorized a new share repurchase program,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2022 Financial Guidance,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 4Q EPS $19.69,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q EPS $19.69 >REGN
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2022 financial guidance,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -4-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: Conference Call Information,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -4-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 4Q Net $2.23B,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q Net $2.23B >REGN
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: December 31, 2021 2020 Assets",PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $ 2,229.0 $ 1,149.2 $",PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 20.99 $ 10.90 $,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 25.53 $ 10.25 $,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,PR Newswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 4Q Rev $4.95B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q Rev $4.95B >REGN
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.82,revenues,up,Regeneron Pharmaceuticals Inc.: Fourth quarter 2021 revenues increased 104% to $4.95 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.78,revenues,up,Regeneron Pharmaceuticals Inc.: Full year 2021 revenues increased 89% to $16.07 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Fourth quarter 2021 GAAP diluted EPS was $19.69,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: we remain focused on building on EYLEA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved Dupixent for children,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: The New England Journal of Medicine published positive results from the Phase 3 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: The FDA accepted the sBLA for Libtayo(R) (cemiplimab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: the Company and Sanofi announced the voluntary withdrawal of the sBLA for Libtayo as a second-line treatment for patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The Company expects to complete enrollment in a potentially pivotal Phase 2 trial in multiple myeloma in the first quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 3 study of pozelimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,98,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Programs Milestones Aflibercept 8 mg - Report results from Phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,98,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Fourth Quarter and Full Year 2021 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,98,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Fourth Quarter and Full Year 2021 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,98,0.54,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues increased by 104% to $4.952 billion in the fourth quarter of 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,98,0.78,revenues,up,"Regeneron Pharmaceuticals Inc.: Full year 2021 total revenues increased 89% to $16.072 billion, compared to $8.497 billion for the full year 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,98,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Non-GAAP SG&A expenses in the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Regeneron Pharmaceuticals Inc.: the Company's collaboration agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.78,earnings,up,"Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $19.69 in the fourth quarter of 2021, compared to $10.24 in the fourth quarter of 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.82,earnings,up,"Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $71.97 for the full year 2021, compared to $30.52 for full year 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.82,earnings,up,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $23.72 in the fourth quarter of 2021, compared to $9.53 in the fourth quarter of 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.82,earnings,up,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $74.66 for the full year 2021, compared to $31.47 for the full year 2020",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,approved,Regeneron Pharmaceuticals Inc.: the Company's board of directors authorized a new share repurchase program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2022 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -4-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: Conference Call Information,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -4-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: December 31, 2021 2020 Assets",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $ 2,229.0 $ 1,149.2 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 20.99 $ 10.90 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 25.53 $ 10.25 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2022-02-04,11:30:07,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2022-02-04,11:32:14,589803,Regeneron Pharmaceuticals Inc.,100,0.78,earnings,up,Regeneron Q4 EPS $19.69 vs. $10.24 a year ago,NEWS-FLASH,MarketWatch,MW Regeneron Q4 EPS $19.69 vs. $10.24 a year ago
REGN,2022-02-04,11:32:27,589803,Regeneron Pharmaceuticals Inc.,100,0.46,earnings,above-expectations,Regeneron Q4 adj. EPS $23.72; FactSet consensus $20.40,NEWS-FLASH,MarketWatch,MW Regeneron Q4 adj. EPS $23.72; FactSet consensus $20.40
REGN,2022-02-04,11:32:51,589803,Regeneron Pharmaceuticals Inc.,100,0.48,revenues,above-expectations,Regeneron Q4 revenue $4.952 bln vs. $2.423 bln a year ago; FactSet consensus $4.563 bln,NEWS-FLASH,MarketWatch,MW Regeneron Q4 revenue $4.952 bln vs. $2.423 bln a year ago; FactSet consensus $4.563 bln
REGN,2022-02-04,11:33:29,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 4Q Adj EPS $23.72,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q Adj EPS $23.72 >REGN
REGN,2022-02-04,11:35:14,589803,Regeneron Pharmaceuticals Inc.,100,0.0,equity-actions,,Regeneron Pharma Sees 2022 Capital Spending $650M-$730M >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Sees 2022 Capital Spending $650M-$730M >REGN
REGN,2022-02-04,11:41:30,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: The company posted net income of $2.229 billion,FULL-ARTICLE,MarketWatch,MW Regeneron shares up premarket after Q4 revenue doubles and blows past estimates
REGN,2022-02-04,11:41:31,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: The company posted net income of $2.229 billion,FULL-ARTICLE,Dow Jones Newswires,Regeneron Shares Up Premarket After Q4 Revenue Doubles And Blows Past Estimates -- MarketWatch
REGN,2022-02-04,14:18:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals on Friday issued financial results,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Fell Despite Strong Earnings. This Is Why. -- Barrons.com
REGN,2022-02-04,14:18:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron (ticker: REGN) reported non-GAAP diluted earnings of $23.72 per share for the fourth quarter of 2021,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Fell Despite Strong Earnings. This Is Why. -- Barrons.com
REGN,2022-02-04,14:18:01,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron Pharmaceuticals Inc.: the company partners with Sanofi (SNY),FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Fell Despite Strong Earnings. This Is Why. -- Barrons.com
REGN,2022-02-04,17:41:27,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals, Inc. CEO Dr. Len Schleifer on Q4 2021 Results -- Earnings Call Transcript",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc. CEO Dr. Len Schleifer on Q4 2021 Results -- Earnings Call Transcript >REGN"
REGN,2022-02-04,17:41:27,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron-pharmaceuticals-inc-regn-ceo-dr-len-schleifer-on-q4-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc. CEO Dr. Len Schleifer on Q4 2021 Results -- Earnings Call Transcript >REGN"
REGN,2022-02-05,09:13:03,589803,Regeneron Pharmaceuticals Inc.,100,-0.45,products-services,,"Regeneron, Sanofi Withdraw Application",FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Withdraw Application For Libtaya As A Cervical Cancer Treatment In The U.S. -- MarketWatch"
REGN,2022-02-05,09:13:10,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: The company posted net income of $2.229 billion,FULL-ARTICLE,Dow Jones Newswires,Regeneron Shares Up Premarket After Q4 Revenue Doubles And Blows Past Estimates -- MarketWatch
REGN,2022-02-05,09:13:15,589803,Regeneron Pharmaceuticals Inc.,100,0.78,earnings,up,Regeneron Q4 EPS $19.69 vs. $10.24 a year ago,NEWS-FLASH,MarketWatch,MW Regeneron Q4 EPS $19.69 vs. $10.24 a year ago
REGN,2022-02-05,09:13:15,589803,Regeneron Pharmaceuticals Inc.,100,0.46,earnings,above-expectations,Regeneron Q4 adj. EPS $23.72; FactSet consensus $20.40,NEWS-FLASH,MarketWatch,MW Regeneron Q4 adj. EPS $23.72; FactSet consensus $20.40
REGN,2022-02-05,09:13:15,589803,Regeneron Pharmaceuticals Inc.,100,0.48,revenues,above-expectations,Regeneron Q4 revenue $4.952 bln vs. $2.423 bln a year ago; FactSet consensus $4.563 bln,NEWS-FLASH,MarketWatch,MW Regeneron Q4 revenue $4.952 bln vs. $2.423 bln a year ago; FactSet consensus $4.563 bln
REGN,2022-02-05,09:13:16,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: The company posted net income of $2.229 billion,FULL-ARTICLE,MarketWatch,MW Regeneron shares up premarket after Q4 revenue doubles and blows past estimates
REGN,2022-02-07,13:54:15,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley
REGN,2022-02-07,13:54:15,589803,Regeneron Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Regeneron Pharma Price Target Raised to $605.00/Share From $585.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $605.00/Share From $585.00 by Morgan Stanley
REGN,2022-02-08,12:54:21,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by Oppenheimer
REGN,2022-02-08,12:54:21,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,price-targets,downgrade,Regeneron Pharma Price Target Cut to $775.00/Share From $825.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $775.00/Share From $825.00 by Oppenheimer
REGN,2022-02-08,15:05:22,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Truist Securities
REGN,2022-02-08,15:05:22,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,price-targets,downgrade,Regeneron Pharma Price Target Cut to $728.00/Share From $754.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $728.00/Share From $754.00 by Truist Securities
REGN,2022-02-10,05:59:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Accepts Dupixent(R) (dupilumab) for,PRESS-RELEASE,PR Newswire,FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
REGN,2022-02-10,05:59:04,589803,Regeneron Pharmaceuticals Inc.,100,0.7,products-services,,Fda granted Breakthrough Therapy designation for Dupixent,PRESS-RELEASE,PR Newswire,FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
REGN,2022-02-10,05:59:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is also approved in Europe,PRESS-RELEASE,PR Newswire,FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
REGN,2022-02-10,05:59:04,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,PR Newswire,FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
REGN,2022-02-10,05:59:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Accepts Dupixent(R) (dupilumab) for,PRESS-RELEASE,PR Newswire,FDA Accepts Dupixent(R) (dupilumab) for Priority -2-
REGN,2022-02-10,05:59:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Accepts Dupixent(R) (dupilumab),PRESS-RELEASE,PR Newswire,FDA Accepts Dupixent(R) (dupilumab) for Priority -3-
REGN,2022-02-10,05:59:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Accepts Dupixent(R) (dupilumab) for,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
REGN,2022-02-10,05:59:04,589803,Regeneron Pharmaceuticals Inc.,100,0.7,products-services,,Fda granted Breakthrough Therapy designation for Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
REGN,2022-02-10,05:59:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is also approved in Europe,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
REGN,2022-02-10,05:59:04,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
REGN,2022-02-10,05:59:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA Accepts Dupixent(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Dupixent(R) -2-
REGN,2022-02-10,05:59:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Accepts Dupixent(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Dupixent(R) -3-
REGN,2022-02-10,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda accepts Dupixent(R) (dupilumab) for,PRESS-RELEASE,GlobeNewswire,FDA accepts Dupixent(R) (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-02-10,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.7,products-services,,Fda granted Breakthrough Therapy designation for Dupixent,PRESS-RELEASE,GlobeNewswire,FDA accepts Dupixent(R) (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-02-10,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is also approved in Europe,PRESS-RELEASE,GlobeNewswire,FDA accepts Dupixent(R) (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-02-10,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,GlobeNewswire,FDA accepts Dupixent(R) (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-02-10,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda accepts Dupixent(R) (dupilumab) for,PRESS-RELEASE,GlobeNewswire,FDA accepts Dupixent(R) (dupilumab) for Priority -2-
REGN,2022-02-10,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda accepts Dupixent(R) (dupilumab) for,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-02-10,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.7,products-services,,Fda granted Breakthrough Therapy designation for Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-02-10,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is also approved in Europe,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-02-10,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-02-10,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA accepts Dupixent(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA accepts Dupixent(R) -2-
REGN,2022-02-10,06:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda accepts Dupixent(R) (dupilumab) for,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-02-10,06:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.7,products-services,,Fda granted Breakthrough Therapy designation for Dupixent,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-02-10,06:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is also approved in Europe,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-02-10,06:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-02-10,06:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda accepts Dupixent(R) (dupilumab) for,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-02-10,06:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.7,products-services,,Fda granted Breakthrough Therapy designation for Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-02-10,06:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is also approved in Europe,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-02-10,06:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-02-10,06:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA accepts Dupixent(R),PRESS-RELEASE,Hugin GlobeNewswire,Press Release: FDA accepts Dupixent(R) -2-
REGN,2022-02-10,06:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA accepts Dupixent(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA accepts Dupixent(R) -2-
REGN,2022-02-10,06:01:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron: FDA Accepts Dupixent(R) (dupilumab),NEWS-FLASH,Dow Jones Newswires,Regeneron: FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years With Moderate-to-severe Atopic Dermatitis >REGN
REGN,2022-02-10,06:02:39,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi: FDA Accepts Dupixent,NEWS-FLASH,Dow Jones Newswires,Sanofi: FDA Accepts Dupixent for Priority Review in Children Aged 6 Mos-5 Yrs With Moderate-To-Severe Atopic Dermatitis
REGN,2022-02-11,12:50:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept,PRESS-RELEASE,PR Newswire,Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting
REGN,2022-02-11,12:50:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Phase 3 results in,PRESS-RELEASE,PR Newswire,Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting
REGN,2022-02-11,12:50:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Aflibercept 8 mg is being jointly developed by Regeneron and Bayer,PRESS-RELEASE,PR Newswire,Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting
REGN,2022-02-11,12:50:02,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Presents Encouraging Phase 2 Results,PRESS-RELEASE,PR Newswire,Regeneron Presents Encouraging Phase 2 Results -2-
REGN,2022-02-11,12:50:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting
REGN,2022-02-11,12:50:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Phase 3 results in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting
REGN,2022-02-11,12:50:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Aflibercept 8 mg is being jointly developed by Regeneron and Bayer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting
REGN,2022-02-11,13:21:48,589803,Regeneron Pharmaceuticals Inc.,100,0.62,products-services,positive,Regeneron's Eye-Disorder Treatment Meets Primary Endpoint in Mid-Stage Trial,FULL-ARTICLE,Dow Jones Newswires,Regeneron's Eye-Disorder Treatment Meets Primary Endpoint in Mid-Stage Trial
REGN,2022-02-11,13:36:48,589803,Regeneron Pharmaceuticals Inc.,100,0.62,products-services,positive,Regeneron's Eye-Disorder Treatment Meets Primary Endpoint in Mid-Stage Trial,FULL-ARTICLE,Dow Jones Newswires,Regeneron's Eye-Disorder Treatment Meets Primary Endpoint in Mid-Stage Trial
REGN,2022-02-16,20:11:34,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Murphy Registers 3,540 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Murphy Registers 3,540 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-02-16,21:19:20,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Murphy Sells 3,540 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Murphy Sells 3,540 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-02-18,05:59:03,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Dupixent is currently approved in the U.S.,PRESS-RELEASE,PR Newswire,Regeneron and Sanofi Provide Update on Ongoing Dupixent(R) (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program
REGN,2022-02-18,05:59:03,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,PR Newswire,Regeneron and Sanofi Provide Update on Ongoing Dupixent(R) (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program
REGN,2022-02-18,05:59:03,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Dupixent is currently approved in the U.S.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron and Sanofi Provide Update on Ongoing Dupixent(R) (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program
REGN,2022-02-18,05:59:03,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron and Sanofi Provide Update on Ongoing Dupixent(R) (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program
REGN,2022-02-18,07:33:15,589803,Regeneron Pharmaceuticals Inc.,100,-0.54,products-services,suspended,Sanofi to Scrap Phase 3 Trial for Dupixent,FULL-ARTICLE,Dow Jones Newswires,Sanofi to Scrap Phase 3 Trial for Dupixent in Chronic Spontaneous Urticaria Patients
REGN,2022-02-18,07:48:15,589803,Regeneron Pharmaceuticals Inc.,100,-0.54,products-services,suspended,Sanofi to Scrap Phase 3 Trial for Dupixent,FULL-ARTICLE,Dow Jones Newswires,Sanofi to Scrap Phase 3 Trial for Dupixent in Chronic Spontaneous Urticaria Patients
REGN,2022-02-24,19:39:03,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp van Plew Registers 6,781 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP van Plew Registers 6,781 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-02-24,21:10:18,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Brown Sells 500 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Brown Sells 500 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-02-24,21:14:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp van Plew Sells 6,781 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP van Plew Sells 6,781 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-02-28,20:56:38,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Sing Registers 10,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Sing Registers 10,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-02-28,21:01:02,589803,Regeneron Pharmaceuticals Inc.,98,0.0,products-services,,Regeneron Announce Updated Phase 1 Data,PRESS-RELEASE,GlobeNewswire,"Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein"
REGN,2022-02-28,21:01:02,589803,Regeneron Pharmaceuticals Inc.,98,0.49,partnerships,,"Discovery, development and commercialization collaboration with Regeneron",PRESS-RELEASE,GlobeNewswire,"Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein"
REGN,2022-02-28,21:01:03,589803,Regeneron Pharmaceuticals Inc.,98,0.0,products-services,,Regeneron Announce Updated Phase 1 Data,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein"
REGN,2022-02-28,21:01:03,589803,Regeneron Pharmaceuticals Inc.,98,0.49,partnerships,,"Discovery, development and commercialization collaboration with Regeneron",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein"
REGN,2022-02-28,21:02:02,589803,Regeneron Pharmaceuticals Inc.,97,0.49,partnerships,,"Discovery, development and commercialization collaboration with Regeneron",PRESS-RELEASE,PR Newswire,"Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein"
REGN,2022-02-28,21:02:03,589803,Regeneron Pharmaceuticals Inc.,97,0.0,products-services,,Regeneron Announce Updated Phase 1 Data,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein"
REGN,2022-02-28,21:02:03,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,"Discovery, development and commercialization collaboration with Regeneron",PRESS-RELEASE,Dow Jones Newswires,Press Release: Intellia and Regeneron Announce -2-
REGN,2022-02-28,21:02:19,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals: Announce Positive Interim Data From an Ongoing Phase 1 Clinical Study,NEWS-FLASH,Dow Jones Newswires,"Intellia Therapeutics and Regeneron Pharmaceuticals: Announce Positive Interim Data From an Ongoing Phase 1 Clinical Study of Their Lead in Vivo Genome Editing Candidate, NTLA-2001, Which Is Being Developed as a Single-Dose Treatment for Transthyretin Amyloidosis >NTLA"
REGN,2022-03-01,21:19:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Sing Sells 4,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sing Sells 4,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-03-02,22:46:04,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-03-03,21:12:21,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-03-03,21:32:27,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-03-08,13:27:07,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Biontech and Regeneron Expand Strategic Collaboration to,PRESS-RELEASE,GlobeNewswire,BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo(R) (cemiplimab) Combination in NSCLC
REGN,2022-03-08,13:27:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Libtayo is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,GlobeNewswire,BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo(R) (cemiplimab) Combination in NSCLC
REGN,2022-03-08,13:27:07,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Biontech and Regeneron Expand Strategic Collaboration to,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo(R) (cemiplimab) Combination in NSCLC
REGN,2022-03-08,13:27:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Libtayo is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo(R) (cemiplimab) Combination in NSCLC
REGN,2022-03-08,13:27:07,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Biontech and Regeneron Expand Strategic Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo(R) (cemiplimab) Combination in NSCLC
REGN,2022-03-08,13:27:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Libtayo is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo(R) (cemiplimab) Combination in NSCLC
REGN,2022-03-08,13:27:08,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Biontech and Regeneron Expand Strategic Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo(R) (cemiplimab) Combination in NSCLC
REGN,2022-03-08,13:27:08,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Libtayo is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo(R) (cemiplimab) Combination in NSCLC
REGN,2022-03-08,13:28:21,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Biontech and Regeneron Expand Strategic Collaboration to,NEWS-FLASH,Dow Jones Newswires,BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo(cemiplimab) Combination in NSCLC
REGN,2022-03-08,14:16:47,589803,Regeneron Pharmaceuticals Inc.,93,0.57,products-services,granted,Libtayo is approved in the U.S.,FULL-ARTICLE,MarketWatch,"MW Regeneron, BioNTech to test experimental combination therapy for lung cancer"
REGN,2022-03-08,14:16:47,589803,Regeneron Pharmaceuticals Inc.,93,0.57,products-services,granted,Libtayo is approved in the U.S.,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, BioNTech To Test Experimental Combination Therapy For Lung Cancer -- MarketWatch"
REGN,2022-03-08,14:17:52,589803,Regeneron Pharmaceuticals Inc.,93,0.57,products-services,granted,Libtayo is approved in the U.S.,FULL-ARTICLE,MarketWatch,"MW Regeneron, BioNTech to test experimental combination therapy for lung cancer"
REGN,2022-03-08,14:17:52,589803,Regeneron Pharmaceuticals Inc.,93,0.57,products-services,granted,Libtayo is approved in the U.S.,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, BioNTech To Test Experimental Combination Therapy For Lung Cancer -- MarketWatch"
REGN,2022-03-15,20:03:04,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Chmn Vagelos Acquires 26,897 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Vagelos Acquires 26,897 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-03-16,01:16:45,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,PR Newswire,Students Win $1.8 Million at Regeneron Science -2-
REGN,2022-03-16,02:13:22,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,PR Newswire,Students Win $1.8 Million at Regeneron Science -2-
REGN,2022-03-17,19:05:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Tessier-Lavigne Registers 4,361 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Tessier-Lavigne Registers 4,361 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-03-17,19:05:52,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Zoghbi Registers 2,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Zoghbi Registers 2,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-03-17,19:36:32,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Cfo Landry Registers 300 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,CFO Landry Registers 300 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-03-18,17:35:55,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Tessier-Lavigne Registers 7,830 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Tessier-Lavigne Registers 7,830 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-03-18,18:30:05,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Cfo Landry Registers 83 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,CFO Landry Registers 83 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-03-18,20:06:15,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Tessier-Lavigne Sells 12,191 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Tessier-Lavigne Sells 12,191 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-03-18,20:09:54,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Cfo Landry Sells 383 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Sells 383 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-03-18,20:15:54,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Zoghbi Sells 2,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Zoghbi Sells 2,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-03-22,19:11:28,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Tessier-Lavigne Registers 7,439 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Tessier-Lavigne Registers 7,439 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-03-22,20:06:15,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Cfo Landry Registers 300 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,CFO Landry Registers 300 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-03-23,20:04:12,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Tessier-Lavigne Sells 7,439 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Tessier-Lavigne Sells 7,439 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-03-23,20:04:32,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Cfo Landry Sells 300 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Sells 300 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-03-25,19:20:25,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Libtayo® (cemiplimab) now approved in Canada,PRESS-RELEASE,Canadian News Wire,Libtayo® (cemiplimab) now approved in Canada for the treatment of recurrent or metastatic cervical cancer
REGN,2022-03-25,19:20:25,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Libtayo is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Canadian News Wire,Libtayo® (cemiplimab) now approved in Canada for the treatment of recurrent or metastatic cervical cancer
REGN,2022-03-25,19:20:26,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Libtayo® (cemiplimab) now approved in Canada,PRESS-RELEASE,Dow Jones Newswires,Press Release: Libtayo® (cemiplimab) now approved in Canada for the treatment of recurrent or metastatic cervical cancer
REGN,2022-03-25,19:20:26,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Libtayo is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Libtayo® (cemiplimab) now approved in Canada for the treatment of recurrent or metastatic cervical cancer
REGN,2022-03-28,12:02:15,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi: Dupixent Approved in Canada,NEWS-FLASH,Dow Jones Newswires,Sanofi: Dupixent Approved in Canada for the Treatment of Severe Asthma in Children Aged Six to 11 Years With Type 2 Inflammation
REGN,2022-03-30,19:11:57,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Brown Registers 1,930 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Brown Registers 1,930 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-03-30,19:14:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Landry Registers 2,683 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"CFO Landry Registers 2,683 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-03-30,20:44:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Landry Sells 2,683 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Landry Sells 2,683 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-03-31,14:29:27,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Goldstein Registers 2,431 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Goldstein Registers 2,431 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-03-31,20:10:04,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Brown Sells 1,930 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Brown Sells 1,930 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-04-01,20:09:40,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Cfo Landry Sells 316 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Sells 316 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-04-01,20:09:59,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Bassler Sells 1,240 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Bassler Sells 1,240 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-04-01,20:10:16,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Vp Fenimore Acquires 3,346 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Fenimore Acquires 3,346 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-04-01,20:11:07,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Goldstein Sells 2,431 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Goldstein Sells 2,431 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-04-01,20:12:03,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Chmn Vagelos Sells 28,572 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Vagelos Sells 28,572 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-04-04,04:59:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Accepts Dupixent(R) (dupilumab) for,PRESS-RELEASE,PR Newswire,FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
REGN,2022-04-04,04:59:02,589803,Regeneron Pharmaceuticals Inc.,100,0.7,products-services,,"September 2020, the U.S. FDA granted Breakthrough Therapy designation to Dupixent",PRESS-RELEASE,PR Newswire,FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
REGN,2022-04-04,04:59:02,589803,Regeneron Pharmaceuticals Inc.,100,0.63,products-services,,Dupixent was also granted Orphan Drug designation for,PRESS-RELEASE,PR Newswire,FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
REGN,2022-04-04,04:59:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is also approved in Europe,PRESS-RELEASE,PR Newswire,FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
REGN,2022-04-04,04:59:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,PR Newswire,FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
REGN,2022-04-04,04:59:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Accepts Dupixent(R) (dupilumab) for,PRESS-RELEASE,PR Newswire,FDA Accepts Dupixent(R) (dupilumab) for Priority -2-
REGN,2022-04-04,04:59:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Accepts Dupixent(R) (dupilumab),PRESS-RELEASE,PR Newswire,FDA Accepts Dupixent(R) (dupilumab) for Priority -3-
REGN,2022-04-04,04:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Accepts Dupixent(R) (dupilumab) for,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
REGN,2022-04-04,04:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.7,products-services,,"September 2020, the U.S. FDA granted Breakthrough Therapy designation to Dupixent",PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
REGN,2022-04-04,04:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.63,products-services,,Dupixent was also granted Orphan Drug designation for,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
REGN,2022-04-04,04:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is also approved in Europe,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
REGN,2022-04-04,04:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
REGN,2022-04-04,04:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA Accepts Dupixent(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Dupixent(R) -2-
REGN,2022-04-04,05:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda accepts Dupixent(R) (dupilumab) for,PRESS-RELEASE,GlobeNewswire,Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
REGN,2022-04-04,05:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.7,products-services,,"September 2020, the U.S. FDA granted Breakthrough Therapy designation to Dupixent",PRESS-RELEASE,GlobeNewswire,Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
REGN,2022-04-04,05:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is also approved in Europe,PRESS-RELEASE,GlobeNewswire,Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
REGN,2022-04-04,05:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,GlobeNewswire,Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
REGN,2022-04-04,05:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA accepts Dupixent(R),PRESS-RELEASE,GlobeNewswire,Press Release: FDA accepts Dupixent(R) -2-
REGN,2022-04-04,05:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda accepts Dupixent(R) (dupilumab) for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
REGN,2022-04-04,05:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.7,products-services,,"September 2020, the U.S. FDA granted Breakthrough Therapy designation to Dupixent",PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
REGN,2022-04-04,05:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is also approved in Europe,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
REGN,2022-04-04,05:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
REGN,2022-04-04,05:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda accepts Dupixent(R) (dupilumab) for,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
REGN,2022-04-04,05:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.7,products-services,,"September 2020, the U.S. FDA granted Breakthrough Therapy designation to Dupixent",PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
REGN,2022-04-04,05:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is also approved in Europe,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
REGN,2022-04-04,05:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
REGN,2022-04-04,05:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda accepts Dupixent(R) (dupilumab) for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
REGN,2022-04-04,05:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.7,products-services,,"September 2020, the U.S. FDA granted Breakthrough Therapy designation to Dupixent",PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
REGN,2022-04-04,05:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is also approved in Europe,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
REGN,2022-04-04,05:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: FDA accepts Dupixent(R) (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
REGN,2022-04-04,05:01:20,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi: FDA Accepts Dupixent,NEWS-FLASH,Dow Jones Newswires,"Regeneron, Sanofi: FDA Accepts Dupixent for Priority Review in Patients 12 Years and Older With Eosinophilic Esophagitis"
REGN,2022-04-04,05:04:52,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi: FDA Accepts Dupixent (dupilumab),NEWS-FLASH,Dow Jones Newswires,Sanofi: FDA Accepts Dupixent (dupilumab) for Priority Review in Patients Aged 12 Years and Older With Eosinophilic Esophagitis
REGN,2022-04-04,20:04:40,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-04-04,20:05:13,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Schleifer Sells 2,886 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Schleifer Sells 2,886 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-04-04,20:06:14,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Larosa Sells 5,114 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Larosa Sells 5,114 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-04-04,20:06:24,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-04-04,20:20:32,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Larosa Registers 5,114 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Larosa Registers 5,114 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-04-04,21:32:52,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-04-04,21:51:04,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Ryan Registers 200 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Ryan Registers 200 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-04-04,21:53:29,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Cfo Landry Registers 316 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,CFO Landry Registers 316 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-04-05,20:05:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report First Quarter 2022 Financial and Operating Results,PRESS-RELEASE,PR Newswire,"Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022"
REGN,2022-04-05,20:05:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time,PRESS-RELEASE,PR Newswire,"Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022"
REGN,2022-04-05,20:05:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report First Quarter 2022 Financial and Operating Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022"
REGN,2022-04-05,20:05:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022"
REGN,2022-04-06,07:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.39,products-services,,Regeneron Pharmaceuticals Inc.: This agreement with Regeneron,PRESS-RELEASE,GlobeNewswire,ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target
REGN,2022-04-06,07:00:37,589803,Regeneron Pharmaceuticals Inc.,99,0.39,products-services,,Regeneron Pharmaceuticals Inc.: This agreement with Regeneron,PRESS-RELEASE,DGAP News,PRESS RELEASE: ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target
REGN,2022-04-06,07:00:37,589803,Regeneron Pharmaceuticals Inc.,99,0.39,products-services,,Regeneron Pharmaceuticals Inc.: This agreement with Regeneron,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target
REGN,2022-04-07,04:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved by European Commission,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
REGN,2022-04-07,04:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved by European,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Approved by European -2-
REGN,2022-04-07,04:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Approved by European -2-
REGN,2022-04-07,04:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved by European,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Approved by European -3-
REGN,2022-04-07,04:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved by European,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Approved by European -4-
REGN,2022-04-07,05:06:32,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi: European Commission Approves Dupixent (dupilumab),NEWS-FLASH,Dow Jones Newswires,"Regeneron, Sanofi: European Commission Approves Dupixent (dupilumab) for Children 6 to 11 Years Old With Severe Asthma With Type 2 Inflammation"
REGN,2022-04-07,20:05:54,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Ceo Schleifer Sells 7,114 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"CEO Schleifer Sells 7,114 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-04-08,15:29:45,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Larosa Registers 5,114 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Larosa Registers 5,114 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-04-11,15:29:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Cfo Landry Registers 325 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,CFO Landry Registers 325 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-04-11,20:40:14,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Bassler Sells 1,240 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Bassler Sells 1,240 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-04-11,20:41:33,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Vp Fenimore Acquires 1,844 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Fenimore Acquires 1,844 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-04-11,20:42:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Larosa Sells 5,114 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Larosa Sells 5,114 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-04-12,13:28:46,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Barclays
REGN,2022-04-12,13:28:46,589803,Regeneron Pharmaceuticals Inc.,100,0.64,price-targets,upgrade,Regeneron Pharma Price Target Raised to $745.00/Share From $700.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $745.00/Share From $700.00 by Barclays
REGN,2022-04-12,14:29:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley
REGN,2022-04-12,14:29:07,589803,Regeneron Pharmaceuticals Inc.,100,0.52,price-targets,upgrade,Regeneron Pharma Price Target Raised to $632.00/Share From $605.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $632.00/Share From $605.00 by Morgan Stanley
REGN,2022-04-12,15:53:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Landry Registers 1,862 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"CFO Landry Registers 1,862 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-04-14,11:23:08,589803,Regeneron Pharmaceuticals Inc.,100,-0.47,regulatory,,Fda Extends Review of Regeneron,FULL-ARTICLE,Dow Jones Newswires,FDA Extends Review of Regeneron's REGEN-COV Covid-19 Drug >REGN
REGN,2022-04-14,11:38:08,589803,Regeneron Pharmaceuticals Inc.,100,-0.47,regulatory,,Fda Extends Review of Regeneron,FULL-ARTICLE,Dow Jones Newswires,FDA Extends Review of Regeneron's REGEN-COV Covid-19 Drug
REGN,2022-04-19,11:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Acquisition of Checkmate by Regeneron,PRESS-RELEASE,GlobeNewswire,Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
REGN,2022-04-19,11:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Acquire Checkmate Pharmaceuticals,PRESS-RELEASE,GlobeNewswire,Regeneron to Acquire Checkmate Pharmaceuticals -2-
REGN,2022-04-19,11:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Acquisition of Checkmate by Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
REGN,2022-04-19,11:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Press Release: Regeneron to Acquire Checkmate,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron to Acquire Checkmate -2-
REGN,2022-04-19,11:00:09,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Acquisition of Checkmate by Regeneron,PRESS-RELEASE,PR Newswire,Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
REGN,2022-04-19,11:00:09,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Acquire Checkmate Pharmaceuticals,PRESS-RELEASE,PR Newswire,Regeneron to Acquire Checkmate Pharmaceuticals -2-
REGN,2022-04-19,11:00:09,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Acquisition of Checkmate by Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
REGN,2022-04-19,11:00:09,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Press Release: Regeneron to Acquire Checkmate,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron to Acquire Checkmate -2-
REGN,2022-04-19,11:00:14,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Acquire Checkmate Pharmaceuticals and,NEWS-FLASH,Dow Jones Newswires,Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
REGN,2022-04-19,11:00:50,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy Checkmate Pharmaceuticals for $10.50 A Share,NEWS-FLASH,Dow Jones Newswires,Regeneron to Buy Checkmate Pharmaceuticals for $10.50 A Share >REGN CMPI
REGN,2022-04-19,11:01:13,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron Pharma to Buy Checkmate Pharmaceuticals for About $250 Million >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma to Buy Checkmate Pharmaceuticals for About $250 Million >REGN
REGN,2022-04-19,11:02:35,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Acquire Checkmate Pharmaceuticals and,NEWS-FLASH,Dow Jones Newswires,Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
REGN,2022-04-19,11:17:45,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy Checkmate Pharmaceuticals for About $250 Million >REGN,FULL-ARTICLE,Dow Jones Newswires,Regeneron to Buy Checkmate Pharmaceuticals for About $250 Million >REGN CMPI
REGN,2022-04-19,11:32:45,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy Checkmate Pharmaceuticals for About $250 Million,FULL-ARTICLE,Dow Jones Newswires,Regeneron to Buy Checkmate Pharmaceuticals for About $250 Million
REGN,2022-04-24,07:34:20,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals Inc, Inst Holders, 1Q 2022 (REGN)",RNS-SEC13F,Dow Jones Newswires,"Regeneron Pharmaceuticals Inc, Inst Holders, 1Q 2022 (REGN)"
REGN,2022-05-02,12:32:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital
REGN,2022-05-02,12:32:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.56,price-targets,downgrade,Regeneron Pharma Price Target Cut to $647.00/Share From $679.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $647.00/Share From $679.00 by RBC Capital
REGN,2022-05-03,18:14:51,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-05-03,21:10:56,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-05-03,21:11:57,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 1Q EPS $8.61,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q EPS $8.61 >REGN
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2022",PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.63,revenues,up,Regeneron Pharmaceuticals Inc.: First quarter 2022 revenues increased 17% to $2.97 billion,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: First quarter 2022 GAAP diluted EPS of $8.61,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: non-GAAP diluted EPS(a) of $11.49,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Regeneron Pharmaceuticals Inc.: EYLEA(R) (aflibercept) Injection,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,"Regeneron Pharmaceuticals Inc.: In February 2022, the Company announced detailed results from its Phase 2 trial",PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Ec) approved Dupixent for the treatment,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Pharmaceuticals Inc.: The U.S. Food and Drug Administration (FDA) accepted for priority review,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,The FDA accepted for priority review the sBLA for Dupixent,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.69,products-services,,Regeneron Pharmaceuticals Inc.: The FDA granted Fast Track designation,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.63,acquisitions-mergers,,"Regeneron Pharmaceuticals Inc.: the Company entered into a definitive merger agreement to acquire Checkmate Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 1Q Net $973.5M,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q Net $973.5M >REGN
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: The Company also recorded Roche collaboration revenue of $216 million,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial -2-
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial -2-
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D in the first quarter of 2022,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial -2-
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $8.61 in the first quarter of 2022,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial -2-
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.4,earnings,up,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $11.49 in the first quarter of 2022, compared to $9.89 in the first quarter of 2021",PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial -2-
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the first quarter of 2022, the Company repurchased shares of common stock",PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial -2-
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2022 Financial Guidance,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial -2-
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 1Q Rev $2.97B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q Rev $2.97B >REGN
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2022 financial guidance,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial -3-
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: Conference Call Information,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial -3-
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: March 31, December 31, 2022 2021 Assets",PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial -4-
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Three Months Ended March 31, 2022 2021 Revenues",PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial -4-
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial -4-
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $ 973.5 $ 1,115.2",PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial -4-
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 9.12 $ 10.58,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial -4-
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 12.34 $ 10.52,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial -4-
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Consequently, the prior year net product sales",PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial -5-
REGN,2022-05-04,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: net product sales of ARCALYST were $18.7 million,PRESS-RELEASE,PR Newswire,Regeneron Reports First Quarter 2022 Financial -5-
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,100,0.63,revenues,up,Regeneron Pharmaceuticals Inc.: First quarter 2022 revenues increased 17% to $2.97 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: First quarter 2022 GAAP diluted EPS of $8.61,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: non-GAAP diluted EPS(a) of $11.49,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Regeneron Pharmaceuticals Inc.: EYLEA(R) (aflibercept) Injection,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,"Regeneron Pharmaceuticals Inc.: In February 2022, the Company announced detailed results from its Phase 2 trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Ec) approved Dupixent for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Pharmaceuticals Inc.: The U.S. Food and Drug Administration (FDA) accepted for priority review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,The FDA accepted for priority review the sBLA for Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,100,0.69,products-services,,Regeneron Pharmaceuticals Inc.: The FDA granted Fast Track designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,100,0.63,acquisitions-mergers,,"Regeneron Pharmaceuticals Inc.: the Company entered into a definitive merger agreement to acquire Checkmate Pharmaceuticals, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2022 Financial and Operating Results
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Other revenue in the first quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D in the first quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $8.61 in the first quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,99,0.4,earnings,up,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $11.49 in the first quarter of 2022, compared to $9.89 in the first quarter of 2021",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the first quarter of 2022, the Company repurchased shares of common stock",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2022 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -3-
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: Conference Call Information,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -3-
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: March 31, December 31, 2022 2021 Assets",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Three Months Ended March 31, 2022 2021 Revenues",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $ 973.5 $ 1,115.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 9.12 $ 10.58,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 12.34 $ 10.52,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Consequently, the prior year net product sales",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -5-
REGN,2022-05-04,10:30:15,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: net product sales of ARCALYST were $18.7 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -5-
REGN,2022-05-04,10:32:57,589803,Regeneron Pharmaceuticals Inc.,100,0.44,revenues,up,Regeneron Pharma 1Q Revenue Excluding REGEN-COV Rose 25%,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q Revenue Excluding REGEN-COV Rose 25% >REGN
REGN,2022-05-04,10:33:18,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharma 1Q Eylea U.S. Net Sales Rose 13% to $1.52B,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q Eylea U.S. Net Sales Rose 13% to $1.52B >REGN
REGN,2022-05-04,10:33:38,589803,Regeneron Pharmaceuticals Inc.,100,0.56,revenues,up,Regeneron Pharma: 1Q Dupixent Global Net Sales Rose 43% to $1.81B,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma: 1Q Dupixent Global Net Sales Rose 43% to $1.81B >REGN
REGN,2022-05-04,10:33:55,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 1Q Adj EPS $11.49,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q Adj EPS $11.49 >REGN
REGN,2022-05-04,10:37:31,589803,Regeneron Pharmaceuticals Inc.,100,-0.3,earnings,down,Regeneron Q1 EPS $8.61 vs. $10.09 a year ago,NEWS-FLASH,MarketWatch,MW Regeneron Q1 EPS $8.61 vs. $10.09 a year ago
REGN,2022-05-04,10:37:47,589803,Regeneron Pharmaceuticals Inc.,100,0.46,earnings,above-expectations,Regeneron Q1 adj. EPS $11.49; FactSet consensus $9.68,NEWS-FLASH,MarketWatch,MW Regeneron Q1 adj. EPS $11.49; FactSet consensus $9.68
REGN,2022-05-04,10:38:08,589803,Regeneron Pharmaceuticals Inc.,100,0.48,revenues,above-expectations,Regeneron Q1 revenue $2.965 bln vs. $2.529 bln a year ago; FactSet consensus $2.690 bln,NEWS-FLASH,MarketWatch,MW Regeneron Q1 revenue $2.965 bln vs. $2.529 bln a year ago; FactSet consensus $2.690 bln
REGN,2022-05-04,10:47:35,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: The company posted net income of $974 million,FULL-ARTICLE,MarketWatch,MW Regeneron shares up 1.4% premarket after earnings top estimates
REGN,2022-05-04,10:47:35,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: The company posted net income of $974 million,FULL-ARTICLE,Dow Jones Newswires,Regeneron Shares Up 1.4% Premarket After Earnings Top Estimates -- MarketWatch
REGN,2022-05-04,11:16:55,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron (ticker: REGN) reported adjusted earnings of $11.49 a share,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Rises as First-Quarter Earnings Top Forecasts -- Barrons.com
REGN,2022-05-04,11:16:55,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron reports since the Food and Drug Administration effectively revoked the emergency use authorization of REGEN-COV,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Rises as First-Quarter Earnings Top Forecasts -- Barrons.com
REGN,2022-05-04,13:16:54,589803,Regeneron Pharmaceuticals Inc.,92,0.0,revenues,,Regeneron reports $2.7B in 1Q revenue,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets A Little Help from Its Friends in 1Q Beat -- Market Talk
REGN,2022-05-04,13:16:55,589803,Regeneron Pharmaceuticals Inc.,92,0.0,revenues,,Regeneron reports $2.7B in 1Q revenue,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets A Little Help from Its Friends in 1Q Beat -- Market Talk
REGN,2022-05-04,17:33:57,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals CEO, Leonard Schleifer on Q1 2022 Results -- Earnings Call",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals CEO, Leonard Schleifer on Q1 2022 Results -- Earnings Call Transcript >REGN"
REGN,2022-05-05,14:11:20,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley
REGN,2022-05-05,14:11:20,589803,Regeneron Pharmaceuticals Inc.,100,-0.36,price-targets,downgrade,Regeneron Pharma Price Target Cut to $620.00/Share From $632.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $620.00/Share From $632.00 by Morgan Stanley
REGN,2022-05-05,14:55:11,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital
REGN,2022-05-05,14:55:11,589803,Regeneron Pharmaceuticals Inc.,100,0.32,price-targets,upgrade,Regeneron Pharma Price Target Raised to $658.00/Share From $647.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $658.00/Share From $647.00 by RBC Capital
REGN,2022-05-16,12:00:05,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Elicio Therapeutics Announces Clinical Supply Agreement with Regeneron,PRESS-RELEASE,GlobeNewswire,Elicio Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate ELI-002 in Combination with Libtayo(R) (cemiplimab) in KRAS-Driven Tumors
REGN,2022-05-16,12:00:05,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Libtayo is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,GlobeNewswire,Elicio Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate ELI-002 in Combination with Libtayo(R) (cemiplimab) in KRAS-Driven Tumors
REGN,2022-05-18,18:26:34,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Murphy Registers 3,543 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Murphy Registers 3,543 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-05-18,20:06:25,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Murphy Sells 3,543 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Murphy Sells 3,543 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-05-20,18:42:31,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Approves Sanofi and Regeneron's Dupixent,NEWS-FLASH,Dow Jones Newswires,FDA Approves Sanofi and Regeneron's Dupixent as Treatment for Eosinophilic Esophagitis
REGN,2022-05-20,19:12:18,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Grants Regeneron Approval for Dupixent,FULL-ARTICLE,Dow Jones Newswires,FDA Grants Regeneron Approval for Dupixent in Inflammatory Disorder Treatment
REGN,2022-05-20,19:12:18,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,FULL-ARTICLE,Dow Jones Newswires,FDA Grants Regeneron Approval for Dupixent in Inflammatory Disorder Treatment
REGN,2022-05-20,19:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda approves Dupixent(R) (dupilumab) as,PRESS-RELEASE,GlobeNewswire,Press Release: FDA approves Dupixent(R) (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
REGN,2022-05-20,19:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,GlobeNewswire,Press Release: FDA approves Dupixent(R) (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
REGN,2022-05-20,19:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Dupixent(R),PRESS-RELEASE,GlobeNewswire,Press Release: FDA approves Dupixent(R) -2-
REGN,2022-05-20,19:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Dupixent(R),PRESS-RELEASE,GlobeNewswire,Press Release: FDA approves Dupixent(R) -3-
REGN,2022-05-20,19:15:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda approves Dupixent(R) (dupilumab) as,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: FDA approves Dupixent(R) (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
REGN,2022-05-20,19:15:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: FDA approves Dupixent(R) (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
REGN,2022-05-20,19:15:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda approves Dupixent(R) (dupilumab) as,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: FDA approves Dupixent(R) (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
REGN,2022-05-20,19:15:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: FDA approves Dupixent(R) (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
REGN,2022-05-20,19:15:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda approves Dupixent(R) (dupilumab) as,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: FDA approves Dupixent(R) (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
REGN,2022-05-20,19:15:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: FDA approves Dupixent(R) (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
REGN,2022-05-20,19:15:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent(R) (dupilumab),PRESS-RELEASE,PR Newswire,FDA Approves Dupixent(R) (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
REGN,2022-05-20,19:15:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Approves Dupixent(R) (dupilumab) as,PRESS-RELEASE,PR Newswire,FDA Approves Dupixent(R) (dupilumab) as First -2-
REGN,2022-05-20,19:15:04,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,PR Newswire,FDA Approves Dupixent(R) (dupilumab) as First -2-
REGN,2022-05-20,19:15:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Approves Dupixent(R) (dupilumab) as,PRESS-RELEASE,PR Newswire,FDA Approves Dupixent(R) (dupilumab) as First -3-
REGN,2022-05-20,19:15:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Approves Dupixent(R) (dupilumab) as,PRESS-RELEASE,PR Newswire,FDA Approves Dupixent(R) (dupilumab) as First -4-
REGN,2022-05-20,19:15:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent(R) (dupilumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Approves Dupixent(R) (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
REGN,2022-05-20,19:15:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA Approves Dupixent(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Approves Dupixent(R) -2-
REGN,2022-05-20,19:15:04,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Approves Dupixent(R) -2-
REGN,2022-05-20,19:15:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA Approves Dupixent(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Approves Dupixent(R) -3-
REGN,2022-05-20,19:15:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA Approves Dupixent(R),NEWS-FLASH,Dow Jones Newswires,Press Release: FDA Approves Dupixent(R) -4-
REGN,2022-05-20,19:20:39,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi: FDA Approved Dupixent,NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharma Regeneron Pharmaceuticals, Inc. and Sanofi: FDA Approved Dupixent 300 Mg Weekly to Treat Patients With Eosinophilic Esophagitis Aged 12 Years and Older, Weighing at Least 40 Kg >REGN"
REGN,2022-05-20,19:27:19,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Grants Regeneron Approval for Dupixent,FULL-ARTICLE,Dow Jones Newswires,FDA Grants Regeneron Approval for Dupixent in Inflammatory Disorder Treatment
REGN,2022-05-20,19:27:19,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,FULL-ARTICLE,Dow Jones Newswires,FDA Grants Regeneron Approval for Dupixent in Inflammatory Disorder Treatment
REGN,2022-05-23,10:09:42,589803,Regeneron Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Regeneron Pharma Initiated at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Initiated at Outperform by SVB Leerink
REGN,2022-05-23,10:09:42,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $738.00/Share by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $738.00/Share by SVB Leerink
REGN,2022-05-31,04:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda Accepts Dupixent(R) (dupilumab) for Priority Review,PRESS-RELEASE,PR Newswire,FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Adults with Prurigo Nodularis
REGN,2022-05-31,04:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent(R),PRESS-RELEASE,PR Newswire,FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Adults with Prurigo Nodularis
REGN,2022-05-31,04:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,PR Newswire,FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Adults with Prurigo Nodularis
REGN,2022-05-31,04:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda Accepts Dupixent(R) (dupilumab) for Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Adults with Prurigo Nodularis
REGN,2022-05-31,04:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Adults with Prurigo Nodularis
REGN,2022-05-31,04:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Dupixent(R) (dupilumab) for Priority Review in Adults with Prurigo Nodularis
REGN,2022-05-31,12:31:49,589803,Regeneron Pharmaceuticals Inc.,100,0.57,acquisitions-mergers,completed,Regeneron Completes Acquisition of Checkmate,PRESS-RELEASE,PR Newswire,Regeneron Completes Acquisition of Checkmate -2-
REGN,2022-05-31,12:31:49,589803,Regeneron Pharmaceuticals Inc.,100,0.57,acquisitions-mergers,completed,Regeneron Completes Acquisition of Checkmate Pharmaceuticals,PRESS-RELEASE,PR Newswire,Regeneron Completes Acquisition of Checkmate Pharmaceuticals
REGN,2022-05-31,12:31:49,589803,Regeneron Pharmaceuticals Inc.,100,0.57,acquisitions-mergers,completed,Regeneron Completes Acquisition Of Checkmate Pharmaceuticals >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Completes Acquisition Of Checkmate Pharmaceuticals >REGN
REGN,2022-05-31,12:31:49,589803,Regeneron Pharmaceuticals Inc.,100,0.57,acquisitions-mergers,completed,Regeneron Completes Acquisition of Checkmate Pharmaceuticals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Completes Acquisition of Checkmate Pharmaceuticals
REGN,2022-05-31,12:31:49,589803,Regeneron Pharmaceuticals Inc.,100,0.57,acquisitions-mergers,completed,Regeneron Completes Acquisition of -2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Completes Acquisition of -2-
REGN,2022-05-31,13:46:03,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Argus Research
REGN,2022-05-31,13:46:03,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $760.00/Share From $680.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $760.00/Share From $680.00 by Argus Research
REGN,2022-06-02,05:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals,PRESS-RELEASE,GlobeNewswire,Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment
REGN,2022-06-02,05:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment
REGN,2022-06-02,05:00:57,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals,PRESS-RELEASE,DGAP News,Kuros Biosciences: Completion of the acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals triggers a USD5 million milestone payment
REGN,2022-06-02,05:00:57,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals,PRESS-RELEASE,Dow Jones Newswires,Kuros Biosciences: Completion of the acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals triggers a USD5 million milestone payment
REGN,2022-06-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,"Oncology collaboration with Regeneron Pharmaceuticals, Inc. Under",PRESS-RELEASE,GlobeNewswire,Press Release: Sanofi grants Regeneron worldwide exclusive license rights to Libtayo(R) (cemiplimab)
REGN,2022-06-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,"Oncology collaboration with Regeneron Pharmaceuticals, Inc. Under",PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Sanofi grants Regeneron worldwide exclusive license rights to Libtayo(R) (cemiplimab)
REGN,2022-06-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,"Oncology collaboration with Regeneron Pharmaceuticals, Inc. Under",PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Sanofi grants Regeneron worldwide exclusive license rights to Libtayo(R) (cemiplimab)
REGN,2022-06-02,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,"Oncology collaboration with Regeneron Pharmaceuticals, Inc. Under",PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Sanofi grants Regeneron worldwide exclusive license rights to Libtayo(R) (cemiplimab)
REGN,2022-06-02,11:30:04,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Sanofi Collaboration on Libtayo(R) (cemiplimab),PRESS-RELEASE,PR Newswire,"Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo(R) (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer"
REGN,2022-06-02,11:30:04,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron will host an investor conference call today at 8:30 am ET,PRESS-RELEASE,PR Newswire,"Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo(R) (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer"
REGN,2022-06-02,11:30:04,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its intent to purchase Sanofi",PRESS-RELEASE,PR Newswire,"Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo(R) (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer"
REGN,2022-06-02,11:30:04,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Sanofi entered into the Immuno-oncology License and Collaboration,PRESS-RELEASE,PR Newswire,"Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo(R) (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer"
REGN,2022-06-02,11:30:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Libtayo is also approved in Canada for the treatment,PRESS-RELEASE,PR Newswire,"Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo(R) (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer"
REGN,2022-06-02,11:30:04,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Sanofi Collaboration on Libtayo(R) (cemiplimab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo(R) (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer"
REGN,2022-06-02,11:30:04,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron will host an investor conference call today at 8:30 am ET,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo(R) (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer"
REGN,2022-06-02,11:30:04,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its intent to purchase Sanofi",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo(R) (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer"
REGN,2022-06-02,11:30:04,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Sanofi entered into the Immuno-oncology License and Collaboration,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo(R) (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer"
REGN,2022-06-02,11:30:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Libtayo is also approved in Canada for the treatment,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo(R) (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer"
REGN,2022-06-02,11:31:52,589803,Regeneron Pharmaceuticals Inc.,100,0.22,acquisitions-mergers,,Regeneron Pharma to Buy Sanofi Stake in,HOT-NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma to Buy Sanofi Stake in Company >REGN
REGN,2022-06-02,11:32:59,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron Pharma to Buy Sanofi,HOT-NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma to Buy Sanofi Collaboration on Libtayo >REGN
REGN,2022-06-02,11:49:55,589803,Regeneron Pharmaceuticals Inc.,100,0.22,acquisitions-mergers,,Regeneron to Buy Sanofi's Stake in Libtayo,FULL-ARTICLE,Dow Jones Newswires,Regeneron to Buy Sanofi's Stake in Libtayo Program
REGN,2022-06-02,11:49:55,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc. on Thursday said it is buying out partner Sanofi SA,FULL-ARTICLE,Dow Jones Newswires,Regeneron to Buy Sanofi's Stake in Libtayo Program
REGN,2022-06-02,11:50:27,589803,Regeneron Pharmaceuticals Inc.,95,0.49,partnerships,,Regeneron-Sanofi collaboration on cancer treatment,FULL-ARTICLE,MarketWatch,MW Regeneron to pay Sanofi up to $1.1 billion plus royalties for its stake in Libtayo collaboration
REGN,2022-06-02,11:50:27,589803,Regeneron Pharmaceuticals Inc.,95,0.49,partnerships,,Regeneron-Sanofi collaboration on cancer treatment,FULL-ARTICLE,Dow Jones Newswires,Regeneron To Pay Sanofi Up To $1.1 Billion Plus Royalties For Its Stake In Libtayo Collaboration -- MarketWatch
REGN,2022-06-02,11:56:31,589803,Regeneron Pharmaceuticals Inc.,95,0.49,partnerships,,Regeneron-Sanofi collaboration on cancer treatment,FULL-ARTICLE,MarketWatch,MW Regeneron to pay Sanofi up to $1.1 billion plus royalties for its stake in Libtayo collaboration
REGN,2022-06-02,11:56:31,589803,Regeneron Pharmaceuticals Inc.,95,0.49,partnerships,,Regeneron-Sanofi collaboration on cancer treatment,FULL-ARTICLE,Dow Jones Newswires,Regeneron To Pay Sanofi Up To $1.1 Billion Plus Royalties For Its Stake In Libtayo Collaboration -- MarketWatch
REGN,2022-06-02,12:04:55,589803,Regeneron Pharmaceuticals Inc.,100,0.22,acquisitions-mergers,,Regeneron to Buy Sanofi's Stake in Libtayo,FULL-ARTICLE,Dow Jones Newswires,Regeneron to Buy Sanofi's Stake in Libtayo Program
REGN,2022-06-02,12:04:55,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc. on Thursday said it is buying out partner Sanofi SA,FULL-ARTICLE,Dow Jones Newswires,Regeneron to Buy Sanofi's Stake in Libtayo Program
REGN,2022-06-02,14:44:17,589803,Regeneron Pharmaceuticals Inc.,100,0.55,acquisitions-mergers,,Regeneron Will Buy Rights to Cancer Drug Libtayo From Sanofi,FULL-ARTICLE,Dow Jones Newswires,Regeneron Will Buy Rights to Cancer Drug Libtayo From Sanofi for Up to $1.1 Billion -- Barrons.com
REGN,2022-06-02,14:44:17,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Libtayo is currently approved by regulatory authorities,FULL-ARTICLE,Dow Jones Newswires,Regeneron Will Buy Rights to Cancer Drug Libtayo From Sanofi for Up to $1.1 Billion -- Barrons.com
REGN,2022-06-02,14:50:04,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Libtayo is currently approved by regulatory authorities,FULL-ARTICLE,Dow Jones Newswires,Regeneron Will Buy Cancer Drug Rights From Sanofi for Up to $1.1 Billion
REGN,2022-06-02,20:34:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-06-03,11:43:41,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Wells Fargo
REGN,2022-06-03,11:43:41,589803,Regeneron Pharmaceuticals Inc.,100,-0.38,price-targets,downgrade,Regeneron Pharma Price Target Cut to $735.00/Share From $750.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $735.00/Share From $750.00 by Wells Fargo
REGN,2022-06-03,12:30:51,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley
REGN,2022-06-03,12:30:51,589803,Regeneron Pharmaceuticals Inc.,100,-0.32,price-targets,downgrade,Regeneron Pharma Price Target Cut to $610.00/Share From $620.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $610.00/Share From $620.00 by Morgan Stanley
REGN,2022-06-03,20:02:20,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-06-06,09:07:59,589803,Regeneron Pharmaceuticals Inc.,100,-0.83,analyst-ratings,negative,Regeneron Pharma Initiated at Underperform by Jefferies,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Initiated at Underperform by Jefferies
REGN,2022-06-06,09:07:59,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $536.00/Share by Jefferies,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $536.00/Share by Jefferies
REGN,2022-06-06,16:54:22,589803,Regeneron Pharmaceuticals Inc.,94,-0.75,revenues,down,Eylea sales could dip,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Gets Wall Street-Low Price Target. The Stock May Be Done Outperforming, Analyst Says. -- Barrons.com"
REGN,2022-06-07,20:44:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent(R) (dupilumab),PRESS-RELEASE,PR Newswire,FDA Approves Dupixent(R) (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
REGN,2022-06-07,20:44:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,PR Newswire,FDA Approves Dupixent(R) (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
REGN,2022-06-07,20:44:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Approves Dupixent(R) (dupilumab) as,PRESS-RELEASE,PR Newswire,FDA Approves Dupixent(R) (dupilumab) as First -2-
REGN,2022-06-07,20:44:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Approves Dupixent(R) (dupilumab) as,PRESS-RELEASE,PR Newswire,FDA Approves Dupixent(R) (dupilumab) as First -3-
REGN,2022-06-07,20:44:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Approves Dupixent(R) (dupilumab) as,PRESS-RELEASE,PR Newswire,FDA Approves Dupixent(R) (dupilumab) as First -4-
REGN,2022-06-07,20:44:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent(R) (dupilumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Approves Dupixent(R) (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
REGN,2022-06-07,20:44:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA Approves Dupixent(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Approves Dupixent(R) -2-
REGN,2022-06-07,20:44:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Approves Dupixent(R) -2-
REGN,2022-06-07,20:44:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA Approves Dupixent(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Approves Dupixent(R) -3-
REGN,2022-06-07,20:44:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA Approves Dupixent(R),NEWS-FLASH,Dow Jones Newswires,Press Release: FDA Approves Dupixent(R) -4-
REGN,2022-06-07,20:44:35,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Approves Dupixent (dupilumab) as,NEWS-FLASH,Dow Jones Newswires,FDA Approves Dupixent (dupilumab) as First Biologic Medicine for Children Aged 6 Mos to 5 Years With Moderate-to-severe Atopic Dermatitis >SNY
REGN,2022-06-07,20:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda approves Dupixent(R) (dupilumab) as,PRESS-RELEASE,GlobeNewswire,Press Release: FDA approves Dupixent(R) (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-06-07,20:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,GlobeNewswire,Press Release: FDA approves Dupixent(R) (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-06-07,20:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Dupixent(R),PRESS-RELEASE,GlobeNewswire,Press Release: FDA approves Dupixent(R) -2-
REGN,2022-06-07,20:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Press Release: FDA approves Dupixent(R),PRESS-RELEASE,GlobeNewswire,Press Release: FDA approves Dupixent(R) -3-
REGN,2022-06-07,20:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda approves Dupixent(R) (dupilumab) as,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: FDA approves Dupixent(R) (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-06-07,20:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: FDA approves Dupixent(R) (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-06-07,20:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda approves Dupixent(R) (dupilumab) as,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: FDA approves Dupixent(R) (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-06-07,20:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: FDA approves Dupixent(R) (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-06-07,20:45:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda approves Dupixent(R) (dupilumab) as,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: FDA approves Dupixent(R) (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-06-07,20:45:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: FDA approves Dupixent(R) (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
REGN,2022-06-07,20:45:53,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron: FDA Approved Dupixent,NEWS-FLASH,Dow Jones Newswires,"Sanofi, Regeneron: FDA Approved Dupixent for Children aged 6 Mos to 5 Yrs With Moderate-to-Severe Atopic Dermatitis >SNY"
REGN,2022-06-08,05:34:24,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi SA said late Tuesday that the U.S. Food and Drug Administration has approved its blockbuster drug Dupixent,FULL-ARTICLE,Dow Jones Newswires,Sanofi Gets U.S. FDA Nod on Use of Dupixent in Children With Atopic Dermatitis
REGN,2022-06-08,05:49:24,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi SA said late Tuesday that the U.S. Food and Drug Administration has approved its blockbuster drug Dupixent,FULL-ARTICLE,Dow Jones Newswires,Sanofi Gets U.S. FDA Nod on Use of Dupixent in Children With Atopic Dermatitis
REGN,2022-06-08,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001,PRESS-RELEASE,GlobeNewswire,Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress(TM) 2022
REGN,2022-06-08,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Discovery, development and commercialization collaboration with Regeneron",PRESS-RELEASE,GlobeNewswire,Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress(TM) 2022
REGN,2022-06-08,11:33:24,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001,PRESS-RELEASE,Dow Jones Newswires,Press Release: Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress(TM) 2022
REGN,2022-06-08,11:33:24,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Discovery, development and commercialization collaboration with Regeneron",PRESS-RELEASE,Dow Jones Newswires,Press Release: Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress(TM) 2022
REGN,2022-06-14,19:25:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,marketing,,"Regeneron Pharmaceuticals, Inc.'s (REGN) Management Presents at Goldman Sachs 43rd Annual Global Healthcare Conference",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc.'s (REGN) Management Presents at Goldman Sachs 43rd Annual Global Healthcare Conference (Transcript) >REGN"
REGN,2022-06-16,10:30:06,589803,Regeneron Pharmaceuticals Inc.,91,0.57,products-services,granted,Fda approved Sanofi/Regeneron's Dupixent,PRESS-RELEASE,PR Newswire,Spherix Global Insights Will Begin Tracking the Launch of Sanofi/Regeneron's Dupixent for the Treatment of Eosinophilic Esophagitis
REGN,2022-06-24,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Present Updated Interim Data from Phase 1 Study,PRESS-RELEASE,GlobeNewswire,Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
REGN,2022-06-24,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Discovery, development and commercialization collaboration with Regeneron",PRESS-RELEASE,GlobeNewswire,Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
REGN,2022-06-24,11:31:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Present Updated Interim Data from Phase 1 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
REGN,2022-06-24,11:31:03,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Discovery, development and commercialization collaboration with Regeneron",PRESS-RELEASE,Dow Jones Newswires,Press Release: Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
REGN,2022-07-01,11:00:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,acquisitions-mergers,completed,Regeneron Completes Purchase of Sanofi,PRESS-RELEASE,PR Newswire,Regeneron Completes Purchase of Sanofi's Stake in Libtayo(R) (cemiplimab)
REGN,2022-07-01,11:00:04,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"In 2015, Regeneron and Sanofi entered into the Immuno-oncology License and Collaboration",PRESS-RELEASE,PR Newswire,Regeneron Completes Purchase of Sanofi's Stake in Libtayo(R) (cemiplimab)
REGN,2022-07-01,11:00:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,acquisitions-mergers,completed,Regeneron Completes Purchase of Sanofi,PRESS-RELEASE,PR Newswire,Regeneron Completes Purchase of Sanofi's Stake in -2-
REGN,2022-07-01,11:00:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,acquisitions-mergers,completed,Regeneron Completes Purchase of Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Completes Purchase of Sanofi's Stake in Libtayo(R) (cemiplimab)
REGN,2022-07-01,11:00:04,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"In 2015, Regeneron and Sanofi entered into the Immuno-oncology License and Collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Completes Purchase of Sanofi's Stake in Libtayo(R) (cemiplimab)
REGN,2022-07-05,16:56:15,589803,Regeneron Pharmaceuticals Inc.,100,-0.03,credit-ratings,affirmation,Moody's Affirms Regeneron At Baa3,NEWS-FLASH,Dow Jones Newswires,"Moody's Affirms Regeneron At Baa3, Revises Outlook To Positive From Stable"
REGN,2022-07-05,20:04:44,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-07-05,21:41:39,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-07-06,20:01:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report Second Quarter 2022 Financial and Operating Results,PRESS-RELEASE,PR Newswire,"Regeneron to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2022"
REGN,2022-07-06,20:01:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time,PRESS-RELEASE,PR Newswire,"Regeneron to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2022"
REGN,2022-07-06,20:01:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report Second Quarter 2022 Financial and Operating Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2022"
REGN,2022-07-06,20:01:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2022"
REGN,2022-07-12,13:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Pharmaceuticals Inc.: Ultima Genomics signs development agreement with Regeneron,PRESS-RELEASE,PR Newswire,Ultima Genomics signs development agreement with Regeneron aimed at driving the scale of genomic information for drug discovery and development
REGN,2022-07-12,13:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron Pharmaceuticals Inc.: We are excited to collaborate with Regeneron on,PRESS-RELEASE,PR Newswire,Ultima Genomics signs development agreement with Regeneron aimed at driving the scale of genomic information for drug discovery and development
REGN,2022-07-12,13:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Genomics signs development agreement with Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Ultima Genomics signs development agreement with Regeneron aimed at driving the scale of genomic information for drug discovery and development
REGN,2022-07-12,13:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron Pharmaceuticals Inc.: We are excited to collaborate with Regeneron on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Ultima Genomics signs development agreement with Regeneron aimed at driving the scale of genomic information for drug discovery and development
REGN,2022-07-15,16:19:24,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley
REGN,2022-07-15,16:19:24,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $619.00/Share From $610.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $619.00/Share From $610.00 by Morgan Stanley
REGN,2022-07-20,14:05:05,589803,Regeneron Pharmaceuticals Inc.,100,0.06,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Market Perform by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Market Perform by Cowen & Co.
REGN,2022-07-20,14:05:05,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $645.00/Share From $635.00 by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $645.00/Share From $635.00 by Cowen & Co.
REGN,2022-07-24,07:50:31,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals Inc, Inst Holders, 2Q 2022 (REGN)",RNS-SEC13F,Dow Jones Newswires,"Regeneron Pharmaceuticals Inc, Inst Holders, 2Q 2022 (REGN)"
REGN,2022-07-25,10:33:05,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Regeneron Pharma Cut to Market Perform From Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Cut to Market Perform From Outperform by SVB Leerink
REGN,2022-07-25,10:33:05,589803,Regeneron Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Regeneron Pharma Price Target Cut to $630.00/Share From $738.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $630.00/Share From $738.00 by SVB Leerink
REGN,2022-07-26,11:00:12,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,PR Newswire,Regeneron Announces the 2022 Winners of the Regeneron Prize for Creative Innovation
REGN,2022-08-02,20:29:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-08-02,22:18:05,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2022",PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,-0.38,revenues,,Regeneron Pharmaceuticals Inc.: Second quarter 2022 revenues decreased 44% to $2.86 billion,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Second quarter 2022 GAAP diluted EPS of $7.47,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: non-GAAP diluted EPS(a) of $9.77,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: FDA approved Dupixent,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: our full-year 2022 financial guidance,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Regeneron Pharmaceuticals Inc.: EYLEA(R) (aflibercept) Injection,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,-0.65,products-services,negative,Regeneron Pharmaceuticals Inc.: A Phase 2 study in heart failure,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.57,acquisitions-mergers,completed,"Regeneron Pharmaceuticals Inc.: In May 2022, the Company completed its acquisition of Checkmate Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial -2-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D in the second quarter of 2022,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial -2-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $7.47 in the second quarter of 2022,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial -2-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $9.77 in the second quarter of 2022,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial -2-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the second quarter of 2022, the Company repurchased shares of common stock",PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial -2-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2022 Financial Guidance,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial -2-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2022 financial guidance,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial -3-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its second quarter 2022 financial and operating results on Wednesday, August 3, 2022, at 8:30 AM Eastern Time",PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial -3-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: June 30, December 31, 2022 2021 Assets",PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial -4-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial -4-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $ 852.1 $ 3,098.9 $",PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial -4-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 7.90 $ 29.51 $,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial -4-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 10.44 $ 27.57 $,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial -4-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 2Q EPS $7.47,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q EPS $7.47 >REGN
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Consequently, the prior year net product sales",PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial -5-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: net product sales of ARCALYST were $22.2 million,PRESS-RELEASE,PR Newswire,Regeneron Reports Second Quarter 2022 Financial -5-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 2Q Adj EPS $9.77,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q Adj EPS $9.77 >REGN
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 2Q Net $852.1M,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q Net $852.1M >REGN
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 2Q Rev $2.86B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q Rev $2.86B >REGN
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,-0.38,revenues,,Regeneron Pharmaceuticals Inc.: Second quarter 2022 revenues decreased 44% to $2.86 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Second quarter 2022 GAAP diluted EPS of $7.47,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: non-GAAP diluted EPS(a) of $9.77,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: FDA approved Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: our full-year 2022 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Regeneron Pharmaceuticals Inc.: EYLEA(R) (aflibercept) Injection,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,-0.65,products-services,negative,Regeneron Pharmaceuticals Inc.: A Phase 2 study in heart failure,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,100,0.57,acquisitions-mergers,completed,"Regeneron Pharmaceuticals Inc.: In May 2022, the Company completed its acquisition of Checkmate Pharmaceuticals, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2022 Financial and Operating Results
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D in the second quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $7.47 in the second quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $9.77 in the second quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the second quarter of 2022, the Company repurchased shares of common stock",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2022 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -3-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its second quarter 2022 financial and operating results on Wednesday, August 3, 2022, at 8:30 AM Eastern Time",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -3-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: June 30, December 31, 2022 2021 Assets",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $ 852.1 $ 3,098.9 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 7.90 $ 29.51 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 10.44 $ 27.57 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Consequently, the prior year net product sales",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -5-
REGN,2022-08-03,10:30:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: net product sales of ARCALYST were $22.2 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -5-
REGN,2022-08-03,10:31:54,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharma 2Q Revenue Excluding REGEN-COV Rose 20%,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q Revenue Excluding REGEN-COV Rose 20% >REGN
REGN,2022-08-03,10:34:41,589803,Regeneron Pharmaceuticals Inc.,100,-0.72,earnings,down,Regeneron Q2 EPS $7.47 vs. $27.97 a year ago,NEWS-FLASH,MarketWatch,MW Regeneron Q2 EPS $7.47 vs. $27.97 a year ago
REGN,2022-08-03,10:34:56,589803,Regeneron Pharmaceuticals Inc.,100,0.46,earnings,above-expectations,Regeneron Q2 adj. EPS $9.77; FactSet consensus $8.62,NEWS-FLASH,MarketWatch,MW Regeneron Q2 adj. EPS $9.77; FactSet consensus $8.62
REGN,2022-08-03,10:35:16,589803,Regeneron Pharmaceuticals Inc.,100,0.48,revenues,above-expectations,Regeneron Q2 revenue $2.86 bln vs. $5.14 bln a year ago; FactSet consensus $2.79 bln,NEWS-FLASH,MarketWatch,MW Regeneron Q2 revenue $2.86 bln vs. $5.14 bln a year ago; FactSet consensus $2.79 bln
REGN,2022-08-03,10:58:22,589803,Regeneron Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Regeneron tops earnings expectations,FULL-ARTICLE,MarketWatch,MW Regeneron tops earnings expectations amid 'record' sales of several products
REGN,2022-08-03,10:58:22,589803,Regeneron Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Regeneron Tops Earnings Expectations,FULL-ARTICLE,Dow Jones Newswires,Regeneron Tops Earnings Expectations Amid 'record' Sales Of Several Products -- MarketWatch
REGN,2022-08-03,18:09:52,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals, Inc.'s CEO Leonard Schleifer on Q2 2022 Results -- Earnings Call",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc.'s CEO Leonard Schleifer on Q2 2022 Results -- Earnings Call Transcript >REGN"
REGN,2022-08-03,18:09:52,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron-pharmaceuticals-inc-s-regn-ceo-leonard-schleifer-on-q2-2022-results-earnings,NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc.'s CEO Leonard Schleifer on Q2 2022 Results -- Earnings Call Transcript >REGN"
REGN,2022-08-04,14:35:49,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Equal-Weight by Morgan Stanley
REGN,2022-08-04,14:35:49,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $625.00/Share From $619.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $625.00/Share From $619.00 by Morgan Stanley
REGN,2022-08-04,17:34:10,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by BMO Capital
REGN,2022-08-04,17:34:10,589803,Regeneron Pharmaceuticals Inc.,100,0.5,price-targets,upgrade,Regeneron Pharma Price Target Raised to $788.00/Share From $757.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $788.00/Share From $757.00 by BMO Capital
REGN,2022-08-08,20:13:30,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Stahl Sells 23,782 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stahl Sells 23,782 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-08-08,20:13:46,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Ryan Sells 10,453 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Ryan Sells 10,453 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-08-08,22:17:46,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Stahl Registers 23,782 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Stahl Registers 23,782 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-08-10,18:47:31,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Ryan Registers 2,500 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Ryan Registers 2,500 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-08-10,19:12:18,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Ryan Registers 10,453 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Ryan Registers 10,453 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-08-10,21:09:32,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Poon Christine Registers 15,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Poon Christine Registers 15,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-08-11,20:11:07,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Poon Sells 15,000 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Poon Sells 15,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-08-17,19:30:29,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Murphy Registers 3,513 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Murphy Registers 3,513 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-08-17,20:06:31,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Murphy Sells 3,513 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Murphy Sells 3,513 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-09-02,19:41:53,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-09-02,20:09:09,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-09-04,22:05:03,589803,Regeneron Pharmaceuticals Inc.,99,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: First-in-class Phase 1 data,PRESS-RELEASE,PR Newswire,"ESMO Presentations of Libtayo(R) (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers"
REGN,2022-09-04,22:05:03,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: regulatory approvals for our PD-1 inhibitor Libtayo,PRESS-RELEASE,PR Newswire,"ESMO Presentations of Libtayo(R) (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers"
REGN,2022-09-04,22:05:03,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron will host a conference call and simultaneous webcast,PRESS-RELEASE,PR Newswire,"ESMO Presentations of Libtayo(R) (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers"
REGN,2022-09-04,22:05:03,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Libtayo Phase 2 study of,PRESS-RELEASE,PR Newswire,"ESMO Presentations of Libtayo(R) (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers"
REGN,2022-09-07,12:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Oncoresponse Announces Clinical Supply Agreement with Regeneron,PRESS-RELEASE,PR Newswire,OncoResponse Announces Clinical Supply Agreement with Regeneron to Evaluate OR2805 in Combination with Libtayo(R) (cemiplimab) in Patients with Advanced Cancer
REGN,2022-09-07,19:26:39,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Coles Registers 6,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Coles Registers 6,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-09-07,19:45:31,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Ryan Registers 400 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Ryan Registers 400 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-09-08,12:55:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.65,equity-actions,halt,Regeneron Pharmaceuticals Inc. (REGN) Halted due to pending news,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharmaceuticals Inc. (REGN) Halted due to pending news
REGN,2022-09-08,12:56:03,589803,Regeneron Pharmaceuticals Inc.,100,-0.65,equity-actions,halt,Regeneron stock halted,NEWS-FLASH,MarketWatch,MW Regeneron stock halted for news pending
REGN,2022-09-08,12:57:57,589803,Regeneron Pharmaceuticals Inc.,100,-0.65,equity-actions,halt,Regeneron stock halted,NEWS-FLASH,MarketWatch,MW Regeneron stock halted for pending news
REGN,2022-09-08,13:07:38,589803,Regeneron Pharmaceuticals Inc.,100,0.48,equity-actions,resumed,Regeneron stock to resume trading,NEWS-FLASH,MarketWatch,MW Regeneron stock to resume trading at 9:50 a.m. ET
REGN,2022-09-08,13:23:41,589803,Regeneron Pharmaceuticals Inc.,95,-0.65,equity-actions,halt,Regeneron's stock was halted,FULL-ARTICLE,MarketWatch,MW Regeneron says Eylea met the primary endpoints in two trials
REGN,2022-09-08,13:23:41,589803,Regeneron Pharmaceuticals Inc.,95,-0.65,equity-actions,halt,Regeneron's stock was halted,FULL-ARTICLE,Dow Jones Newswires,Regeneron Says Eylea Met The Primary Endpoints In Two Trials -- MarketWatch
REGN,2022-09-08,13:50:00,589803,Regeneron Pharmaceuticals Inc.,100,0.48,equity-actions,resumed,Regeneron Pharmaceuticals Inc. (REGN) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharmaceuticals Inc. (REGN) Resumed Trading
REGN,2022-09-08,14:27:50,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron stock price target raised to $760 from $635 at Evercore ISI,NEWS-FLASH,MarketWatch,MW Regeneron stock price target raised to $760 from $635 at Evercore ISI
REGN,2022-09-08,20:08:09,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Coles Sells 6,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Coles Sells 6,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-09-08,20:09:12,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-09-09,09:17:25,589803,Regeneron Pharmaceuticals Inc.,100,0.62,analyst-ratings,positive,Regeneron Pharma Raised to Hold From Underperform by Jefferies,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Raised to Hold From Underperform by Jefferies
REGN,2022-09-09,09:17:25,589803,Regeneron Pharmaceuticals Inc.,100,0.8,price-targets,upgrade,Regeneron Pharma Price Target Raised to $675.00/Share From $536.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $675.00/Share From $536.00 by Jefferies
REGN,2022-09-09,10:18:45,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Market Perform by SVB Leerink
REGN,2022-09-09,10:18:45,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $756.00/Share From $630.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $756.00/Share From $630.00 by SVB Leerink
REGN,2022-09-09,10:31:35,589803,Regeneron Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Regeneron Pharma Raised to Overweight From Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Raised to Overweight From Equal-Weight by Morgan Stanley
REGN,2022-09-09,10:31:35,589803,Regeneron Pharmaceuticals Inc.,100,0.82,price-targets,upgrade,Regeneron Pharma Price Target Raised to $851.00/Share From $625.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $851.00/Share From $625.00 by Morgan Stanley
REGN,2022-09-09,11:09:41,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron stock price target raised to $790 from $718,NEWS-FLASH,MarketWatch,MW Regeneron stock price target raised to $790 from $718 at Truist
REGN,2022-09-09,11:12:35,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Barclays
REGN,2022-09-09,11:12:35,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $815.00/Share From $735.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $815.00/Share From $735.00 by Barclays
REGN,2022-09-09,14:00:04,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast",PRESS-RELEASE,PR Newswire,Regeneron Announces Investor Call and Webcast at ESMO 2022
REGN,2022-09-09,14:00:04,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces Investor Call and Webcast at ESMO 2022
REGN,2022-09-10,06:30:03,589803,Regeneron Pharmaceuticals Inc.,99,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: First-in-class Phase 1 data,PRESS-RELEASE,PR Newswire,Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors
REGN,2022-09-10,06:30:03,589803,Regeneron Pharmaceuticals Inc.,99,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: First-in-class Phase 1 data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors
REGN,2022-09-12,06:40:07,589803,Regeneron Pharmaceuticals Inc.,100,0.4,products-services,start,Regeneron: Enrolling Patients for Phase 3 Trial,NEWS-FLASH,Dow Jones Newswires,Regeneron: Enrolling Patients for Phase 3 Trial in First-Line Metastatic Melanoma >REGN
REGN,2022-09-12,11:26:35,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharmaceuticals price target raised to $925 from $740 at Guggenheim,NEWS-FLASH,MarketWatch,MW Regeneron Pharmaceuticals price target raised to $925 from $740 at Guggenheim
REGN,2022-09-12,11:49:46,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Wells Fargo
REGN,2022-09-12,11:49:46,589803,Regeneron Pharmaceuticals Inc.,100,0.74,price-targets,upgrade,Regeneron Pharma Price Target Raised to $800.00/Share From $735.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $800.00/Share From $735.00 by Wells Fargo
REGN,2022-09-12,20:32:49,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Bassler Sells 3,167 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Bassler Sells 3,167 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-09-12,20:35:41,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Vp Larosa Acquires 9,270 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Larosa Acquires 9,270 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-09-13,10:51:21,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Piper Sandler
REGN,2022-09-13,10:51:21,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $775.00/Share From $692.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $775.00/Share From $692.00 by Piper Sandler
REGN,2022-09-13,20:05:31,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp van Plew Sells 4,696 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP van Plew Sells 4,696 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-09-13,20:20:55,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp van Plew Registers 4,696 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP van Plew Registers 4,696 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-09-15,11:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD,PRESS-RELEASE,Business Wire,Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
REGN,2022-09-15,11:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.41,products-services,start,Alnylam and Regeneron intend to initiate a Phase 2 study in late 2022,PRESS-RELEASE,Business Wire,Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
REGN,2022-09-15,11:00:05,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD,PRESS-RELEASE,PR Newswire,Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
REGN,2022-09-15,11:00:05,589803,Regeneron Pharmaceuticals Inc.,100,0.41,products-services,start,Regeneron and Alnylam intend to initiate a Phase 2 study in late 2022,PRESS-RELEASE,PR Newswire,Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
REGN,2022-09-15,11:00:05,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
REGN,2022-09-15,11:00:05,589803,Regeneron Pharmaceuticals Inc.,100,0.41,products-services,start,Regeneron and Alnylam intend to initiate a Phase 2 study in late 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
REGN,2022-09-15,11:00:10,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron and Alnylam Report Promising Data From Ongoing Phase 1 Study of ALN-HSD,NEWS-FLASH,Dow Jones Newswires,Regeneron and Alnylam Report Promising Data From Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
REGN,2022-09-15,11:00:21,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Alnylam and Regeneron Report Promising Data From Ongoing Phase 1 Study of ALN-HSD,NEWS-FLASH,Dow Jones Newswires,Alnylam and Regeneron Report Promising Data From Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
REGN,2022-09-15,11:01:00,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD,PRESS-RELEASE,Dow Jones Newswires,Press Release: Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
REGN,2022-09-15,11:01:00,589803,Regeneron Pharmaceuticals Inc.,100,0.41,products-services,start,Alnylam and Regeneron intend to initiate a Phase 2 study in late 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
REGN,2022-09-16,11:15:00,589803,Regeneron Pharmaceuticals Inc.,98,0.0,products-services,,"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim results from an ongoing Phase 1 clinical trial of NTLA-2001",PRESS-RELEASE,GlobeNewswire,"Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis"
REGN,2022-09-16,11:15:00,589803,Regeneron Pharmaceuticals Inc.,98,0.49,partnerships,,Intellia and Regeneron are working together diligently to,PRESS-RELEASE,GlobeNewswire,"Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis"
REGN,2022-09-16,11:15:01,589803,Regeneron Pharmaceuticals Inc.,98,0.0,products-services,,"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim results from an ongoing Phase 1 clinical trial of NTLA-2001",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis"
REGN,2022-09-16,11:15:01,589803,Regeneron Pharmaceuticals Inc.,98,0.49,partnerships,,Intellia and Regeneron are working together diligently to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis"
REGN,2022-09-16,12:12:07,589803,Regeneron Pharmaceuticals Inc.,100,0.66,price-targets,upgrade,Regeneron Pharma Price Target Raised to $750.00/Share From $700.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $750.00/Share From $700.00 by Canaccord Genuity
REGN,2022-09-16,11:15:03,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim results from an ongoing Phase 1 clinical trial of NTLA-2001",PRESS-RELEASE,PR Newswire,"Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis"
REGN,2022-09-16,11:15:03,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Intellia and Regeneron are working together diligently to,PRESS-RELEASE,PR Newswire,"Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis"
REGN,2022-09-16,11:15:03,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim results from an ongoing Phase 1 clinical trial of NTLA-2001",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis"
REGN,2022-09-16,11:15:03,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Intellia and Regeneron are working together diligently to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis"
REGN,2022-09-16,12:12:07,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Canaccord Genuity
REGN,2022-09-19,10:24:26,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron stock price target raised to $725 from $611 at J.P. Morgan,NEWS-FLASH,MarketWatch,MW Regeneron stock price target raised to $725 from $611 at J.P. Morgan
REGN,2022-09-21,17:35:33,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bassler Registers 609 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Bassler Registers 609 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-09-21,17:50:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Bassler Registers 2,558 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Bassler Registers 2,558 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-09-26,07:04:36,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Bayer: Eylea Approved in Japan,NEWS-FLASH,Dow Jones Newswires,Bayer: Eylea Approved in Japan for Treatment of Preterm Infants With Retinopathy of Prematurity
REGN,2022-09-28,21:44:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent(R) (dupilumab),PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis
REGN,2022-09-28,21:44:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis
REGN,2022-09-28,21:44:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved by FDA,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Approved by FDA as the -2-
REGN,2022-09-28,21:44:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved by FDA,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Approved by FDA as the -3-
REGN,2022-09-28,21:44:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved by FDA,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Approved by FDA as the -4-
REGN,2022-09-28,22:35:39,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Sanofi, Regeneron Say Dupixent Gets FDA Approval",FULL-ARTICLE,Dow Jones Newswires,"Sanofi, Regeneron Say Dupixent Gets FDA Approval to Treat Prurigo Nodularis Skin Disease"
REGN,2022-09-28,22:50:39,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Sanofi, Regeneron Say Dupixent Gets FDA Approval",FULL-ARTICLE,Dow Jones Newswires,"Sanofi, Regeneron Say Dupixent Gets FDA Approval to Treat Prurigo Nodularis Skin Disease"
REGN,2022-09-30,15:54:56,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Tessier-Lavigne Registers 7,226 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Tessier-Lavigne Registers 7,226 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-09-30,18:41:45,589803,Regeneron Pharmaceuticals Inc.,92,0.57,products-services,granted,"Sanofi, Regeneron Say Dupixent Gets FDA Approval",FULL-ARTICLE,Dow Jones Newswires,Correction to Sanofi and Regeneron Pharmaceuticals Article on Sept. 28
REGN,2022-09-30,18:56:45,589803,Regeneron Pharmaceuticals Inc.,92,0.57,products-services,granted,"Sanofi, Regeneron Say Dupixent Gets FDA Approval",FULL-ARTICLE,Dow Jones Newswires,Correction to Sanofi and Regeneron Pharmaceuticals Article on Sept. 28
REGN,2022-10-03,11:00:06,589803,Regeneron Pharmaceuticals Inc.,100,0.47,labor-issues,,Regeneron Elects Dr. Craig B. Thompson to Board of Directors,PRESS-RELEASE,PR Newswire,Regeneron Elects Dr. Craig B. Thompson to Board of Directors
REGN,2022-10-03,11:00:14,589803,Regeneron Pharmaceuticals Inc.,100,0.47,labor-issues,,Regeneron Elects Dr. Craig B. Thompson to Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Elects Dr. Craig B. Thompson to Board of Directors
REGN,2022-10-03,11:00:18,589803,Regeneron Pharmaceuticals Inc.,100,0.47,labor-issues,,Regeneron Elects Dr. Craig B. Thompson to Board of Directors,NEWS-FLASH,Dow Jones Newswires,Regeneron Elects Dr. Craig B. Thompson to Board of Directors >REGN
REGN,2022-10-03,13:17:05,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Goldman Sachs
REGN,2022-10-03,13:17:05,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $970.00/Share From $796.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $970.00/Share From $796.00 by Goldman Sachs
REGN,2022-10-03,20:07:45,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Tessier-Lavigne Sells 10,838 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Tessier-Lavigne Sells 10,838 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-10-04,18:36:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-10-04,18:37:07,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Fenimore Registers 3,346 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Fenimore Registers 3,346 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-10-04,18:39:39,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Tessier-Lavigne Registers 3,612 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Tessier-Lavigne Registers 3,612 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-10-04,20:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report Third Quarter 2022 Financial and Operating Results,PRESS-RELEASE,PR Newswire,"Regeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022"
REGN,2022-10-04,20:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time,PRESS-RELEASE,PR Newswire,"Regeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022"
REGN,2022-10-04,20:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report Third Quarter 2022 Financial and Operating Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022"
REGN,2022-10-04,20:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022"
REGN,2022-10-05,20:12:26,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Fenimore Sells 3,346 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Fenimore Sells 3,346 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-10-05,20:12:43,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-10-05,20:12:54,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-10-06,18:21:28,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Fenimore Registers 1,844 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Fenimore Registers 1,844 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-10-07,20:04:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Fenimore Sells 1,844 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Fenimore Sells 1,844 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-10-12,11:00:53,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Pharma Gets FDA Priority Review of Eylea,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Gets FDA Priority Review of Eylea for Retinopathy of Prematurity>REGN
REGN,2022-10-12,11:15:41,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Gets FDA Priority Review of Eylea,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets FDA Priority Review of Eylea in Retinopathy of Prematurity >REGN
REGN,2022-10-12,11:15:41,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets FDA Priority Review of Eylea in Retinopathy of Prematurity >REGN
REGN,2022-10-12,11:30:42,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Gets FDA Priority Review of Eylea,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets FDA Priority Review of Eylea in Retinopathy of Prematurity
REGN,2022-10-12,11:30:42,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets FDA Priority Review of Eylea in Retinopathy of Prematurity
REGN,2022-10-14,11:00:11,589803,Regeneron Pharmaceuticals Inc.,93,0.57,products-services,granted,Dupixent (dupilumab) was granted approval by the U.S. FDA,PRESS-RELEASE,PR Newswire,"Early Launch Metrics Reveal an Impressive Start for Sanofi/Regeneron's Dupixent in Eosinophilic Esophagitis, According to Recent Research Conducted by Spherix Global Insights"
REGN,2022-10-14,11:04:39,589803,Regeneron Pharmaceuticals Inc.,100,0.82,products-services,positive,Libtayo(R) (cemiplimab) Receives Positive CHMP Opinion,PRESS-RELEASE,PR Newswire,Libtayo(R) (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer
REGN,2022-10-14,11:04:39,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Libtayo is currently approved in the European Union,PRESS-RELEASE,PR Newswire,Libtayo(R) (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer
REGN,2022-10-14,11:04:39,589803,Regeneron Pharmaceuticals Inc.,100,0.82,products-services,positive,Libtayo(R) (cemiplimab) Receives Positive CHMP Opinion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Libtayo(R) (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer
REGN,2022-10-14,11:04:39,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Libtayo is currently approved in the European Union,PRESS-RELEASE,Dow Jones Newswires,Press Release: Libtayo(R) (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer
REGN,2022-10-17,10:58:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Regeneron downgraded to in line from outperform at Evercore ISI,NEWS-FLASH,MarketWatch,MW Regeneron downgraded to in line from outperform at Evercore ISI
REGN,2022-10-17,12:12:46,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Regeneron Pharma Cut to In-Line From Outperform by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Cut to In-Line From Outperform by Evercore ISI Group
REGN,2022-10-17,12:12:46,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $760.00/Share by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $760.00/Share by Evercore ISI Group
REGN,2022-10-18,18:31:07,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Cfo Landry Registers 358 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,CFO Landry Registers 358 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-10-18,20:07:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Cfo Landry Sells 358 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Sells 358 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-10-20,14:32:12,589803,Regeneron Pharmaceuticals Inc.,100,0.06,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Market Perform by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Market Perform by Cowen & Co.
REGN,2022-10-20,14:32:12,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $750.00/Share From $655.00 by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $750.00/Share From $655.00 by Cowen & Co.
REGN,2022-10-21,11:00:04,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The two Phase 3 trials,PRESS-RELEASE,PR Newswire,Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
REGN,2022-10-21,11:00:04,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Bayer and Regeneron are collaborating on,PRESS-RELEASE,PR Newswire,Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
REGN,2022-10-21,11:00:13,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The two Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
REGN,2022-10-21,11:00:13,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Bayer and Regeneron are collaborating on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
REGN,2022-10-24,07:44:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals Inc, Inst Holders, 3Q 2022 (REGN)",RNS-SEC13F,Dow Jones Newswires,"Regeneron Pharmaceuticals Inc, Inst Holders, 3Q 2022 (REGN)"
REGN,2022-10-26,10:26:33,589803,Regeneron Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Regeneron Pharma Cut to Underperform From Market Perform by Raymond James,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Cut to Underperform From Market Perform by Raymond James
REGN,2022-10-26,11:27:52,589803,Regeneron Pharmaceuticals Inc.,100,-0.98,analyst-ratings,negative,Regeneron downgraded to underperform from market perform at Raymond James,NEWS-FLASH,MarketWatch,MW Regeneron downgraded to underperform from market perform at Raymond James
REGN,2022-11-01,09:03:44,589803,Regeneron Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Regeneron Pharma Initiated at Buy,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Initiated at Buy by EF Hutton
REGN,2022-11-01,09:03:44,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $851.00,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $851.00/Share by EF Hutton
REGN,2022-11-02,13:00:00,589803,Regeneron Pharmaceuticals Inc.,97,0.49,partnerships,,AbCellera Biologics Inc.: our partnership with Regeneron,PRESS-RELEASE,Business Wire,AbCellera's First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development
REGN,2022-11-02,13:00:20,589803,Regeneron Pharmaceuticals Inc.,98,0.49,partnerships,,AbCellera Biologics Inc.: our partnership with Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: AbCellera's First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development
REGN,2022-11-02,19:27:54,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-11-02,19:31:46,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Cfo Landry Registers 482 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,CFO Landry Registers 482 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-11-02,20:04:45,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-11-02,20:06:18,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Cfo Landry Sells 482 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Sells 482 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 3Q EPS $11.66,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q EPS $11.66 >REGN
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2022",PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,100,-0.2,revenues,,Regeneron Pharmaceuticals Inc.: Third quarter 2022 revenues decreased 15% to $2.94 billion,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Third quarter 2022 GAAP diluted EPS of $11.66,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: non-GAAP diluted EPS(a) of $11.14,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: FDA approved Dupixent,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Regeneron Pharmaceuticals Inc.: EYLEA (aflibercept) Injection,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,The U.S. Food and Drug Administration (FDA) accepted for priority review the supplemental BLA (sBLA) for EYLEA,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: The Company presented positive data from the Phase 2 trial for Libtayo,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,100,0.51,products-services,complete,Regeneron Pharmaceuticals Inc.: Enrollment was completed,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,100,-0.45,products-services,,"Regeneron Pharmaceuticals Inc.: The Company has discontinued (i) further clinical development of fasinumab, an antibody",PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,99,-0.3,revenues,down,Regeneron Pharmaceuticals Inc.: Total revenues decreased 15% to $2.936 billion,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial -2-
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial -2-
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $11.66 in the third quarter of 2022,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial -2-
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $11.14 in the third quarter of 2022,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial -2-
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the third quarter of 2022, the Company repurchased shares of common stock",PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial -2-
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2022 Financial Guidance,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial -2-
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2022 financial guidance,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial -3-
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its third quarter 2022 financial and operating results on Thursday, November 3, 2022, at 8:30 AM Eastern Time",PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial -3-
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: Total assets $ 27,677.8 $ 25,434.8",PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial -4-
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,95,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial -5-
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,95,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $ 1,270.4 $ 1,772.7 $",PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial -5-
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,95,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 12.31 $ 15.37 $,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial -5-
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,95,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 11.88 $ 16.69 $,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial -5-
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,95,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial -5-
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Consequently, the prior year net product sales",PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial -6-
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Third Quarter 2022 Financial Results",PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial -6-
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: net product sales of ARCALYST were $27 million,PRESS-RELEASE,PR Newswire,Regeneron Reports Third Quarter 2022 Financial -6-
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 3Q Net $1.32B,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q Net $1.32B >REGN
REGN,2022-11-03,10:30:19,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 3Q Rev $2.94B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q Rev $2.94B >REGN
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,100,-0.2,revenues,,Regeneron Pharmaceuticals Inc.: Third quarter 2022 revenues decreased 15% to $2.94 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Third quarter 2022 GAAP diluted EPS of $11.66,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: non-GAAP diluted EPS(a) of $11.14,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: FDA approved Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Regeneron Pharmaceuticals Inc.: EYLEA (aflibercept) Injection,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,The U.S. Food and Drug Administration (FDA) accepted for priority review the supplemental BLA (sBLA) for EYLEA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: The Company presented positive data from the Phase 2 trial for Libtayo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,100,0.51,products-services,complete,Regeneron Pharmaceuticals Inc.: Enrollment was completed,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,100,-0.45,products-services,,"Regeneron Pharmaceuticals Inc.: The Company has discontinued (i) further clinical development of fasinumab, an antibody",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2022 Financial and Operating Results
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,99,-0.3,revenues,down,Regeneron Pharmaceuticals Inc.: Total revenues decreased 15% to $2.936 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $11.66 in the third quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $11.14 in the third quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the third quarter of 2022, the Company repurchased shares of common stock",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2022 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -3-
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its third quarter 2022 financial and operating results on Thursday, November 3, 2022, at 8:30 AM Eastern Time",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -3-
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: Total assets $ 27,677.8 $ 25,434.8",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,95,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -5-
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,95,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $ 1,270.4 $ 1,772.7 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -5-
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,95,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 12.31 $ 15.37 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -5-
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,95,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 11.88 $ 16.69 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -5-
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,95,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -5-
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Consequently, the prior year net product sales",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -6-
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Third Quarter 2022 Financial Results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -6-
REGN,2022-11-03,10:31:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: net product sales of ARCALYST were $27 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -6-
REGN,2022-11-03,10:31:39,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 3Q Adj EPS $11.14,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q Adj EPS $11.14 >REGN
REGN,2022-11-03,10:34:38,589803,Regeneron Pharmaceuticals Inc.,100,-0.36,earnings,down,Regeneron Q3 EPS $11.66 vs. $14.3 a year ago,NEWS-FLASH,MarketWatch,MW Regeneron Q3 EPS $11.66 vs. $14.3 a year ago
REGN,2022-11-03,10:34:59,589803,Regeneron Pharmaceuticals Inc.,100,0.46,earnings,above-expectations,Regeneron Q3 adj. EPS $11.14; FactSet consensus $9.76,NEWS-FLASH,MarketWatch,MW Regeneron Q3 adj. EPS $11.14; FactSet consensus $9.76
REGN,2022-11-03,10:35:21,589803,Regeneron Pharmaceuticals Inc.,100,0.48,revenues,above-expectations,Regeneron Q3 revenue $2.94 bln vs. $3.45 bln a year ago; FactSet consensus $2.92 bln,NEWS-FLASH,MarketWatch,MW Regeneron Q3 revenue $2.94 bln vs. $3.45 bln a year ago; FactSet consensus $2.92 bln
REGN,2022-11-03,10:51:13,589803,Regeneron Pharmaceuticals Inc.,95,-0.38,earnings,down,Regeneron Pharmaceuticals Inc. said Thursday its third-quarter net income fell 19% to $1.32 billion,FULL-ARTICLE,MarketWatch,MW Regeneron Pharmaceuticals Q3 tops earnings and revenue marks
REGN,2022-11-03,10:51:13,589803,Regeneron Pharmaceuticals Inc.,95,0.0,earnings,,Analysts expected Regeneron to earn $9.76 a share,FULL-ARTICLE,MarketWatch,MW Regeneron Pharmaceuticals Q3 tops earnings and revenue marks
REGN,2022-11-03,10:51:13,589803,Regeneron Pharmaceuticals Inc.,95,-0.38,earnings,down,Regeneron Pharmaceuticals Inc. said Thursday its third-quarter net income fell 19% to $1.32 billion,FULL-ARTICLE,Dow Jones Newswires,Regeneron Pharmaceuticals Q3 Tops Earnings And Revenue Marks -- MarketWatch
REGN,2022-11-03,10:51:13,589803,Regeneron Pharmaceuticals Inc.,95,0.0,earnings,,Analysts expected Regeneron to earn $9.76 a share,FULL-ARTICLE,Dow Jones Newswires,Regeneron Pharmaceuticals Q3 Tops Earnings And Revenue Marks -- MarketWatch
REGN,2022-11-03,13:00:18,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: First Phase 2 data for odronextamab,PRESS-RELEASE,PR Newswire,Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders
REGN,2022-11-03,13:00:18,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Updated Phase 1/2 data,PRESS-RELEASE,PR Newswire,Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders
REGN,2022-11-03,13:00:18,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron will host a conference call and simultaneous webcast,PRESS-RELEASE,PR Newswire,Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders
REGN,2022-11-03,13:01:23,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: First Phase 2 data for odronextamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders
REGN,2022-11-03,13:01:23,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Updated Phase 1/2 data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders
REGN,2022-11-03,13:01:23,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron will host a conference call and simultaneous webcast,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders
REGN,2022-11-03,20:05:06,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-11-04,10:27:41,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Piper Sandler
REGN,2022-11-04,10:27:41,589803,Regeneron Pharmaceuticals Inc.,100,-0.26,price-targets,downgrade,Regeneron Pharma Price Target Cut to $765.00/Share From $775.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $765.00/Share From $775.00 by Piper Sandler
REGN,2022-11-04,11:09:41,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Market Perform by SVB Leerink
REGN,2022-11-04,11:09:41,589803,Regeneron Pharmaceuticals Inc.,100,0.34,price-targets,upgrade,Regeneron Pharma Price Target Raised to $770.00/Share From $756.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $770.00/Share From $756.00 by SVB Leerink
REGN,2022-11-04,13:31:11,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley
REGN,2022-11-04,13:31:11,589803,Regeneron Pharmaceuticals Inc.,100,0.38,price-targets,upgrade,Regeneron Pharma Price Target Raised to $868.00/Share From $851.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $868.00/Share From $851.00 by Morgan Stanley
REGN,2022-11-07,21:07:03,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-11-07,21:33:52,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-11-08,21:01:46,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp van Plew Sells 7,886 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP van Plew Sells 7,886 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-11-08,22:09:54,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp van Plew Registers 7,886 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP van Plew Registers 7,886 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-11-09,21:06:41,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Brown Registers 4,995 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Brown Registers 4,995 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-11-10,21:01:53,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Brown Sells 4,495 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Brown Sells 4,495 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-11-11,11:59:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Recommended for EU Approval,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis
REGN,2022-11-11,11:59:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent was approved by the U.S. Food and Drug Administration for the treatment,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis
REGN,2022-11-11,11:59:04,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis
REGN,2022-11-11,11:59:13,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Recommended for EU Approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis
REGN,2022-11-11,11:59:13,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent was approved by the U.S. Food and Drug Administration for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis
REGN,2022-11-11,11:59:13,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis
REGN,2022-11-11,11:59:46,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent Recommended for EU Approval,NEWS-FLASH,Dow Jones Newswires,"Regeneron, Sanofi: Dupixent Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis"
REGN,2022-11-11,12:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) recommended for EU approval,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
REGN,2022-11-11,12:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
REGN,2022-11-11,12:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
REGN,2022-11-11,12:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) recommended for EU approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
REGN,2022-11-11,12:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
REGN,2022-11-11,12:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
REGN,2022-11-11,12:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) recommended for EU approval,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
REGN,2022-11-11,12:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent was approved by the U.S. Food and Drug Administration for the treatment,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
REGN,2022-11-11,12:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
REGN,2022-11-11,12:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) recommended for EU approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
REGN,2022-11-11,12:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent was approved by the U.S. Food and Drug Administration for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
REGN,2022-11-11,12:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
REGN,2022-11-11,12:03:06,589803,Regeneron Pharmaceuticals Inc.,100,-0.22,price-targets,downgrade,Regeneron Pharmaceuticals price target cut to $915 from $925 at Guggenheim,NEWS-FLASH,MarketWatch,MW Regeneron Pharmaceuticals price target cut to $915 from $925 at Guggenheim
REGN,2022-11-11,12:26:20,589803,Regeneron Pharmaceuticals Inc.,94,0.57,products-services,granted,The U.S. Food and Drug Administration in September approved Dupixent,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Get CHMP Backing for Dupixent in Prurigo Nodularis >REGN SNY"
REGN,2022-11-11,12:41:20,589803,Regeneron Pharmaceuticals Inc.,93,0.57,products-services,granted,The U.S. Food and Drug Administration in September approved Dupixent,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Get CHMP Backing for Dupixent in Prurigo Nodularis"
REGN,2022-11-11,14:04:49,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Guggenheim
REGN,2022-11-11,14:04:49,589803,Regeneron Pharmaceuticals Inc.,100,-0.22,price-targets,downgrade,Regeneron Pharma Price Target Cut to $915.00/Share From $925.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $915.00/Share From $925.00 by Guggenheim
REGN,2022-11-16,20:36:44,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Murphy Registers 3,720 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Murphy Registers 3,720 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-11-16,21:03:12,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Murphy Sells 3,720 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Murphy Sells 3,720 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-11-17,12:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Cytomx and Regeneron Announce Strategic Research Collaboration,PRESS-RELEASE,GlobeNewswire,CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
REGN,2022-11-17,12:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Cytomx and Regeneron Announce Strategic Research Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
REGN,2022-11-17,12:00:09,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and CytomX Announce Strategic Research Collaboration,PRESS-RELEASE,PR Newswire,Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
REGN,2022-11-17,12:00:26,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and CytomX Announce Strategic Research Collaboration,NEWS-FLASH,Dow Jones Newswires,Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
REGN,2022-11-17,12:00:53,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and CytomX Announce Strategic Research Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
REGN,2022-11-25,18:11:57,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp van Plew Sells 11,972 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP van Plew Sells 11,972 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-11-29,23:12:50,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp van Plew Registers 11,972 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP van Plew Registers 11,972 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-12-01,12:00:24,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The results are from two expansion cohorts of a Phase 1 trial,PRESS-RELEASE,PR Newswire,Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo(R) (cemiplimab) in Multiple Solid Tumor Types
REGN,2022-12-01,12:00:24,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,"Regeneron Pharmaceuticals Inc.: Libtayo, Phase 1 study of",PRESS-RELEASE,PR Newswire,Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo(R) (cemiplimab) in Multiple Solid Tumor Types
REGN,2022-12-01,12:10:32,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The results are from two expansion cohorts of a Phase 1 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo(R) (cemiplimab) in Multiple Solid Tumor Types
REGN,2022-12-01,12:10:32,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,"Regeneron Pharmaceuticals Inc.: Libtayo, Phase 1 study of",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo(R) (cemiplimab) in Multiple Solid Tumor Types
REGN,2022-12-02,21:09:16,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-12-02,21:10:06,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-12-02,21:10:16,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Cfo Landry Sells 610 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Sells 610 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-12-05,15:00:11,589803,Regeneron Pharmaceuticals Inc.,91,0.57,products-services,granted,Last May when the FDA approved Dupixent (dupilumab),PRESS-RELEASE,PR Newswire,"With Approximately 45% of Eosinophilic Esophagitis Patients Going Undiagnosed, the Growth Opportunity for Sanofi/Regeneron's Dupixent and Future Advanced Therapies Could Be Significant, According to Spherix"
REGN,2022-12-05,20:33:40,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-12-05,22:42:33,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Cfo Landry Registers 610 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,CFO Landry Registers 610 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-12-12,12:30:03,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron Pharmaceuticals Inc.: the company has been included on the Dow Jones Sustainability World Index (DJSI World,PRESS-RELEASE,PR Newswire,Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year
REGN,2022-12-12,12:30:03,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,PR Newswire,Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year
REGN,2022-12-12,12:32:33,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron Pharmaceuticals Inc.: the company has been included on the Dow Jones Sustainability World Index (DJSI World,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year
REGN,2022-12-12,12:32:33,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year
REGN,2022-12-12,21:37:06,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bassler Sells 218 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bassler Sells 218 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-12-12,21:37:16,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,Cfo Landry Acquires 247 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Acquires 247 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-12-13,21:11:33,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp van Plew Surrenders 492 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP van Plew Surrenders 492 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-12-13,21:11:54,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Fenimore Surrenders 247 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP Fenimore Surrenders 247 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-12-13,21:12:11,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Stahl Surrenders 466 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP Stahl Surrenders 466 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-12-13,21:14:39,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp McCourt Sells 264 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP McCourt Sells 264 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-12-13,21:14:58,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Murphy Surrenders 492 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP Murphy Surrenders 492 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-12-13,21:15:19,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Larosa Surrenders 492 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP Larosa Surrenders 492 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-12-13,21:16:12,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Chmn Vagelos Surrenders 57 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,Chmn Vagelos Surrenders 57 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-12-13,21:47:15,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp McCourt Registers 264 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,VP McCourt Registers 264 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2022-12-15,05:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved by European Commission,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis
REGN,2022-12-15,05:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis
REGN,2022-12-15,05:59:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved by European,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Approved by European -2-
REGN,2022-12-15,05:59:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved by European,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Approved by European -3-
REGN,2022-12-15,05:59:04,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved by European,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Approved by European -4-
REGN,2022-12-15,06:02:16,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi Gets EU Approval for Dupixent,NEWS-FLASH,Dow Jones Newswires,Sanofi Gets EU Approval for Dupixent
REGN,2022-12-16,12:29:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Recommended for EU Approval,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis
REGN,2022-12-16,12:29:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis
REGN,2022-12-16,12:29:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,PR Newswire,Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis
REGN,2022-12-16,12:29:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Recommended for EU Approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis
REGN,2022-12-16,12:29:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis
REGN,2022-12-16,12:29:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis
REGN,2022-12-16,12:29:57,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent Recommended for EU Approval,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharmaceuticals: Dupixent Recommended for EU Approval by CHMP for Treatment of Eosinophilic Esophagitis
REGN,2022-12-16,12:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) recommended for EU approval,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
REGN,2022-12-16,12:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
REGN,2022-12-16,12:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
REGN,2022-12-16,12:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) recommended for EU approval,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
REGN,2022-12-16,12:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
REGN,2022-12-16,12:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
REGN,2022-12-16,12:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) recommended for EU approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
REGN,2022-12-16,12:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
REGN,2022-12-16,12:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
REGN,2022-12-16,12:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) recommended for EU approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
REGN,2022-12-16,12:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
REGN,2022-12-16,12:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent(R) (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
REGN,2022-12-21,18:12:30,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Bassler Registers 1,239 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Bassler Registers 1,239 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-12-23,13:31:46,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharma: Libtayo Cemiplimab Approved in Japan,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma: Libtayo Cemiplimab Approved in Japan for Advanced or Recurrent Cervical Cancer >REGN
REGN,2022-12-29,16:45:48,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Coles Registers 5,758 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Coles Registers 5,758 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2022-12-30,21:11:26,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Coles Sells 5,758 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Coles Sells 5,758 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-01-03,21:01:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023"
REGN,2023-01-03,21:01:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023"
REGN,2023-01-03,21:01:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023"
REGN,2023-01-03,21:01:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023"
REGN,2023-01-04,20:03:46,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Ryan Registers 300 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Ryan Registers 300 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-01-04,20:06:38,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-01-05,12:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron,PRESS-RELEASE,GlobeNewswire,"Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo(R) (cemiplimab) in Solid Tumors"
REGN,2023-01-05,12:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Regeneron on our planned clinical trial of SNS-101,PRESS-RELEASE,GlobeNewswire,"Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo(R) (cemiplimab) in Solid Tumors"
REGN,2023-01-05,12:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo(R) (cemiplimab) in Solid Tumors"
REGN,2023-01-05,12:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Regeneron on our planned clinical trial of SNS-101,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo(R) (cemiplimab) in Solid Tumors"
REGN,2023-01-05,12:31:40,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Sensei Biotherapeutics Announces Clinical Supply Agreement With Regeneron,NEWS-FLASH,Dow Jones Newswires,Sensei Biotherapeutics Announces Clinical Supply Agreement With Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101 in Combination With Libtayo (cemiplimab) in Solid Tumors
REGN,2023-01-05,12:31:40,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Phase 1/2 Clinical Trial Evaluating SNS-101 in Combination With Libtayo (cemiplimab),NEWS-FLASH,Dow Jones Newswires,Sensei Biotherapeutics Announces Clinical Supply Agreement With Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101 in Combination With Libtayo (cemiplimab) in Solid Tumors
REGN,2023-01-05,12:31:40,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Phase 1/2 Clinical Trial Evaluating SNS-101 in Combination With Libtayo (cemiplimab),NEWS-FLASH,Dow Jones Newswires,Sensei Biotherapeutics Announces Clinical Supply Agreement With Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101 in Combination With Libtayo (cemiplimab) in Solid Tumors
REGN,2023-01-05,21:25:41,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-01-05,21:40:25,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-01-06,14:11:00,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,2seventy bio Announces Expanded Translational Collaboration with Regeneron,PRESS-RELEASE,Business Wire,2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors
REGN,2023-01-06,14:11:00,589803,Regeneron Pharmaceuticals Inc.,100,0.22,acquisitions-mergers,,Regeneron Investing $20 million in 2seventy,PRESS-RELEASE,Business Wire,2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors
REGN,2023-01-06,14:11:01,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,2seventy bio Announces Expanded Translational Collaboration with Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: 2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors
REGN,2023-01-06,14:11:01,589803,Regeneron Pharmaceuticals Inc.,100,0.22,acquisitions-mergers,,Regeneron Investing $20 million in 2seventy,PRESS-RELEASE,Dow Jones Newswires,Press Release: 2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors
REGN,2023-01-06,14:43:18,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"2seventy Bio, Regeneron in Amended Collaboration",FULL-ARTICLE,Dow Jones Newswires,"2seventy Bio, Regeneron in Amended Collaboration >TSVT REGN"
REGN,2023-01-06,14:58:18,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"2seventy Bio, Regeneron in Amended Collaboration",FULL-ARTICLE,Dow Jones Newswires,"2seventy Bio, Regeneron in Amended Collaboration"
REGN,2023-01-09,17:07:20,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron (REGN) said fourth-quarter sales of Eylea were $1.5 billion,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Sinks on Disappointing Sales of Eylea Vaccine -- Barrons.com
REGN,2023-01-09,17:10:11,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron (REGN) said fourth-quarter sales of Eylea were $1.5 billion,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Sinks on Disappointing Sales of Eylea Vaccine
REGN,2023-01-09,19:33:55,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Brown Registers 6,142 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Brown Registers 6,142 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-01-09,20:37:56,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron (ticker: REGN) said fourth-quarter sales of Eylea were $1.5 billion,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Sinks on Disappointing Sales of Eylea Treatment -- Barrons.com
REGN,2023-01-10,21:05:10,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Brown Sells 3,070 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Brown Sells 3,070 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-01-11,12:20:40,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by EF Hutton,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by EF Hutton
REGN,2023-01-20,12:08:00,589803,Regeneron Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Regeneron Pharmaceuticals upgraded to overweight from neutral at J.P. Morgan,NEWS-FLASH,MarketWatch,MW Regeneron Pharmaceuticals upgraded to overweight from neutral at J.P. Morgan
REGN,2023-01-23,09:25:48,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals Inc, Inst Holders, 4Q 2022 (REGN)",RNS-SEC13F,Dow Jones Newswires,"Regeneron Pharmaceuticals Inc, Inst Holders, 4Q 2022 (REGN)"
REGN,2023-01-24,14:34:24,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley
REGN,2023-01-24,14:34:24,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $873.00/Share From $868.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $873.00/Share From $868.00 by Morgan Stanley
REGN,2023-01-24,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,GlobeNewswire,"Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition"
REGN,2023-01-24,17:00:01,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition"
REGN,2023-01-24,17:02:03,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,PR Newswire,"Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition"
REGN,2023-01-27,06:02:34,589803,Regeneron Pharmaceuticals Inc.,100,0.82,products-services,positive,Sanofi: CHMP Adopted Positive Opinion for Dupixent,NEWS-FLASH,Dow Jones Newswires,Sanofi: CHMP Adopted Positive Opinion for Dupixent
REGN,2023-01-27,06:05:30,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent Was Approved by FDA in June 2022,NEWS-FLASH,Dow Jones Newswires,Sanofi: Dupixent Was Approved by FDA in June 2022 for Children in This Age Group
REGN,2023-01-27,13:28:13,589803,Regeneron Pharmaceuticals Inc.,92,0.57,products-services,granted,Committee for Medicinal Products for Human Use recommended approval of Dupixent,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi's Dupixent Is One Step Closer To Approval For Young Children In Europe -- MarketWatch"
REGN,2023-01-27,13:28:13,589803,Regeneron Pharmaceuticals Inc.,92,0.57,products-services,granted,Committee for Medicinal Products for Human Use recommended approval of Dupixent,FULL-ARTICLE,MarketWatch,"MW Regeneron, Sanofi's Dupixent is one step closer to approval for young children in Europe"
REGN,2023-01-30,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved by European Commission,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
REGN,2023-01-30,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved by European,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved by European -2-
REGN,2023-01-30,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved by European -2-
REGN,2023-01-30,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved by European,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved by European -3-
REGN,2023-01-30,06:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved by European,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved by European -4-
REGN,2023-01-30,06:01:33,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi: Dupixent Approved by European Commission,NEWS-FLASH,Dow Jones Newswires,Sanofi: Dupixent Approved by European Commission as First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
REGN,2023-01-30,12:13:19,589803,Regeneron Pharmaceuticals Inc.,91,0.57,products-services,granted,Regeneron score European expanded approval of their blockbuster eczema drug,FULL-ARTICLE,Dow Jones Newswires,"Sanofi, Regeneron Add Another Dupixent Arrow in EU -- Market Talk"
REGN,2023-01-30,13:38:22,589803,Regeneron Pharmaceuticals Inc.,100,0.82,analyst-ratings,positive,Regeneron Pharma Raised to Outperform From Market Perform by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Raised to Outperform From Market Perform by Cowen & Co.
REGN,2023-01-30,13:38:22,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $875.00/Share From $775.00 by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $875.00/Share From $775.00 by Cowen & Co.
REGN,2023-02-02,21:16:54,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 4Q EPS $10.50,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q EPS $10.50 >REGN
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 4Q Rev $3.41B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q Rev $3.41B >REGN
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2022",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2022",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,revenues,down,Regeneron Pharmaceuticals Inc.: Fourth quarter 2022 revenues decreased 31% to $3.41 billion,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.18,revenues,,Regeneron Pharmaceuticals Inc.: Full year 2022 revenues decreased 24% to $12.17 billion,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Fourth quarter 2022 GAAP diluted EPS of $10.50,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: FDA approved Libtayo(R),PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: European Commission approved Dupixent,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Regeneron Pharmaceuticals Inc.: new $3.0 billion share repurchase program authorized,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.65,revenues,up,Regeneron reported record revenue for EYLEA,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,filed,Regeneron Pharmaceuticals Inc.: we submitted our Biologics License Application,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Regeneron Pharmaceuticals Inc.: EYLEA (aflibercept) Injection,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"January 2023, the EC also approved Dupixent",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Ministry of Health, Labour and Welfare (MHLW) in Japan also approved Libtayo",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda accepted for priority review the sBLA for Kevzara(R) (sarilumab),PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,"Regeneron Pharmaceuticals Inc.: In November 2022, the Company and CytomX Therapeutics, Inc. entered into a license and collaboration agreement",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.58,indexes,,Regeneron Pharmaceuticals Inc.: The Company was included on the Dow Jones Sustainability World Index (DJSI World,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.62,products-services,start,Regeneron Pharmaceuticals Inc.: Solid Organ Oncology - Initiate Phase 3 study,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Fourth Quarter 2022 Financial Results,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $3,414 $4,952",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA in the U.S. in the fourth quarter of 2022,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.66,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased 61% to $836 million in the fourth quarter of 2022,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Roche collaboration revenue increased in the fourth quarter,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D for full year 2022,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,"Regeneron Pharmaceuticals Inc.: the Company's collaboration agreement with Adicet Bio, Inc.",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $10.50 in the fourth quarter of 2022,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $38.22 for the full year 2022,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $12.56 in the fourth quarter of 2022,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $44.98 for the full year 2022,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,approved,"Regeneron Pharmaceuticals Inc.: During the full year 2022, the Company repurchased shares of common stock",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2023 Financial Guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2023 financial guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -4-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: Conference Call Information,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -4-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: Total assets $29,214.5 $25,434.8",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Net income $1,197.1 $2,229.0",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 11.19 $ 20.99 $,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,96,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $1,197.1 $2,229.0",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -6-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,96,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,449.0 $2,676.7",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -6-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,96,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 13.54 $ 25.20 $,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -6-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,96,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -6-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,95,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Consequently, the prior year net product sales",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -7-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,95,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Fourth Quarter 2022 Financial Results",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -7-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,revenues,down,Regeneron Pharmaceuticals Inc.: Fourth quarter 2022 revenues decreased 31% to $3.41 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.18,revenues,,Regeneron Pharmaceuticals Inc.: Full year 2022 revenues decreased 24% to $12.17 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Fourth quarter 2022 GAAP diluted EPS of $10.50,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: FDA approved Libtayo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: European Commission approved Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Regeneron Pharmaceuticals Inc.: new $3.0 billion share repurchase program authorized,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.65,revenues,up,Regeneron reported record revenue for EYLEA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,filed,Regeneron Pharmaceuticals Inc.: we submitted our Biologics License Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Regeneron Pharmaceuticals Inc.: EYLEA (aflibercept) Injection,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"January 2023, the EC also approved Dupixent",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Ministry of Health, Labour and Welfare (MHLW) in Japan also approved Libtayo",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda accepted for priority review the sBLA for Kevzara(R) (sarilumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,"Regeneron Pharmaceuticals Inc.: In November 2022, the Company and CytomX Therapeutics, Inc. entered into a license and collaboration agreement",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.58,indexes,,Regeneron Pharmaceuticals Inc.: The Company was included on the Dow Jones Sustainability World Index (DJSI World,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.62,products-services,start,Regeneron Pharmaceuticals Inc.: Solid Organ Oncology - Initiate Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Fourth Quarter 2022 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $3,414 $4,952",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA in the U.S. in the fourth quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.66,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased 61% to $836 million in the fourth quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Roche collaboration revenue increased in the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D for full year 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,"Regeneron Pharmaceuticals Inc.: the Company's collaboration agreement with Adicet Bio, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $10.50 in the fourth quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $38.22 for the full year 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $12.56 in the fourth quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $44.98 for the full year 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,approved,"Regeneron Pharmaceuticals Inc.: During the full year 2022, the Company repurchased shares of common stock",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2023 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -4-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: Conference Call Information,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -4-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: Total assets $29,214.5 $25,434.8",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Net income $1,197.1 $2,229.0",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 11.19 $ 20.99 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,96,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $1,197.1 $2,229.0",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -6-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,96,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,449.0 $2,676.7",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -6-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,96,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 13.54 $ 25.20 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -6-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,96,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -6-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,95,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Consequently, the prior year net product sales",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -7-
REGN,2023-02-03,11:30:01,589803,Regeneron Pharmaceuticals Inc.,95,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Fourth Quarter 2022 Financial Results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -7-
REGN,2023-02-03,11:30:18,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 4Q Net $1.2B,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q Net $1.2B >REGN
REGN,2023-02-03,11:30:50,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,"Regeneron Pharma 4Q Revenue Excluding Regen-COV, RonapreveTM Rose 14%",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharma 4Q Revenue Excluding Regen-COV, RonapreveTM Rose 14% >REGN"
REGN,2023-02-03,11:31:17,589803,Regeneron Pharmaceuticals Inc.,100,-0.24,revenues,down,Regeneron Pharma 4Q Eylea U.S. Net Sales Fell 3%,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q Eylea U.S. Net Sales Fell 3% to $1.5B >REGN
REGN,2023-02-03,11:31:45,589803,Regeneron Pharmaceuticals Inc.,100,0.52,revenues,up,"Regeneron Pharma: 4Q Dupixent Global Net Sales, Recorded by Sanofi, Rose 38%",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharma: 4Q Dupixent Global Net Sales, Recorded by Sanofi, Rose 38% to $2.45B >REGN"
REGN,2023-02-03,11:31:58,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 4Q Adj EPS $12.56,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q Adj EPS $12.56 >REGN
REGN,2023-02-03,11:33:27,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,earnings,down,Regeneron Q4 adj. EPS $12.56 falls from $23.42 a year,NEWS-FLASH,MarketWatch,"MW Regeneron Q4 adj. EPS $12.56 falls from $23.42 a year ago, but beats the FactSet consensus $10.17"
REGN,2023-02-03,11:33:28,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,revenues,down,Regeneron Q4 revenue falls 31% to $3.41 bln,NEWS-FLASH,MarketWatch,MW Regeneron Q4 revenue falls 31% to $3.41 bln but beats the FactSet consensus $3.13 bln; stock gains 1.9% premarket
REGN,2023-02-03,11:33:34,589803,Regeneron Pharmaceuticals Inc.,100,0.56,revenues,,Regeneron Pharma Sees 2023 Adjusted Gross Margin on Net Product Sales 90%-92%,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Sees 2023 Adjusted Gross Margin on Net Product Sales 90%-92% >REGN
REGN,2023-02-03,11:33:54,589803,Regeneron Pharmaceuticals Inc.,100,0.0,equity-actions,,Regeneron Pharma Sees 2023 Capital Spending $825M-$950M >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Sees 2023 Capital Spending $825M-$950M >REGN
REGN,2023-02-03,13:15:29,589803,Regeneron Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Regeneron's Earnings Beat Forecasts,FULL-ARTICLE,Dow Jones Newswires,"Regeneron's Earnings Beat Forecasts, With No Sales of Covid-19 Treatment -- Barrons.com"
REGN,2023-02-03,13:20:11,589803,Regeneron Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Regeneron's Earnings Beat Forecasts,FULL-ARTICLE,Dow Jones Newswires,"Regeneron's Earnings Beat Forecasts, With No Sales of Covid-19 Treatment"
REGN,2023-02-03,14:03:51,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron earnings came in at $12.56 per share,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples -- IBD"
REGN,2023-02-03,15:30:41,589803,Regeneron Pharmaceuticals Inc.,99,0.52,revenues,up,Dupixent sales rocketed 38%,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples -- IBD"
REGN,2023-02-03,21:02:16,589803,Regeneron Pharmaceuticals Inc.,99,0.52,revenues,up,Dupixent sales rocketed 38%,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples -- IBD"
REGN,2023-02-03,21:16:31,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-02-03,21:27:14,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-02-06,11:31:11,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Market Perform by SVB Leerink
REGN,2023-02-06,11:31:11,589803,Regeneron Pharmaceuticals Inc.,100,0.72,price-targets,upgrade,Regeneron Pharma Price Target Raised to $834.00/Share From $770.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $834.00/Share From $770.00 by SVB Leerink
REGN,2023-02-06,13:17:41,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley
REGN,2023-02-06,13:17:42,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $883.00/Share From $873.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $883.00/Share From $873.00 by Morgan Stanley
REGN,2023-02-06,14:35:52,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital
REGN,2023-02-06,14:35:52,589803,Regeneron Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Regeneron Pharma Price Target Cut to $787.00/Share From $789.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $787.00/Share From $789.00 by RBC Capital
REGN,2023-02-06,19:42:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Cfo Landry Registers 739 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,CFO Landry Registers 739 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-02-07,21:10:30,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Landry Sells 1,491 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Landry Sells 1,491 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-02-07,21:11:18,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Bassler Sells 1,021 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Bassler Sells 1,021 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-02-07,21:16:30,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Vp Fenimore Acquires 1,714 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Fenimore Acquires 1,714 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-02-07,22:13:05,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Cfo Landry Registers 752 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,CFO Landry Registers 752 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-02-08,10:04:26,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by EF Hutton,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by EF Hutton
REGN,2023-02-08,20:33:47,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-02-08,21:15:48,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-02-08,21:17:12,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Pres Yancopoulos Sells 13,189 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Pres Yancopoulos Sells 13,189 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-02-08,21:17:48,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Goldstein Sells 3,613 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Goldstein Sells 3,613 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-02-08,21:17:59,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Brown Sells 3,571 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Brown Sells 3,571 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-02-08,23:51:41,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron: FDA Approves EYLEA (aflibercept),NEWS-FLASH,Dow Jones Newswires,Regeneron: FDA Approves EYLEA (aflibercept) Injection for Preterm Infants With Retinopathy of Prematurity
REGN,2023-02-14,21:40:20,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp McCourt Surrenders 1,276 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Surrenders 1,276 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-02-17,15:12:16,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Wells Fargo
REGN,2023-02-17,15:12:16,589803,Regeneron Pharmaceuticals Inc.,100,0.68,price-targets,upgrade,Regeneron Pharma Price Target Raised to $860.00/Share From $800.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $860.00/Share From $800.00 by Wells Fargo
REGN,2023-02-21,12:35:05,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Gets FDA Priority Review of Pozelimab,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets FDA Priority Review of Pozelimab in Chaple >REGN
REGN,2023-02-21,12:35:05,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets FDA Priority Review of Pozelimab in Chaple >REGN
REGN,2023-02-21,12:44:18,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Wells Fargo
REGN,2023-02-21,12:44:18,589803,Regeneron Pharmaceuticals Inc.,100,0.68,price-targets,upgrade,Regeneron Pharma Price Target Raised to $860.00/Share From $800.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $860.00/Share From $800.00 by Wells Fargo
REGN,2023-02-21,12:50:05,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Gets FDA Priority Review of Pozelimab,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets FDA Priority Review of Pozelimab in Chaple
REGN,2023-02-21,12:50:05,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets FDA Priority Review of Pozelimab in Chaple
REGN,2023-02-22,14:00:16,589803,Regeneron Pharmaceuticals Inc.,100,0.51,products-services,complete,"Alteogen, Completed Patient Enrollment in Global Phase 3 Clinical Trial of Eylea(R)",PRESS-RELEASE,PR Newswire,"Altos Biologics, a Subsidiary of Alteogen, Completed Patient Enrollment in Global Phase 3 Clinical Trial of Eylea(R) Biosimilar in Neovascular Age-related Macular Degeneration"
REGN,2023-02-22,14:00:35,589803,Regeneron Pharmaceuticals Inc.,100,0.51,products-services,complete,"Alteogen, Completed Patient Enrollment in Global Phase 3 Clinical Trial of Eylea(R)",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Altos Biologics, a Subsidiary of Alteogen, Completed Patient Enrollment in Global Phase 3 Clinical Trial of Eylea(R) Biosimilar in Neovascular Age-related Macular Degeneration"
REGN,2023-02-23,20:53:20,589803,Regeneron Pharmaceuticals Inc.,100,0.64,credit-ratings,upgrade,Moody's Upgrades Regeneron To Baa2,NEWS-FLASH,Dow Jones Newswires,Moody's Upgrades Regeneron To Baa2; Outlook Positive
REGN,2023-02-24,21:11:32,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Chmn Vagelos Acquires 13,495 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Vagelos Acquires 13,495 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-02-28,13:00:03,589803,Regeneron Pharmaceuticals Inc.,96,0.39,products-services,,Nasdaq: OLK) today announced an agreement with Regeneron,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Olink establishes agreement with Regeneron Genetics Center to scale their proteomics efforts, potentially enabling a new era of drug discovery"
REGN,2023-02-28,13:00:03,589803,Regeneron Pharmaceuticals Inc.,96,0.39,products-services,,Nasdaq: OLK) today announced an agreement with Regeneron,PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: Olink establishes agreement with Regeneron Genetics Center to scale their proteomics efforts, potentially enabling a new era of drug discovery"
REGN,2023-02-28,13:00:04,589803,Regeneron Pharmaceuticals Inc.,97,0.39,products-services,,Nasdaq: OLK) today announced an agreement with Regeneron,PRESS-RELEASE,GlobeNewswire,"Olink establishes agreement with Regeneron Genetics Center to scale their proteomics efforts, potentially enabling a new era of drug discovery"
REGN,2023-02-28,13:00:04,589803,Regeneron Pharmaceuticals Inc.,97,0.39,products-services,,Nasdaq: OLK) today announced an agreement with Regeneron,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Olink establishes agreement with Regeneron Genetics Center to scale their proteomics efforts, potentially enabling a new era of drug discovery"
REGN,2023-03-01,01:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Kevzara(R) (sarilumab) Approved by FDA,PRESS-RELEASE,GlobeNewswire,Kevzara(R) (sarilumab) Approved by FDA as First -2-
REGN,2023-03-01,01:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Kevzara(R) (sarilumab) Approved by FDA,PRESS-RELEASE,GlobeNewswire,Kevzara(R) (sarilumab) Approved by FDA as First -3-
REGN,2023-03-01,01:05:39,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Regeneron, Sanofi Get FDA Approval for Kevzara",NEWS-FLASH,Dow Jones Newswires,"Regeneron, Sanofi Get FDA Approval for Kevzara to Treat Polymyalgia Rheumatica"
REGN,2023-03-01,01:08:14,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi: Kevzara Is First FDA-Approved,NEWS-FLASH,Dow Jones Newswires,"Regeneron, Sanofi: Kevzara Is First FDA-Approved Biologic Indicated for Patients With PMR"
REGN,2023-03-02,22:00:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-03-03,21:04:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-03-03,21:05:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-03-09,14:06:30,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital
REGN,2023-03-09,14:06:30,589803,Regeneron Pharmaceuticals Inc.,100,0.4,price-targets,upgrade,Regeneron Pharma Price Target Raised to $806.00/Share From $787.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $806.00/Share From $787.00 by RBC Capital
REGN,2023-03-11,15:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Regeneron partners with Bayer outside,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Borrows From Big Pharma Playbook to Keep Roche, Shorts at Bay -- Heard on the Street -- WSJ"
REGN,2023-03-13,06:05:23,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Regeneron partners with Bayer outside,FULL-ARTICLE,Dow Jones Newswires,"Heard on the Street:  Regeneron Takes Drug-Playbook Page  ---  Eylea, the biotech company's blockbuster,  isn't going away soon  ----  By David Wainer"
REGN,2023-03-13,06:32:21,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Regeneron partners with Bayer outside,FULL-ARTICLE,Wall Street Journal,Heard on the Street: Regeneron Takes Drug-Playbook Page -- WSJ
REGN,2023-03-14,11:44:48,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by BMO Capital
REGN,2023-03-14,11:44:48,589803,Regeneron Pharmaceuticals Inc.,100,0.4,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1025.00/Share From $1001.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1025.00/Share From $1001.00 by BMO Capital
REGN,2023-03-14,20:09:30,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Larosa Gifts 1,006 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Larosa Gifts 1,006 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-03-21,05:59:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved by European Commission,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
REGN,2023-03-21,05:59:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi today announced that the European Commission (EC) has approved Dupixent(R) (dupilumab),PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
REGN,2023-03-21,05:59:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved by European,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved by European -2-
REGN,2023-03-21,05:59:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved by European -2-
REGN,2023-03-21,05:59:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved by European,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved by European -3-
REGN,2023-03-21,05:59:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab) Approved by European,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved by European -4-
REGN,2023-03-21,06:03:06,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi: EU Commission Approves Dupixent,NEWS-FLASH,Dow Jones Newswires,Sanofi: EU Commission Approves Dupixent for Children as Young as Six Months
REGN,2023-03-22,11:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda Approves First-in-class Evkeeza(R) -2,PRESS-RELEASE,GlobeNewswire,FDA Approves First-in-class Evkeeza(R) -2-
REGN,2023-03-22,11:15:46,589803,Regeneron Pharmaceuticals Inc.,93,0.57,products-services,granted,Fda first approved Evkeeza,FULL-ARTICLE,Dow Jones Newswires,Regeneron: FDA Extends Evkeeza Approval to Children Ages 5 to 11 >REGN
REGN,2023-03-22,11:15:46,589803,Regeneron Pharmaceuticals Inc.,93,0.0,revenues,,Regeneron reported U.S. sales,FULL-ARTICLE,Dow Jones Newswires,Regeneron: FDA Extends Evkeeza Approval to Children Ages 5 to 11 >REGN
REGN,2023-03-22,11:30:46,589803,Regeneron Pharmaceuticals Inc.,92,0.57,products-services,granted,Fda first approved Evkeeza,FULL-ARTICLE,Dow Jones Newswires,Regeneron: FDA Extends Evkeeza Approval to Children Ages 5 to 11
REGN,2023-03-22,11:30:46,589803,Regeneron Pharmaceuticals Inc.,92,0.0,revenues,,Regeneron reported U.S. sales,FULL-ARTICLE,Dow Jones Newswires,Regeneron: FDA Extends Evkeeza Approval to Children Ages 5 to 11
REGN,2023-03-23,10:59:04,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Partner Sanofi SA reported positive late-stage study data for their blockbuster anti-inflammatory drug Dupixent,FULL-ARTICLE,Dow Jones Newswires,Regeneron Shares Rise Premarket on Dupixent COPD Study Success >REGN
REGN,2023-03-23,11:14:04,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Partner Sanofi SA reported positive late-stage study data for their blockbuster anti-inflammatory drug Dupixent,FULL-ARTICLE,Dow Jones Newswires,Regeneron Shares Rise Premarket on Dupixent COPD Study Success
REGN,2023-03-23,16:42:10,589803,Regeneron Pharmaceuticals Inc.,100,0.62,analyst-ratings,positive,Regeneron Pharma Raised to Market Perform From Underperform by Raymond James,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Raised to Market Perform From Underperform by Raymond James
REGN,2023-03-24,08:51:14,589803,Regeneron Pharmaceuticals Inc.,100,0.62,analyst-ratings,positive,Regeneron Pharma Raised to Market Perform From Underperform by Raymond James,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Raised to Market Perform From Underperform by Raymond James
REGN,2023-03-24,09:39:14,589803,Regeneron Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Regeneron Pharma Raised to Buy From Hold by Jefferies,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Raised to Buy From Hold by Jefferies
REGN,2023-03-24,09:39:14,589803,Regeneron Pharmaceuticals Inc.,100,0.82,price-targets,upgrade,Regeneron Pharma Price Target Raised to $925.00/Share From $675.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $925.00/Share From $675.00 by Jefferies
REGN,2023-03-24,10:19:46,589803,Regeneron Pharmaceuticals Inc.,100,0.62,analyst-ratings,positive,Regeneron upgraded to market perform from underperform at Raymond James,FULL-ARTICLE,MarketWatch,MW Regeneron upgraded to market perform from underperform at Raymond James
REGN,2023-03-24,10:37:24,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Barclays
REGN,2023-03-24,10:37:24,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $915.00/Share From $815.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $915.00/Share From $815.00 by Barclays
REGN,2023-03-24,10:50:14,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Wells Fargo
REGN,2023-03-24,10:50:14,589803,Regeneron Pharmaceuticals Inc.,100,0.64,price-targets,upgrade,Regeneron Pharma Price Target Raised to $915.00/Share From $860.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $915.00/Share From $860.00 by Wells Fargo
REGN,2023-03-24,10:53:44,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Neutral by Baird,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Neutral by Baird
REGN,2023-03-24,10:53:44,589803,Regeneron Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Regeneron Pharma Price Target Raised to $800.00/Share From $756.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $800.00/Share From $756.00 by Baird
REGN,2023-03-24,12:21:06,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by BMO Capital
REGN,2023-03-24,12:21:06,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1040.00/Share From $1025.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1040.00/Share From $1025.00 by BMO Capital
REGN,2023-03-24,15:24:28,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Fenimore Registers 2,192 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Fenimore Registers 2,192 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-03-27,06:03:22,589803,Regeneron Pharmaceuticals Inc.,100,0.68,products-services,positive,"Regeneron, Sanofi say Dupixent showed positive",FULL-ARTICLE,Dow Jones Newswires,"Heard on the Street:  COPD Drug Could Be a Smash  ---  Regeneron, Sanofi say Dupixent showed positive results in late-stage trial  ----  By David Wainer"
REGN,2023-03-27,10:42:30,589803,Regeneron Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Regeneron Pharma Raised to Outperform From Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Raised to Outperform From Market Perform by SVB Leerink
REGN,2023-03-27,10:42:30,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $976.00/Share From $834.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $976.00/Share From $834.00 by SVB Leerink
REGN,2023-03-27,20:38:59,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Fenimore Sells 2,192 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Fenimore Sells 2,192 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-03-27,20:40:23,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Vp Larosa Acquires 3,258 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Larosa Acquires 3,258 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-03-27,20:43:18,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Pres Yancopoulos Sells 3,656 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Pres Yancopoulos Sells 3,656 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-03-27,20:44:04,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Chmn Vagelos Gifts 25,000 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Vagelos Gifts 25,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-03-27,20:44:24,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Bassler Sells 1,240 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Bassler Sells 1,240 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-03-28,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Sonoma Biotherapeutics Announce Collaboration to,PRESS-RELEASE,GlobeNewswire,"Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases"
REGN,2023-03-28,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Sonoma Biotherapeutics and Regeneron Announce Collaboration to,PRESS-RELEASE,Business Wire,"Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize T(reg) Cell Therapies for Autoimmune Diseases"
REGN,2023-03-28,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Sonoma Biotherapeutics Announce Collaboration to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases"
REGN,2023-03-28,11:30:24,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Sonoma Biotherapeutics, Regeneron Announce Collaboration",NEWS-FLASH,Dow Jones Newswires,"Sonoma Biotherapeutics, Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases"
REGN,2023-03-28,11:35:39,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Sonoma Biotherapeutics and Regeneron Announce Collaboration to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases"
REGN,2023-03-28,19:33:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Cfo Landry Registers 183 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,CFO Landry Registers 183 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-03-29,16:38:13,589803,Regeneron Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Underperform by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Underperform by B of A Securities
REGN,2023-03-29,16:38:13,589803,Regeneron Pharmaceuticals Inc.,100,0.68,price-targets,upgrade,Regeneron Pharma Price Target Raised to $650.00/Share From $605.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $650.00/Share From $605.00 by B of A Securities
REGN,2023-03-29,19:24:38,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Cfo Landry Registers 1,007 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"CFO Landry Registers 1,007 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-03-29,20:08:17,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Cfo Landry Sells 1,190 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Landry Sells 1,190 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-03-31,12:03:10,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by JP Morgan
REGN,2023-03-31,12:03:10,589803,Regeneron Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Regeneron Pharma Price Target Raised to $950.00/Share From $900.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $950.00/Share From $900.00 by JP Morgan
REGN,2023-04-03,20:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report First Quarter 2023 Financial and Operating Results,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023"
REGN,2023-04-03,20:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023"
REGN,2023-04-03,20:27:13,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report First Quarter 2023 Financial and Operating Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023"
REGN,2023-04-03,20:27:13,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023"
REGN,2023-04-04,00:30:06,589803,Regeneron Pharmaceuticals Inc.,93,0.52,products-services,,Dupixent's launch for the first,PRESS-RELEASE,PR Newswire,"Sanofi/Regeneron's Dupixent Performance in Eosinophilic Esophagitis is Paving the Way for Future Therapies in an Underserved and Growing Market, According to Spherix Global Insights"
REGN,2023-04-04,21:03:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-04-04,21:29:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Ryan Registers 300 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Ryan Registers 300 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-04-05,17:19:51,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Xeris Biopharma enters research collaboration with Regeneron Pharmaceuticals to advance,PRESS-RELEASE,DJ Global Press Release Wire,Xeris Biopharma enters research collaboration with Regeneron Pharmaceuticals to advance XeriJect
REGN,2023-04-05,20:02:44,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,100 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-04-05,20:03:53,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-04-05,20:09:20,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Chmn Vagelos Gifts 259 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,Chmn Vagelos Gifts 259 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-04-12,17:39:27,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Bassler Registers 1,240 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Bassler Registers 1,240 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-04-17,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.43,labor-issues,,Regeneron Announces Retirement of Board Chair,PRESS-RELEASE,GlobeNewswire,"Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary"
REGN,2023-04-17,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.43,labor-issues,,Regeneron Announces Retirement of Board Chair,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary"
REGN,2023-04-17,11:30:24,589803,Regeneron Pharmaceuticals Inc.,100,-0.43,labor-issues,,Regeneron Chairman P. Roy Vagelos to Retire,NEWS-FLASH,Dow Jones Newswires,Regeneron Chairman P. Roy Vagelos to Retire >REGN
REGN,2023-04-17,11:31:16,589803,Regeneron Pharmaceuticals Inc.,100,0.53,labor-issues,,Regeneron Pharma to Name Christine Poon Lead Independent Director >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma to Name Christine Poon Lead Independent Director >REGN
REGN,2023-04-17,11:59:53,589803,Regeneron Pharmaceuticals Inc.,100,-0.43,labor-issues,,Regeneron Pharmaceuticals Chairman P. Roy Vagelos to Retire,FULL-ARTICLE,Dow Jones Newswires,Regeneron Pharmaceuticals Chairman P. Roy Vagelos to Retire
REGN,2023-04-17,12:14:53,589803,Regeneron Pharmaceuticals Inc.,100,-0.43,labor-issues,,Regeneron Pharmaceuticals Chairman P. Roy Vagelos to Retire,FULL-ARTICLE,Dow Jones Newswires,Regeneron Pharmaceuticals Chairman P. Roy Vagelos to Retire
REGN,2023-04-20,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent® (dupilumab injection) now approved in Canada,PRESS-RELEASE,Canadian News Wire,DUPIXENT® (dupilumab injection) now approved in Canada for children as young as six months old with severe atopic dermatitis
REGN,2023-04-20,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupixent(R) is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Canadian News Wire,DUPIXENT® (dupilumab injection) now approved in Canada for children as young as six months old with severe atopic dermatitis
REGN,2023-04-20,11:51:45,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by TD,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by TD Cowen
REGN,2023-04-20,11:51:45,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $885.00/Share From $875.00 by TD,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $885.00/Share From $875.00 by TD Cowen
REGN,2023-04-21,20:33:32,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Brown Registers 3,070 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Brown Registers 3,070 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-04-23,08:25:45,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals Inc, Inst Holders, 1Q 2023 (REGN)",RNS-SEC13F,Dow Jones Newswires,"Regeneron Pharmaceuticals Inc, Inst Holders, 1Q 2023 (REGN)"
REGN,2023-04-24,20:06:20,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Brown Sells 3,070 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Brown Sells 3,070 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-04-26,20:05:01,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Report Positive Interim Phase 1 Clinical Data,PRESS-RELEASE,Business Wire,"Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer's Disease and Cerebral Amyloid Angiopathy"
REGN,2023-04-26,20:05:37,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Report Positive Interim Phase 1 Clinical Data,NEWS-FLASH,Dow Jones Newswires,"Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer's Disease and Cerebral Amyloid Angiopathy"
REGN,2023-04-26,20:06:30,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Report Positive Interim Phase 1 Clinical Data,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer's Disease and Cerebral Amyloid Angiopathy"
REGN,2023-05-02,11:00:45,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,"Regeneron Pharmaceuticals Inc.: Libtayo, A phase 1 study of",PRESS-RELEASE,GlobeNewswire,Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research
REGN,2023-05-02,11:00:45,589803,Regeneron Pharmaceuticals Inc.,94,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The extensive clinical program for Libtayo,PRESS-RELEASE,GlobeNewswire,Regeneron to Highlight New and Updated Clinical -2-
REGN,2023-05-02,11:08:42,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,"Regeneron Pharmaceuticals Inc.: Libtayo, A phase 1 study of",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research
REGN,2023-05-02,11:08:42,589803,Regeneron Pharmaceuticals Inc.,94,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The extensive clinical program for Libtayo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron to Highlight New and -2-
REGN,2023-05-03,15:13:24,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Truist Securities
REGN,2023-05-03,15:13:24,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1050.00/Share From $856.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1050.00/Share From $856.00 by Truist Securities
REGN,2023-05-03,20:02:09,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 1Q EPS $7.17,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q EPS $7.17 >REGN
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: First Quarter 2023 Financial Results,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: First quarter 2023 revenues increased 7% to $3.16 billion,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: First quarter 2023 GAAP diluted EPS of $7.17,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:44:36,589803,Regeneron Pharmaceuticals Inc.,100,0.65,revenues,up,Regeneron Posts Higher 1Q Sales,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Posts Higher 1Q Sales, Boosted by Sanofi Work"
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: European Commission approved Dupixent,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: Positive interim Phase 1 data,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,162 $ 2,965",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Pharmaceuticals Inc.: The U.S. Food and Drug Administration (FDA) accepted for priority review,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Regeneron Pharmaceuticals Inc.: EYLEA (aflibercept) Injection,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,The FDA approved EYLEA for the treatment,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"March 2023, the EC approved Libtayo (cemiplimab)",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,100,0.69,products-services,,Regeneron Pharmaceuticals Inc.: The FDA granted Fast Track designation,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: The FDA approved Kevzara(R) (sarilumab),PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: The FDA approved Evkeeza(R) (evinacumab),PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda accepted for priority review the BLA for pozelimab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,"Regeneron Pharmaceuticals Inc.: In March 2023, the Company and Sonoma Biotherapeutics, Inc. entered into a license and collaboration agreement",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,162 $ 2,965",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -2-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA in the U.S. decreased in the first quarter of 2023,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -2-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the first quarter,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -2-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -2-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D for first quarter of 2023,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -2-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D for the first quarter of 2022,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -2-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,"Regeneron Pharmaceuticals Inc.: the Company's collaboration agreement with Adicet Bio, Inc.",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -2-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,-0.49,equity-actions,up,Regeneron Pharmaceuticals Inc.: COCM expenses increased in the first quarter of 2023,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -2-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $7.17 in the first quarter of 2023,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -2-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $10.09 in the first quarter of 2023,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -2-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,approved,Regeneron Pharmaceuticals Inc.: the Company's Board of Directors authorized a new share repurchase program,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -2-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the first quarter of 2023, the Company repurchased shares of its common stock",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -2-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2023 Financial Guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -2-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 1Q Rev $3.16B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q Rev $3.16B >REGN
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2023 financial guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -3-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its first quarter 2023 financial and operating results on Thursday, May 4, 2023, at 8:30 AM Eastern Time",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -3-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: Total assets $30,059.9 $ 29,214.5",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -4-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -4-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income $ 817.8 $ 973.5,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -4-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 7.64 $ 9.12,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -4-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,167.5 $1,317.6",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -5-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 10.90 $ 12.34,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -5-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -5-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""First Quarter 2023 Financial Results",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -5-
REGN,2023-05-04,10:30:35,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: net product sales of ARCALYST were $40 million,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2023 Financial -5-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: First Quarter 2023 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: First quarter 2023 revenues increased 7% to $3.16 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: First quarter 2023 GAAP diluted EPS of $7.17,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: European Commission approved Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: Positive interim Phase 1 data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,162 $ 2,965",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Pharmaceuticals Inc.: The U.S. Food and Drug Administration (FDA) accepted for priority review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Regeneron Pharmaceuticals Inc.: EYLEA (aflibercept) Injection,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,The FDA approved EYLEA for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"March 2023, the EC approved Libtayo (cemiplimab)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,100,0.69,products-services,,Regeneron Pharmaceuticals Inc.: The FDA granted Fast Track designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: The FDA approved Kevzara(R) (sarilumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: The FDA approved Evkeeza(R) (evinacumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda accepted for priority review the BLA for pozelimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,"Regeneron Pharmaceuticals Inc.: In March 2023, the Company and Sonoma Biotherapeutics, Inc. entered into a license and collaboration agreement",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2023 Financial and Operating Results
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,162 $ 2,965",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA in the U.S. decreased in the first quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the first quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D for first quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D for the first quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,"Regeneron Pharmaceuticals Inc.: the Company's collaboration agreement with Adicet Bio, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,-0.49,equity-actions,up,Regeneron Pharmaceuticals Inc.: COCM expenses increased in the first quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $7.17 in the first quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $10.09 in the first quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,approved,Regeneron Pharmaceuticals Inc.: the Company's Board of Directors authorized a new share repurchase program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the first quarter of 2023, the Company repurchased shares of its common stock",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2023 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -3-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its first quarter 2023 financial and operating results on Thursday, May 4, 2023, at 8:30 AM Eastern Time",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -3-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: Total assets $30,059.9 $ 29,214.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income $ 817.8 $ 973.5,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 7.64 $ 9.12,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,167.5 $1,317.6",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -5-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 10.90 $ 12.34,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -5-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -5-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""First Quarter 2023 Financial Results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -5-
REGN,2023-05-04,10:30:36,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: net product sales of ARCALYST were $40 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -5-
REGN,2023-05-04,10:32:27,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 1Q Adj EPS $10.09,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q Adj EPS $10.09 >REGN
REGN,2023-05-04,10:59:36,589803,Regeneron Pharmaceuticals Inc.,100,0.65,revenues,up,Regeneron Posts Higher 1Q Sales,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Posts Higher 1Q Sales, Boosted by Sanofi Work"
REGN,2023-05-04,11:37:44,589803,Regeneron Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Regeneron tops Q1 estimates,FULL-ARTICLE,MarketWatch,"MW Regeneron tops Q1 estimates but lowers margin guidance, sending stock lower"
REGN,2023-05-04,11:37:44,589803,Regeneron Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Regeneron Tops Q1 Estimates,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Tops Q1 Estimates But Lowers Margin Guidance, Sending Stock Lower -- MarketWatch"
REGN,2023-05-04,12:50:57,589803,Regeneron Pharmaceuticals Inc.,95,0.61,earnings,positive,Regeneron Pharmaceuticals reported adjusted earnings of $10.09 per share,FULL-ARTICLE,Dow Jones Newswires,Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker -- IBD
REGN,2023-05-05,15:42:05,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley
REGN,2023-05-05,15:42:05,589803,Regeneron Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Regeneron Pharma Price Target Raised to $927.00/Share From $880.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $927.00/Share From $880.00 by Morgan Stanley
REGN,2023-05-05,16:23:36,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital
REGN,2023-05-05,16:23:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.4,price-targets,downgrade,Regeneron Pharma Price Target Cut to $811.00/Share From $830.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $811.00/Share From $830.00 by RBC Capital
REGN,2023-05-08,15:02:52,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Guggenheim
REGN,2023-05-08,15:02:52,589803,Regeneron Pharmaceuticals Inc.,100,-0.42,price-targets,downgrade,Regeneron Pharma Price Target Cut to $935.00/Share From $960.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $935.00/Share From $960.00 by Guggenheim
REGN,2023-05-10,08:01:52,589803,Regeneron Pharmaceuticals Inc.,100,0.41,products-services,start,Bayer Starts Phase 3 Study on Aflibercept,NEWS-FLASH,Dow Jones Newswires,Bayer Starts Phase 3 Study on Aflibercept 8 Mg in Retinal Vein Occlusion
REGN,2023-05-10,20:09:48,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Murphy Gifts 1,326 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Murphy Gifts 1,326 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-05-15,11:54:52,589803,Regeneron Pharmaceuticals Inc.,100,0.41,products-services,start,Decibel Therapeutics Initiates CHORD Phase 1/2 Clinical Trial of DB-OTO,NEWS-FLASH,Dow Jones Newswires,Decibel Therapeutics Initiates CHORD Phase 1/2 Clinical Trial of DB-OTO Hearing Loss Gene Therapy >DBTX
REGN,2023-06-01,20:30:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp McCourt Registers 250 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,VP McCourt Registers 250 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-06-02,20:15:41,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp McCourt Sells 250 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP McCourt Sells 250 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-06-02,20:17:26,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-06-09,16:00:40,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital
REGN,2023-06-09,16:00:40,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $816.00/Share From $811.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $816.00/Share From $811.00 by RBC Capital
REGN,2023-06-27,18:25:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.65,equity-actions,halt,Regeneron Pharmaceuticals Inc. (REGN) Halted due to pending news,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharmaceuticals Inc. (REGN) Halted due to pending news
REGN,2023-06-27,18:45:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,products-services,denied,Fda Issues Complete Response Letter (CRL) for Aflibercept,PRESS-RELEASE,GlobeNewswire,FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler
REGN,2023-06-27,18:45:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Aflibercept 8 mg is being jointly developed by Regeneron and Bayer AG,PRESS-RELEASE,GlobeNewswire,FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler
REGN,2023-06-27,18:45:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,products-services,denied,Fda Issues Complete Response Letter (CRL) for Aflibercept,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler
REGN,2023-06-27,18:45:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Aflibercept 8 mg is being jointly developed by Regeneron and Bayer AG,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler
REGN,2023-06-27,18:45:48,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,products-services,denied,Regeneron Pharmaceuticals: FDA Issues Complete Response Letter for Aflibercept,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharmaceuticals: FDA Issues Complete Response Letter for Aflibercept 8 Mg Biologics License Application Solely Due to Continuing Review of Inspection Findings at Third-Party Filler
REGN,2023-06-27,19:02:26,589803,Regeneron Pharmaceuticals Inc.,97,0.0,products-services,,"Aflibercept 8 mg, is being jointly developed by Regeneron and Bayer AG",FULL-ARTICLE,MarketWatch,MW Regeneron's high-dose Eylea not approved by FDA
REGN,2023-06-27,19:02:26,589803,Regeneron Pharmaceuticals Inc.,97,0.0,products-services,,"Aflibercept 8 mg, is being jointly developed by Regeneron and Bayer AG",FULL-ARTICLE,Dow Jones Newswires,Regeneron's High-dose Eylea Not Approved By FDA -- MarketWatch
REGN,2023-06-27,19:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.48,equity-actions,resumed,Regeneron Pharmaceuticals Inc. (REGN) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharmaceuticals Inc. (REGN) Resumed Trading
REGN,2023-06-27,19:23:00,589803,Regeneron Pharmaceuticals Inc.,97,0.0,products-services,,Aflibercept 8 mg is being jointly developed by Regeneron and Bayer AG,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Gets FDA Response Letter on Aflibercept 8 Mg Application, Says Issue Involves Third-Party Filler"
REGN,2023-06-27,19:23:00,589803,Regeneron Pharmaceuticals Inc.,97,0.0,earnings,,Regeneron also reported two-year results,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Gets FDA Response Letter on Aflibercept 8 Mg Application, Says Issue Involves Third-Party Filler"
REGN,2023-06-27,19:38:00,589803,Regeneron Pharmaceuticals Inc.,97,0.0,products-services,,Aflibercept 8 mg is being jointly developed by Regeneron and Bayer AG,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Gets FDA Response Letter on Aflibercept 8 Mg Application, Says Issue Involves Third-Party Filler"
REGN,2023-06-27,19:38:00,589803,Regeneron Pharmaceuticals Inc.,97,0.0,earnings,,Regeneron also reported two-year results,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Gets FDA Response Letter on Aflibercept 8 Mg Application, Says Issue Involves Third-Party Filler"
REGN,2023-06-27,20:21:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.24,revenues,down,Eylea sales fell 4% to $2.28 billion,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Crumbles After FDA Rejects Its Next Blockbuster Contender -- IBD
REGN,2023-06-28,10:42:18,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Regeneron Pharma Cut to Hold From Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Cut to Hold From Buy by Canaccord Genuity
REGN,2023-06-28,10:42:18,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Regeneron Pharma Price Target Cut to $720.00/Share From $953.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $720.00/Share From $953.00 by Canaccord Genuity
REGN,2023-06-28,12:53:48,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Barclays
REGN,2023-06-28,12:53:48,589803,Regeneron Pharmaceuticals Inc.,100,-0.44,price-targets,downgrade,Regeneron Pharma Price Target Cut to $888.00/Share From $915.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $888.00/Share From $915.00 by Barclays
REGN,2023-06-28,13:35:58,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital
REGN,2023-06-28,13:35:58,589803,Regeneron Pharmaceuticals Inc.,100,-0.46,price-targets,downgrade,Regeneron Pharma Price Target Cut to $789.00/Share From $816.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $789.00/Share From $816.00 by RBC Capital
REGN,2023-06-28,14:18:28,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Neutral by Baird,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Neutral by Baird
REGN,2023-06-28,14:18:28,589803,Regeneron Pharmaceuticals Inc.,100,-0.6,price-targets,downgrade,Regeneron Pharma Price Target Cut to $760.00/Share From $800.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $760.00/Share From $800.00 by Baird
REGN,2023-06-28,14:34:01,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Truist Securities
REGN,2023-06-28,14:34:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1045.00/Share From $1050.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1045.00/Share From $1050.00 by Truist Securities
REGN,2023-06-29,20:01:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report Second Quarter 2023 Financial and Operating Results,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023"
REGN,2023-06-29,20:01:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023"
REGN,2023-07-03,16:12:30,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Ryan Registers 200 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Ryan Registers 200 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-07-03,18:15:32,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp McCourt Registers 250 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,VP McCourt Registers 250 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-07-06,12:12:24,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Neutral by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Neutral by Cantor Fitzgerald
REGN,2023-07-06,12:12:24,589803,Regeneron Pharmaceuticals Inc.,100,-0.42,price-targets,downgrade,Regeneron Pharma Price Target Cut to $795.00/Share From $815.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $795.00/Share From $815.00 by Cantor Fitzgerald
REGN,2023-07-06,20:02:49,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-07-06,20:03:31,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp McCourt Sells 250 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP McCourt Sells 250 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-07-17,16:24:51,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Guggenheim
REGN,2023-07-17,16:24:51,589803,Regeneron Pharmaceuticals Inc.,100,-0.5,price-targets,downgrade,Regeneron Pharma Price Target Cut to $900.00/Share From $935.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $900.00/Share From $935.00 by Guggenheim
REGN,2023-07-24,21:30:05,589803,Regeneron Pharmaceuticals Inc.,94,0.84,products-services,positive,"Regeneron Pharmaceuticals, Inc. announced positive two-year results from the Phase III PANORAMA trial",PRESS-RELEASE,PR Newswire,"Global Eylea Market Sees Impressive Growth with Major Players Regeneron Pharmaceuticals, Bayer AG, and More Expanding Research and Development Efforts"
REGN,2023-08-01,11:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,GlobeNewswire,Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation
REGN,2023-08-01,11:00:01,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation
REGN,2023-08-01,20:22:07,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp McCourt Registers 250 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,VP McCourt Registers 250 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 2Q EPS $8.50,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q EPS $8.50 >REGN
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 2Q Net $968.4M,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q Net $968.4M >REGN
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 2Q Rev $3.16B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q Rev $3.16B >REGN
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Second Quarter 2023 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2023 Financial and Operating Results
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Second quarter 2023 revenues increased 11% to $3.16 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2023 Financial and Operating Results
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Second quarter 2023 GAAP diluted EPS of $8.50,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2023 Financial and Operating Results
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Two-year results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2023 Financial and Operating Results
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,158 $ 2,857",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2023 Financial and Operating Results
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.7,products-services,,Regeneron Pharmaceuticals Inc.: The FDA granted Breakthrough Therapy designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2023 Financial and Operating Results
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: The Company announced promising data from three independent expansion cohorts of a Phase 1 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2023 Financial and Operating Results
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,-0.53,products-services,suspended,Regeneron Pharmaceuticals Inc.: the Company has discontinued enrollment of patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2023 Financial and Operating Results
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $3,158 $ 2,857",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA in the U.S. decreased in the second quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the second quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D in the second quarter of 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.49,equity-actions,up,Regeneron Pharmaceuticals Inc.: COCM expenses increased in the second quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.4,earnings,up,"Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $8.50 in the second quarter of 2023, compared to $7.47 in the second quarter of 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.4,earnings,up,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $10.24 in the second quarter of 2023, compared to $9.77 in the second quarter of 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the second quarter of 2023, the Company repurchased shares of its common stock",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2023 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -3-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its second quarter 2023 financial and operating results on Thursday, August 3, 2023, at 8:30 AM Eastern Time",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -3-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: Total assets $30,657.5 $ 29,214.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,181.6 $1,126.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 9.05 $ 7.90 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 11.04 $ 10.44 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -5-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Second Quarter 2023 Financial Results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -5-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: net product sales of ARCALYST were $43 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -5-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Second Quarter 2023 Financial Results,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial and Operating Results
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Second quarter 2023 revenues increased 11% to $3.16 billion,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial and Operating Results
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Second quarter 2023 GAAP diluted EPS of $8.50,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial and Operating Results
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Two-year results,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial and Operating Results
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,158 $ 2,857",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial and Operating Results
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.7,products-services,,Regeneron Pharmaceuticals Inc.: The FDA granted Breakthrough Therapy designation,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial and Operating Results
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: The Company announced promising data from three independent expansion cohorts of a Phase 1 trial,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial and Operating Results
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,-0.53,products-services,suspended,Regeneron Pharmaceuticals Inc.: the Company has discontinued enrollment of patients,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial and Operating Results
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $3,158 $ 2,857",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA in the U.S. decreased in the second quarter of 2023,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the second quarter,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D in the second quarter of 2022,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.49,equity-actions,up,Regeneron Pharmaceuticals Inc.: COCM expenses increased in the second quarter of 2023,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.4,earnings,up,"Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $8.50 in the second quarter of 2023, compared to $7.47 in the second quarter of 2022",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.4,earnings,up,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $10.24 in the second quarter of 2023, compared to $9.77 in the second quarter of 2022",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the second quarter of 2023, the Company repurchased shares of its common stock",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2023 Financial Guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -2-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2023 financial guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -3-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its second quarter 2023 financial and operating results on Thursday, August 3, 2023, at 8:30 AM Eastern Time",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -3-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: Total assets $30,657.5 $ 29,214.5",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -4-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -4-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,181.6 $1,126.9",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -4-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 9.05 $ 7.90 $,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -4-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 11.04 $ 10.44 $,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -4-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -5-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Second Quarter 2023 Financial Results",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -5-
REGN,2023-08-03,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: net product sales of ARCALYST were $43 million,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2023 Financial -5-
REGN,2023-08-03,10:33:37,589803,Regeneron Pharmaceuticals Inc.,100,0.48,revenues,up,"Regeneron Pharma: 2Q Dupixent Global Net Sales, Recorded by Sanofi, Rose 33%",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharma: 2Q Dupixent Global Net Sales, Recorded by Sanofi, Rose 33% to $2.79B >REGN"
REGN,2023-08-03,10:33:51,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 2Q Adj EPS $10.24,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q Adj EPS $10.24 >REGN
REGN,2023-08-03,12:11:48,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Q2 revenue up 11% to $3.16 bln,FULL-ARTICLE,MarketWatch,"MW Regeneron Q2 revenue up 11% to $3.16 bln, above the FactSet consensus $3.02 bln"
REGN,2023-08-03,12:11:48,589803,Regeneron Pharmaceuticals Inc.,100,0.4,earnings,up,Regeneron Q2 adj. EPS $10.24 vs. $9.77 a year ago,FULL-ARTICLE,MarketWatch,"MW Regeneron Q2 adj. EPS $10.24 vs. $9.77 a year ago, beats the FactSet consensus $9.88"
REGN,2023-08-03,13:05:29,589803,Regeneron Pharmaceuticals Inc.,95,0.61,earnings,positive,Regeneron Pharmaceuticals reported adjusted earnings of $10.24 per share,FULL-ARTICLE,Dow Jones Newswires,Regeneron Surmounts Its 200-Day Line On A Handy Second-Quarter Beat -- IBD
REGN,2023-08-03,15:53:05,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron earned $10.24 per share,FULL-ARTICLE,Dow Jones Newswires,The Unexpectedly Good News That Helped Regeneron Retake Its 200-Day Line -- IBD
REGN,2023-08-03,15:53:05,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron recorded $1.32 billion in collaboration revenue,FULL-ARTICLE,Dow Jones Newswires,The Unexpectedly Good News That Helped Regeneron Retake Its 200-Day Line -- IBD
REGN,2023-08-03,15:53:05,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Regeneron partners with Sanofi on Dupixent,FULL-ARTICLE,Dow Jones Newswires,The Unexpectedly Good News That Helped Regeneron Retake Its 200-Day Line -- IBD
REGN,2023-08-03,16:33:02,589803,Regeneron Pharmaceuticals Inc.,95,0.0,earnings,,Regeneron Pharmaceuticals Inc.: the company said on its 2Q earnings,FULL-ARTICLE,Dow Jones Newswires,Regeneron Eyes Quick Rebound from FDA Rejection -- Market Talk
REGN,2023-08-03,16:33:02,589803,Regeneron Pharmaceuticals Inc.,95,0.57,products-services,granted,Fda approval would let Regeneron launch the drug,FULL-ARTICLE,Dow Jones Newswires,Regeneron Eyes Quick Rebound from FDA Rejection -- Market Talk
REGN,2023-08-03,16:33:02,589803,Regeneron Pharmaceuticals Inc.,95,0.0,earnings,,Regeneron Pharmaceuticals Inc.: the company said on its 2Q earnings,FULL-ARTICLE,Dow Jones Newswires,Regeneron Eyes Quick Rebound from FDA Rejection -- Market Talk
REGN,2023-08-03,16:33:02,589803,Regeneron Pharmaceuticals Inc.,95,0.57,products-services,granted,Fda approval would let Regeneron launch the drug,FULL-ARTICLE,Dow Jones Newswires,Regeneron Eyes Quick Rebound from FDA Rejection -- Market Talk
REGN,2023-08-03,20:03:34,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp McCourt Sells 250 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP McCourt Sells 250 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-08-03,20:05:37,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron earned $10.24 per share,FULL-ARTICLE,Dow Jones Newswires,The Unexpectedly Good News That Helped Regeneron Retake Its 200-Day Line -- IBD
REGN,2023-08-03,20:05:37,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron recorded $1.32 billion in collaboration revenue,FULL-ARTICLE,Dow Jones Newswires,The Unexpectedly Good News That Helped Regeneron Retake Its 200-Day Line -- IBD
REGN,2023-08-03,20:05:37,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Regeneron partners with Sanofi on Dupixent,FULL-ARTICLE,Dow Jones Newswires,The Unexpectedly Good News That Helped Regeneron Retake Its 200-Day Line -- IBD
REGN,2023-08-03,20:26:39,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-08-04,13:32:35,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by Oppenheimer
REGN,2023-08-04,13:32:35,589803,Regeneron Pharmaceuticals Inc.,100,0.6,price-targets,upgrade,Regeneron Pharma Price Target Raised to $950.00/Share From $900.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $950.00/Share From $900.00 by Oppenheimer
REGN,2023-08-04,16:03:05,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital
REGN,2023-08-04,16:03:05,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $820.00/Share From $818.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $820.00/Share From $818.00 by RBC Capital
REGN,2023-08-04,19:10:45,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley
REGN,2023-08-04,19:10:46,589803,Regeneron Pharmaceuticals Inc.,100,0.32,price-targets,upgrade,Regeneron Pharma Price Target Raised to $912.00/Share From $897.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $912.00/Share From $897.00 by Morgan Stanley
REGN,2023-08-07,14:34:36,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Barclays
REGN,2023-08-07,14:34:36,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $900.00/Share From $888.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $900.00/Share From $888.00 by Barclays
REGN,2023-08-09,11:30:53,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron To Acquire Decibel Therapeutics,NEWS-FLASH,Dow Jones Newswires,"Regeneron To Acquire Decibel Therapeutics, Strengthening Gene Therapy And Hearing Loss Programs >REGN"
REGN,2023-08-09,11:30:53,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Acquisition of Decibel by Regeneron,PRESS-RELEASE,GlobeNewswire,"Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs"
REGN,2023-08-09,11:30:53,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Collaboration between Decibel and Regeneron,PRESS-RELEASE,GlobeNewswire,"Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs"
REGN,2023-08-09,11:30:53,589803,Regeneron Pharmaceuticals Inc.,100,0.41,products-services,start,First participant being administered with DB-OTO,PRESS-RELEASE,GlobeNewswire,"Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs"
REGN,2023-08-09,11:30:53,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Acquire Decibel Therapeutics,PRESS-RELEASE,GlobeNewswire,"Regeneron to Acquire Decibel Therapeutics, -2-"
REGN,2023-08-09,11:30:53,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regulatory approval of Regeneron's Products,PRESS-RELEASE,GlobeNewswire,"Regeneron to Acquire Decibel Therapeutics, -2-"
REGN,2023-08-09,11:30:54,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Acquisition of Decibel by Regeneron,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs"
REGN,2023-08-09,11:30:54,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Collaboration between Decibel and Regeneron,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs"
REGN,2023-08-09,11:30:54,589803,Regeneron Pharmaceuticals Inc.,100,0.41,products-services,start,First participant being administered with DB-OTO,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs"
REGN,2023-08-09,11:30:54,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Regulatory approval of Regeneron's Products,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron to Acquire Decibel -2-
REGN,2023-08-09,11:33:07,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Acquire Decibel Therapeutics for $4/Shr in Cash,NEWS-FLASH,Dow Jones Newswires,Regeneron to Acquire Decibel Therapeutics for $4/Shr in Cash >REGN DBTX
REGN,2023-08-09,11:34:25,589803,Regeneron Pharmaceuticals Inc.,100,0.55,acquisitions-mergers,interest,Regeneron: Proposed Acquisition,NEWS-FLASH,Dow Jones Newswires,Regeneron: Proposed Acquisition Values Decibel at Total Equity Value of About $109 M >REGN
REGN,2023-08-09,11:44:41,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron To Acquire Decibel Therapeutics,FULL-ARTICLE,Dow Jones Newswires,Regeneron To Acquire Decibel Therapeutics
REGN,2023-08-09,11:56:43,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc. (REGN) said Wednesday it would pay $4 a share for Decibel Therapeutics Inc. (DBTX),FULL-ARTICLE,MarketWatch,MW Regeneron buying small cap Decibel Therapeutics for $4 a share
REGN,2023-08-09,11:56:43,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc. (REGN) said Wednesday it would pay $4 a share for Decibel Therapeutics Inc. (DBTX),FULL-ARTICLE,Dow Jones Newswires,Regeneron Buying Small Cap Decibel Therapeutics For $4 A Share -- MarketWatch
REGN,2023-08-09,11:59:41,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron To Acquire Decibel Therapeutics,FULL-ARTICLE,Dow Jones Newswires,Regeneron To Acquire Decibel Therapeutics
REGN,2023-08-09,13:04:13,589803,Regeneron Pharmaceuticals Inc.,92,0.65,acquisitions-mergers,,Decibel Therapeutics Inc.: the company signed a deal to be acquired by Regeneron Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Decibel Therapeutics Shares Surge on Regeneron Acquisition
REGN,2023-08-09,13:04:13,589803,Regeneron Pharmaceuticals Inc.,92,0.62,acquisitions-mergers,,Agreed to be acquired by Regeneron for $4,FULL-ARTICLE,Dow Jones Newswires,Decibel Therapeutics Shares Surge on Regeneron Acquisition
REGN,2023-08-09,13:19:14,589803,Regeneron Pharmaceuticals Inc.,92,0.65,acquisitions-mergers,,Decibel Therapeutics Inc.: the company signed a deal to be acquired by Regeneron Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Decibel Therapeutics Shares Surge on Regeneron Acquisition
REGN,2023-08-09,13:19:14,589803,Regeneron Pharmaceuticals Inc.,92,0.62,acquisitions-mergers,,Agreed to be acquired by Regeneron for $4,FULL-ARTICLE,Dow Jones Newswires,Decibel Therapeutics Shares Surge on Regeneron Acquisition
REGN,2023-08-09,13:31:23,589803,Regeneron Pharmaceuticals Inc.,94,0.62,acquisitions-mergers,,"Decibel"") has agreed to be sold to Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,DBTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Decibel Therapeutics to Regeneron Pharmaceuticals
REGN,2023-08-10,18:06:27,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bassler Registers 853 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Bassler Registers 853 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-08-11,20:14:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bassler Sells 853 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bassler Sells 853 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-08-15,05:19:54,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Sandoz to File for Regulatory Approval for Aflibercept in US,NEWS-FLASH,Dow Jones Newswires,Novartis: Sandoz to File for Regulatory Approval for Aflibercept in US and EU in Coming Months
REGN,2023-08-18,18:11:53,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc. (REGN) said Friday that the U.S. Food and Drug Administration has approved its treatment,FULL-ARTICLE,MarketWatch,MW Regeneron gets FDA green light on first treatment for life-threatening immune disease
REGN,2023-08-18,18:11:54,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc. (REGN) said Friday that the U.S. Food and Drug Administration has approved its treatment,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets FDA Green Light On First Treatment For Life-threatening Immune Disease -- MarketWatch
REGN,2023-08-18,20:25:31,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Hold by Canaccord Genuity
REGN,2023-08-18,23:09:37,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Gets FDA OK for High-Dose Eylea,FULL-ARTICLE,Dow Jones Newswires,Regeneron Pharmaceuticals Gets FDA OK for High-Dose Eylea Eye Treatment
REGN,2023-08-18,23:24:37,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Gets FDA OK for High-Dose Eylea,FULL-ARTICLE,Dow Jones Newswires,Regeneron Pharmaceuticals Gets FDA OK for High-Dose Eylea Eye Treatment
REGN,2023-08-19,07:20:05,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals Inc, Inst Holders, 2Q 2023 (REGN)",RNS-SEC13F,Dow Jones Newswires,"Regeneron Pharmaceuticals Inc, Inst Holders, 2Q 2023 (REGN)"
REGN,2023-08-21,11:06:37,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Barclays
REGN,2023-08-21,11:06:38,589803,Regeneron Pharmaceuticals Inc.,100,0.44,price-targets,upgrade,Regeneron Pharma Price Target Raised to $925.00/Share From $900.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $925.00/Share From $900.00 by Barclays
REGN,2023-08-21,11:53:41,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: the company said late Friday that the U.S. Food and Drug Administration had approved a higher-dose formulation,FULL-ARTICLE,Dow Jones Newswires,Regeneron Shares Climb After FDA Approval Of Macular Degeneration Treatment -- MarketWatch
REGN,2023-08-21,11:53:41,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda's approval last week of Regeneron's Veopoz treatment,FULL-ARTICLE,Dow Jones Newswires,Regeneron Shares Climb After FDA Approval Of Macular Degeneration Treatment -- MarketWatch
REGN,2023-08-21,11:53:41,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: the company said late Friday that the U.S. Food and Drug Administration had approved a higher-dose formulation,FULL-ARTICLE,MarketWatch,MW Regeneron shares climb after FDA approval of macular degeneration treatment
REGN,2023-08-21,11:53:41,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda's approval last week of Regeneron's Veopoz treatment,FULL-ARTICLE,MarketWatch,MW Regeneron shares climb after FDA approval of macular degeneration treatment
REGN,2023-08-21,12:13:28,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by BMO Capital
REGN,2023-08-21,12:13:28,589803,Regeneron Pharmaceuticals Inc.,100,0.42,price-targets,upgrade,Regeneron Pharma Price Target Raised to $985.00/Share From $960.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $985.00/Share From $960.00 by BMO Capital
REGN,2023-08-21,12:25:18,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital
REGN,2023-08-21,12:25:18,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $830.00/Share From $820.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $830.00/Share From $820.00 by RBC Capital
REGN,2023-08-21,12:45:28,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by Oppenheimer
REGN,2023-08-21,12:45:28,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1050.00/Share From $950.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1050.00/Share From $950.00 by Oppenheimer
REGN,2023-08-21,13:23:11,589803,Regeneron Pharmaceuticals Inc.,97,0.0,revenues,,Regeneron Pharmaceuticals Inc.: the company's sales in 2022,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock-Price Targets Rise as FDA Approves Higher Dose of Eye Drug -- Barrons.com
REGN,2023-08-21,13:48:43,589803,Regeneron Pharmaceuticals Inc.,100,0.54,price-targets,upgrade,Regeneron stock price target raised to $985 at BMO,FULL-ARTICLE,MarketWatch,"MW Regeneron stock price target raised to $985 at BMO, reiterated as outperform"
REGN,2023-08-21,14:01:22,589803,Regeneron Pharmaceuticals Inc.,97,0.57,products-services,granted,The Food and Drug Administration approved Regeneron Pharmaceuticals' high-dose Eylea,FULL-ARTICLE,Dow Jones Newswires,Why This Regeneron Approval 'Could Not Come Soon Enough' As Novartis Looms -- IBD
REGN,2023-08-21,14:01:22,589803,Regeneron Pharmaceuticals Inc.,97,0.0,products-services,,"Eylea costs $1,850",FULL-ARTICLE,Dow Jones Newswires,Why This Regeneron Approval 'Could Not Come Soon Enough' As Novartis Looms -- IBD
REGN,2023-08-21,14:11:43,589803,Regeneron Pharmaceuticals Inc.,100,0.94,price-targets,upgrade,Regeneron stock price target raised to $1.050 vs. $950 at Oppenheimer,FULL-ARTICLE,MarketWatch,MW Regeneron stock price target raised to $1.050 vs. $950 at Oppenheimer
REGN,2023-08-21,14:21:28,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Wells Fargo
REGN,2023-08-21,14:21:28,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $980.00/Share From $875.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $980.00/Share From $875.00 by Wells Fargo
REGN,2023-08-21,15:36:28,589803,Regeneron Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Regeneron Pharma Raised to Buy From Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Raised to Buy From Hold by Canaccord Genuity
REGN,2023-08-21,15:36:28,589803,Regeneron Pharmaceuticals Inc.,100,0.82,price-targets,upgrade,Regeneron Pharma Price Target Raised to $992.00/Share From $720.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $992.00/Share From $720.00 by Canaccord Genuity
REGN,2023-08-21,16:30:34,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bassler Registers 853 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Bassler Registers 853 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-08-21,20:07:40,589803,Regeneron Pharmaceuticals Inc.,98,0.57,products-services,granted,The Food and Drug Administration approved Regeneron Pharmaceuticals' high-dose Eylea,FULL-ARTICLE,Dow Jones Newswires,Regeneron Hits A New Record High On The Approval That 'Could Not Come Soon Enough' -- IBD
REGN,2023-08-21,20:07:40,589803,Regeneron Pharmaceuticals Inc.,98,0.0,products-services,,"Eylea costs $1,850",FULL-ARTICLE,Dow Jones Newswires,Regeneron Hits A New Record High On The Approval That 'Could Not Come Soon Enough' -- IBD
REGN,2023-08-22,18:15:41,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy,PRESS-RELEASE,GlobeNewswire,Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention
REGN,2023-08-22,18:15:41,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Hhs, and Regeneron have previously worked together to",PRESS-RELEASE,GlobeNewswire,Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention
REGN,2023-08-22,18:15:42,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention
REGN,2023-08-22,18:15:42,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Hhs, and Regeneron have previously worked together to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention
REGN,2023-08-22,18:18:53,589803,Regeneron Pharmaceuticals Inc.,93,0.4,products-services,,Regeneron Pharmaceuticals is receiving $326 million to support,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets Funding for Durable Covid-19 Treatment -- Market Talk
REGN,2023-08-22,18:18:53,589803,Regeneron Pharmaceuticals Inc.,93,0.0,products-services,,Regeneron's new monoclonal antibody is expected to enter clinical trials,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets Funding for Durable Covid-19 Treatment -- Market Talk
REGN,2023-08-22,18:18:54,589803,Regeneron Pharmaceuticals Inc.,93,0.4,products-services,,Regeneron Pharmaceuticals is receiving $326 million to support,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets Funding for Durable Covid-19 Treatment -- Market Talk
REGN,2023-08-22,18:18:54,589803,Regeneron Pharmaceuticals Inc.,93,0.0,products-services,,Regeneron's new monoclonal antibody is expected to enter clinical trials,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets Funding for Durable Covid-19 Treatment -- Market Talk
REGN,2023-08-22,19:51:26,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Stahl Registers 11,665 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Stahl Registers 11,665 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-08-23,20:04:19,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bassler Sells 853 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bassler Sells 853 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-08-23,20:04:56,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Stahl Sells 11,665 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stahl Sells 11,665 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-08-23,20:54:39,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Poon Registers 12,280 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Poon Registers 12,280 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-08-23,21:09:27,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Cfo Landry Registers 223 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,CFO Landry Registers 223 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-08-24,20:30:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp van Plew Registers 6,197 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP van Plew Registers 6,197 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-08-25,20:03:28,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp van Plew Sells 6,197 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP van Plew Sells 6,197 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-08-25,20:03:46,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Poon Sells 12,280 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Poon Sells 12,280 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-08-25,20:03:57,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Cfo Landry Sells 223 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Sells 223 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-08-25,20:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Vp Fenimore Acquires 1,802 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Fenimore Acquires 1,802 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-08-29,13:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron,PRESS-RELEASE,GlobeNewswire,Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron
REGN,2023-08-29,13:01:16,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Celularity Announces Multi-Yr Research Collaboration Services Agreement With Regeneron,NEWS-FLASH,Dow Jones Newswires,Celularity Announces Multi-Yr Research Collaboration Services Agreement With Regeneron
REGN,2023-09-01,20:28:08,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp McCourt Registers 250 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,VP McCourt Registers 250 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-09-06,12:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Onconano and Regeneron Enter into Clinical Trial Supply Agreement,PRESS-RELEASE,Business Wire,OncoNano and Regeneron Enter into Clinical Trial Supply Agreement for Use of Libtayo(R) (cemiplimab) in ONM-501 Study
REGN,2023-09-06,20:04:21,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp McCourt Sells 250 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP McCourt Sells 250 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-09-08,20:45:00,589803,Regeneron Pharmaceuticals Inc.,99,0.47,labor-issues,,Regeneron Pharmaceuticals Inc.: I am thrilled to join Regeneron's Board of Directors,PRESS-RELEASE,GlobeNewswire,Regeneron Announces Updates to Board of Directors
REGN,2023-09-08,20:45:01,589803,Regeneron Pharmaceuticals Inc.,99,0.47,labor-issues,,Regeneron Pharmaceuticals Inc.: I am thrilled to join Regeneron's Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces Updates to Board of Directors
REGN,2023-09-08,20:46:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.49,labor-issues,,"Chief Financial Officer of Regeneron, will retire in February 2024",PRESS-RELEASE,GlobeNewswire,Regeneron Provides Update on Planned Chief Financial Officer Transition
REGN,2023-09-08,20:46:01,589803,Regeneron Pharmaceuticals Inc.,99,-0.49,labor-issues,,"Chief Financial Officer of Regeneron, will retire in February 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Provides Update on Planned Chief Financial Officer Transition
REGN,2023-09-08,20:46:56,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,labor-issues,,"Executive Vice Pres, Finance and Chief Fincl Officer of Regeneron, Will Retire in Feb 2024",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharma: Robert E. Landry, Executive Vice Pres, Finance and Chief Fincl Officer of Regeneron, Will Retire in Feb 2024 >REGN"
REGN,2023-09-08,20:46:56,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,labor-issues,,"Executive Vice Pres, Finance and Chief Fincl Officer of Regeneron, Will Retire in Feb 2024",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharma: Robert E. Landry, Executive Vice Pres, Finance and Chief Fincl Officer of Regeneron, Will Retire in Feb 2024 >REGN"
REGN,2023-09-08,20:54:07,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,labor-issues,,Regeneron Finance Chief Robert Landry to Retire,FULL-ARTICLE,Dow Jones Newswires,Regeneron Finance Chief Robert Landry to Retire
REGN,2023-09-08,21:03:55,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,labor-issues,,Regeneron CFO Landry To Retire,FULL-ARTICLE,Dow Jones Newswires,"Regeneron CFO Landry To Retire, Top Accountant Fenimore To Become CFO -- MarketWatch"
REGN,2023-09-08,21:03:55,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,labor-issues,,Regeneron Pharmaceuticals Inc. (REGN) said late Friday that Chief Financial Officer Robert E. Landry will retire in February,FULL-ARTICLE,MarketWatch,"MW Regeneron CFO Landry to retire, top accountant Fenimore to become CFO"
REGN,2023-09-08,21:09:07,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,labor-issues,,Regeneron Finance Chief Robert Landry to Retire,FULL-ARTICLE,Dow Jones Newswires,Regeneron Finance Chief Robert Landry to Retire
REGN,2023-09-15,13:56:16,589803,Regeneron Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Regeneron Pharma Initiated at Hold by WestPark Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Initiated at Hold by WestPark Capital
REGN,2023-09-15,15:13:16,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Argus Research
REGN,2023-09-15,15:13:16,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $920.00/Share From $825.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $920.00/Share From $825.00 by Argus Research
REGN,2023-09-20,13:00:20,589803,Regeneron Pharmaceuticals Inc.,98,0.49,partnerships,,Target collaboration with Regeneron (Nasdaq: REGN) to,PRESS-RELEASE,Dow Jones Newswires,Press Release: AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
REGN,2023-09-20,13:00:46,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Discovery Collaboration With Regeneron for,NEWS-FLASH,Dow Jones Newswires,AbCellera Expands Multi-Target Antibody Discovery Collaboration With Regeneron for Up to 8 Targets
REGN,2023-09-20,21:02:00,589803,Regeneron Pharmaceuticals Inc.,97,0.49,partnerships,,Target collaboration with Regeneron (Nasdaq: REGN) to,PRESS-RELEASE,Business Wire,CORRECTING AND REPLACING/ AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
REGN,2023-09-25,12:34:45,589803,Regeneron Pharmaceuticals Inc.,100,0.57,acquisitions-mergers,completed,Regeneron Completes Acquisition of Decibel Therapeutics,PRESS-RELEASE,GlobeNewswire,"Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss"
REGN,2023-09-25,12:34:45,589803,Regeneron Pharmaceuticals Inc.,100,0.41,products-services,start,First participant being administered with DB-OTO,PRESS-RELEASE,GlobeNewswire,"Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss"
REGN,2023-09-25,12:34:45,589803,Regeneron Pharmaceuticals Inc.,100,0.57,acquisitions-mergers,completed,Regeneron Completes Acquisition of Decibel -2,PRESS-RELEASE,GlobeNewswire,Regeneron Completes Acquisition of Decibel -2-
REGN,2023-09-25,12:34:45,589803,Regeneron Pharmaceuticals Inc.,100,0.57,acquisitions-mergers,completed,Regeneron Completes Acquisition Of Decibel Therapeutics,NEWS-FLASH,Dow Jones Newswires,"Regeneron Completes Acquisition Of Decibel Therapeutics, Adding Promising Gene Therapy Programs For Hearing Loss >REGN"
REGN,2023-09-25,12:34:45,589803,Regeneron Pharmaceuticals Inc.,100,0.57,acquisitions-mergers,completed,Regeneron Completes Acquisition Of Decibel Therapeutics,NEWS-FLASH,Dow Jones Newswires,"Regeneron Completes Acquisition Of Decibel Therapeutics, Adding Promising Gene Therapy Programs For Hearing Loss >REGN"
REGN,2023-09-25,12:34:48,589803,Regeneron Pharmaceuticals Inc.,100,0.57,acquisitions-mergers,completed,Regeneron Completes Acquisition of Decibel Therapeutics,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss"
REGN,2023-09-25,12:34:48,589803,Regeneron Pharmaceuticals Inc.,100,0.41,products-services,start,First participant being administered with DB-OTO,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss"
REGN,2023-09-25,12:34:48,589803,Regeneron Pharmaceuticals Inc.,100,0.57,acquisitions-mergers,completed,Regeneron Completes Acquisition of -2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Completes Acquisition of -2-
REGN,2023-09-25,21:13:21,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Ultragenyx Launches Evkeeza(R) (evinacumab for,PRESS-RELEASE,GlobeNewswire,Ultragenyx Launches Evkeeza(R) (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
REGN,2023-09-25,21:13:21,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Evkeeza is a first-in-class medicine approved by Health Canada,PRESS-RELEASE,GlobeNewswire,Ultragenyx Launches Evkeeza(R) (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
REGN,2023-09-25,21:13:24,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Ultragenyx Launches Evkeeza(R) (evinacumab for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Ultragenyx Launches Evkeeza(R) (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
REGN,2023-09-25,21:13:24,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Evkeeza is a first-in-class medicine approved by Health Canada,PRESS-RELEASE,Dow Jones Newswires,Press Release: Ultragenyx Launches Evkeeza(R) (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
REGN,2023-09-25,21:14:05,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,Ultragenyx Pharma: Launched Evkeeza in,NEWS-FLASH,Dow Jones Newswires,Ultragenyx Pharma: Launched Evkeeza in Canadato Treat Homozygous Familial Hypercholesterolemia >RARE
REGN,2023-09-25,21:42:14,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Evkeeza Gets Canadian Approval,FULL-ARTICLE,Dow Jones Newswires,Ultragenyx Says the Cholesterol Evkeeza Gets Canadian Approval
REGN,2023-09-25,21:57:14,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Evkeeza Gets Canadian Approval,FULL-ARTICLE,Dow Jones Newswires,Ultragenyx Says the Cholesterol Evkeeza Gets Canadian Approval
REGN,2023-09-26,05:36:56,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent Is Approved in US,NEWS-FLASH,Dow Jones Newswires,"Sanofi: Dupixent Is Approved in US for Children, Adults Aged 12 Years and Older"
REGN,2023-09-28,20:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report Third Quarter 2023 Financial and Operating Results,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023"
REGN,2023-09-28,20:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023"
REGN,2023-09-29,12:31:37,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Gets FDA Priority Review of Odronextamab,NEWS-FLASH,Dow Jones Newswires,"Regeneron Gets FDA Priority Review of Odronextamab in Relapsed/Refractory Follicular Lymphoma, Diffuse Large B-cell Lymphoma"
REGN,2023-09-29,12:41:59,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Gets FDA Priority Review of Odronextamab,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Gets FDA Priority Review of Odronextamab in Follicular, Diffuse Large B-cell Lymphoma"
REGN,2023-09-29,12:56:59,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Gets FDA Priority Review of Odronextamab,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Gets FDA Priority Review of Odronextamab in Follicular, Diffuse Large B-cell Lymphoma"
REGN,2023-10-02,20:21:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,038 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,038 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-10-03,11:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Intellia Announce Expanded Research Collaboration,PRESS-RELEASE,GlobeNewswire,Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
REGN,2023-10-03,11:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Intellia Announce Expanded Research Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
REGN,2023-10-03,11:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Intellia Announce Expanded Research Collaboration,PRESS-RELEASE,GlobeNewswire,Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
REGN,2023-10-03,11:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Intellia Announce Expanded Research Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
REGN,2023-10-03,20:05:08,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,038 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,038 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-10-05,20:08:02,589803,Regeneron Pharmaceuticals Inc.,100,-0.45,equity-actions,charge,Regeneron Pharmaceuticals Sees 3Q IPR&D Charge of $100M,RNS-SEC8K,Dow Jones Newswires,Regeneron Pharmaceuticals Sees 3Q IPR&D Charge of $100M Pretax
REGN,2023-10-05,20:08:45,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Sees 3Q EPS Effect of About 78c,RNS-SEC8K,Dow Jones Newswires,Regeneron Pharmaceuticals Sees 3Q EPS Effect of About 78c
REGN,2023-10-11,14:54:52,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley
REGN,2023-10-11,14:54:52,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $915.00/Share From $912.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $915.00/Share From $912.00 by Morgan Stanley
REGN,2023-10-12,17:03:26,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital
REGN,2023-10-12,17:03:26,589803,Regeneron Pharmaceuticals Inc.,100,0.32,price-targets,upgrade,Regeneron Pharma Price Target Raised to $847.00/Share From $833.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $847.00/Share From $833.00 by RBC Capital
REGN,2023-10-13,20:03:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Zoghbi Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Zoghbi Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-10-15,22:05:23,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Libtayo A Phase 2 Study of,PRESS-RELEASE,GlobeNewswire,Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO
REGN,2023-10-15,22:05:23,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The extensive clinical program for Libtayo,PRESS-RELEASE,GlobeNewswire,Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO
REGN,2023-10-16,16:47:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Neutral by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Neutral by Cantor Fitzgerald
REGN,2023-10-16,16:47:01,589803,Regeneron Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Regeneron Pharma Price Target Raised to $850.00/Share From $800.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $850.00/Share From $800.00 by Cantor Fitzgerald
REGN,2023-10-17,20:07:32,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Zoghbi Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Zoghbi Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-10-18,13:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Regeneron will collaborate with the Nashville STEM ecosystem to support,PRESS-RELEASE,GlobeNewswire,"Regeneron builds on Together for CHANGE(TM) initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN"
REGN,2023-10-18,13:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,GlobeNewswire,"Regeneron builds on Together for CHANGE(TM) initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN"
REGN,2023-10-18,13:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Regeneron will collaborate with the Nashville STEM ecosystem to support,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron builds on Together for CHANGE(TM) initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN"
REGN,2023-10-18,13:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron builds on Together for CHANGE(TM) initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN"
REGN,2023-10-20,21:00:37,589803,Regeneron Pharmaceuticals Inc.,96,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,GlobeNewswire,Regeneron and Sanofi Provide Update on Dupixent(R) (dupilumab) sBLA for Chronic Spontaneous Urticaria
REGN,2023-10-20,21:00:37,589803,Regeneron Pharmaceuticals Inc.,96,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,GlobeNewswire,Regeneron and Sanofi Provide Update on Dupixent(R) (dupilumab) sBLA for Chronic Spontaneous Urticaria
REGN,2023-10-20,21:00:38,589803,Regeneron Pharmaceuticals Inc.,96,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron and Sanofi Provide Update on Dupixent(R) (dupilumab) sBLA for Chronic Spontaneous Urticaria
REGN,2023-10-20,21:00:38,589803,Regeneron Pharmaceuticals Inc.,96,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron and Sanofi Provide Update on Dupixent(R) (dupilumab) sBLA for Chronic Spontaneous Urticaria
REGN,2023-10-26,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001,PRESS-RELEASE,GlobeNewswire,Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November
REGN,2023-10-26,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Discovery, development and commercialization collaboration with Regeneron",PRESS-RELEASE,GlobeNewswire,Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November
REGN,2023-10-26,20:00:07,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Collaboration between Regeneron and Decibel Therapeutics,PRESS-RELEASE,GlobeNewswire,Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss
REGN,2023-10-26,20:00:07,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Regeneron Pharmaceuticals Inc.: In September 2023, Regeneron acquired Decibel Therapeutics",PRESS-RELEASE,GlobeNewswire,Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss
REGN,2023-10-26,20:00:08,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Collaboration between Regeneron and Decibel Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss
REGN,2023-10-26,20:00:08,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Regeneron Pharmaceuticals Inc.: In September 2023, Regeneron acquired Decibel Therapeutics",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss
REGN,2023-11-01,20:52:13,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP McCourt Registers 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2023",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Third quarter 2023 revenues increased 15% to $3.36 billion,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Third quarter 2023 U.S. net sales,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Third quarter 2023 GAAP diluted EPS of $8.89,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: FDA approved EYLEA HD,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Two-year results,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Pharmaceuticals Inc.: FDA accepted for priority review BLA for odronextamab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquisition of Decibel Therapeutics,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,363 $ 2,936",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: An ongoing Phase 3 clinical trial (in,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Phase 3 studies were initiated for odronextamab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.69,products-services,,Regeneron Pharmaceuticals Inc.: The FDA granted Fast Track designation,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,acquisitions-mergers,completed,"Regeneron Pharmaceuticals Inc.: In September 2023, the Company completed its acquisition of Decibel Therapeutics, Inc.",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Regeneron Pharmaceuticals Inc.: the Company and Intellia Therapeutics, Inc. expanded their existing collaboration",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,-0.49,labor-issues,,"Chief Financial Officer of Regeneron, will retire in February 2024",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.47,labor-issues,,"Regeneron Pharmaceuticals Inc.: D., joined the Company's Board of Directors effective September 8, 2023",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Third Quarter 2023 Financial Results ------,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,363 $ 2,936",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA in the U.S. decreased in the third quarter of 2023,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,"August 2023, the FDA approved EYLEA HD",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the third quarter,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D expense in the third quarter of 2023,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $8.89 in the third quarter of 2023,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.4,earnings,up,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $11.59 in the third quarter of 2023, compared to $11.14 in the third quarter of 2022",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the third quarter of 2023, the Company repurchased shares of its common stock",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2023 Financial Guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2023 financial guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -3-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its third quarter 2023 financial and operating results on Thursday, November 2, 2023, at 8:30 AM Eastern Time",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -3-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: Total assets $ 32,163.3 $ 29,214.5",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -4-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -4-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Net income $1,007.8 $1,315.7",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -4-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 9.48 $ 12.31 $,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -4-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,96,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $1,007.8 $1,315.7",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -5-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,96,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,329.1 $1,270.4",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -5-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,96,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 12.50 $ 11.88 $,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -5-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,96,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -5-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Third Quarter 2023 Financial Results",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -6-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.0,revenues,,Regeneron Pharmaceuticals Inc.: net product sales of ARCALYST were $54 million,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2023 Financial -6-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 3Q EPS $8.89,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q EPS $8.89 >REGN
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 3Q Net $1.01B,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q Net $1.01B >REGN
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 3Q Rev $3.36B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q Rev $3.36B >REGN
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Third quarter 2023 revenues increased 15% to $3.36 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Third quarter 2023 U.S. net sales,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Third quarter 2023 GAAP diluted EPS of $8.89,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: FDA approved EYLEA HD,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Two-year results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Pharmaceuticals Inc.: FDA accepted for priority review BLA for odronextamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquisition of Decibel Therapeutics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,363 $ 2,936",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: An ongoing Phase 3 clinical trial (in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Phase 3 studies were initiated for odronextamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.69,products-services,,Regeneron Pharmaceuticals Inc.: The FDA granted Fast Track designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,acquisitions-mergers,completed,"Regeneron Pharmaceuticals Inc.: In September 2023, the Company completed its acquisition of Decibel Therapeutics, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Regeneron Pharmaceuticals Inc.: the Company and Intellia Therapeutics, Inc. expanded their existing collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2023 Financial and Operating Results
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,-0.49,labor-issues,,"Chief Financial Officer of Regeneron, will retire in February 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.47,labor-issues,,"Regeneron Pharmaceuticals Inc.: D., joined the Company's Board of Directors effective September 8, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Third Quarter 2023 Financial Results ------,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,363 $ 2,936",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA in the U.S. decreased in the third quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,"August 2023, the FDA approved EYLEA HD",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the third quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D expense in the third quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $8.89 in the third quarter of 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.4,earnings,up,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $11.59 in the third quarter of 2023, compared to $11.14 in the third quarter of 2022",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the third quarter of 2023, the Company repurchased shares of its common stock",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2023 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -3-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its third quarter 2023 financial and operating results on Thursday, November 2, 2023, at 8:30 AM Eastern Time",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -3-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: Total assets $ 32,163.3 $ 29,214.5",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Net income $1,007.8 $1,315.7",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2023-11-02,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 9.48 $ 12.31 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2023-11-02,10:30:02,589803,Regeneron Pharmaceuticals Inc.,96,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $1,007.8 $1,315.7",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -5-
REGN,2023-11-02,10:30:02,589803,Regeneron Pharmaceuticals Inc.,96,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,329.1 $1,270.4",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -5-
REGN,2023-11-02,10:30:02,589803,Regeneron Pharmaceuticals Inc.,96,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 12.50 $ 11.88 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -5-
REGN,2023-11-02,10:30:02,589803,Regeneron Pharmaceuticals Inc.,96,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -5-
REGN,2023-11-02,10:30:02,589803,Regeneron Pharmaceuticals Inc.,94,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Third Quarter 2023 Financial Results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -6-
REGN,2023-11-02,10:30:02,589803,Regeneron Pharmaceuticals Inc.,94,0.0,revenues,,Regeneron Pharmaceuticals Inc.: net product sales of ARCALYST were $54 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -6-
REGN,2023-11-02,10:36:23,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 3Q Adj EPS $11.59,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q Adj EPS $11.59 >REGN
REGN,2023-11-02,10:37:01,589803,Regeneron Pharmaceuticals Inc.,100,0.48,revenues,up,Regeneron Pharma: 3Q Dupixent Global Net Sales Recorded by Sanofi Rose 33%,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma: 3Q Dupixent Global Net Sales Recorded by Sanofi Rose 33% to $3.1B >REGN
REGN,2023-11-02,10:38:09,589803,Regeneron Pharmaceuticals Inc.,100,0.66,revenues,up,Regeneron Pharma 3Q Libtayo Global Net Sales Rose 62% to $232M,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q Libtayo Global Net Sales Rose 62% to $232M >REGN
REGN,2023-11-02,10:38:26,589803,Regeneron Pharmaceuticals Inc.,100,-0.67,earnings,down,Regeneron Pharma 3Q EPS Cut 77c,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q EPS Cut 77c by In-Process R&D Charges >REGN
REGN,2023-11-02,10:48:25,589803,Regeneron Pharmaceuticals Inc.,92,-0.42,earnings,down,Regeneron said its third-quarter net income fell 23% to $1 billion,FULL-ARTICLE,MarketWatch,MW Regeneron Pharma adjusted earnings beat estimates
REGN,2023-11-02,10:48:25,589803,Regeneron Pharmaceuticals Inc.,92,-0.42,earnings,down,Regeneron said its third-quarter net income fell 23% to $1 billion,FULL-ARTICLE,Dow Jones Newswires,Regeneron Pharma Adjusted Earnings Beat Estimates -- MarketWatch
REGN,2023-11-02,10:52:03,589803,Regeneron Pharmaceuticals Inc.,92,-0.42,earnings,down,Regeneron said its third-quarter net income fell 23% to $1 billion,FULL-ARTICLE,MarketWatch,MW Regeneron Pharma's adjusted earnings beat estimates
REGN,2023-11-02,10:52:03,589803,Regeneron Pharmaceuticals Inc.,92,-0.42,earnings,down,Regeneron said its third-quarter net income fell 23% to $1 billion,FULL-ARTICLE,Dow Jones Newswires,Update: Regeneron Pharma's Adjusted Earnings Beat Estimates -- MarketWatch
REGN,2023-11-02,11:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001,PRESS-RELEASE,GlobeNewswire,Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting
REGN,2023-11-02,11:00:07,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Discovery, development and commercialization collaboration with Regeneron",PRESS-RELEASE,GlobeNewswire,Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting
REGN,2023-11-02,11:00:08,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001,PRESS-RELEASE,Dow Jones Newswires,Press Release: Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting
REGN,2023-11-02,11:00:08,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Discovery, development and commercialization collaboration with Regeneron",PRESS-RELEASE,Dow Jones Newswires,Press Release: Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting
REGN,2023-11-02,11:09:21,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Intellia Presents New Interim Data From the Ongoing Phase 1 Study of NTLA-2001,NEWS-FLASH,Dow Jones Newswires,Intellia Presents New Interim Data From the Ongoing Phase 1 Study of NTLA-2001 at the 4th Intl ATTR Amyloidosis Meeting
REGN,2023-11-02,13:38:55,589803,Regeneron Pharmaceuticals Inc.,95,0.61,earnings,positive,Regeneron Pharmaceuticals reported third-quarter earnings of $11.58 per share,FULL-ARTICLE,Dow Jones Newswires,Regeneron Edges Higher On Third-Quarter Beat As High-Dose Eylea Delivers -- IBD
REGN,2023-11-02,13:38:55,589803,Regeneron Pharmaceuticals Inc.,95,0.0,earnings,,Factset expected Regeneron to earn $10.73 per share,FULL-ARTICLE,Dow Jones Newswires,Regeneron Edges Higher On Third-Quarter Beat As High-Dose Eylea Delivers -- IBD
REGN,2023-11-02,16:10:25,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Bayer reports Eylea sales,FULL-ARTICLE,Dow Jones Newswires,Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers -- IBD
REGN,2023-11-02,16:10:25,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron's sales climbed 15% to $3.36 billion,FULL-ARTICLE,Dow Jones Newswires,Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers -- IBD
REGN,2023-11-02,16:10:25,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Sanofi collaborate on Dupixent,FULL-ARTICLE,Dow Jones Newswires,Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers -- IBD
REGN,2023-11-02,20:04:18,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Sells 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-11-02,20:07:16,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Bayer reports Eylea sales,FULL-ARTICLE,Dow Jones Newswires,Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers -- IBD
REGN,2023-11-02,20:07:16,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron's sales climbed 15% to $3.36 billion,FULL-ARTICLE,Dow Jones Newswires,Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers -- IBD
REGN,2023-11-02,20:07:16,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron and Sanofi collaborate on Dupixent,FULL-ARTICLE,Dow Jones Newswires,Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers -- IBD
REGN,2023-11-03,09:45:37,589803,Regeneron Pharmaceuticals Inc.,100,0.82,analyst-ratings,positive,Regeneron Pharma Raised to Outperform From Market Perform by Raymond James,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Raised to Outperform From Market Perform by Raymond James
REGN,2023-11-03,09:45:37,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $950.00/Share by Raymond James,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $950.00/Share by Raymond James
REGN,2023-11-03,11:00:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,"Regeneron Pharmaceuticals Inc.: Additionally, two presentations will review the latest results from three Phase 2 studies",PRESS-RELEASE,GlobeNewswire,Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
REGN,2023-11-03,11:28:13,589803,Regeneron Pharmaceuticals Inc.,100,0.82,analyst-ratings,positive,Regeneron upgraded to outperform at Raymond James,FULL-ARTICLE,MarketWatch,MW Regeneron upgraded to outperform at Raymond James
REGN,2023-11-03,13:33:57,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley
REGN,2023-11-03,13:33:57,589803,Regeneron Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Regeneron Pharma Price Target Cut to $914.00/Share From $915.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $914.00/Share From $915.00 by Morgan Stanley
REGN,2023-11-03,19:32:48,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital
REGN,2023-11-03,19:32:48,589803,Regeneron Pharmaceuticals Inc.,100,-0.24,price-targets,downgrade,Regeneron Pharma Price Target Cut to $837.00/Share From $847.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $837.00/Share From $847.00 by RBC Capital
REGN,2023-11-03,21:25:08,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Piper Sandler
REGN,2023-11-03,21:25:08,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $895.00/Share From $885.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $895.00/Share From $885.00 by Piper Sandler
REGN,2023-11-07,21:48:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Ryan Registers 300 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Ryan Registers 300 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-11-08,21:09:10,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-11-09,10:21:49,589803,Regeneron Pharmaceuticals Inc.,100,0.01,analyst-ratings,neutral,Regeneron Pharma Initiated at Hold by Deutsche Bank,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Initiated at Hold by Deutsche Bank
REGN,2023-11-09,10:21:49,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $800.00/Share by Deutsche Bank,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $800.00/Share by Deutsche Bank
REGN,2023-11-13,13:00:01,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Strong relationship with Regeneron to,PRESS-RELEASE,Business Wire,Ankyra Therapeutics Announces Clinical Trial Supply Agreement with Regeneron to Evaluate ANK-101 in Combination with Libtayo(R) (cemiplimab) in Patients with Cutaneous Squamous Cell Carcinoma
REGN,2023-11-13,14:00:02,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,GlobeNewswire,Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)
REGN,2023-11-13,14:00:03,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)
REGN,2023-11-14,21:24:29,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Murphy Registers 6,492 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Murphy Registers 6,492 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-11-14,22:19:25,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,Vp Stahl Gifts 400 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,VP Stahl Gifts 400 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-11-15,21:04:34,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Murphy Sells 6,492 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Murphy Sells 6,492 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-11-19,08:35:32,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals Inc, Inst Holders, 3Q 2023 (REGN)",RNS-SEC13F,Dow Jones Newswires,"Regeneron Pharmaceuticals  Inc, Inst Holders, 3Q 2023 (REGN)"
REGN,2023-11-22,08:40:52,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Decibel THERAPEUTICS INC COM, Inst Holders, 3Q 2023 (DBTX)",RNS-SEC13F,Dow Jones Newswires,"DECIBEL THERAPEUTICS INC  COM, Inst Holders, 3Q 2023 (DBTX)"
REGN,2023-11-27,07:10:34,589803,Regeneron Pharmaceuticals Inc.,100,0.62,products-services,positive,Sanofi Says Notus Phase 3 Trial of Dupixent Met Primary Endpoint,FULL-ARTICLE,Dow Jones Newswires,Sanofi Says Notus Phase 3 Trial of Dupixent Met Primary Endpoint
REGN,2023-11-27,07:25:34,589803,Regeneron Pharmaceuticals Inc.,100,0.62,products-services,positive,Sanofi Says Notus Phase 3 Trial of Dupixent Met Primary Endpoint,FULL-ARTICLE,Dow Jones Newswires,Sanofi Says Notus Phase 3 Trial of Dupixent Met Primary Endpoint
REGN,2023-11-27,15:30:28,589803,Regeneron Pharmaceuticals Inc.,94,0.57,products-services,granted,Regeneron and Sanofi are planning to ask the Food and Drug Administration to approve their drug,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales -- IBD"
REGN,2023-11-27,15:30:28,589803,Regeneron Pharmaceuticals Inc.,94,-0.47,assets,expired,Dupixent's patents expire in 2032,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales -- IBD"
REGN,2023-11-27,21:28:01,589803,Regeneron Pharmaceuticals Inc.,94,0.57,products-services,granted,Regeneron and Sanofi are planning to ask the Food and Drug Administration to approve their drug,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales -- IBD"
REGN,2023-11-27,21:28:01,589803,Regeneron Pharmaceuticals Inc.,94,-0.47,assets,expired,Dupixent's patents expire in 2032,FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales -- IBD"
REGN,2023-11-28,19:36:11,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Jefferies
REGN,2023-11-28,19:36:11,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $937.00/Share From $935.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $937.00/Share From $935.00 by Jefferies
REGN,2023-11-30,21:05:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast",PRESS-RELEASE,GlobeNewswire,"Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio"
REGN,2023-11-30,21:05:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio"
REGN,2023-12-04,21:03:33,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Ryan Sells 100 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-12-05,21:06:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Murphy Registers 6,536 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Murphy Registers 6,536 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-12-06,17:44:51,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by TD Cowen
REGN,2023-12-06,17:44:51,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $1000.00/Share From $900.00 by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $1000.00/Share From $900.00 by TD Cowen
REGN,2023-12-06,21:04:10,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Murphy Sells 6,536 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Murphy Sells 6,536 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-12-07,07:30:59,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The extensive clinical program for Libtayo,PRESS-RELEASE,GlobeNewswire,Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO
REGN,2023-12-07,07:31:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The extensive clinical program for Libtayo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO
REGN,2023-12-11,21:18:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Vp McCourt Registers 270 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,VP McCourt Registers 270 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-12-12,21:02:22,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Cfo Landry Surrenders 4,234 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Landry Surrenders 4,234 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-12-12,21:02:47,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Larosa Surrenders 1,521 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Larosa Surrenders 1,521 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-12-12,21:02:53,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Fenimore Surrenders 2,010 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Fenimore Surrenders 2,010 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-12-12,21:05:33,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Vp McCourt Sells 270 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,VP McCourt Sells 270 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-12-12,21:05:58,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Murphy Surrenders 6,657 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Murphy Surrenders 6,657 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-12-12,21:09:21,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Stahl Surrenders 1,534 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stahl Surrenders 1,534 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-12-12,21:10:42,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp van Plew Surrenders 4,329 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP van Plew Surrenders 4,329 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-12-13,16:45:32,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,Dir Bassler Registers 610 Of Regeneron Pharmaceuticals Inc >REGN,RNS-SEC144,Dow Jones Newswires,Dir Bassler Registers 610 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-12-13,21:07:15,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Chmn Schleifer Acquires 12,314 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Schleifer Acquires 12,314 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-12-13,21:07:44,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Chmn Yancopoulos Acquires 12,314 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Yancopoulos Acquires 12,314 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-12-14,21:09:07,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,Dir Bassler Sells 610 Of Regeneron Pharmaceuticals Inc,TABULAR-MATERIAL,Dow Jones Newswires,Dir Bassler Sells 610 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-12-14,21:13:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Fenimore Surrenders 2,552 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Fenimore Surrenders 2,552 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-12-14,21:13:06,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Cfo Landry Acquires 1,000 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Landry Acquires 1,000 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-12-14,21:13:20,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp Murphy Surrenders 7,657 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP Murphy Surrenders 7,657 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-12-14,21:13:40,589803,Regeneron Pharmaceuticals Inc.,100,0.0,insider-trading,,"Vp McCourt Surrenders 5,105 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"VP McCourt Surrenders 5,105 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-12-21,21:24:58,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Vp Fenimore Registers 4,378 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"VP Fenimore Registers 4,378 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-12-26,21:09:49,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Fenimore Sells 1,930 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Fenimore Sells 1,930 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-12-27,21:24:27,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Brown Registers 2,049 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Brown Registers 2,049 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-12-29,21:06:07,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Vp Fenimore Sells 2,448 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"VP Fenimore Sells 2,448 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2023-12-29,21:06:58,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,Cfo Landry Acquires 446 Of Regeneron Pharmaceuticals Inc >REGN,TABULAR-MATERIAL,Dow Jones Newswires,CFO Landry Acquires 446 Of Regeneron Pharmaceuticals Inc >REGN
REGN,2023-12-29,21:07:49,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Brown Sells 2,049 Of Regeneron Pharmaceuticals Inc",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Brown Sells 2,049 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2025-01-03,21:04:11,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Dir Sing Acquires 1,390 Of Regeneron Pharmaceuticals Inc >REGN",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Sing Acquires 1,390 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2025-01-06,07:00:43,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission (EC) Extends the Approval of Evkeeza(R) (evinacumab),PRESS-RELEASE,DJ Global Press Release Wire,European Commission (EC) Extends the Approval of Evkeeza(R) (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)
REGN,2025-01-06,07:00:43,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission (EC) Extends the Approval of Evkeeza(R) (evinacumab),FULL-ARTICLE,Dow Jones Newswires,European Commission (EC) Extends the Approval of Evkeeza(R) (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)
REGN,2025-01-06,07:00:44,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,European Commission (EC) Extends the Approval of Evkeeza(R) (evinacumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: European Commission (EC) Extends the Approval of Evkeeza(R) (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)
REGN,2025-01-07,17:26:46,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by Bernstein
REGN,2025-01-07,17:26:46,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1070.00/Share From $1110.00 by Bernstein,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1070.00/Share From $1110.00 by Bernstein
REGN,2025-01-07,21:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025"
REGN,2025-01-07,21:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025"
REGN,2025-01-08,03:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,Business Wire,"REGN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit On Behalf Of Regeneron Pharmaceuticals, Inc. Investors"
REGN,2025-01-08,03:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,Business Wire,"REGN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit On Behalf Of Regeneron Pharmaceuticals, Inc. Investors"
REGN,2025-01-08,03:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,Business Wire,"REGN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit On Behalf Of Regeneron Pharmaceuticals, Inc. Investors"
REGN,2025-01-08,11:55:47,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Truist Securities
REGN,2025-01-08,11:55:47,589803,Regeneron Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1004.00/Share From $1126.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1004.00/Share From $1126.00 by Truist Securities
REGN,2025-01-08,19:53:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.6,legal,,"Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud",PRESS-RELEASE,Business Wire,"Law Offices of Frank R. Cruz Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action"
REGN,2025-01-08,19:53:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,Business Wire,"Law Offices of Frank R. Cruz Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action"
REGN,2025-01-08,19:53:00,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,Business Wire,"Law Offices of Frank R. Cruz Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action"
REGN,2025-01-08,21:30:35,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Class action lawsuit has been filed against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-01-08,21:39:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,Business Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-08,21:39:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,Business Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-08,21:39:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,Business Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-08,21:39:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,Business Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-08,21:45:42,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Class action lawsuit has been filed against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-01-08,22:07:45,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit"
REGN,2025-01-08,22:07:45,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron announced its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit"
REGN,2025-01-08,22:07:45,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit"
REGN,2025-01-08,23:11:55,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,GlobeNewswire,"Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)"
REGN,2025-01-09,00:30:23,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-01-09,02:29:23,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After,PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report-- Hagens Berman
REGN,2025-01-09,02:29:23,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron announced financial results for Q3 2024",PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report-- Hagens Berman
REGN,2025-01-09,12:01:54,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Class action lawsuit has been filed against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-01-09,17:16:36,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-09,19:25:03,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
REGN,2025-01-09,19:25:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron announced financial results for Q3 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
REGN,2025-01-09,20:00:48,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline"
REGN,2025-01-09,21:00:01,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-09,21:16:52,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors Who Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky About Pending Class Action - REGN"
REGN,2025-01-10,00:44:24,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-10,00:44:24,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-10,00:44:24,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-10,00:44:24,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-10,01:00:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REGN"
REGN,2025-01-10,12:02:11,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-01-10,12:31:06,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc. (REGN) of a Class Action Lawsuit and an Upcoming Deadline"
REGN,2025-01-10,13:38:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After,PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report-- Hagens Berman
REGN,2025-01-10,13:38:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron announced financial results for Q3 2024",PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report-- Hagens Berman
REGN,2025-01-10,14:01:54,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky"
REGN,2025-01-10,14:22:32,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Wells Fargo
REGN,2025-01-10,14:22:32,589803,Regeneron Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Regeneron Pharma Price Target Cut to $900.00/Share From $1050.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $900.00/Share From $1050.00 by Wells Fargo
REGN,2025-01-10,16:15:28,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-01-10,16:52:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-10,18:00:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-10,19:25:56,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-10,19:25:56,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron announced its third quarter 2024 financial results,PRESS-RELEASE,PR Newswire,"REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-10,19:25:56,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron reported sales had only increased 3%,PRESS-RELEASE,PR Newswire,"REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-10,19:45:12,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-10,19:49:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.6,legal,,"Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud",PRESS-RELEASE,Business Wire,"Law Offices of Howard G. Smith Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action"
REGN,2025-01-10,19:49:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,Business Wire,"Law Offices of Howard G. Smith Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action"
REGN,2025-01-10,19:49:00,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,Business Wire,"Law Offices of Howard G. Smith Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action"
REGN,2025-01-10,21:00:36,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-10,21:15:47,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-10,22:55:11,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel"
REGN,2025-01-10,22:55:11,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron released its third quarter 2024 financial results",PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel"
REGN,2025-01-10,22:55:11,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company's reported sales had only increased 3% year-over-year,PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel"
REGN,2025-01-10,22:55:11,589803,Regeneron Pharmaceuticals Inc.,100,0.46,legal,,"Regeneron Pharmaceuticals Inc.: whether by trial, settlement",PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel"
REGN,2025-01-10,23:15:20,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN"
REGN,2025-01-11,02:30:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,Business Wire,"REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-11,02:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron announced its third quarter 2024 financial results,PRESS-RELEASE,Business Wire,"REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-11,02:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron reported sales had only increased 3%,PRESS-RELEASE,Business Wire,"REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-11,23:12:59,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-12,12:02:45,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-01-12,13:13:53,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc.(REGN) of a Class Action Lawsuit and an Upcoming Deadline"
REGN,2025-01-12,13:44:26,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,Securities Fraud Lawsuit Against Regeneron Pharmaceuticals (REGN),PRESS-RELEASE,DJ Global Press Release Wire,STOCKHOLDER ALERT: Pending Securities Fraud Lawsuit Against Regeneron Pharmaceuticals (REGN)
REGN,2025-01-12,13:44:26,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,DJ Global Press Release Wire,STOCKHOLDER ALERT: Pending Securities Fraud Lawsuit Against Regeneron Pharmaceuticals (REGN)
REGN,2025-01-12,13:44:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-12,13:44:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-12,13:44:26,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-12,13:44:26,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-12,14:00:19,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against REGN,PRESS-RELEASE,DJ Global Press Release Wire,"March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN"
REGN,2025-01-12,15:47:21,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-01-12,16:06:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline"
REGN,2025-01-12,21:00:04,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,PR Newswire,"REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-12,21:24:13,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-13,10:48:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,Business Wire,"REGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-13,10:48:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron announced its third quarter 2024 financial results,PRESS-RELEASE,Business Wire,"REGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-13,10:48:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron reported sales had only increased 3%,PRESS-RELEASE,Business Wire,"REGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-13,11:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron Collaborates with Truveta and Leading American Health Systems to,PRESS-RELEASE,GlobeNewswire,Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
REGN,2025-01-13,11:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.46,equity-actions,,Regeneron investing $119.5 million in Truveta's Series,PRESS-RELEASE,GlobeNewswire,Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
REGN,2025-01-13,11:05:01,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Regeneron Collaborates with Truveta and Leading American Health Systems to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
REGN,2025-01-13,11:05:01,589803,Regeneron Pharmaceuticals Inc.,99,0.46,equity-actions,,Regeneron investing $119.5 million in Truveta's Series,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
REGN,2025-01-13,11:05:32,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron Pharma Sets Strategic Collaboration With Truveta >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Sets Strategic Collaboration With Truveta >REGN
REGN,2025-01-13,11:05:41,589803,Regeneron Pharmaceuticals Inc.,100,0.46,equity-actions,,Regeneron Pharma Investing $119.5 Million in Truveta's Series,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Investing $119.5 Million in Truveta's Series C Financing Round >REGN
REGN,2025-01-13,11:06:31,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Regeneron: Collaborating With Truveta, U.S. Health Systems to",NEWS-FLASH,Dow Jones Newswires,"Regeneron: Collaborating With Truveta, U.S. Health Systems to Massively Extend DNA Sequence-Linked Healthcare Database >REGN"
REGN,2025-01-13,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,Regeneron collaborates with Truveta and leading American health systems to,PRESS-RELEASE,GlobeNewswire,Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
REGN,2025-01-13,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Odronextamab) has been approved in the European Union,PRESS-RELEASE,GlobeNewswire,Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
REGN,2025-01-13,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Odronextamab is approved in the European Union,PRESS-RELEASE,GlobeNewswire,Regeneron Provides Business Updates and -2-
REGN,2025-01-13,11:35:46,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,"Regeneron: 2024 Eylea HD, Eylea U.S. Net Product Sales $6 Billion, Up 1%",NEWS-FLASH,Dow Jones Newswires,"Regeneron: 2024 Eylea HD, Eylea U.S. Net Product Sales $6 Billion, Up 1% >REGN"
REGN,2025-01-13,12:02:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc.. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-01-13,12:30:40,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More"
REGN,2025-01-13,14:23:06,589803,Regeneron Pharmaceuticals Inc.,95,-0.75,revenues,below-expectations,"Regeneron Pharmaceuticals' Eylea HD generated $305 million in U.S. sales, missing forecasts",FULL-ARTICLE,Dow Jones Newswires,Regeneron Pharmaceuticals Slumps As Sales Of High-Dose Eylea Disappoint -- IBD
REGN,2025-01-13,15:42:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After,PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report-- Hagens Berman
REGN,2025-01-13,15:42:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron announced financial results for Q3 2024",PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report-- Hagens Berman
REGN,2025-01-13,16:22:44,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky"
REGN,2025-01-13,16:45:30,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-13,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,Business Wire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-01-13,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,Business Wire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-01-13,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,Business Wire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-01-13,17:29:38,589803,Regeneron Pharmaceuticals Inc.,100,0.64,earnings,up,Regeneron Culls Losses,FULL-ARTICLE,Dow Jones Newswires,Regeneron Culls Losses After High-Dose Eylea Sales Disappoint -- IBD
REGN,2025-01-13,17:29:38,589803,Regeneron Pharmaceuticals Inc.,100,-0.75,revenues,below-expectations,"Regeneron Pharmaceuticals' Eylea HD generated $305 million in U.S. sales, missing forecasts",FULL-ARTICLE,Dow Jones Newswires,Regeneron Culls Losses After High-Dose Eylea Sales Disappoint -- IBD
REGN,2025-01-13,17:29:38,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,He has an overweight rating on Regeneron,FULL-ARTICLE,Dow Jones Newswires,Regeneron Culls Losses After High-Dose Eylea Sales Disappoint -- IBD
REGN,2025-01-13,20:44:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Securities class action lawsuit has been filed against REGENERON PHARMACEUTICALS, INC. (""Regeneron",PRESS-RELEASE,PR Newswire,"ATTENTION NASDAQ: REGN INVESTORS: Contact Berger Montague About a Regeneron Pharmaceuticals, Inc. Class Action Lawsuit"
REGN,2025-01-13,20:44:03,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,PR Newswire,"ATTENTION NASDAQ: REGN INVESTORS: Contact Berger Montague About a Regeneron Pharmaceuticals, Inc. Class Action Lawsuit"
REGN,2025-01-13,20:44:04,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Securities class action lawsuit has been filed against REGENERON PHARMACEUTICALS, INC. (""Regeneron",PRESS-RELEASE,Dow Jones Newswires,"Press Release: ATTENTION NASDAQ: REGN INVESTORS: Contact Berger Montague About a Regeneron Pharmaceuticals, Inc. Class Action Lawsuit"
REGN,2025-01-13,20:44:04,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,Dow Jones Newswires,"Press Release: ATTENTION NASDAQ: REGN INVESTORS: Contact Berger Montague About a Regeneron Pharmaceuticals, Inc. Class Action Lawsuit"
REGN,2025-01-13,21:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,Business Wire,"(BW) REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-13,21:16:01,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN"
REGN,2025-01-13,21:18:07,589803,Regeneron Pharmaceuticals Inc.,100,0.64,earnings,up,Regeneron Culls Losses,FULL-ARTICLE,Dow Jones Newswires,Regeneron Culls Losses After High-Dose Eylea Sales Disappoint -- IBD
REGN,2025-01-13,21:18:07,589803,Regeneron Pharmaceuticals Inc.,100,-0.75,revenues,below-expectations,"Regeneron Pharmaceuticals' Eylea HD generated $305 million in U.S. sales, missing forecasts",FULL-ARTICLE,Dow Jones Newswires,Regeneron Culls Losses After High-Dose Eylea Sales Disappoint -- IBD
REGN,2025-01-13,21:18:07,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,He has an overweight rating on Regeneron,FULL-ARTICLE,Dow Jones Newswires,Regeneron Culls Losses After High-Dose Eylea Sales Disappoint -- IBD
REGN,2025-01-14,03:03:41,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-14,12:02:31,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-01-14,12:26:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky"
REGN,2025-01-14,13:19:41,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Neutral by Citigroup,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Neutral by Citigroup
REGN,2025-01-14,13:19:41,589803,Regeneron Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Regeneron Pharma Price Target Cut to $795.00/Share From $895.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $795.00/Share From $895.00 by Citigroup
REGN,2025-01-14,15:46:14,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Investor filed a lawsuit against Regeneron Pharmaceuticals, Inc. over alleged",PRESS-RELEASE,DJ Global Press Release Wire,"Investors Who Hold Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Should Contact the Shareholders Foundation in Connection With Lawsuit"
REGN,2025-01-14,16:01:13,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders"
REGN,2025-01-14,16:16:10,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-01-14,16:22:17,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-14,16:22:17,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-14,16:22:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-14,16:22:17,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-14,16:32:12,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN)"
REGN,2025-01-14,16:33:23,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against REGENERON PHARMACEUTICALS, INC. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. (REGN) Securities Fraud: Contact Berger Montague To Discuss Your Rights"
REGN,2025-01-14,16:33:23,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. (REGN) Securities Fraud: Contact Berger Montague To Discuss Your Rights"
REGN,2025-01-14,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,Business Wire,"Deadline Approaching: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged to Contact Law Offices of Howard G. Smith"
REGN,2025-01-14,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,Business Wire,"Deadline Approaching: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged to Contact Law Offices of Howard G. Smith"
REGN,2025-01-14,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,Business Wire,"Deadline Approaching: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged to Contact Law Offices of Howard G. Smith"
REGN,2025-01-14,17:01:05,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc.(REGN) Shareholders"
REGN,2025-01-14,21:05:05,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-14,21:05:05,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron announced its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-14,21:05:05,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-14,21:31:15,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN"
REGN,2025-01-14,21:31:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After,PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report - Hagens Berman
REGN,2025-01-14,21:31:37,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron announced financial results for Q3 2024",PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report - Hagens Berman
REGN,2025-01-15,12:02:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-01-15,12:31:36,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc. (REGN) of a Class Action Lawsuit and an Upcoming Deadline"
REGN,2025-01-15,15:34:04,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-15,15:34:04,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-15,15:34:04,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-15,15:34:04,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-15,15:47:05,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders"
REGN,2025-01-15,17:05:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-01-15,17:05:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-01-15,17:05:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-01-15,17:31:30,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-15,18:48:03,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,PR Newswire,"REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-01-15,18:48:04,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-01-15,19:10:33,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After,PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report -- Hagens Berman
REGN,2025-01-15,19:10:33,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron announced financial results for Q3 2024",PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report -- Hagens Berman
REGN,2025-01-15,19:15:57,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-16,02:15:47,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-16,12:24:13,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-01-16,14:16:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-01-16,14:28:06,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-16,14:28:06,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron announced its third quarter 2024 financial results,PRESS-RELEASE,PR Newswire,"REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-16,14:28:06,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron reported sales had only increased 3%,PRESS-RELEASE,PR Newswire,"REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-16,14:45:59,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN"
REGN,2025-01-16,20:22:56,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Regeneron Pharma Cut to Neutral From Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Cut to Neutral From Buy by UBS
REGN,2025-01-16,20:22:56,589803,Regeneron Pharmaceuticals Inc.,100,-0.84,price-targets,downgrade,Regeneron Pharma Price Target Cut to $738.00/Share From $1130.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $738.00/Share From $1130.00 by UBS
REGN,2025-01-16,21:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-16,22:36:25,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-16,22:36:25,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-16,22:36:25,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-16,22:36:25,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-16,23:16:32,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors who Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky about Pending Class Action - REGN"
REGN,2025-01-17,12:01:04,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-01-17,13:33:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,GlobeNewswire,"NASDAQ: REGN INVESTOR ALERT: Berger Montague Advises Regeneron Pharmaceuticals (NASDAQ: REGN) Investors of a March 10, 2025 Deadline"
REGN,2025-01-17,13:33:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,GlobeNewswire,"NASDAQ: REGN INVESTOR ALERT: Berger Montague Advises Regeneron Pharmaceuticals (NASDAQ: REGN) Investors of a March 10, 2025 Deadline"
REGN,2025-01-17,14:31:46,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-17,16:30:43,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders That Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More"
REGN,2025-01-17,17:31:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders"
REGN,2025-01-17,17:38:19,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After,PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report-- Hagens Berman
REGN,2025-01-17,17:38:19,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron announced financial results for Q3 2024",PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report-- Hagens Berman
REGN,2025-01-17,18:00:21,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline"
REGN,2025-01-17,18:30:55,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders That Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More"
REGN,2025-01-17,22:49:32,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-18,12:52:24,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-18,12:52:24,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-18,12:52:24,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-18,12:52:24,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-18,13:55:12,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"
REGN,2025-01-18,13:55:12,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron announced its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"
REGN,2025-01-18,13:55:12,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"
REGN,2025-01-18,16:16:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-01-18,17:03:05,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-01-18,17:03:05,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-01-18,17:03:05,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-01-18,23:22:14,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-18,23:50:42,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-19,12:01:28,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-01-19,13:18:57,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against REGN,PRESS-RELEASE,DJ Global Press Release Wire,"March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN"
REGN,2025-01-19,15:31:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc.(REGN) Shareholders"
REGN,2025-01-19,16:31:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors who lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN"
REGN,2025-01-19,21:00:35,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-19,21:15:55,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc.(REGN) of a Class Action Lawsuit and an Upcoming Deadline"
REGN,2025-01-20,12:01:19,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-01-20,12:36:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors who lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN"
REGN,2025-01-20,14:00:08,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,PR Newswire,"REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-01-20,14:00:08,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-01-20,15:01:50,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors who Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky About Pending Class Action - REGN"
REGN,2025-01-20,16:16:12,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-01-20,17:01:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders"
REGN,2025-01-20,19:56:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After,PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report -- Hagens Berman
REGN,2025-01-20,19:56:37,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron announced financial results for Q3 2024",PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report -- Hagens Berman
REGN,2025-01-20,21:00:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,PR Newswire,"REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-20,21:01:30,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders that Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More"
REGN,2025-01-20,21:33:47,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-21,11:09:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-21,11:09:03,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron announced its third quarter 2024 financial results,PRESS-RELEASE,PR Newswire,"REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-21,11:09:03,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron reported sales had only increased 3%,PRESS-RELEASE,PR Newswire,"REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-21,11:30:58,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Lawsuit - REGN"
REGN,2025-01-21,12:02:06,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-01-21,12:25:59,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN)"
REGN,2025-01-21,13:33:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Securities class action lawsuit has been filed against REGENERON PHARMACEUTICALS, INC. (""Regeneron",PRESS-RELEASE,GlobeNewswire,"INVESTOR REMINDER: Berger Montague Notifies Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors of a Class Action Lawsuit and Deadline"
REGN,2025-01-21,13:33:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,GlobeNewswire,"INVESTOR REMINDER: Berger Montague Notifies Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors of a Class Action Lawsuit and Deadline"
REGN,2025-01-21,13:47:01,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN"
REGN,2025-01-21,15:37:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-21,15:37:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-21,15:37:26,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-21,15:37:26,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-21,16:01:28,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-21,17:00:05,589803,Regeneron Pharmaceuticals Inc.,99,-0.64,legal,,"Securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"
REGN,2025-01-21,17:00:05,589803,Regeneron Pharmaceuticals Inc.,99,-0.64,legal,,"Securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"
REGN,2025-01-21,17:36:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations -- Investors Should Contact The Gross Law Firm for More Information -- REGN"
REGN,2025-01-21,19:31:21,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN"
REGN,2025-01-21,19:35:59,589803,Regeneron Pharmaceuticals Inc.,99,0.41,assets,open,In CANADA BY OPENING ITS FIRST HEADQUARTERS,PRESS-RELEASE,Canadian News Wire,REGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES
REGN,2025-01-21,19:35:59,589803,Regeneron Pharmaceuticals Inc.,99,0.41,assets,open,In CANADA BY OPENING ITS FIRST HEADQUARTERS,PRESS-RELEASE,Dow Jones Newswires,Press Release: REGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES
REGN,2025-01-21,21:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,Business Wire,"(BW) REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-21,21:00:32,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After,PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report - Hagens Berman
REGN,2025-01-21,21:00:32,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron announced financial results for Q3 2024",PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report - Hagens Berman
REGN,2025-01-21,22:50:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,PR Newswire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-21,22:50:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,PR Newswire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-21,22:50:02,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-21,23:30:49,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc.(REGN) Shareholders"
REGN,2025-01-22,07:06:24,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against REGENERON PHARMACEUTICALS, INC. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGENERON PHARMACEUTICALS SECURITIES FRAUD NOTICE: Berger Montague Informs Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors of Securities Fraud Lawsuit"
REGN,2025-01-22,07:06:24,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,DJ Global Press Release Wire,"REGENERON PHARMACEUTICALS SECURITIES FRAUD NOTICE: Berger Montague Informs Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors of Securities Fraud Lawsuit"
REGN,2025-01-22,07:20:26,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky"
REGN,2025-01-22,12:01:51,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-01-22,12:26:08,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky"
REGN,2025-01-22,15:16:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-01-22,15:16:59,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-22,15:16:59,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-22,15:16:59,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-22,15:45:34,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-22,16:32:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-22,16:32:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-22,16:32:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-22,16:32:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-22,17:01:09,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky"
REGN,2025-01-22,18:08:41,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-01-22,18:08:41,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-01-22,18:08:41,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-01-22,18:32:04,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors who Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky About Pending Class Action - REGN"
REGN,2025-01-22,18:39:44,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After,PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report-- Hagens Berman
REGN,2025-01-22,18:39:44,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron announced financial results for Q3 2024",PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report-- Hagens Berman
REGN,2025-01-22,19:32:57,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky"
REGN,2025-01-22,21:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,GlobeNewswire,"(PMZN) REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-22,21:30:41,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN"
REGN,2025-01-23,00:03:55,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky"
REGN,2025-01-23,07:55:53,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-23,12:02:38,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-01-23,12:30:50,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN"
REGN,2025-01-23,13:56:26,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron announced financial results for Q3 2024",PRESS-RELEASE,DJ Global Press Release Wire,Securities Class Action Allegations Cast Shadow Over Regeneron Pharmaceuticals (REGN)- Hagens Berman
REGN,2025-01-23,14:15:44,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against REGN,PRESS-RELEASE,DJ Global Press Release Wire,"March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN"
REGN,2025-01-23,15:49:07,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-23,17:00:04,589803,Regeneron Pharmaceuticals Inc.,99,-0.64,legal,,"Securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"
REGN,2025-01-23,17:00:04,589803,Regeneron Pharmaceuticals Inc.,99,-0.64,legal,,"Securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"
REGN,2025-01-23,17:00:14,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,GlobeNewswire,America's Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search
REGN,2025-01-23,17:00:14,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,Dow Jones Newswires,Press Release: America's Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search
REGN,2025-01-23,17:32:45,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-23,20:01:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-23,20:01:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-23,20:01:03,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,PR Newswire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-23,20:01:03,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,PR Newswire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-23,22:40:30,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"
REGN,2025-01-23,22:40:30,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron announced its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"
REGN,2025-01-23,22:40:30,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"
REGN,2025-01-24,12:01:12,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN Investors Have Opportunity to Lead Regeneron Therapeutics, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!"
REGN,2025-01-24,12:30:41,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-24,13:33:25,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Securities class action lawsuit has been filed against REGENERON PHARMACEUTICALS, INC. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN CLASS ACTION NOTICE: Berger Montague Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors to Inquire About a Securities Fraud Class Action"
REGN,2025-01-24,13:33:25,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,DJ Global Press Release Wire,"REGN CLASS ACTION NOTICE: Berger Montague Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors to Inquire About a Securities Fraud Class Action"
REGN,2025-01-24,14:01:07,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors Who Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky About Pending Class Action - REGN"
REGN,2025-01-24,14:42:39,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-24,14:42:39,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-24,14:42:39,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-24,14:42:39,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-24,15:15:47,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline"
REGN,2025-01-24,15:30:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After,PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report -- Hagens Berman
REGN,2025-01-24,15:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron announced financial results for Q3 2024",PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report -- Hagens Berman
REGN,2025-01-24,15:46:32,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky"
REGN,2025-01-24,16:15:55,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-01-24,16:47:34,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders"
REGN,2025-01-24,17:04:30,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-24,17:04:30,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-24,17:04:30,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-24,17:04:59,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-24,17:04:59,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-24,17:04:59,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-24,18:16:25,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky"
REGN,2025-01-24,19:45:19,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN)"
REGN,2025-01-24,21:00:35,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline"
REGN,2025-01-24,21:31:28,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky"
REGN,2025-01-25,23:37:58,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-26,12:01:22,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN Shareholders Have Opportunity to Lead Regeneron Therapeutics, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!"
REGN,2025-01-26,12:35:32,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-26,12:35:32,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-26,12:35:32,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-26,12:35:32,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-26,13:15:34,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc.(REGN) Shareholders"
REGN,2025-01-26,15:15:44,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"
REGN,2025-01-26,15:15:44,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron announced its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"
REGN,2025-01-26,15:15:44,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"
REGN,2025-01-26,15:16:18,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-01-26,16:08:27,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky"
REGN,2025-01-26,17:01:57,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-26,17:01:57,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-26,17:01:57,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-26,18:17:18,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN"
REGN,2025-01-26,19:01:06,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)"
REGN,2025-01-26,20:30:56,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN"
REGN,2025-01-27,07:06:25,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against REGENERON PHARMACEUTICALS, INC. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION REMINDER: Berger Montague Advises Regeneron Pharmaceuticals, Inc. (REGN) Investors to Inquire About a Securities Fraud Lawsuit by March 10, 2025"
REGN,2025-01-27,07:06:25,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION REMINDER: Berger Montague Advises Regeneron Pharmaceuticals, Inc. (REGN) Investors to Inquire About a Securities Fraud Lawsuit by March 10, 2025"
REGN,2025-01-27,07:30:24,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline"
REGN,2025-01-27,12:02:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN Stockholders Have Opportunity to Lead Regeneron Therapeutics, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!"
REGN,2025-01-27,12:26:40,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline"
REGN,2025-01-27,13:22:27,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron announced financial results for Q3 2024",PRESS-RELEASE,GlobeNewswire,Securities Class Action Allegations Cast Shadow Over Regeneron Pharmaceuticals (REGN)-- Hagens Berman
REGN,2025-01-27,13:47:44,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-27,15:07:09,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Piper Sandler
REGN,2025-01-27,15:07:09,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1013.00/Share From $1195.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1013.00/Share From $1195.00 by Piper Sandler
REGN,2025-01-27,16:01:17,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors who Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky About Pending Class Action - REGN"
REGN,2025-01-27,16:33:08,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders that Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More"
REGN,2025-01-27,22:07:03,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,PR Newswire,"REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-01-27,22:07:03,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-01-27,23:00:33,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky"
REGN,2025-01-28,00:00:23,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)"
REGN,2025-01-28,12:02:46,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Regeneron Therapeutics, Inc. to Contact the Firm Today!"
REGN,2025-01-28,12:43:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Neutral by Citigroup,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Neutral by Citigroup
REGN,2025-01-28,12:43:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.62,price-targets,downgrade,Regeneron Pharma Price Target Cut to $750.00/Share From $795.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $750.00/Share From $795.00 by Citigroup
REGN,2025-01-28,16:06:57,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-01-28,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-01-28,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-01-28,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-01-28,17:31:05,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-28,19:30:31,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After,PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report - Hagens Berman
REGN,2025-01-28,19:30:31,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron announced financial results for Q3 2024",PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report - Hagens Berman
REGN,2025-01-28,21:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-01-28,22:30:17,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-29,00:36:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-29,00:36:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-29,00:36:26,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-29,00:36:26,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-29,01:00:54,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky"
REGN,2025-01-29,01:31:49,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky"
REGN,2025-01-29,02:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
REGN,2025-01-29,02:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)",PRESS-RELEASE,GlobeNewswire,"REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
REGN,2025-01-29,02:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
REGN,2025-01-29,02:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
REGN,2025-01-29,02:31:05,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REGN"
REGN,2025-01-29,03:00:05,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,PR Newswire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-29,03:00:05,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,PR Newswire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-29,03:00:05,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-29,03:22:35,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky"
REGN,2025-01-29,07:06:27,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Investor Alert: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action
REGN,2025-01-29,07:06:27,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Investor Alert: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action
REGN,2025-01-29,07:46:14,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline"
REGN,2025-01-29,12:02:15,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-01-29,12:30:48,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky"
REGN,2025-01-29,15:57:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-29,15:57:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-29,15:57:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-29,15:57:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-29,16:30:50,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-29,16:33:04,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"
REGN,2025-01-29,16:33:04,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron announced its third quarter 2024 financial results,PRESS-RELEASE,PR Newswire,"REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"
REGN,2025-01-29,16:33:04,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron reported sales had only increased 3%,PRESS-RELEASE,PR Newswire,"REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"
REGN,2025-01-29,17:16:04,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Lawsuit - REGN"
REGN,2025-01-29,18:15:40,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders That Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky About Pending Class Action - REGN"
REGN,2025-01-29,21:47:14,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron announced financial results for Q3 2024",PRESS-RELEASE,GlobeNewswire,Securities Class Action Allegations Cast Shadow Over Regeneron Pharmaceuticals (REGN)-- Hagens Berman
REGN,2025-01-29,22:15:31,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky"
REGN,2025-01-30,05:00:49,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-30,05:00:49,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-30,05:00:49,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-01-30,05:12:25,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"testREGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline"
REGN,2025-01-30,12:01:16,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-01-30,12:26:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline"
REGN,2025-01-30,16:02:31,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-01-30,16:30:48,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky"
REGN,2025-01-30,17:42:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,GlobeNewswire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join -- Contact Levi & Korsinsky"
REGN,2025-01-30,19:25:24,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After,PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
REGN,2025-01-30,19:25:24,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron announced financial results for Q3 2024",PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
REGN,2025-01-30,19:45:20,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors who lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN"
REGN,2025-01-30,22:46:01,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-30,23:12:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-30,23:12:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-30,23:12:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,PR Newswire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-30,23:12:02,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,PR Newswire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-01-30,23:51:27,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-31,01:30:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against REGN,PRESS-RELEASE,DJ Global Press Release Wire,"March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN"
REGN,2025-01-31,12:01:18,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-01-31,12:30:23,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-01-31,15:32:31,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-31,15:32:31,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-31,15:32:31,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-31,15:32:31,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-31,16:02:29,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-01-31,16:45:23,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders That Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky About Pending Class Action - REGN"
REGN,2025-01-31,17:31:56,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky"
REGN,2025-01-31,20:40:27,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities class action lawsuit has been filed against REGENERON PHARMACEUTICALS, INC. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"ATTENTION REGENERON PHARMACEUTICALS, INC. (REGN) Shareholders: Securities Fraud Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (REGN)"
REGN,2025-01-31,20:40:27,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,DJ Global Press Release Wire,"ATTENTION REGENERON PHARMACEUTICALS, INC. (REGN) Shareholders: Securities Fraud Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (REGN)"
REGN,2025-01-31,21:00:37,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN"
REGN,2025-01-31,22:50:03,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,PR Newswire,"REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-01-31,22:50:03,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-01-31,23:15:20,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky"
REGN,2025-02-01,16:01:26,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-02-01,17:05:07,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-02-01,17:05:07,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-02-01,17:05:07,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN"
REGN,2025-02-01,23:13:49,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN"
REGN,2025-02-01,23:39:35,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc.(REGN) Shareholders"
REGN,2025-02-01,23:50:29,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc.(REGN) Shareholders"
REGN,2025-02-02,12:01:38,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-02-02,12:43:34,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc.(REGN) Shareholders"
REGN,2025-02-02,12:46:28,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-02,12:46:28,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-02,12:46:28,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-02,12:46:28,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-02,13:00:48,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-02,16:19:21,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-03,00:45:25,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)"
REGN,2025-02-03,01:31:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-03,07:36:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE REMINDER: Berger Montague Reminds Regeneron Pharmaceuticals, Inc. (REGN) Investors of Important Class Action Lawsuit Deadline"
REGN,2025-02-03,07:36:26,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE REMINDER: Berger Montague Reminds Regeneron Pharmaceuticals, Inc. (REGN) Investors of Important Class Action Lawsuit Deadline"
REGN,2025-02-03,08:05:39,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc.(REGN) of a Class Action Lawsuit and an Upcoming Deadline"
REGN,2025-02-03,12:01:10,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-02-03,12:25:24,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REGN"
REGN,2025-02-03,14:11:48,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After,PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report-- Hagens Berman
REGN,2025-02-03,14:11:48,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron announced financial results for Q3 2024",PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report-- Hagens Berman
REGN,2025-02-03,14:31:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-03,16:01:56,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors With Losses Have Opportunity To Lead The Schall Law Firm In A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-02-03,16:20:28,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights -- REGN"
REGN,2025-02-03,16:25:19,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN"
REGN,2025-02-03,17:46:08,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-03,21:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-02-03,21:30:32,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky"
REGN,2025-02-03,21:55:09,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,U.S. Department of Justice (DOJ) filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 10, 2025 Deadline to file Lead Plaintiff Motion"
REGN,2025-02-03,21:55:09,589803,Regeneron Pharmaceuticals Inc.,99,-0.34,earnings,,Regeneron reported disappointing third-quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 10, 2025 Deadline to file Lead Plaintiff Motion"
REGN,2025-02-03,22:15:27,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN"
REGN,2025-02-03,23:31:17,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-04,01:00:22,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)"
REGN,2025-02-04,10:55:27,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"
REGN,2025-02-04,10:55:27,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron announced its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"
REGN,2025-02-04,10:55:27,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"
REGN,2025-02-04,11:05:11,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against REGN,PRESS-RELEASE,DJ Global Press Release Wire,"March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN"
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 4Q EPS $8.06,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q EPS $8.06 >REGN
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 4Q Net $917.7M,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q Net $917.7M >REGN
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 4Q Rev $3.79B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q Rev $3.79B >REGN
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2024",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2024",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,dividends,,Regeneron Pharmaceuticals Inc.: Initiates Quarterly Dividend,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Fourth quarter 2024 revenues increased 10% to $3.79 billion,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Full year 2024 revenues increased 8% to $14.20 billion,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Fourth quarter 2024 U.S. net sales,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: full year 2024 U.S. net sales,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Fourth quarter 2024 GAAP diluted EPS of $8.06,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Regeneron Pharmaceuticals Inc.: additional $3.0 billion share repurchase program authorized,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: Positive Phase 3 results,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $3,789 $3,434",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The FDA accepted for review the resubmission of an sBLA for,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The Company plans to submit a supplemental Biologics License Application (sBLA),PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"November 2024, the European Commission (EC) approved Dupixent",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,filed,Regeneron Pharmaceuticals Inc.: An sBLA for Dupixent,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: The Company announced positive results from a Phase 3 trial of Libtayo,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: The Company announced positive updated data from a Phase 3 study of pozelimab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: The EC approved Kevzara(R) (sarilumab),PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 3 study for mibavademab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.51,products-services,complete,Regeneron Pharmaceuticals Inc.: Enrollment was completed,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 2 study for itepekimab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Pharmaceuticals Inc.: the Company entered into an agreement with Truveta Inc,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.0,products-services,,Results from Phase 3 study for itepekimab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Genetic Medicines - Report additional data from Phase 1/2 study for DB-OTO,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.0,products-services,,Results from Phase 3 study for pozelimab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.0,products-services,,Results from Phase 2 study for semaglutide in combination with trevogrumab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.0,products-services,,Results from Phase 2 study for semaglutide in combination with trevogrumab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.0,products-services,,Results from Phase 2 study for mibavademab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.0,products-services,,Results from Phase 3 study for garetosmab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Fourth Quarter and Full Year 2024 Financial Results,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Fourth Quarter and Full Year 2024 Financial Results,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $3,789 $3,434",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.57,products-services,granted,Eylea HD was approved by the FDA in August 2023,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA HD and EYLEA in the fourth quarter,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,94,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the fourth quarter,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -2-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D expense for full year 2024,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,"Regeneron Pharmaceuticals Inc.: the Company's collaboration agreement with Sonoma Biotherapeutics, Inc.",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Regeneron Pharmaceuticals Inc.: the Company's 2023 acquisition of Decibel Therapeutics, Inc.",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $8.06 in the fourth quarter of 2024,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.4,earnings,up,"Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $38.34 for the full year 2024, compared to $34.77 for the full year 2023",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.4,earnings,up,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $12.07 in the fourth quarter of 2024, compared to $11.86 in the fourth quarter of 2023",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.4,earnings,up,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $45.62 for the full year 2024, compared to $43.79 for the full year 2023",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.22,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: The Company repurchased $976 million and $2.6 billion of shares,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2025 Financial Guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -3-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2025 financial guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -4-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: Conference Call Information,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -4-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: Total assets $37,759.4 $33,080.2",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,389.7 $1,366.3",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 8.53 $ 10.88 $,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2025-02-04,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 12.92 $ 12.82 $,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -5-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -6-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Fourth Quarter and Full Year 2024 Financial Results",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Fourth Quarter and Full Year -6-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,dividends,,Regeneron Pharmaceuticals Inc.: Initiates Quarterly Dividend,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Fourth quarter 2024 revenues increased 10% to $3.79 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Full year 2024 revenues increased 8% to $14.20 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Fourth quarter 2024 U.S. net sales,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharmaceuticals Inc.: full year 2024 U.S. net sales,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Fourth quarter 2024 GAAP diluted EPS of $8.06,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.59,equity-actions,approved,Regeneron Pharmaceuticals Inc.: additional $3.0 billion share repurchase program authorized,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: Positive Phase 3 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $3,789 $3,434",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The FDA accepted for review the resubmission of an sBLA for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The Company plans to submit a supplemental Biologics License Application (sBLA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"November 2024, the European Commission (EC) approved Dupixent",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,filed,Regeneron Pharmaceuticals Inc.: An sBLA for Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: The Company announced positive results from a Phase 3 trial of Libtayo,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: The Company announced positive updated data from a Phase 3 study of pozelimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: The EC approved Kevzara(R) (sarilumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 3 study for mibavademab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.51,products-services,complete,Regeneron Pharmaceuticals Inc.: Enrollment was completed,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 2 study for itepekimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Pharmaceuticals Inc.: the Company entered into an agreement with Truveta Inc,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to $4.5 Billion
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,94,0.0,products-services,,Results from Phase 3 study for itepekimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,94,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Genetic Medicines - Report additional data from Phase 1/2 study for DB-OTO,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,94,0.0,products-services,,Results from Phase 3 study for pozelimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,94,0.0,products-services,,Results from Phase 2 study for semaglutide in combination with trevogrumab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,94,0.0,products-services,,Results from Phase 2 study for semaglutide in combination with trevogrumab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,94,0.0,products-services,,Results from Phase 2 study for mibavademab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,94,0.0,products-services,,Results from Phase 3 study for garetosmab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,94,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Fourth Quarter and Full Year 2024 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,94,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Fourth Quarter and Full Year 2024 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,94,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $3,789 $3,434",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,94,0.57,products-services,granted,Eylea HD was approved by the FDA in August 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,94,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA HD and EYLEA in the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,94,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the fourth quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -2-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D expense for full year 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.49,partnerships,,"Regeneron Pharmaceuticals Inc.: the Company's collaboration agreement with Sonoma Biotherapeutics, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,"Regeneron Pharmaceuticals Inc.: the Company's 2023 acquisition of Decibel Therapeutics, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $8.06 in the fourth quarter of 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.4,earnings,up,"Regeneron Pharmaceuticals Inc.: GAAP net income per diluted share was $38.34 for the full year 2024, compared to $34.77 for the full year 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.4,earnings,up,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $12.07 in the fourth quarter of 2024, compared to $11.86 in the fourth quarter of 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.4,earnings,up,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income per diluted share was $45.62 for the full year 2024, compared to $43.79 for the full year 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.22,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: The Company repurchased $976 million and $2.6 billion of shares,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2025 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -3-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2025 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -4-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: Conference Call Information,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -4-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: Total assets $37,759.4 $33,080.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,389.7 $1,366.3",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 8.53 $ 10.88 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 12.92 $ 12.82 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -5-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -6-
REGN,2025-02-04,11:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Fourth Quarter and Full Year 2024 Financial Results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Fourth Quarter -6-
REGN,2025-02-04,11:31:55,589803,Regeneron Pharmaceuticals Inc.,100,0.0,dividends,,Regeneron Pharma Initiates Quarterly Cash Dividend,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Initiates Quarterly Cash Dividend Program >REGN
REGN,2025-02-04,11:32:14,589803,Regeneron Pharmaceuticals Inc.,100,0.59,equity-actions,extended,Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase >REGN
REGN,2025-02-04,11:34:12,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15%,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN
REGN,2025-02-04,11:34:45,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,"Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2%",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN"
REGN,2025-02-04,11:35:06,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 4Q Adj EPS $12.07,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 4Q Adj EPS $12.07 >REGN
REGN,2025-02-04,11:35:58,589803,Regeneron Pharmaceuticals Inc.,100,0.0,dividends,,Regeneron Pharma Declares Initial Quarterly Dividend of 88c,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN
REGN,2025-02-04,11:36:57,589803,Regeneron Pharmaceuticals Inc.,100,0.0,equity-actions,,Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN
REGN,2025-02-04,11:37:15,589803,Regeneron Pharmaceuticals Inc.,100,0.54,revenues,,Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88%,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN
REGN,2025-02-04,11:55:38,589803,Regeneron Pharmaceuticals Inc.,100,0.44,products-services,,"Regeneron Launches Dividend Program, Boost",FULL-ARTICLE,Dow Jones Newswires,"Regeneron Launches Dividend Program, Boost Stock Buybacks"
REGN,2025-02-04,11:58:18,589803,Regeneron Pharmaceuticals Inc.,100,0.65,revenues,up,Regeneron 4Q Rev Up,FULL-ARTICLE,Dow Jones Newswires,Regeneron 4Q Rev Up on Strong Sales of EYLEA HD
REGN,2025-02-04,11:58:18,589803,Regeneron Pharmaceuticals Inc.,100,0.0,equity-actions,,"For 2025, Regeneron forecast research-and-development capital expenditure",FULL-ARTICLE,Dow Jones Newswires,Regeneron 4Q Rev Up on Strong Sales of EYLEA HD
REGN,2025-02-04,12:01:35,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-02-04,12:10:37,589803,Regeneron Pharmaceuticals Inc.,100,0.44,products-services,,"Regeneron Launches Dividend Program, Boost",FULL-ARTICLE,Dow Jones Newswires,"Regeneron Launches Dividend Program, Boost Stock Buybacks"
REGN,2025-02-04,12:11:32,589803,Regeneron Pharmaceuticals Inc.,97,0.0,dividends,,"Regeneron Pharmaceuticals Inc.: On February 4, 2025, the Company announced that Regeneron's board of directors initiated a quarterly cash dividend",RNS-SEC8K,Dow Jones Newswires,Regeneron Pharma Files 8K - Other Events >REGN
REGN,2025-02-04,12:13:18,589803,Regeneron Pharmaceuticals Inc.,100,0.65,revenues,up,Regeneron 4Q Revenue Up,FULL-ARTICLE,Dow Jones Newswires,Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD
REGN,2025-02-04,12:13:18,589803,Regeneron Pharmaceuticals Inc.,100,0.0,equity-actions,,"For 2025, Regeneron forecast research-and-development capital expenditure",FULL-ARTICLE,Dow Jones Newswires,Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD
REGN,2025-02-04,12:15:44,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc.(REGN) Shareholders"
REGN,2025-02-04,13:03:31,589803,Regeneron Pharmaceuticals Inc.,100,0.64,earnings,up,Regeneron's earnings boosted by,FULL-ARTICLE,MarketWatch,MW Regeneron's earnings boosted by demand for blockbuster eye drug Eylea
REGN,2025-02-04,13:03:31,589803,Regeneron Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Regeneron Pharmaceuticals Inc.: the company posted better-than-expected fourth-quarter earnings,FULL-ARTICLE,MarketWatch,MW Regeneron's earnings boosted by demand for blockbuster eye drug Eylea
REGN,2025-02-04,13:03:31,589803,Regeneron Pharmaceuticals Inc.,100,-0.24,revenues,down,Eylea sales fell 11% to $1.190 billion,FULL-ARTICLE,MarketWatch,MW Regeneron's earnings boosted by demand for blockbuster eye drug Eylea
REGN,2025-02-04,13:03:31,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,The Food and Drug Administration approved Eylea HD,FULL-ARTICLE,MarketWatch,MW Regeneron's earnings boosted by demand for blockbuster eye drug Eylea
REGN,2025-02-04,13:31:24,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REGN"
REGN,2025-02-04,13:57:06,589803,Regeneron Pharmaceuticals Inc.,97,0.61,earnings,positive,Regeneron Pharmaceuticals to earn $11.35 per share,FULL-ARTICLE,Dow Jones Newswires,Regeneron Advances On Fourth-Quarter Beat As Eylea Meets Expectations -- IBD
REGN,2025-02-04,16:47:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-04,16:47:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-04,16:47:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-04,16:47:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-04,16:57:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations -- Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights -- REGN"
REGN,2025-02-04,17:00:05,589803,Regeneron Pharmaceuticals Inc.,99,-0.64,legal,,"Securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"
REGN,2025-02-04,17:00:05,589803,Regeneron Pharmaceuticals Inc.,99,-0.64,legal,,"Securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"
REGN,2025-02-04,17:15:07,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-04,18:04:45,589803,Regeneron Pharmaceuticals Inc.,100,0.64,earnings,up,Regeneron's earnings boosted by,FULL-ARTICLE,MarketWatch,MW Regeneron's earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
REGN,2025-02-04,18:04:45,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Dupixent's sales are up 15%,FULL-ARTICLE,MarketWatch,MW Regeneron's earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
REGN,2025-02-04,18:04:45,589803,Regeneron Pharmaceuticals Inc.,100,0.7,earnings,above-expectations,Regeneron Pharmaceuticals Inc.: the company posted better-than-expected fourth-quarter earnings,FULL-ARTICLE,MarketWatch,MW Regeneron's earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
REGN,2025-02-04,18:04:45,589803,Regeneron Pharmaceuticals Inc.,100,-0.24,revenues,down,Eylea sales fell 11% to $1.190 billion,FULL-ARTICLE,MarketWatch,MW Regeneron's earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
REGN,2025-02-04,18:04:45,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,The Food and Drug Administration in August 2023 approved Eylea HD,FULL-ARTICLE,MarketWatch,MW Regeneron's earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
REGN,2025-02-04,20:05:03,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-04,20:05:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,PR Newswire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-04,20:05:03,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,PR Newswire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-04,20:31:15,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc. (REGN) of a Class Action Lawsuit and an Upcoming Deadline"
REGN,2025-02-04,21:12:06,589803,Regeneron Pharmaceuticals Inc.,99,0.34,analyst-ratings,neutral,Rbc Capital Markets analyst Brian Abrahams kept his outperform rating on Regeneron,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend -- IBD"
REGN,2025-02-04,21:45:38,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders"
REGN,2025-02-05,00:18:28,589803,Regeneron Pharmaceuticals Inc.,100,-0.51,labor-issues,,Regeneron Pharmaceuticals Inc.: Analyst Cuts,PRESS-RELEASE,DJ Global Press Release Wire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit - Hagens Berman
REGN,2025-02-05,00:18:28,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,"Analysts TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,DJ Global Press Release Wire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit - Hagens Berman
REGN,2025-02-05,00:18:28,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron released its Q3 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit - Hagens Berman
REGN,2025-02-05,00:52:04,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN)"
REGN,2025-02-05,01:15:50,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN)"
REGN,2025-02-05,12:02:42,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-02-05,12:26:28,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-05,12:28:59,589803,Regeneron Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Regeneron Pharma Raised to Outperform From Market Perform by Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Raised to Outperform From Market Perform by Leerink Partners
REGN,2025-02-05,12:28:59,589803,Regeneron Pharmaceuticals Inc.,100,0.76,price-targets,upgrade,Regeneron Pharma Price Target Raised to $834.00/Share From $762.00 by Leerink,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $834.00/Share From $762.00 by Leerink Partners
REGN,2025-02-05,14:37:19,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Neutral by Baird,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Neutral by Baird
REGN,2025-02-05,14:37:19,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Regeneron Pharma Price Target Cut to $759.00/Share From $940.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $759.00/Share From $940.00 by Baird
REGN,2025-02-05,16:11:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-05,16:11:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-05,16:11:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-05,16:11:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-05,16:49:30,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-05,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-02-05,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-02-05,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-02-05,17:02:28,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-05,17:02:28,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-05,17:02:28,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-05,17:22:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.51,labor-issues,,Regeneron Pharmaceuticals Inc.: Analyst Cuts,PRESS-RELEASE,GlobeNewswire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit-- Hagens Berman
REGN,2025-02-05,17:22:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,"Analysts TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,GlobeNewswire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit-- Hagens Berman
REGN,2025-02-05,17:22:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron released its Q3 2024 financial results,PRESS-RELEASE,GlobeNewswire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit-- Hagens Berman
REGN,2025-02-05,17:32:15,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-05,20:00:49,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN"
REGN,2025-02-05,23:42:02,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,PR Newswire,"REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-02-05,23:42:02,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-02-06,00:00:24,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-06,10:45:03,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,PR Newswire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact The Gross Law Firm"
REGN,2025-02-06,10:45:03,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact The Gross Law Firm"
REGN,2025-02-06,12:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals,PRESS-RELEASE,GlobeNewswire,Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo(R) (cemiplimab)
REGN,2025-02-06,12:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo(R) (cemiplimab)
REGN,2025-02-06,12:01:10,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-02-06,12:01:30,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Immuneering Announces Clinical Supply Agreement With Regeneron Pharmaceuticals,NEWS-FLASH,Dow Jones Newswires,Immuneering Announces Clinical Supply Agreement With Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination With Libtayo
REGN,2025-02-06,12:26:17,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REGN"
REGN,2025-02-06,16:01:36,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-02-06,16:31:40,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN"
REGN,2025-02-06,17:00:06,589803,Regeneron Pharmaceuticals Inc.,99,-0.64,legal,,"Securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"
REGN,2025-02-06,17:00:06,589803,Regeneron Pharmaceuticals Inc.,99,-0.64,legal,,"Securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"
REGN,2025-02-06,17:31:39,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline"
REGN,2025-02-06,21:00:21,589803,Regeneron Pharmaceuticals Inc.,100,-0.51,labor-issues,,Regeneron Pharmaceuticals Inc.: Analyst Cuts,PRESS-RELEASE,DJ Global Press Release Wire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit- Hagens Berman
REGN,2025-02-06,21:00:21,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,"Analysts TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,DJ Global Press Release Wire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit- Hagens Berman
REGN,2025-02-06,21:00:21,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron released its Q3 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit- Hagens Berman
REGN,2025-02-06,21:30:48,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-06,22:19:27,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-06,22:19:27,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-06,22:19:27,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-06,22:19:27,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-06,23:00:21,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors who Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky about Pending Class Action - REGN"
REGN,2025-02-07,02:02:29,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN)"
REGN,2025-02-07,07:06:27,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER DEADLINE: Regeneron Pharmaceuticals (REGN) Investors Are Reminded of Deadline in Securities Action
REGN,2025-02-07,07:06:27,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER DEADLINE: Regeneron Pharmaceuticals (REGN) Investors Are Reminded of Deadline in Securities Action
REGN,2025-02-07,07:20:44,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-07,10:45:04,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against REGN,PRESS-RELEASE,PR Newswire,"March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN"
REGN,2025-02-07,12:02:19,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-02-07,12:28:12,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-07,14:43:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.51,labor-issues,,Regeneron Pharmaceuticals Inc.: Analyst Cuts,PRESS-RELEASE,GlobeNewswire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit-- Hagens Berman
REGN,2025-02-07,14:43:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,"Analysts TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,GlobeNewswire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit-- Hagens Berman
REGN,2025-02-07,14:43:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron released its Q3 2024 financial results,PRESS-RELEASE,GlobeNewswire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit-- Hagens Berman
REGN,2025-02-07,15:02:15,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-07,15:02:15,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-07,15:02:15,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-07,15:05:38,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN"
REGN,2025-02-07,16:14:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-07,16:14:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-07,16:14:03,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-07,16:14:03,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-07,16:30:47,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline"
REGN,2025-02-07,19:30:33,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline"
REGN,2025-02-08,16:02:48,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-02-08,23:08:40,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-09,03:52:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-09,11:00:58,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky"
REGN,2025-02-09,11:01:23,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-09,11:01:45,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-09,12:02:48,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-02-09,12:21:09,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky"
REGN,2025-02-09,13:56:24,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-09,13:56:24,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-09,13:56:24,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-09,13:56:24,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-09,14:05:47,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REGN"
REGN,2025-02-09,15:02:46,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-09,15:02:46,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-09,15:02:46,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-09,15:23:16,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN"
REGN,2025-02-09,16:22:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky"
REGN,2025-02-09,16:43:08,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc.(REGN) Shareholders"
REGN,2025-02-09,21:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-02-09,21:23:47,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky"
REGN,2025-02-09,23:30:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More"
REGN,2025-02-10,05:18:04,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Lawsuit - REGN"
REGN,2025-02-10,07:36:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Securities class action lawsuit has been filed against REGENERON PHARMACEUTICALS, INC. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Berger Montague Advises Regeneron Pharmaceuticals, Inc. (REGN) Investors to Inquire About a Securities Fraud Class Action by March 10, 2025"
REGN,2025-02-10,07:36:26,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Berger Montague Advises Regeneron Pharmaceuticals, Inc. (REGN) Investors to Inquire About a Securities Fraud Class Action by March 10, 2025"
REGN,2025-02-10,08:00:28,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky"
REGN,2025-02-10,08:00:29,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN"
REGN,2025-02-10,12:01:11,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-02-10,12:26:41,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Lawsuit - REGN"
REGN,2025-02-10,16:01:55,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-02-10,16:32:19,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-10,18:02:19,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-10,18:48:08,589803,Regeneron Pharmaceuticals Inc.,100,-0.51,labor-issues,,Regeneron Pharmaceuticals Inc.: Analyst Cuts,PRESS-RELEASE,GlobeNewswire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit-- Hagens Berman
REGN,2025-02-10,18:48:08,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,"Analysts TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,GlobeNewswire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit-- Hagens Berman
REGN,2025-02-10,18:48:08,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron released its Q3 2024 financial results,PRESS-RELEASE,GlobeNewswire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit-- Hagens Berman
REGN,2025-02-10,19:15:15,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-10,21:00:04,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,PR Newswire,"REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-02-10,21:00:05,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-02-10,21:00:50,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REGN"
REGN,2025-02-10,21:05:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"
REGN,2025-02-10,21:05:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron announced its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"
REGN,2025-02-10,21:05:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"
REGN,2025-02-10,23:30:27,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)"
REGN,2025-02-11,01:00:27,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More"
REGN,2025-02-11,03:00:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REGN"
REGN,2025-02-11,04:55:45,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky"
REGN,2025-02-11,07:21:08,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors who lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN"
REGN,2025-02-11,10:00:45,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky"
REGN,2025-02-11,10:45:03,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,PR Newswire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REGN"
REGN,2025-02-11,12:01:53,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-02-11,12:36:49,589803,Regeneron Pharmaceuticals Inc.,100,-0.47,regulatory,,Fda Review of Linvoseltamab for,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets New FDA Review of Linvoseltamab for Multiple Myeloma
REGN,2025-02-11,12:51:49,589803,Regeneron Pharmaceuticals Inc.,100,-0.47,regulatory,,Fda Review of Linvoseltamab for,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets New FDA Review of Linvoseltamab for Multiple Myeloma
REGN,2025-02-11,17:03:55,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-02-11,17:03:55,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-02-11,17:03:55,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-02-11,18:50:02,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After,PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report - Hagens Berman
REGN,2025-02-11,18:50:02,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,"Analysts TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report - Hagens Berman
REGN,2025-02-11,18:50:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron released its Q3 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report - Hagens Berman
REGN,2025-02-11,19:28:25,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-11,19:28:25,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-11,19:28:25,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-11,19:28:25,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-11,20:31:05,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-11,20:31:05,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,PR Newswire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-11,20:31:05,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,PR Newswire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-11,23:18:38,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Lawsuit - REGN"
REGN,2025-02-12,02:20:23,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky"
REGN,2025-02-12,12:02:40,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-02-12,12:27:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-12,16:04:52,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-02-12,16:31:50,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN"
REGN,2025-02-12,18:18:36,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-12,23:57:50,589803,Regeneron Pharmaceuticals Inc.,100,-0.51,labor-issues,,Regeneron Pharmaceuticals Inc.: Analyst Cuts,PRESS-RELEASE,GlobeNewswire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit-- Hagens Berman
REGN,2025-02-12,23:57:50,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,"Analysts TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,GlobeNewswire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit-- Hagens Berman
REGN,2025-02-12,23:57:50,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron released its Q3 2024 financial results,PRESS-RELEASE,GlobeNewswire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit-- Hagens Berman
REGN,2025-02-13,00:15:39,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN)"
REGN,2025-02-13,12:01:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!"
REGN,2025-02-13,12:18:43,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-13,15:02:46,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-13,15:02:46,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-13,15:02:46,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-13,15:28:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-13,15:28:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-13,15:28:03,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,PR Newswire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-13,15:28:03,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,PR Newswire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-13,15:32:25,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against REGN,PRESS-RELEASE,DJ Global Press Release Wire,"March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN"
REGN,2025-02-13,16:30:45,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors Who Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky About Pending Class Action - REGN"
REGN,2025-02-13,17:39:23,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against REGN,PRESS-RELEASE,GlobeNewswire,"March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN"
REGN,2025-02-13,18:49:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After,PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
REGN,2025-02-13,18:49:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,"Analysts TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
REGN,2025-02-13,18:49:42,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron released its Q3 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
REGN,2025-02-13,19:15:37,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-13,21:30:44,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN"
REGN,2025-02-14,10:45:05,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,PR Newswire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-14,12:01:40,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN Shareholders Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!"
REGN,2025-02-14,12:25:57,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-14,16:01:21,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-02-14,16:03:43,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-14,16:31:35,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders that lost money on Regeneron Pharmaceuticals, Inc. (REGN) should contact Levi & Korsinsky about pending Class Action - REGN"
REGN,2025-02-14,17:19:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.51,labor-issues,,Regeneron Pharmaceuticals Inc.: Analyst Cuts,PRESS-RELEASE,GlobeNewswire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit-- Hagens Berman
REGN,2025-02-14,17:19:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,"Analysts TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,GlobeNewswire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit-- Hagens Berman
REGN,2025-02-14,17:19:35,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron released its Q3 2024 financial results,PRESS-RELEASE,GlobeNewswire,Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit-- Hagens Berman
REGN,2025-02-14,17:45:58,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders That Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky About Pending Class Action - REGN"
REGN,2025-02-14,21:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-02-14,21:31:41,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc. (REGN) of a Class Action Lawsuit and an Upcoming Deadline"
REGN,2025-02-15,14:00:04,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,PR Newswire,"REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-02-15,14:00:04,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-02-15,14:18:25,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-15,14:18:25,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-15,14:18:25,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-15,14:18:25,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-15,15:02:34,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-15,15:02:34,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-15,15:02:34,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-15,23:16:41,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)"
REGN,2025-02-16,12:05:49,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN Stockholders Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!"
REGN,2025-02-16,13:01:01,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc.(REGN) of a Class Action Lawsuit and an Upcoming Deadline"
REGN,2025-02-16,14:41:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-16,14:41:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-16,14:41:26,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-16,14:41:26,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-16,16:01:49,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-02-16,16:03:05,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN"
REGN,2025-02-16,16:51:28,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders that Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky About Pending Class Action - REGN"
REGN,2025-02-16,18:01:01,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-17,07:36:25,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against REGENERON PHARMACEUTICALS, INC. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGENERON PHARMACEUTICALS, INC. (REGN) CLASS ACTION NOTICE: Berger Montague Encourages Investors With Substantial Losses to Contact the Firm By March 10, 2025"
REGN,2025-02-17,07:36:25,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,DJ Global Press Release Wire,"REGENERON PHARMACEUTICALS, INC. (REGN) CLASS ACTION NOTICE: Berger Montague Encourages Investors With Substantial Losses to Contact the Firm By March 10, 2025"
REGN,2025-02-17,08:00:35,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders"
REGN,2025-02-17,12:01:38,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Regeneron Pharmaceuticals, Inc. to Contact the Firm Today!"
REGN,2025-02-17,12:31:40,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN"
REGN,2025-02-17,16:47:12,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors Who Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky About Pending Class Action - REGN"
REGN,2025-02-17,17:03:23,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-17,17:03:23,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-17,17:03:23,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-17,17:03:23,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-17,17:32:25,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-17,18:17:02,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After,PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report-- Hagens Berman
REGN,2025-02-17,18:17:02,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,"Analysts TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report-- Hagens Berman
REGN,2025-02-17,18:17:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron released its Q3 2024 financial results,PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report-- Hagens Berman
REGN,2025-02-17,18:38:53,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN"
REGN,2025-02-17,20:30:33,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-18,06:02:11,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Say FDA Accepted for Priority Review,NEWS-FLASH,Dow Jones Newswires,"Sanofi, Regeneron Say FDA Accepted for Priority Review Dupixent Supplemental Application"
REGN,2025-02-18,12:02:36,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Regeneron Pharmaceuticals, Inc. to Contact the Firm Today!"
REGN,2025-02-18,12:32:25,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REGN"
REGN,2025-02-18,16:03:12,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-02-18,16:31:19,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-18,17:00:05,589803,Regeneron Pharmaceuticals Inc.,99,-0.64,legal,,"Securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"
REGN,2025-02-18,17:00:06,589803,Regeneron Pharmaceuticals Inc.,99,-0.64,legal,,"Securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"
REGN,2025-02-18,17:31:31,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-18,17:45:42,589803,Regeneron Pharmaceuticals Inc.,99,-0.82,price-targets,downgrade,"Td Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts - Hagens Berman"
REGN,2025-02-18,17:45:42,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,When the Department of Justice (DOJ) sued Regeneron for,PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts - Hagens Berman"
REGN,2025-02-18,17:45:42,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released Q3 2024 results,PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts - Hagens Berman"
REGN,2025-02-18,18:15:34,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-18,20:31:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against REGN,PRESS-RELEASE,DJ Global Press Release Wire,"March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN"
REGN,2025-02-18,23:21:05,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-18,23:21:05,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,PR Newswire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-18,23:21:05,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,PR Newswire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-19,00:04:55,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-19,00:04:55,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-19,00:04:55,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-19,00:04:55,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-19,01:48:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN"
REGN,2025-02-19,03:18:07,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-19,08:08:21,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals Inc, Inst Holders, 4Q 2024 (REGN)",RNS-SEC13F,Dow Jones Newswires,"Regeneron Pharmaceuticals  Inc, Inst Holders, 4Q 2024 (REGN)"
REGN,2025-02-19,12:03:11,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-02-19,12:27:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky"
REGN,2025-02-19,15:01:44,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-19,15:01:44,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-19,15:01:44,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-19,15:31:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against REGN,PRESS-RELEASE,DJ Global Press Release Wire,"March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN"
REGN,2025-02-19,16:33:28,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGENERON PHARMACEUTICALS (REGN) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by March 10, 2025"
REGN,2025-02-19,16:33:28,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,DJ Global Press Release Wire,"REGENERON PHARMACEUTICALS (REGN) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by March 10, 2025"
REGN,2025-02-19,17:17:41,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-19,20:45:55,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-19,20:56:10,589803,Regeneron Pharmaceuticals Inc.,99,-0.82,price-targets,downgrade,"Td Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts -- Hagens Berman"
REGN,2025-02-19,20:56:10,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,When the Department of Justice (DOJ) sued Regeneron for,PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts -- Hagens Berman"
REGN,2025-02-19,20:56:10,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released Q3 2024 results,PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts -- Hagens Berman"
REGN,2025-02-19,22:16:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders that Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky about Pending Class Action - REGN"
REGN,2025-02-20,08:08:30,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals Inc, Inst Holders, 4Q 2024 (REGN)",RNS-SEC13F,Dow Jones Newswires,"Regeneron Pharmaceuticals  Inc, Inst Holders, 4Q 2024 (REGN)"
REGN,2025-02-20,10:45:04,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,PR Newswire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-20,10:45:04,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-20,12:01:35,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-02-20,12:30:47,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders that Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More"
REGN,2025-02-20,16:02:31,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-02-20,16:31:47,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky"
REGN,2025-02-20,16:38:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-20,16:38:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-20,16:38:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,PR Newswire,"Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-20,16:38:02,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,PR Newswire,"Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-20,16:44:28,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Securities class action lawsuit has been filed against REGENERON PHARMACEUTICALS, INC. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. (REGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit"
REGN,2025-02-20,16:44:28,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. (REGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit"
REGN,2025-02-20,17:00:04,589803,Regeneron Pharmaceuticals Inc.,99,-0.64,legal,,"Securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"
REGN,2025-02-20,17:00:04,589803,Regeneron Pharmaceuticals Inc.,99,-0.64,legal,,"Securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"
REGN,2025-02-20,17:01:19,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders"
REGN,2025-02-20,18:16:06,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN)"
REGN,2025-02-20,20:40:43,589803,Regeneron Pharmaceuticals Inc.,99,-0.82,price-targets,downgrade,"Td Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts- Hagens Berman"
REGN,2025-02-20,20:40:43,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,When the Department of Justice (DOJ) sued Regeneron for,PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts- Hagens Berman"
REGN,2025-02-20,20:40:43,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released Q3 2024 results,PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts- Hagens Berman"
REGN,2025-02-20,21:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-02-20,21:30:43,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-21,01:01:22,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)"
REGN,2025-02-21,05:39:02,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,PR Newswire,"REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-02-21,05:39:02,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-02-21,12:03:08,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-02-21,12:15:56,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-21,15:04:48,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-21,15:04:48,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-21,15:04:48,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-21,15:46:18,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN)"
REGN,2025-02-21,16:31:03,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against - REGN,PRESS-RELEASE,DJ Global Press Release Wire,"March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - REGN"
REGN,2025-02-21,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-02-21,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-02-21,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-02-21,17:45:51,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN"
REGN,2025-02-21,18:15:24,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders that lost money on Regeneron Pharmaceuticals, Inc. (REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More"
REGN,2025-02-21,18:30:37,589803,Regeneron Pharmaceuticals Inc.,99,-0.82,price-targets,downgrade,"Td Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts -- Hagens Berman"
REGN,2025-02-21,18:30:37,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,When the Department of Justice (DOJ) sued Regeneron for,PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts -- Hagens Berman"
REGN,2025-02-21,18:30:37,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released Q3 2024 results,PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts -- Hagens Berman"
REGN,2025-02-21,18:44:00,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations -- Investors Should Contact Levi & Korsinsky for More Information -- REGN"
REGN,2025-02-21,18:45:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-21,23:02:39,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders"
REGN,2025-02-22,13:01:23,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-22,13:01:23,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-22,13:01:23,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-22,13:01:23,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-22,15:01:57,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-02-22,23:15:13,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-23,12:02:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-02-23,12:16:51,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-23,13:51:14,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Lawsuit - REGN"
REGN,2025-02-23,15:04:53,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"A Securities Fraud Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. And Shareholders With Losses Are Urged To Contact The Schall Law Firm"
REGN,2025-02-23,15:06:23,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-23,15:06:23,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-23,15:06:23,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-23,15:25:52,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc.(REGN) of a Class Action Lawsuit and an Upcoming Deadline"
REGN,2025-02-23,19:34:45,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-24,12:02:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-02-24,12:26:36,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-24,15:01:45,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-02-24,15:32:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-24,16:33:24,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against REGENERON PHARMACEUTICALS, INC. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE APPROACHING: Berger Montague Advises Regeneron Pharmaceuticals, Inc. (REGN) Investors to Inquire About a Securities Fraud Class Action by March 10, 2025"
REGN,2025-02-24,16:33:24,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE APPROACHING: Berger Montague Advises Regeneron Pharmaceuticals, Inc. (REGN) Investors to Inquire About a Securities Fraud Class Action by March 10, 2025"
REGN,2025-02-24,16:46:14,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-24,17:31:46,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc.(REGN) of a Class Action Lawsuit and an Upcoming Deadline"
REGN,2025-02-24,21:22:12,589803,Regeneron Pharmaceuticals Inc.,99,-0.82,price-targets,downgrade,"Td Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts-- Hagens Berman"
REGN,2025-02-24,21:22:12,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,When the Department of Justice (DOJ) sued Regeneron for,PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts-- Hagens Berman"
REGN,2025-02-24,21:22:12,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released Q3 2024 results,PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts-- Hagens Berman"
REGN,2025-02-24,21:45:33,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-24,23:18:24,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-24,23:18:24,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-24,23:18:24,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-24,23:18:24,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-24,23:31:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)"
REGN,2025-02-25,12:03:04,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-02-25,12:31:55,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-25,14:31:15,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After,PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
REGN,2025-02-25,14:31:15,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,When the Department of Justice (DOJ) sued Regeneron for,PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
REGN,2025-02-25,14:31:15,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,"Td Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
REGN,2025-02-25,14:31:15,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron released Q3 2024 results,PRESS-RELEASE,DJ Global Press Release Wire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
REGN,2025-02-25,15:04:21,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline"
REGN,2025-02-25,15:07:14,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"A Securities Fraud Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. And Shareholders With Losses Are Urged To Contact The Schall Law Firm"
REGN,2025-02-25,17:31:46,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-25,20:01:08,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-25,21:38:02,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-25,21:38:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,PR Newswire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-25,21:38:02,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,PR Newswire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-25,22:00:08,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,PR Newswire,"REGN Deadline: REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-02-25,22:00:08,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: REGN Deadline: REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-02-25,22:16:12,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN"
REGN,2025-02-25,23:19:25,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-25,23:19:25,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-25,23:19:25,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-25,23:19:25,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-25,23:30:05,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit"
REGN,2025-02-25,23:30:05,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron announced its third quarter 2024 financial results,PRESS-RELEASE,PR Newswire,"REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit"
REGN,2025-02-25,23:30:05,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron reported sales had only increased 3%,PRESS-RELEASE,PR Newswire,"REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit"
REGN,2025-02-25,23:31:05,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors who lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN"
REGN,2025-02-25,23:45:45,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN"
REGN,2025-02-26,07:36:27,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"Berger Montague Reminds Regeneron Pharmaceuticals (REGN) Investors With Substantial Losses to Inquire About a Securities Fraud Class Action by March 10, 2025"
REGN,2025-02-26,07:36:27,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,DJ Global Press Release Wire,"Berger Montague Reminds Regeneron Pharmaceuticals (REGN) Investors With Substantial Losses to Inquire About a Securities Fraud Class Action by March 10, 2025"
REGN,2025-02-26,08:06:09,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders that lost money on Regeneron Pharmaceuticals, Inc. (REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More"
REGN,2025-02-26,12:03:40,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-02-26,12:33:41,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-26,12:43:49,589803,Regeneron Pharmaceuticals Inc.,94,0.57,products-services,granted,Fda nod for odronextamab in relapsed/refractory follicular lymphoma,FULL-ARTICLE,Dow Jones Newswires,Regeneron: FDA Accepts Odronextamab Lymphoma Drug Resubmission
REGN,2025-02-26,12:43:49,589803,Regeneron Pharmaceuticals Inc.,94,0.57,products-services,granted,Year won European Commission approval of odronextamab,FULL-ARTICLE,Dow Jones Newswires,Regeneron: FDA Accepts Odronextamab Lymphoma Drug Resubmission
REGN,2025-02-26,12:58:49,589803,Regeneron Pharmaceuticals Inc.,94,0.57,products-services,granted,Fda nod for odronextamab in relapsed/refractory follicular lymphoma,FULL-ARTICLE,Dow Jones Newswires,Regeneron: FDA Accepts Odronextamab Lymphoma Drug Resubmission
REGN,2025-02-26,12:58:49,589803,Regeneron Pharmaceuticals Inc.,94,0.57,products-services,granted,Year won European Commission approval of odronextamab,FULL-ARTICLE,Dow Jones Newswires,Regeneron: FDA Accepts Odronextamab Lymphoma Drug Resubmission
REGN,2025-02-26,15:01:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-02-26,15:32:03,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc.(REGN) of a Class Action Lawsuit and an Upcoming Deadline"
REGN,2025-02-26,16:46:34,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-26,16:46:34,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-26,16:46:34,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-26,17:16:35,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN)"
REGN,2025-02-26,17:47:08,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky"
REGN,2025-02-26,19:01:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky"
REGN,2025-02-26,21:00:01,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-02-26,21:31:38,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Lawsuit - REGN"
REGN,2025-02-27,01:02:44,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-27,01:02:44,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-27,01:02:44,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-27,01:10:46,589803,Regeneron Pharmaceuticals Inc.,99,-0.82,price-targets,downgrade,"Td Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,GlobeNewswire,REGN DEADLINE ALERT: Regeneron Pharmaceuticals (REGN) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 10th Deadline in Securities Class Action
REGN,2025-02-27,01:10:46,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,When the Department of Justice (DOJ) sued Regeneron for,PRESS-RELEASE,GlobeNewswire,REGN DEADLINE ALERT: Regeneron Pharmaceuticals (REGN) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 10th Deadline in Securities Class Action
REGN,2025-02-27,01:10:46,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released Q3 2024 results,PRESS-RELEASE,GlobeNewswire,REGN DEADLINE ALERT: Regeneron Pharmaceuticals (REGN) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 10th Deadline in Securities Class Action
REGN,2025-02-27,01:33:34,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN"
REGN,2025-02-27,12:03:12,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc.. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-02-27,12:37:09,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN"
REGN,2025-02-27,15:04:52,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-27,15:04:52,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-27,15:04:52,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-02-27,15:05:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"A Securities Fraud Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. And Shareholders With Losses Are Urged To Contact The Schall Law Firm"
REGN,2025-02-27,15:06:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-27,15:06:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-27,15:06:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,PR Newswire,"SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-27,15:06:02,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,PR Newswire,"SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-02-27,15:17:11,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-27,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-02-27,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-02-27,17:00:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-02-27,17:46:11,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-27,18:42:23,589803,Regeneron Pharmaceuticals Inc.,99,-0.82,price-targets,downgrade,"Td Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts- Hagens Berman"
REGN,2025-02-27,18:42:23,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,When the Department of Justice (DOJ) sued Regeneron for,PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts- Hagens Berman"
REGN,2025-02-27,18:42:23,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released Q3 2024 results,PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts- Hagens Berman"
REGN,2025-02-27,19:02:40,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN"
REGN,2025-02-28,01:46:44,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky"
REGN,2025-02-28,12:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Linvoseltamab Recommended for EU Approval,PRESS-RELEASE,GlobeNewswire,Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
REGN,2025-02-28,12:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Linvoseltamab Recommended for EU Approval,PRESS-RELEASE,GlobeNewswire,Linvoseltamab Recommended for EU Approval by the -2-
REGN,2025-02-28,12:00:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Linvoseltamab Recommended for EU Approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
REGN,2025-02-28,12:00:26,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Linvoseltamab Recommended for EU Approval,NEWS-FLASH,Dow Jones Newswires,Regeneron: Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma >REGN
REGN,2025-02-28,12:03:48,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-02-28,12:26:41,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-28,12:34:31,589803,Regeneron Pharmaceuticals Inc.,93,0.57,products-services,granted,Committee for Medicinal Products for Human Use has recommended conditional marketing approval of linvoseltamab,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets CHMP Backing of Linvoseltamab in Multiple Myeloma
REGN,2025-02-28,12:49:31,589803,Regeneron Pharmaceuticals Inc.,93,0.57,products-services,granted,Committee for Medicinal Products for Human Use has recommended conditional marketing approval of linvoseltamab,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets CHMP Backing of Linvoseltamab in Multiple Myeloma
REGN,2025-02-28,16:01:40,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-02-28,16:31:50,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-02-28,17:31:11,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-02-28,17:43:28,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After,PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report -- Hagens Berman
REGN,2025-02-28,17:43:28,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,When the Department of Justice (DOJ) sued Regeneron for,PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report -- Hagens Berman
REGN,2025-02-28,17:43:28,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,"Td Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report -- Hagens Berman
REGN,2025-02-28,17:43:28,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron released Q3 2024 results,PRESS-RELEASE,GlobeNewswire,Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report -- Hagens Berman
REGN,2025-02-28,18:16:45,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky"
REGN,2025-02-28,19:31:10,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc. (REGN) of a Class Action Lawsuit and an Upcoming Deadline"
REGN,2025-03-01,13:21:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-01,13:21:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-01,13:21:26,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-01,13:21:26,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-01,15:03:40,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-03-01,15:03:40,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-03-01,15:03:40,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-03-01,16:05:08,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"A Securities Fraud Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. And Shareholders With Losses Are Urged To Contact The Schall Law Firm"
REGN,2025-03-01,23:01:08,589803,Regeneron Pharmaceuticals Inc.,99,-0.82,price-targets,downgrade,"Td Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,DJ Global Press Release Wire,REGN DEADLINE ALERT: Regeneron Pharmaceuticals (REGN) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 10th Deadline in Securities Class Action
REGN,2025-03-01,23:01:08,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,When the Department of Justice (DOJ) sued Regeneron for,PRESS-RELEASE,DJ Global Press Release Wire,REGN DEADLINE ALERT: Regeneron Pharmaceuticals (REGN) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 10th Deadline in Securities Class Action
REGN,2025-03-01,23:01:08,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released Q3 2024 results,PRESS-RELEASE,DJ Global Press Release Wire,REGN DEADLINE ALERT: Regeneron Pharmaceuticals (REGN) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 10th Deadline in Securities Class Action
REGN,2025-03-01,23:08:40,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors who lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN"
REGN,2025-03-02,12:03:06,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-03-02,12:17:08,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against REGN,PRESS-RELEASE,DJ Global Press Release Wire,"March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN"
REGN,2025-03-02,13:33:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Securities class action lawsuit has been filed against REGENERON PHARMACEUTICALS, INC. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. (REGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit"
REGN,2025-03-02,13:33:26,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. (REGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit"
REGN,2025-03-02,13:46:34,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-03-02,16:01:19,589803,Regeneron Pharmaceuticals Inc.,100,-0.64,legal,,"Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc."
REGN,2025-03-02,16:20:39,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Lawsuit - REGN"
REGN,2025-03-02,17:52:03,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,PR Newswire,"REGN Deadline: REGN Investors with Losses in Excess of $100K Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-03-02,17:52:03,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: REGN Deadline: REGN Investors with Losses in Excess of $100K Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-03-02,18:10:43,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-02,18:11:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.82,price-targets,downgrade,"Td Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts -- Hagens Berman"
REGN,2025-03-02,18:11:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,When the Department of Justice (DOJ) sued Regeneron for,PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts -- Hagens Berman"
REGN,2025-03-02,18:11:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released Q3 2024 results,PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts -- Hagens Berman"
REGN,2025-03-02,18:31:08,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc.(REGN) Shareholders"
REGN,2025-03-03,12:03:20,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-03-03,12:18:50,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-03,14:03:50,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-03-03,14:32:06,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Shares filed a lawsuit against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"NASDAQ:REGN Lawsuit Notice: Investors Who Hold Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Should Contact the Shareholders Foundation"
REGN,2025-03-03,14:32:54,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN"
REGN,2025-03-03,15:02:09,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-03-03,18:15:03,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-03-03,18:15:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,PR Newswire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-03-03,18:15:03,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,PR Newswire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-03-03,18:28:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-03-03,18:28:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-03-03,18:28:26,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-03-03,18:28:26,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-03-03,18:47:38,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights- REGN"
REGN,2025-03-03,20:32:12,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"2024, filing a complaint against Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,Regeneron's (REGN) Transparency Questioned as Investors Sue Over Eylea Pricing Practices- Hagens Berman
REGN,2025-03-03,21:01:46,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-04,00:16:48,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-04,03:46:44,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-03-04,12:03:19,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-03-04,12:26:07,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-03-04,15:29:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"2024, filing a complaint against Regeneron",PRESS-RELEASE,GlobeNewswire,REGN DEADLINE ALERT: Regeneron Pharmaceuticals (REGN) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 10th Deadline in Securities Class Action
REGN,2025-03-04,15:46:11,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky"
REGN,2025-03-04,16:31:36,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)"
REGN,2025-03-04,17:00:06,589803,Regeneron Pharmaceuticals Inc.,99,-0.64,legal,,"Securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"
REGN,2025-03-04,17:00:07,589803,Regeneron Pharmaceuticals Inc.,99,-0.64,legal,,"Securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"
REGN,2025-03-04,17:45:41,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-04,21:00:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,GlobeNewswire,"REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-03-04,21:15:43,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-03-05,01:01:35,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-03-05,12:03:21,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Regeneron Therapeutics, Inc. to Contact the Firm Today!"
REGN,2025-03-05,12:26:37,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-05,13:33:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,PR Newswire,"CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Regeneron Pharmaceuticals (NASDAQ: REGN) Investors to Inquire About a Securities Fraud Class Action by March 10, 2025"
REGN,2025-03-05,13:33:02,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,PR Newswire,"CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Regeneron Pharmaceuticals (NASDAQ: REGN) Investors to Inquire About a Securities Fraud Class Action by March 10, 2025"
REGN,2025-03-05,13:33:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,Dow Jones Newswires,"Press Release: CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Regeneron Pharmaceuticals (NASDAQ: REGN) Investors to Inquire About a Securities Fraud Class Action by March 10, 2025"
REGN,2025-03-05,13:33:02,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,Dow Jones Newswires,"Press Release: CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Regeneron Pharmaceuticals (NASDAQ: REGN) Investors to Inquire About a Securities Fraud Class Action by March 10, 2025"
REGN,2025-03-05,14:03:09,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-05,15:01:58,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-03-05,15:01:58,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-03-05,15:01:58,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-03-05,16:03:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-03-05,16:03:02,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-03-05,16:03:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-03-05,16:03:02,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-03-05,16:31:37,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against REGN,PRESS-RELEASE,DJ Global Press Release Wire,"March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN"
REGN,2025-03-05,17:00:01,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-03-05,17:00:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-03-05,17:00:01,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit"
REGN,2025-03-05,17:26:16,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-05,23:31:35,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-05,23:47:59,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,U.S. Department of Justice (DOJ) filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 10, 2025 Deadline to file Lead Plaintiff Motion"
REGN,2025-03-05,23:47:59,589803,Regeneron Pharmaceuticals Inc.,99,-0.34,earnings,,Regeneron reported disappointing third-quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 10, 2025 Deadline to file Lead Plaintiff Motion"
REGN,2025-03-06,00:16:34,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders that lost money on Regeneron Pharmaceuticals, Inc. (REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More"
REGN,2025-03-06,02:15:39,589803,Regeneron Pharmaceuticals Inc.,99,-0.82,price-targets,downgrade,"Td Cowen recently lowered its price target for Regeneron to $1,030 from $1,230",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts - Hagens Berman"
REGN,2025-03-06,02:15:39,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,When the Department of Justice (DOJ) sued Regeneron for,PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts - Hagens Berman"
REGN,2025-03-06,02:15:39,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released Q3 2024 results,PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts - Hagens Berman"
REGN,2025-03-06,02:46:35,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-03-06,12:04:29,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-03-06,12:31:53,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky"
REGN,2025-03-06,17:00:05,589803,Regeneron Pharmaceuticals Inc.,99,-0.64,legal,,"Securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,"Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"
REGN,2025-03-06,17:00:05,589803,Regeneron Pharmaceuticals Inc.,99,-0.64,legal,,"Securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"
REGN,2025-03-06,17:26:17,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-03-06,17:41:17,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-03-06,18:53:40,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"2024, filing a complaint against Regeneron",PRESS-RELEASE,GlobeNewswire,Regeneron's (REGN) Transparency Questioned as Investors Sue Over Eylea Pricing Practices-- Hagens Berman
REGN,2025-03-06,19:18:10,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN"
REGN,2025-03-06,20:44:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Securities class action lawsuit has been filed against REGENERON PHARMACEUTICALS, INC. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER REMINDER: Berger Montague Reminds Regeneron Pharmaceuticals, Inc. (REGN) Investors of the March 10, 2025 Deadline"
REGN,2025-03-06,20:44:26,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER REMINDER: Berger Montague Reminds Regeneron Pharmaceuticals, Inc. (REGN) Investors of the March 10, 2025 Deadline"
REGN,2025-03-06,21:17:07,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-03-06,21:46:37,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN)"
REGN,2025-03-07,12:01:57,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!"
REGN,2025-03-07,15:02:03,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-03-07,15:02:03,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Then, on October 31, 2024, Regeneron reported its third quarter 2024 financial results",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-03-07,15:02:03,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported that sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN"
REGN,2025-03-07,15:53:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-07,15:53:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-07,15:53:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-07,15:53:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-07,17:00:01,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,Business Wire,"Deadline Soon: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit"
REGN,2025-03-07,17:00:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,Business Wire,"Deadline Soon: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit"
REGN,2025-03-07,17:00:01,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,Business Wire,"Deadline Soon: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit"
REGN,2025-03-07,19:45:50,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-03-07,20:35:03,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,PR Newswire,"REGN Deadline: REGN Investors with Losses in Excess of $100K Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-03-07,20:35:03,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: Rosen Law Firm achieved the largest ever securities class action settlement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: REGN Deadline: REGN Investors with Losses in Excess of $100K Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit"
REGN,2025-03-07,20:44:23,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against REGENERON PHARMACEUTICALS, INC. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"MONDAY DEADLINE: Berger Montague Advises Regeneron Pharmaceuticals, Inc. (REGN) Investors to Inquire About a Securities Fraud Class Action by March 10, 2025"
REGN,2025-03-07,20:44:23,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,"Regeneron Pharmaceuticals Inc.: in Q3 2024, the Company's sales had only increased 3%",PRESS-RELEASE,DJ Global Press Release Wire,"MONDAY DEADLINE: Berger Montague Advises Regeneron Pharmaceuticals, Inc. (REGN) Investors to Inquire About a Securities Fraud Class Action by March 10, 2025"
REGN,2025-03-07,21:03:09,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors who Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) should contact Levi & Korsinsky about pending Class Action - REGN"
REGN,2025-03-08,00:08:30,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"2024, filing a complaint against Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,REGN DEADLINE ALERT: Regeneron Pharmaceuticals (REGN) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 10th Deadline in Securities Class Action
REGN,2025-03-08,23:22:37,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors who lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN"
REGN,2025-03-09,11:03:35,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"FINAL REGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Regeneron Therapeutics, Inc. Investors to Join the Class Action Lawsuit"
REGN,2025-03-09,11:32:32,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-03-09,11:32:32,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-03-09,11:32:32,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-03-09,11:32:32,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-03-09,11:32:46,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-09,11:51:16,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More"
REGN,2025-03-09,16:49:06,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More"
REGN,2025-03-09,20:00:57,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"FINAL REGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Regeneron Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit"
REGN,2025-03-09,20:33:11,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN"
REGN,2025-03-10,00:02:08,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-10,08:00:33,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN"
REGN,2025-03-10,11:02:25,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"FINAL REMINDER REGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Regeneron Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit"
REGN,2025-03-10,14:17:40,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Investors Who Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky About Pending Class Action - REGN"
REGN,2025-03-10,15:23:13,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN"
REGN,2025-03-10,17:49:39,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,Had filed a complaint against Regeneron,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-03-10,17:49:39,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-03-10,17:49:39,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-03-10,17:49:39,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals"
REGN,2025-03-10,18:03:44,589803,Regeneron Pharmaceuticals Inc.,100,-0.52,legal,,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN)",PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky"
REGN,2025-03-10,20:00:50,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"FINAL REMINDER REGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Regeneron Pharmaceuticals, Inc. Investors to Participate in the Class Action Lawsuit"
REGN,2025-03-10,20:16:41,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky"
REGN,2025-03-10,20:40:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,U.S. Department of Justice (DOJ) filed a complaint against Regeneron,PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 10, 2025 Deadline to file Lead Plaintiff Motion"
REGN,2025-03-10,20:40:26,589803,Regeneron Pharmaceuticals Inc.,99,-0.34,earnings,,Regeneron reported disappointing third-quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"Regeneron Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 10, 2025 Deadline to file Lead Plaintiff Motion"
REGN,2025-03-10,22:01:06,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Lawsuit was filed against Regeneron Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN"
REGN,2025-03-11,11:03:21,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (""Regeneron",PRESS-RELEASE,DJ Global Press Release Wire,"REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
REGN,2025-03-12,01:32:16,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: He created an algorithm,PRESS-RELEASE,GlobeNewswire,"Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem"
REGN,2025-03-12,01:32:16,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,GlobeNewswire,Regeneron Science Talent Search 2025 Awards More -2-
REGN,2025-03-12,01:32:17,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: He created an algorithm,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem"
REGN,2025-03-12,01:32:17,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Science Talent Search -2-
REGN,2025-03-12,02:49:54,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: He created an algorithm,PRESS-RELEASE,PR Newswire,"Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem"
REGN,2025-03-12,02:49:54,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,PR Newswire,Regeneron Science Talent Search 2025 Awards More -2-
REGN,2025-03-25,20:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report First Quarter 2025 Financial and Operating Results,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025"
REGN,2025-03-25,20:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025"
REGN,2025-03-25,20:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report First Quarter 2025 Financial and Operating Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025"
REGN,2025-03-25,20:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025"
REGN,2025-03-28,06:01:20,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Say Dupixent Approved in Japan,NEWS-FLASH,Dow Jones Newswires,"Sanofi, Regeneron Say Dupixent Approved in Japan for Patients With COPD"
REGN,2025-03-31,14:45:28,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by JP Morgan
REGN,2025-03-31,14:45:28,589803,Regeneron Pharmaceuticals Inc.,100,-0.76,price-targets,downgrade,Regeneron Pharma Price Target Cut to $1000.00/Share From $1100.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $1000.00/Share From $1100.00 by JP Morgan
REGN,2025-04-07,20:54:01,589803,Regeneron Pharmaceuticals Inc.,100,0.44,labor-issues,,"Regeneron Pharmaceuticals, Inc.: Pres, Chief Scientific Officer George Yancopoulos 2024 Total Compensation $6.7M",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc.: Pres, Chief Scientific Officer George Yancopoulos 2024 Total Compensation $6.7M >REGN"
REGN,2025-04-07,20:54:01,589803,Regeneron Pharmaceuticals Inc.,100,0.44,labor-issues,,"Regeneron Pharmaceuticals, Inc.: CFO Christopher Fenimore 2024 Total Compensation $6.2M",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharmaceuticals, Inc.: CFO Christopher Fenimore 2024 Total Compensation $6.2M >REGN"
REGN,2025-04-14,18:13:24,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Goldman Sachs
REGN,2025-04-14,18:13:24,589803,Regeneron Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Regeneron Pharma Price Target Cut to $917.00/Share From $1019.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $917.00/Share From $1019.00 by Goldman Sachs
REGN,2025-04-17,11:01:50,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron: Eylea HD Gets FDA Priority Review,NEWS-FLASH,Dow Jones Newswires,"Regeneron: Eylea HD Gets FDA Priority Review for Treatment of Macular Edema Following Retinal Vein Occlusion, Monthly Dosing in Approved Indications >REGN"
REGN,2025-04-17,11:20:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Underperform by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Underperform by B of A Securities
REGN,2025-04-17,11:20:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,price-targets,downgrade,Regeneron Pharma Price Target Cut to $547.00/Share From $575.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $547.00/Share From $575.00 by B of A Securities
REGN,2025-04-17,11:46:40,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Gets FDA Priority Review,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets FDA Priority Review for Expanded Eylea HD Use
REGN,2025-04-17,12:01:39,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Regeneron Gets FDA Priority Review,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets FDA Priority Review for Expanded Eylea HD Use
REGN,2025-04-17,12:43:42,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Hold by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Hold by Canaccord Genuity
REGN,2025-04-17,12:43:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Regeneron Pharma Price Target Cut to $150.00/Share From $170.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $150.00/Share From $170.00 by Canaccord Genuity
REGN,2025-04-18,15:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in the US as the first new targeted therapy,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
REGN,2025-04-18,15:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is already approved for CSU in Japan,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
REGN,2025-04-18,15:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,GlobeNewswire,Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
REGN,2025-04-18,15:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in the US as the first new targeted therapy,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
REGN,2025-04-18,15:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is already approved for CSU in Japan,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
REGN,2025-04-18,15:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
REGN,2025-04-18,15:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in the US as the first new targeted therapy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
REGN,2025-04-18,15:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is already approved for CSU in Japan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
REGN,2025-04-18,15:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
REGN,2025-04-18,15:15:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent approved in the US as the first new targeted therapy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
REGN,2025-04-18,15:15:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is already approved for CSU in Japan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
REGN,2025-04-18,15:15:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
REGN,2025-04-18,15:15:32,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent(R) (dupilumab),PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
REGN,2025-04-18,15:15:32,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is already approved for CSU in Japan,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
REGN,2025-04-18,15:15:32,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,GlobeNewswire,Dupixent(R) (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
REGN,2025-04-18,15:15:32,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent(R) (dupilumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
REGN,2025-04-18,15:15:32,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent is already approved for CSU in Japan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
REGN,2025-04-18,15:15:32,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Dupilumab is being jointly developed by Regeneron and Sanofi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Dupixent(R) (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
REGN,2025-04-18,15:16:32,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron: FDA Approves Dupixent in Chronic Spontaneous Urticaria,NEWS-FLASH,Dow Jones Newswires,Regeneron: FDA Approves Dupixent in Chronic Spontaneous Urticaria >REGN
REGN,2025-04-18,15:18:21,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent Approved in US as 1st New Targeted Therapy,NEWS-FLASH,Dow Jones Newswires,Sanofi: Dupixent Approved in US as 1st New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria >SAN.FR
REGN,2025-04-18,15:34:18,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Regeneron, Sanofi Get FDA Approval For Dupixent",FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Get FDA Approval For Dupixent in Skin Disease CSU"
REGN,2025-04-18,15:49:18,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Regeneron, Sanofi Get FDA Approval For Dupixent",FULL-ARTICLE,Dow Jones Newswires,"Regeneron, Sanofi Get FDA Approval For Dupixent in Skin Disease CSU"
REGN,2025-04-18,19:00:22,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Eylea(TM) 8 mg in the European Union and Japan) is being jointly developed by Regeneron and Bayer AG,PRESS-RELEASE,GlobeNewswire,Regeneron Provides Update on EYLEA HD(R) (aflibercept) Injection 8 mg Supplemental Biologics License Application
REGN,2025-04-18,19:00:23,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Eylea(TM) 8 mg in the European Union and Japan) is being jointly developed by Regeneron and Bayer AG,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Provides Update on EYLEA HD(R) (aflibercept) Injection 8 mg Supplemental Biologics License Application
REGN,2025-04-18,19:37:43,589803,Regeneron Pharmaceuticals Inc.,96,0.0,products-services,filed,Regeneron Pharmaceuticals Inc.: The company previously submitted a supplemental biologics license application,FULL-ARTICLE,Dow Jones Newswires,Regeneron to Reassess Strategy for Retinal Condition Treatment After FDA Rejects Dosing Plan
REGN,2025-04-18,19:52:42,589803,Regeneron Pharmaceuticals Inc.,96,0.0,products-services,filed,Regeneron Pharmaceuticals Inc.: The company previously submitted a supplemental biologics license application,FULL-ARTICLE,Dow Jones Newswires,Regeneron to Reassess Strategy for Retinal Condition Treatment After FDA Rejects Dosing Plan
REGN,2025-04-22,10:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.46,equity-actions,,Regeneron Announces New Investment,PRESS-RELEASE,GlobeNewswire,Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
REGN,2025-04-22,10:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Pharmaceuticals Inc.: New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina,PRESS-RELEASE,GlobeNewswire,Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
REGN,2025-04-22,10:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron Pharmaceuticals Inc.: Partnering with Regeneron,PRESS-RELEASE,GlobeNewswire,Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
REGN,2025-04-22,10:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.46,equity-actions,,Regeneron Announces New Investment in -2,PRESS-RELEASE,GlobeNewswire,Regeneron Announces New Investment in -2-
REGN,2025-04-22,10:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.46,equity-actions,,Regeneron Announces New Investment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
REGN,2025-04-22,10:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Pharmaceuticals Inc.: New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
REGN,2025-04-22,10:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron Pharmaceuticals Inc.: Partnering with Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
REGN,2025-04-22,10:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.46,equity-actions,,Regeneron Announces New Investment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces New Investment -2-
REGN,2025-04-22,10:00:13,589803,Regeneron Pharmaceuticals Inc.,100,0.46,equity-actions,,Regeneron Announces New Investment,NEWS-FLASH,Dow Jones Newswires,Regeneron Announces New Investment in Manufacturing of Its Industry-Leading Biologic Medicines
REGN,2025-04-22,10:03:43,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,"Regeneron in Manufacturing, Supply Pact With Fujifilm Diosynth Biotechnologies",NEWS-FLASH,Dow Jones Newswires,"Regeneron in Manufacturing, Supply Pact With Fujifilm Diosynth Biotechnologies in North Carolina >REGN"
REGN,2025-04-22,10:54:21,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron Partners With Fujifilm to,FULL-ARTICLE,Dow Jones Newswires,Regeneron Partners With Fujifilm to Expand Manufacturing Capacity
REGN,2025-04-22,10:54:21,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Pharmaceuticals signed a new manufacturing-and-supply agreement with Fujifilm Diosynth Biotechnologies,FULL-ARTICLE,Dow Jones Newswires,Regeneron Partners With Fujifilm to Expand Manufacturing Capacity
REGN,2025-04-22,11:09:20,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Regeneron Partners With Fujifilm to,FULL-ARTICLE,Dow Jones Newswires,Regeneron Partners With Fujifilm to Expand Manufacturing Capacity
REGN,2025-04-22,11:09:20,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Pharmaceuticals signed a new manufacturing-and-supply agreement with Fujifilm Diosynth Biotechnologies,FULL-ARTICLE,Dow Jones Newswires,Regeneron Partners With Fujifilm to Expand Manufacturing Capacity
REGN,2025-04-22,11:59:42,589803,Regeneron Pharmaceuticals Inc.,100,0.95,analyst-ratings,positive,Regeneron Pharma Coverage Assumed by Cantor Fitzgerald at Overweight,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Coverage Assumed by Cantor Fitzgerald at Overweight
REGN,2025-04-22,11:59:42,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,set,Regeneron Pharma Price Target Announced at $695.00/Share by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Announced at $695.00/Share by Cantor Fitzgerald
REGN,2025-04-22,13:49:12,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Canaccord Genuity
REGN,2025-04-22,13:49:12,589803,Regeneron Pharmaceuticals Inc.,100,-0.84,price-targets,downgrade,Regeneron Pharma Price Target Cut to $850.00/Share From $1152.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $850.00/Share From $1152.00 by Canaccord Genuity
REGN,2025-04-23,16:59:25,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Truist Securities
REGN,2025-04-23,16:59:25,589803,Regeneron Pharmaceuticals Inc.,100,-0.44,price-targets,downgrade,Regeneron Pharma Price Target Cut to $975.00/Share From $1004.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $975.00/Share From $1004.00 by Truist Securities
REGN,2025-04-25,12:31:59,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Neutral by Baird,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Neutral by Baird
REGN,2025-04-25,12:31:59,589803,Regeneron Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Regeneron Pharma Price Target Cut to $652.00/Share From $759.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $652.00/Share From $759.00 by Baird
REGN,2025-04-29,10:24:26,589803,Regeneron Pharmaceuticals Inc.,100,0.44,labor-issues,,Regeneron CEO Leonard Schleifer 2024 Total Compensation $6.8M,NEWS-FLASH,Dow Jones Newswires,Regeneron CEO Leonard Schleifer 2024 Total Compensation $6.8M
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 1Q EPS $7.27,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q EPS $7.27 >REGN
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 1Q Adj EPS $8.22,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q Adj EPS $8.22 >REGN
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 1Q Net $808.7M,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q Net $808.7M >REGN
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2025",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.64,revenues,up,Regeneron Pharmaceuticals Inc.: First quarter 2025 EYLEA HD(R) U.S. net sales increased 54%,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP diluted EPS of $7.27,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: Dupixent approved for chronic spontaneous urticaria (CSU) in U.S.,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda accepted for priority review EYLEA HD sBLA,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"March 2025, Japan's Ministry of Health, Labour and Welfare (MHLW) approved Dupixent",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: The Company presented positive results from the Phase 3 QUASAR trial,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The Company submitted an sBLA to the FDA,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.44,products-services,conditional,Regeneron Pharmaceuticals Inc.: The European Commission (EC) granted conditional marketing approval of Lynozyfic (linvoseltamab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.51,products-services,complete,Regeneron Pharmaceuticals Inc.: Enrollment was completed,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The Company presented updated data from the Phase 1/2 trial of DB-OTO,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 3 study for itepekimab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.63,products-services,,Regeneron Pharmaceuticals Inc.: The FDA granted Orphan Drug designation for,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 1Q Rev $3.03B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 1Q Rev $3.03B >REGN
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: The Company reached resolution of its patent infringement litigation,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -2-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: First Quarter 2025 Financial Results,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -2-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,029 $ 3,145",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -2-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA HD increased in the first quarter of 2025,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -2-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.46,revenues,down,Eylea and EYLEA HD net product sales decreased 30%,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -2-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the first quarter,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -2-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -2-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,approved,Regeneron Pharmaceuticals Inc.: the Company's board of directors authorized a new share repurchase program,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -2-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the first quarter of 2025, the Company repurchased shares of its common stock",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -2-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,dividends,,Regeneron Pharmaceuticals Inc.: the Company's board of directors declared a cash dividend of $0.88,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -2-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2025 Financial Guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -2-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2025 financial guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -3-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its first quarter 2025 financial and operating results on Tuesday, April 29, 2025, at 8:30 AM Eastern Time",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -3-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: Total assets $37,545.2 $ 37,759.4",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -4-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -4-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income $ 808.7 $ 722.0,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -4-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 7.58 $ 6.70,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -4-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income $ 808.7 $ 722.0,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -5-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $ 928.4 $1,115.9",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -5-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 8.70 $ 10.35,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -5-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,98,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total collaboration revenue,PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -5-
REGN,2025-04-29,10:30:00,589803,Regeneron Pharmaceuticals Inc.,98,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""First Quarter 2025 Financial Results",PRESS-RELEASE,GlobeNewswire,Regeneron Reports First Quarter 2025 Financial -5-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2025",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.64,revenues,up,Regeneron Pharmaceuticals Inc.: First quarter 2025 EYLEA HD(R) U.S. net sales increased 54%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP diluted EPS of $7.27,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: Dupixent approved for chronic spontaneous urticaria (CSU) in U.S.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda accepted for priority review EYLEA HD sBLA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"March 2025, Japan's Ministry of Health, Labour and Welfare (MHLW) approved Dupixent",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: The Company presented positive results from the Phase 3 QUASAR trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The Company submitted an sBLA to the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.44,products-services,conditional,Regeneron Pharmaceuticals Inc.: The European Commission (EC) granted conditional marketing approval of Lynozyfic (linvoseltamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.51,products-services,complete,Regeneron Pharmaceuticals Inc.: Enrollment was completed,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The Company presented updated data from the Phase 1/2 trial of DB-OTO,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 3 study for itepekimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.63,products-services,,Regeneron Pharmaceuticals Inc.: The FDA granted Orphan Drug designation for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter 2025 Financial and Operating Results
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.46,legal,,Regeneron Pharmaceuticals Inc.: The Company reached resolution of its patent infringement litigation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: First Quarter 2025 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,029 $ 3,145",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA HD increased in the first quarter of 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,-0.46,revenues,down,Eylea and EYLEA HD net product sales decreased 30%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the first quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,approved,Regeneron Pharmaceuticals Inc.: the Company's board of directors authorized a new share repurchase program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the first quarter of 2025, the Company repurchased shares of its common stock",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,dividends,,Regeneron Pharmaceuticals Inc.: the Company's board of directors declared a cash dividend of $0.88,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2025 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -2-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2025 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -3-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its first quarter 2025 financial and operating results on Tuesday, April 29, 2025, at 8:30 AM Eastern Time",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -3-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: Total assets $37,545.2 $ 37,759.4",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income $ 808.7 $ 722.0,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 7.58 $ 6.70,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -4-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP net income $ 808.7 $ 722.0,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -5-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $ 928.4 $1,115.9",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -5-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 8.70 $ 10.35,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -5-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,98,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total collaboration revenue,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -5-
REGN,2025-04-29,10:30:01,589803,Regeneron Pharmaceuticals Inc.,98,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""First Quarter 2025 Financial Results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports First Quarter -5-
REGN,2025-04-29,10:32:08,589803,Regeneron Pharmaceuticals Inc.,100,-0.44,equity-actions,down,Regeneron Pharma Cuts 2025 CapEx to $850M-$950M,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Cuts 2025 CapEx to $850M-$950M >REGN
REGN,2025-04-29,10:52:51,589803,Regeneron Pharmaceuticals Inc.,100,0.64,earnings,up,Regeneron 1Q Profit Rises,FULL-ARTICLE,Dow Jones Newswires,"Regeneron 1Q Profit Rises, Revenue Falls; FY25 CapEx Target Trimmed"
REGN,2025-04-29,10:52:51,589803,Regeneron Pharmaceuticals Inc.,100,0.0,equity-actions,,Regeneron now anticipates capital expenditures of $850,FULL-ARTICLE,Dow Jones Newswires,"Regeneron 1Q Profit Rises, Revenue Falls; FY25 CapEx Target Trimmed"
REGN,2025-04-29,11:07:51,589803,Regeneron Pharmaceuticals Inc.,100,0.64,earnings,up,Regeneron 1Q Profit Rises,FULL-ARTICLE,Dow Jones Newswires,"Regeneron 1Q Profit Rises, Revenue Falls; FY25 CapEx Target Trimmed"
REGN,2025-04-29,11:07:51,589803,Regeneron Pharmaceuticals Inc.,100,0.0,equity-actions,,Regeneron now anticipates capital expenditures of $850,FULL-ARTICLE,Dow Jones Newswires,"Regeneron 1Q Profit Rises, Revenue Falls; FY25 CapEx Target Trimmed"
REGN,2025-04-29,13:42:42,589803,Regeneron Pharmaceuticals Inc.,95,0.61,earnings,positive,"For the first quarter, Regeneron Pharmaceuticals reported adjusted profit of $8.22",FULL-ARTICLE,Dow Jones Newswires,Regeneron Crashes 10% After Eylea Miss Drags Its Earnings Report -- IBD
REGN,2025-04-29,14:29:21,589803,Regeneron Pharmaceuticals Inc.,100,-0.44,revenues,down,Eylea sales fell 26%,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Plummets After Earnings Miss -- Barrons.com
REGN,2025-04-29,20:14:07,589803,Regeneron Pharmaceuticals Inc.,99,-0.24,revenues,down,Regeneron's sales fell 4% to $3.03 billion,FULL-ARTICLE,Dow Jones Newswires,Regeneron Crashes 7% After Eylea Miss Drags Its Earnings Down -- IBD
REGN,2025-04-29,20:14:07,589803,Regeneron Pharmaceuticals Inc.,99,0.34,analyst-ratings,neutral,Risinger maintained his outperform rating on Regeneron,FULL-ARTICLE,Dow Jones Newswires,Regeneron Crashes 7% After Eylea Miss Drags Its Earnings Down -- IBD
REGN,2025-04-29,20:14:07,589803,Regeneron Pharmaceuticals Inc.,99,-0.44,equity-actions,down,Regeneron also lowered its capital expenditures,FULL-ARTICLE,Dow Jones Newswires,Regeneron Crashes 7% After Eylea Miss Drags Its Earnings Down -- IBD
REGN,2025-04-30,14:26:50,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Neutral by Baird,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Neutral by Baird
REGN,2025-04-30,14:26:50,589803,Regeneron Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Regeneron Pharma Price Target Cut to $587.00/Share From $652.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $587.00/Share From $652.00 by Baird
REGN,2025-04-30,14:47:20,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Neutral by UBS,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Neutral by UBS
REGN,2025-04-30,14:47:21,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Regeneron Pharma Price Target Cut to $633.00/Share From $768.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $633.00/Share From $768.00 by UBS
REGN,2025-04-30,15:04:20,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by BMO Capital
REGN,2025-04-30,15:04:21,589803,Regeneron Pharmaceuticals Inc.,100,-0.7,price-targets,downgrade,Regeneron Pharma Price Target Cut to $800.00/Share From $865.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $800.00/Share From $865.00 by BMO Capital
REGN,2025-04-30,16:10:01,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Wells Fargo
REGN,2025-04-30,16:10:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.66,price-targets,downgrade,Regeneron Pharma Price Target Cut to $700.00/Share From $750.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $700.00/Share From $750.00 by Wells Fargo
REGN,2025-04-30,16:12:31,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by RBC Capital
REGN,2025-04-30,16:12:31,589803,Regeneron Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Regeneron Pharma Price Target Cut to $943.00/Share From $1051.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $943.00/Share From $1051.00 by RBC Capital
REGN,2025-04-30,17:17:51,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Goldman Sachs
REGN,2025-04-30,17:17:51,589803,Regeneron Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Regeneron Pharma Price Target Cut to $804.00/Share From $917.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $804.00/Share From $917.00 by Goldman Sachs
REGN,2025-04-30,17:56:31,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Truist Securities
REGN,2025-04-30,17:56:31,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,price-targets,downgrade,Regeneron Pharma Price Target Cut to $940.00/Share From $975.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $940.00/Share From $975.00 by Truist Securities
REGN,2025-05-01,13:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Libtayo Phase 3 trial of,PRESS-RELEASE,GlobeNewswire,Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo(R) (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination
REGN,2025-05-01,13:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 12:00 Interim results from Cancers p.m.,PRESS-RELEASE,GlobeNewswire,Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo(R) (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination
REGN,2025-05-01,13:30:00,589803,Regeneron Pharmaceuticals Inc.,94,0.0,products-services,,"Regeneron Pharmaceuticals Inc.: Fianlimab, A Phase 2 study of",PRESS-RELEASE,GlobeNewswire,Regeneron to Highlight Advances at ASCO with -2-
REGN,2025-05-01,14:58:33,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Guggenheim
REGN,2025-05-01,14:58:33,589803,Regeneron Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Regeneron Pharma Price Target Cut to $810.00/Share From $940.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $810.00/Share From $940.00 by Guggenheim
REGN,2025-05-06,16:37:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharma received approval from the U.S. FDA for Dupixent (dupilumab),PRESS-RELEASE,Business Wire,"Chronic Spontaneous Urticaria Market Analysis and Forecast Report, 2025-2035 | FDA Approval Boosts Dupixent as Treatment for Chronic Spontaneous Urticaria in Adolescents and Adults - ResearchAndMarkets.com"
REGN,2025-05-14,12:32:39,589803,Regeneron Pharmaceuticals Inc.,100,0.94,analyst-ratings,positive,Regeneron Pharma Raised to Buy From Neutral by Citigroup,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Raised to Buy From Neutral by Citigroup
REGN,2025-05-14,12:32:39,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $700.00/Share From $600.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $700.00/Share From $600.00 by Citigroup
REGN,2025-05-15,18:02:43,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Fda approved Praluent in 2015,PRESS-RELEASE,GlobeNewswire,Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
REGN,2025-05-15,18:02:43,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Praluent was developed by Regeneron and Sanofi,PRESS-RELEASE,GlobeNewswire,Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
REGN,2025-05-15,19:18:59,589803,Regeneron Pharmaceuticals Inc.,94,0.53,legal,,Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets $407M in Damages From Amgen in Antitrust Drug Lawsuit
REGN,2025-05-15,19:33:59,589803,Regeneron Pharmaceuticals Inc.,94,0.53,legal,,Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets $407 Million in Damages From Amgen in Antitrust Drug Lawsuit
REGN,2025-05-16,15:24:50,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,Dow Jones Newswires,Press Release: 75th Annual Regeneron -2-
REGN,2025-05-16,15:24:50,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,GlobeNewswire,75th Annual Regeneron International Science and -2-
REGN,2025-05-16,17:29:41,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,PR Newswire,(PR) 75th Annual Regeneron International Science -2-
REGN,2025-05-19,07:08:55,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals Inc, Inst Holders, 1Q 2025 (REGN)",RNS-SEC13F,Dow Jones Newswires,"Regeneron Pharmaceuticals  Inc, Inst Holders, 1Q 2025 (REGN)"
REGN,2025-05-19,11:07:52,589803,Regeneron Pharmaceuticals Inc.,99,0.55,acquisitions-mergers,interest,Regeneron intends to acquire 23andMe,PRESS-RELEASE,GlobeNewswire,Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe(R) for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness
REGN,2025-05-19,11:07:53,589803,Regeneron Pharmaceuticals Inc.,99,0.55,acquisitions-mergers,interest,Regeneron intends to acquire 23andMe,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe(R) for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness
REGN,2025-05-19,11:40:37,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million,FULL-ARTICLE,Dow Jones Newswires,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million
REGN,2025-05-19,11:55:37,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million,FULL-ARTICLE,Dow Jones Newswires,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million
REGN,2025-05-19,12:02:40,589803,Regeneron Pharmaceuticals Inc.,97,0.57,products-services,granted,"November 2011, the FDA approved Eylea",PRESS-RELEASE,DJ Global Press Release Wire,"Lifshitz Law PLLC Announces Investigations of Kyverna Therapeutics, Inc. (NASDAQ: KYTX), Sun Communities, Inc. (NYSE: SUI), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), and Integral Ad Science Holding Corp. (NASDAQ: IAS)"
REGN,2025-05-19,12:02:40,589803,Regeneron Pharmaceuticals Inc.,97,0.57,products-services,granted,"August 2023, the FDA approved Eylea HD",PRESS-RELEASE,DJ Global Press Release Wire,"Lifshitz Law PLLC Announces Investigations of Kyverna Therapeutics, Inc. (NASDAQ: KYTX), Sun Communities, Inc. (NYSE: SUI), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), and Integral Ad Science Holding Corp. (NASDAQ: IAS)"
REGN,2025-05-19,12:40:14,589803,Regeneron Pharmaceuticals Inc.,99,0.64,earnings,up,Regeneron's earnings boosted by,FULL-ARTICLE,MarketWatch,MW 23andMe sells its most valuable asset. Regeneron promises keep your DNA private.
REGN,2025-05-19,13:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million,FULL-ARTICLE,Dow Jones Newswires,Dow Jones Top Company Headlines at 9 AM ET: Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million | Blackstone ...
REGN,2025-05-19,13:15:02,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million,FULL-ARTICLE,Dow Jones Newswires,Dow Jones Top Company Headlines at 9 AM ET: Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million | Blackstone ...
REGN,2025-05-19,13:33:27,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million,FULL-ARTICLE,Dow Jones Newswires,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- Update
REGN,2025-05-19,14:17:23,589803,Regeneron Pharmaceuticals Inc.,100,0.55,acquisitions-mergers,,23andMe sells its most valuable asset to biotech company Regeneron,FULL-ARTICLE,MarketWatch,"MW 23andMe sells its most valuable asset to biotech company Regeneron, which promises to keep your DNA private"
REGN,2025-05-19,14:17:23,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron develops new medicines,FULL-ARTICLE,MarketWatch,"MW 23andMe sells its most valuable asset to biotech company Regeneron, which promises to keep your DNA private"
REGN,2025-05-19,14:17:23,589803,Regeneron Pharmaceuticals Inc.,100,0.64,earnings,up,Regeneron's earnings boosted by,FULL-ARTICLE,MarketWatch,"MW 23andMe sells its most valuable asset to biotech company Regeneron, which promises to keep your DNA private"
REGN,2025-05-19,14:42:31,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million,FULL-ARTICLE,Dow Jones Newswires,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- Update
REGN,2025-05-19,15:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million,FULL-ARTICLE,Dow Jones Newswires,Dow Jones Top Company Headlines at 11 AM ET: Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million | JPMorgan ...
REGN,2025-05-19,15:15:01,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million,FULL-ARTICLE,Dow Jones Newswires,Dow Jones Top Company Headlines at 11 AM ET: Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million | JPMorgan ...
REGN,2025-05-19,16:13:14,589803,Regeneron Pharmaceuticals Inc.,100,0.55,acquisitions-mergers,,Regeneron is buying 23andMe's consumer genetic-testing business,FULL-ARTICLE,Dow Jones Newswires,Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com
REGN,2025-05-19,17:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million,FULL-ARTICLE,Dow Jones Newswires,Dow Jones Top Company Headlines at 1 PM ET: Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million | Jamie ...
REGN,2025-05-19,17:15:02,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million,FULL-ARTICLE,Dow Jones Newswires,Dow Jones Top Company Headlines at 1 PM ET: Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million | Jamie ...
REGN,2025-05-19,17:52:25,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million,FULL-ARTICLE,Dow Jones Newswires,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update
REGN,2025-05-19,17:52:25,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Regulators sign off, Regeneron would acquire 23andMe",FULL-ARTICLE,Dow Jones Newswires,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update
REGN,2025-05-19,17:52:25,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron said it expects the deal to close in the third quarter,FULL-ARTICLE,Dow Jones Newswires,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update
REGN,2025-05-19,19:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million,FULL-ARTICLE,Dow Jones Newswires,Dow Jones Top Company Headlines at 3 PM ET: Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million | Jamie ...
REGN,2025-05-19,19:15:02,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million,FULL-ARTICLE,Dow Jones Newswires,Dow Jones Top Company Headlines at 3 PM ET: Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million | Jamie ...
REGN,2025-05-19,21:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million,FULL-ARTICLE,Dow Jones Newswires,Dow Jones Top Company Headlines at 5 PM ET: Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million | Jamie ...
REGN,2025-05-19,21:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million,FULL-ARTICLE,Dow Jones Newswires,Dow Jones Top Company Headlines at 5 PM ET: Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million | Jamie ...
REGN,2025-05-19,23:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million,FULL-ARTICLE,Dow Jones Newswires,Dow Jones Top Company Headlines at 7 PM ET: Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million | Jamie ...
REGN,2025-05-19,23:15:01,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million,FULL-ARTICLE,Dow Jones Newswires,Dow Jones Top Company Headlines at 7 PM ET: Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million | Jamie ...
REGN,2025-05-20,06:32:05,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Acquire 23andMe -- WSJ,FULL-ARTICLE,Wall Street Journal,Regeneron to Acquire 23andMe -- WSJ
REGN,2025-05-20,06:32:05,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron to Acquire 23andMe -- WSJ,FULL-ARTICLE,Wall Street Journal,Regeneron to Acquire 23andMe -- WSJ
REGN,2025-05-20,06:32:05,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Regulators sign off, Regeneron would acquire 23andMe",FULL-ARTICLE,Wall Street Journal,Regeneron to Acquire 23andMe -- WSJ
REGN,2025-05-20,06:32:05,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron said it expects the deal to close in the third quarter,FULL-ARTICLE,Wall Street Journal,Regeneron to Acquire 23andMe -- WSJ
REGN,2025-05-20,11:30:00,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Viz.ai Announces Collaboration With Sanofi and Regeneron,PRESS-RELEASE,Business Wire,Viz.ai Announces Collaboration With Sanofi and Regeneron to Improve Management and Care of Chronic Obstructive Pulmonary Disease (COPD)
REGN,2025-05-22,06:35:28,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Bayer's Eylea Approved in China,NEWS-FLASH,Dow Jones Newswires,Bayer's Eylea Approved in China for Wet Age-Related Macular Degeneration
REGN,2025-05-22,12:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals announced its acquisition of 23andMe for,PRESS-RELEASE,GlobeNewswire,AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition
REGN,2025-05-22,12:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron's $256M 23andMe Acquisition,PRESS-RELEASE,GlobeNewswire,AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition
REGN,2025-05-22,12:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals announced its acquisition of 23andMe for,PRESS-RELEASE,Dow Jones Newswires,Press Release: AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition
REGN,2025-05-22,12:15:00,589803,Regeneron Pharmaceuticals Inc.,100,0.62,acquisitions-mergers,,Regeneron's $256M 23andMe Acquisition,PRESS-RELEASE,Dow Jones Newswires,Press Release: AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition
REGN,2025-05-27,14:27:29,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,unchanged,Regeneron Pharma Price Target Maintained With a $943.00/Share by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Maintained With a $943.00/Share by RBC Capital
REGN,2025-05-28,13:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Telesis Bio Announces Licensing Agreement with Regeneron,PRESS-RELEASE,Business Wire,Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA(TM) Platform for Rapid On-Site DNA and Gene Synthesis
REGN,2025-05-30,10:23:52,589803,Regeneron Pharmaceuticals Inc.,95,0.0,products-services,,Sanofi and Regeneron Pharmaceuticals reported mixed results for two late-stage trials,FULL-ARTICLE,Dow Jones Newswires,"Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials -- Update"
REGN,2025-05-30,10:38:52,589803,Regeneron Pharmaceuticals Inc.,95,0.0,products-services,,Sanofi and Regeneron Pharmaceuticals reported mixed results for two late-stage trials,FULL-ARTICLE,Dow Jones Newswires,"Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials -- Update"
REGN,2025-05-30,12:32:19,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,The U.S. Food and Drug Administration approved Dupixent as,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Plunges. Why a Drug Trial Missed the Mark. -- Barrons.com
REGN,2025-05-30,14:11:34,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,The U.S. Food and Drug Administration approved Dupixent as,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Plunges. Why a Drug Trial Missed the Mark. -- Barrons.com
REGN,2025-05-30,14:11:34,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Cantor Fitzgerald L.P.: the firm reiterated an Overweight rating and $695 target price on Regeneron,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Plunges. Why a Drug Trial Missed the Mark. -- Barrons.com
REGN,2025-05-30,14:11:34,589803,Regeneron Pharmaceuticals Inc.,100,0.65,revenues,up,Dupixent sales higher,FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Plunges. Why a Drug Trial Missed the Mark. -- Barrons.com
REGN,2025-05-30,18:31:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,analyst-ratings,negative,Regeneron Pharma Cut to Equal-Weight From Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Cut to Equal-Weight From Overweight by Wells Fargo
REGN,2025-05-30,18:31:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Regeneron Pharma Price Target Cut to $580.00/Share From $700.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $580.00/Share From $700.00 by Wells Fargo
REGN,2025-05-30,19:19:24,589803,Regeneron Pharmaceuticals Inc.,95,0.0,products-services,,Regeneron said one Phase 3 trial of itepekimab,FULL-ARTICLE,MarketWatch,MW Regeneron dashes Wall Street's hopes as COPD treatment trial suffers a failure
REGN,2025-06-02,11:05:33,589803,Regeneron Pharmaceuticals Inc.,99,0.39,products-services,,Regeneron Pharmaceuticals Inc.: New licensing agreement with Hansoh Pharma,PRESS-RELEASE,GlobeNewswire,Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
REGN,2025-06-02,11:05:33,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 3 trial in,PRESS-RELEASE,GlobeNewswire,Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
REGN,2025-06-02,11:05:33,589803,Regeneron Pharmaceuticals Inc.,99,0.39,products-services,,Regeneron Pharmaceuticals Inc.: New licensing agreement with Hansoh Pharma,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
REGN,2025-06-02,11:05:33,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 3 trial in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
REGN,2025-06-02,11:06:06,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Pharma in Licensing Agreement With Hansoh Pharmaceuticals,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma in Licensing Agreement With Hansoh Pharmaceuticals >REGN
REGN,2025-06-02,11:38:26,589803,Regeneron Pharmaceuticals Inc.,95,0.0,products-services,,Partner Regeneron last week said itepekimab missed the primary goal of a late-stage clinical trial,FULL-ARTICLE,Dow Jones Newswires,"Sanofi, Regeneron's Respiratory Drug Itepekimab Could Be Delayed by Two Years -- Market Talk"
REGN,2025-06-02,11:39:46,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Signs Licensing Agreement for Chinese,FULL-ARTICLE,Dow Jones Newswires,Regeneron Signs Licensing Agreement for Chinese Weight Loss Drug
REGN,2025-06-02,11:54:46,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Signs Licensing Agreement for Chinese,FULL-ARTICLE,Dow Jones Newswires,Regeneron Signs Licensing Agreement for Chinese Weight Loss Drug
REGN,2025-06-02,12:51:05,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley
REGN,2025-06-02,12:51:05,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Regeneron Pharma Price Target Cut to $755.00/Share From $958.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $755.00/Share From $958.00 by Morgan Stanley
REGN,2025-06-02,13:48:15,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by BMO Capital
REGN,2025-06-02,13:48:15,589803,Regeneron Pharmaceuticals Inc.,100,-0.84,price-targets,downgrade,Regeneron Pharma Price Target Cut to $600.00/Share From $800.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $600.00/Share From $800.00 by BMO Capital
REGN,2025-06-02,14:54:35,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Citigroup
REGN,2025-06-02,14:54:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.68,price-targets,downgrade,Regeneron Pharma Price Target Cut to $650.00/Share From $700.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $650.00/Share From $700.00 by Citigroup
REGN,2025-06-05,13:32:42,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Neutral by UBS,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Neutral by UBS
REGN,2025-06-05,13:32:42,589803,Regeneron Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Regeneron Pharma Price Target Cut to $560.00/Share From $633.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $560.00/Share From $633.00 by UBS
REGN,2025-06-05,14:17:36,589803,Regeneron Pharmaceuticals Inc.,97,0.55,acquisitions-mergers,interest,Regeneron planned to acquire 23andMe,FULL-ARTICLE,Dow Jones Newswires,23andMe Angles For A Bigger Regeneron Bid As Ex-CEO Steps Up With A Better Offer -- IBD
REGN,2025-06-05,20:06:36,589803,Regeneron Pharmaceuticals Inc.,97,0.55,acquisitions-mergers,interest,Regeneron planned to acquire 23andMe,FULL-ARTICLE,Dow Jones Newswires,The New Twist In Regeneron's 23andMe Bankruptcy Buyout -- IBD
REGN,2025-06-09,15:43:51,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by JP Morgan
REGN,2025-06-09,15:43:51,589803,Regeneron Pharmaceuticals Inc.,100,-0.82,price-targets,downgrade,Regeneron Pharma Price Target Cut to $800.00/Share From $950.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $800.00/Share From $950.00 by JP Morgan
REGN,2025-06-13,20:14:28,589803,Regeneron Pharmaceuticals Inc.,100,-0.62,acquisitions-mergers,failed,Regeneron Walks Away From 23andMe Acquisition,NEWS-FLASH,Dow Jones Newswires,Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ
REGN,2025-06-16,13:30:43,589803,Regeneron Pharmaceuticals Inc.,92,0.55,acquisitions-mergers,interest,Regeneron's bid for 23andMe,PRESS-RELEASE,DJ Global Press Release Wire,"Silver Scott Health, Inc. Unveils Health Trust NFT to Empower Patient Data Control in Response to Regeneron's $600 Million 23andMe Bid"
REGN,2025-06-20,05:01:40,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Say Dupixent Approved in U.S.,NEWS-FLASH,Dow Jones Newswires,"Sanofi, Regeneron Say Dupixent Approved in U.S. for Bullous Pemphigoid"
REGN,2025-06-20,05:03:33,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron: Dupixent Is Now Approved in U.S.,NEWS-FLASH,Dow Jones Newswires,"Sanofi, Regeneron: Dupixent Is Now Approved in U.S. to Treat Eight Distinct Diseases"
REGN,2025-06-20,05:25:47,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Sanofi, Regeneron Get FDA Approval for Dupixent",FULL-ARTICLE,Dow Jones Newswires,"Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease"
REGN,2025-06-20,05:40:47,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Sanofi, Regeneron Get FDA Approval for Dupixent",FULL-ARTICLE,Dow Jones Newswires,"Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease"
REGN,2025-06-24,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,GlobeNewswire,Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
REGN,2025-06-24,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
REGN,2025-06-26,20:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report Second Quarter 2025 Financial and Operating Results,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025"
REGN,2025-06-26,20:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025"
REGN,2025-07-02,14:45:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Apotex receives Health Canada approval for Aflivu(TM), a biosimilar to Eylea(R)",PRESS-RELEASE,Canadian News Wire,"Apotex receives Health Canada approval for Aflivu(TM), a biosimilar to Eylea(R), available in pre-filled syringe and vial formats"
REGN,2025-07-02,14:45:03,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Apotex receives Health Canada approval for Aflivu(TM), a biosimilar to Eylea(R)",PRESS-RELEASE,PR Newswire,"(PR) Apotex receives Health Canada approval for Aflivu(TM), a biosimilar to Eylea(R), available in pre-filled syringe and vial formats"
REGN,2025-07-02,14:49:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Apotex Receives Health Canada Approval for Aflivu Biosimilar to Eylea,NEWS-FLASH,Dow Jones Newswires,Apotex Receives Health Canada Approval for Aflivu Biosimilar to Eylea
REGN,2025-07-02,14:49:26,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Apotex receives Health Canada approval for Aflivu(TM), a biosimilar to Eylea(R)",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Apotex receives Health Canada approval for Aflivu(TM), a biosimilar to Eylea(R), available in pre-filled syringe and vial formats"
REGN,2025-07-02,15:00:36,589803,Regeneron Pharmaceuticals Inc.,100,0.71,products-services,,Linvoseltamab-gcpt) Receives FDA Accelerated Approval,PRESS-RELEASE,GlobeNewswire,Lynozyfic(TM) (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma
REGN,2025-07-02,15:00:37,589803,Regeneron Pharmaceuticals Inc.,100,0.71,products-services,,Linvoseltamab-gcpt) Receives FDA Accelerated Approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Lynozyfic(TM) (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma
REGN,2025-07-02,15:01:08,589803,Regeneron Pharmaceuticals Inc.,100,0.71,products-services,,Regeneron: Lynozyfic Gets FDA Accelerated Approval,NEWS-FLASH,Dow Jones Newswires,Regeneron: Lynozyfic Gets FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma >REGN
REGN,2025-07-02,15:24:18,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment
REGN,2025-07-02,15:24:18,589803,Regeneron Pharmaceuticals Inc.,100,0.71,products-services,,Regeneron Pharmaceuticals has won Food and Drug Administration accelerated approval,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment
REGN,2025-07-02,15:39:18,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment
REGN,2025-07-02,15:39:18,589803,Regeneron Pharmaceuticals Inc.,100,0.71,products-services,,Regeneron Pharmaceuticals has won Food and Drug Administration accelerated approval,FULL-ARTICLE,Dow Jones Newswires,Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment
REGN,2025-07-03,06:33:08,589803,Regeneron Pharmaceuticals Inc.,94,0.71,products-services,,Regeneron Pharmaceuticals has won Food and Drug Administration accelerated approval,FULL-ARTICLE,Wall Street Journal,Regeneron Blood-Cancer Drug Cleared For Some -- WSJ
REGN,2025-07-10,16:23:23,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley
REGN,2025-07-10,16:23:23,589803,Regeneron Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Regeneron Pharma Price Target Cut to $754.00/Share From $755.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $754.00/Share From $755.00 by Morgan Stanley
REGN,2025-07-11,19:09:55,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Neutral by UBS,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Neutral by UBS
REGN,2025-07-11,19:09:55,589803,Regeneron Pharmaceuticals Inc.,100,0.52,price-targets,upgrade,Regeneron Pharma Price Target Raised to $584.00/Share From $560.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $584.00/Share From $560.00 by UBS
REGN,2025-07-14,12:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Extends the Approval of Evkeeza(R) (evinacumab),PRESS-RELEASE,GlobeNewswire,Health Canada Extends the Approval of Evkeeza(R) (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)
REGN,2025-07-14,12:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Extends the Approval of Evkeeza(R),PRESS-RELEASE,GlobeNewswire,Health Canada Extends the Approval of Evkeeza(R) -2-
REGN,2025-07-14,12:00:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Extends the Approval of Evkeeza(R) (evinacumab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Health Canada Extends the Approval of Evkeeza(R) (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)
REGN,2025-07-14,12:04:52,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Health Canada Extends Approval of Evkeeza,NEWS-FLASH,Dow Jones Newswires,Health Canada Extends Approval of Evkeeza to Children as Young as 6-Mos Old With Homozygous Familial Hypercholesterolemia
REGN,2025-07-23,13:20:02,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Canaccord Genuity
REGN,2025-07-23,13:20:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,unchanged,Regeneron Pharma Price Target Maintained With a $850.00/Share by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Maintained With a $850.00/Share by Canaccord Genuity
REGN,2025-07-24,11:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,GlobeNewswire,Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation
REGN,2025-07-24,11:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.58,indexes,,Regeneron is proud to be included on the Dow Jones Sustainability World Index,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation
REGN,2025-07-28,06:00:42,589803,Regeneron Pharmaceuticals Inc.,100,0.82,products-services,positive,Alteogen Receives Positive CHMP Opinion for Aflibercept,PRESS-RELEASE,PR Newswire,"Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI(R) (ALT-L9)'"
REGN,2025-07-28,06:00:42,589803,Regeneron Pharmaceuticals Inc.,100,0.82,products-services,positive,Alteogen Receives Positive CHMP Opinion for Aflibercept,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI(R) (ALT-L9)'"
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 2Q EPS $12.81,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q EPS $12.81 >REGN
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2025",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Second quarter 2025 revenues increased 4% to $3.68 billion,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.4,earnings,up,Regeneron Pharmaceuticals Inc.: GAAP EPS increased 3% to $12.81,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.4,earnings,up,Regeneron Pharmaceuticals Inc.: non-GAAP EPS(a) increased 12% to $12.89,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda accepted for priority review Libtayo(R) sBLA,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,676 $ 3,547",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"June 2025, the FDA approved Dupixent",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"April 2025, the FDA approved Dupixent",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: The European Commission (EC) approved EYLEA,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda granted accelerated approval for Lynozyfic (linvoseltamab,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.41,products-services,start,Regeneron Pharmaceuticals Inc.: Initiation of additional Phase 3 studies,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Pharmaceuticals Inc.: the Company's license agreement with Hansoh Pharmaceuticals Group Company Limited to,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,"Regeneron Pharmaceuticals Inc.: In June 2025, the Company announced the launch of a matching program",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Second Quarter 2025 Financial Results,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial -2-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,676 $ 3,547",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial -2-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA HD increased in the second quarter of 2025,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial -2-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the second quarter,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial -2-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial -2-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the second quarter of 2025, the Company repurchased shares of its common stock",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial -2-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,dividends,,Regeneron Pharmaceuticals Inc.: the Company's board of directors declared a cash dividend of $0.88,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial -2-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2025 Financial Guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial -2-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2025 financial guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial -3-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its second quarter 2025 financial and operating results on Friday, August 1, 2025, at 8:30 AM Eastern Time",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial -3-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: June 30, December 31, 2025 2024 Assets",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial -4-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial -4-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Net income $1,391.6 $1,432.3",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial -4-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 13.24 $ 13.25 $,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial -4-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $1,391.6 $1,432.3",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial -5-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,423.6 $1,351.2",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial -5-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 13.55 $ 12.50 $,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial -5-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total collaboration revenue,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial -5-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Second Quarter 2025 Financial Results",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Second Quarter 2025 Financial -5-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 2Q Net $1.39B,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q Net $1.39B >REGN
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 2Q Rev $3.68B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q Rev $3.68B >REGN
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2025",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Second quarter 2025 revenues increased 4% to $3.68 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.4,earnings,up,Regeneron Pharmaceuticals Inc.: GAAP EPS increased 3% to $12.81,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.4,earnings,up,Regeneron Pharmaceuticals Inc.: non-GAAP EPS(a) increased 12% to $12.89,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.65,products-services,,Fda accepted for priority review Libtayo(R) sBLA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,676 $ 3,547",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"June 2025, the FDA approved Dupixent",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"April 2025, the FDA approved Dupixent",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: The European Commission (EC) approved EYLEA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Fda granted accelerated approval for Lynozyfic (linvoseltamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.41,products-services,start,Regeneron Pharmaceuticals Inc.: Initiation of additional Phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Regeneron Pharmaceuticals Inc.: the Company's license agreement with Hansoh Pharmaceuticals Group Company Limited to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.52,products-services,,"Regeneron Pharmaceuticals Inc.: In June 2025, the Company announced the launch of a matching program",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter 2025 Financial and Operating Results
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Second Quarter 2025 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,676 $ 3,547",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA HD increased in the second quarter of 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the second quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the second quarter of 2025, the Company repurchased shares of its common stock",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,dividends,,Regeneron Pharmaceuticals Inc.: the Company's board of directors declared a cash dividend of $0.88,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2025 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -2-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: The Company's 2025 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -3-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its second quarter 2025 financial and operating results on Friday, August 1, 2025, at 8:30 AM Eastern Time",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -3-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: June 30, December 31, 2025 2024 Assets",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Net income $1,391.6 $1,432.3",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 13.24 $ 13.25 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -4-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $1,391.6 $1,432.3",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -5-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,423.6 $1,351.2",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -5-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 13.55 $ 12.50 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -5-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total collaboration revenue,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -5-
REGN,2025-08-01,10:30:02,589803,Regeneron Pharmaceuticals Inc.,98,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Second Quarter 2025 Financial Results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Second Quarter -5-
REGN,2025-08-01,10:30:37,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 2Q Adj EPS $12.89,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 2Q Adj EPS $12.89 >REGN
REGN,2025-08-01,10:31:06,589803,Regeneron Pharmaceuticals Inc.,100,0.42,revenues,up,Regeneron Pharma: 2Q Dupixent Global Net Sales Recorded by Sanofi Rose 22%,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma: 2Q Dupixent Global Net Sales Recorded by Sanofi Rose 22% to $4.34B >REGN
REGN,2025-08-01,10:31:38,589803,Regeneron Pharmaceuticals Inc.,100,-0.44,revenues,down,"Regeneron Pharma 2Q Eylea HD, Eylea U.S. Net Sales Fell 25%",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharma 2Q Eylea HD, Eylea U.S. Net Sales Fell 25% to $1.15B >REGN"
REGN,2025-08-01,10:37:29,589803,Regeneron Pharmaceuticals Inc.,100,-0.58,products-services,denied,Regeneron Gets FDA Complete Response Letter for Odronextamab,NEWS-FLASH,Dow Jones Newswires,Regeneron Gets FDA Complete Response Letter for Odronextamab in Follicular Lymphoma >REGN
REGN,2025-08-01,10:41:16,589803,Regeneron Pharmaceuticals Inc.,100,0.32,equity-actions,up,Regeneron Now Sees 2025 Capital Spending $880M-$950M; Had Seen $850M-$950M,NEWS-FLASH,Dow Jones Newswires,Regeneron Now Sees 2025 Capital Spending $880M-$950M; Had Seen $850M-$950M >REGN
REGN,2025-08-01,11:18:45,589803,Regeneron Pharmaceuticals Inc.,92,0.72,revenues,above-expectations,Regeneron Pharmaceuticals posted better-than-expected revenue,FULL-ARTICLE,Dow Jones Newswires,"Regeneron 2Q Revenue, Adjusted EPS Top Estimates"
REGN,2025-08-01,11:33:45,589803,Regeneron Pharmaceuticals Inc.,92,0.72,revenues,above-expectations,Regeneron Pharmaceuticals posted better-than-expected revenue,FULL-ARTICLE,Dow Jones Newswires,"Regeneron 2Q Revenue, Adjusted EPS Top Estimates"
REGN,2025-08-01,12:07:39,589803,Regeneron Pharmaceuticals Inc.,98,0.0,products-services,,Regeneron is seeking approval of odronextamab,FULL-ARTICLE,Dow Jones Newswires,"Regeneron's Eylea HD, Odronextamab Applications Hit FDA Snag"
REGN,2025-08-01,12:22:39,589803,Regeneron Pharmaceuticals Inc.,98,0.0,products-services,,Regeneron is seeking approval of odronextamab,FULL-ARTICLE,Dow Jones Newswires,"Regeneron's Eylea HD, Odronextamab Applications Hit FDA Snag"
REGN,2025-08-01,12:40:54,589803,Regeneron Pharmaceuticals Inc.,94,0.42,revenues,up,"Revenue by Regeneron, rose 22%",FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com
REGN,2025-08-01,13:16:54,589803,Regeneron Pharmaceuticals Inc.,94,0.42,revenues,up,"Revenue by Regeneron, rose 22%",FULL-ARTICLE,Dow Jones Newswires,Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com
REGN,2025-08-04,13:37:49,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Guggenheim
REGN,2025-08-04,13:37:49,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $815.00/Share From $810.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $815.00/Share From $810.00 by Guggenheim
REGN,2025-08-04,14:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital
REGN,2025-08-04,14:30:09,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $695.00/Share From $688.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $695.00/Share From $688.00 by RBC Capital
REGN,2025-08-04,15:01:30,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley
REGN,2025-08-04,15:01:30,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $761.00/Share From $754.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $761.00/Share From $754.00 by Morgan Stanley
REGN,2025-08-04,18:09:50,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by BMO Capital
REGN,2025-08-04,18:09:50,589803,Regeneron Pharmaceuticals Inc.,100,0.64,price-targets,upgrade,Regeneron Pharma Price Target Raised to $640.00/Share From $600.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $640.00/Share From $600.00 by BMO Capital
REGN,2025-08-11,15:17:35,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Truist Securities
REGN,2025-08-11,15:17:35,589803,Regeneron Pharmaceuticals Inc.,100,-0.8,price-targets,downgrade,Regeneron Pharma Price Target Cut to $812.00/Share From $940.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $812.00/Share From $940.00 by Truist Securities
REGN,2025-08-14,20:29:03,589803,Regeneron Pharmaceuticals Inc.,100,0.37,equity-actions,increase,Llc Takes New Stake in Regeneron Pharmaceuticals,RNS-SEC13F,Dow Jones Newswires,"Scion Asset Management, LLC Takes New Stake in Regeneron Pharmaceuticals, With 215,000 Shares"
REGN,2025-08-19,07:08:10,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,"Regeneron Pharmaceuticals Inc, Inst Holders, 2Q 2025 (REGN)",RNS-SEC13F,Dow Jones Newswires,"Regeneron Pharmaceuticals  Inc, Inst Holders, 2Q 2025 (REGN)"
REGN,2025-08-26,11:00:20,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Announces Positive Results from Phase 3 Trial,PRESS-RELEASE,GlobeNewswire,Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
REGN,2025-08-26,11:00:20,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: U.S. regulatory submission for cemdisiran,PRESS-RELEASE,GlobeNewswire,Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
REGN,2025-08-26,11:00:20,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The NIMBLE trial results underscore the potential for cemdisiran,PRESS-RELEASE,GlobeNewswire,Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
REGN,2025-08-26,11:00:20,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Regeneron Pharmaceuticals Inc.: In the U.S., pozelimab monotherapy is approved as Veopoz(R) (pozelimab-bbfg)",PRESS-RELEASE,GlobeNewswire,Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
REGN,2025-08-26,11:00:20,589803,Regeneron Pharmaceuticals Inc.,99,0.39,products-services,,Regeneron and Alnylam entered into an amended and restated C5 License Agreement,PRESS-RELEASE,GlobeNewswire,Regeneron Announces Positive Results from Phase 3 -2-
REGN,2025-08-26,11:00:21,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Announces Positive Results from Phase 3 Trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
REGN,2025-08-26,11:00:21,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: U.S. regulatory submission for cemdisiran,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
REGN,2025-08-26,11:00:21,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The NIMBLE trial results underscore the potential for cemdisiran,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
REGN,2025-08-26,11:00:21,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Regeneron Pharmaceuticals Inc.: In the U.S., pozelimab monotherapy is approved as Veopoz(R) (pozelimab-bbfg)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
REGN,2025-08-26,11:00:21,589803,Regeneron Pharmaceuticals Inc.,99,0.39,products-services,,Regeneron and Alnylam entered into an amended and restated C5 License Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces Positive -2-
REGN,2025-08-26,11:00:28,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Announces Positive Results From Phase 3 Trial,NEWS-FLASH,Dow Jones Newswires,Regeneron Announces Positive Results From Phase 3 Trial in Generalized Myasthenia Gravis >REGN
REGN,2025-08-26,11:01:11,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharma Plans U.S. Regulatory Submission for Cemdisiran,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Plans U.S. Regulatory Submission for Cemdisiran Monotherapy in 1Q 2026 >REGN
REGN,2025-08-26,11:38:48,589803,Regeneron Pharmaceuticals Inc.,93,0.0,products-services,,Regeneron Pharmaceuticals said a late-stage study of,FULL-ARTICLE,Dow Jones Newswires,Regeneron: Cemdisiran Hits Goals in Generalized Myasthenia Gravis
REGN,2025-08-26,11:53:48,589803,Regeneron Pharmaceuticals Inc.,93,0.0,products-services,,Regeneron Pharmaceuticals said a late-stage study of,FULL-ARTICLE,Dow Jones Newswires,Regeneron: Cemdisiran Hits Goals in Generalized Myasthenia Gravis
REGN,2025-08-27,12:22:42,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Jefferies
REGN,2025-08-27,12:22:42,589803,Regeneron Pharmaceuticals Inc.,100,0.4,price-targets,upgrade,Regeneron Pharma Price Target Raised to $831.00/Share From $813.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $831.00/Share From $813.00 by Jefferies
REGN,2025-08-27,15:01:42,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Outperform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Outperform by Bernstein
REGN,2025-08-27,15:01:42,589803,Regeneron Pharmaceuticals Inc.,100,0.48,price-targets,upgrade,Regeneron Pharma Price Target Raised to $781.00/Share From $753.00 by Bernstein,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $781.00/Share From $753.00 by Bernstein
REGN,2025-09-04,20:05:02,589803,Regeneron Pharmaceuticals Inc.,99,0.0,marketing,,"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will now present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET",PRESS-RELEASE,GlobeNewswire,Regeneron Announces Updated Presentation Time for Upcoming Investor Conference
REGN,2025-09-08,10:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Data from the Phase 3 trials,PRESS-RELEASE,GlobeNewswire,Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
REGN,2025-09-08,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Data from the Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
REGN,2025-09-09,05:00:18,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Sandoz reaches agreement with Regeneron,PRESS-RELEASE,Dow Jones Newswires,"Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar"
REGN,2025-09-09,05:00:18,589803,Regeneron Pharmaceuticals Inc.,100,0.46,legal,,"Sandoz reaches agreement with Regeneron, resolving all patent litigation",PRESS-RELEASE,Dow Jones Newswires,"Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar"
REGN,2025-09-09,05:00:18,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,The US Food and Drug Administration (FDA)-approved Sandoz aflibercept,PRESS-RELEASE,Dow Jones Newswires,"Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar"
REGN,2025-09-09,05:00:18,589803,Regeneron Pharmaceuticals Inc.,100,-0.53,legal,,Patent infringement proceedings were initially filed by Regeneron in the US Federal District Court,PRESS-RELEASE,Dow Jones Newswires,"Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar"
REGN,2025-09-09,05:00:18,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Sandoz reaches agreement with Regeneron,PRESS-RELEASE,DGAP News,"Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar"
REGN,2025-09-09,05:00:18,589803,Regeneron Pharmaceuticals Inc.,100,0.46,legal,,"Sandoz reaches agreement with Regeneron, resolving all patent litigation",PRESS-RELEASE,DGAP News,"Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar"
REGN,2025-09-09,05:00:18,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,The US Food and Drug Administration (FDA)-approved Sandoz aflibercept,PRESS-RELEASE,DGAP News,"Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar"
REGN,2025-09-09,05:00:18,589803,Regeneron Pharmaceuticals Inc.,100,-0.53,legal,,Patent infringement proceedings were initially filed by Regeneron in the US Federal District Court,PRESS-RELEASE,DGAP News,"Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar"
REGN,2025-09-09,05:03:08,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Sandoz Reaches Pact With Regeneron,NEWS-FLASH,Dow Jones Newswires,Sandoz Reaches Pact With Regeneron
REGN,2025-09-09,05:54:58,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Sandoz Reaches Pact With Regeneron,FULL-ARTICLE,Dow Jones Newswires,Sandoz Reaches Pact With Regeneron on Enzeevu Patent Disputes
REGN,2025-09-09,06:09:58,589803,Regeneron Pharmaceuticals Inc.,100,0.39,products-services,,Sandoz Reaches Pact With Regeneron,FULL-ARTICLE,Dow Jones Newswires,Sandoz Reaches Pact With Regeneron on Enzeevu Patent Disputes
REGN,2025-09-09,08:04:22,589803,Regeneron Pharmaceuticals Inc.,93,0.39,products-services,,Sandoz's agreement with Regeneron to,FULL-ARTICLE,Dow Jones Newswires,Sandoz's Patent Resolution With Regeneron to Help U.S. Growth -- Market Talk
REGN,2025-09-09,21:46:00,589803,Regeneron Pharmaceuticals Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)",PRESS-RELEASE,GlobeNewswire,"REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
REGN,2025-09-09,21:46:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron released its third quarter 2024 financial results,PRESS-RELEASE,GlobeNewswire,"REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
REGN,2025-09-09,21:46:00,589803,Regeneron Pharmaceuticals Inc.,99,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: The Company reported sales had only increased 3%,PRESS-RELEASE,GlobeNewswire,"REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
REGN,2025-09-17,11:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Announces Positive Phase 3 Trial,PRESS-RELEASE,GlobeNewswire,"Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation"
REGN,2025-09-17,11:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: U.S. regulatory submission of garetosmab,PRESS-RELEASE,GlobeNewswire,"Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation"
REGN,2025-09-17,11:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 3 trial of garetosmab,PRESS-RELEASE,GlobeNewswire,"Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation"
REGN,2025-09-17,11:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Announces Positive Phase 3 Trial,PRESS-RELEASE,GlobeNewswire,Regeneron Announces Positive Phase 3 Trial in -2-
REGN,2025-09-17,11:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.69,products-services,,"In 2017, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for garetosmab",PRESS-RELEASE,GlobeNewswire,Regeneron Announces Positive Phase 3 Trial in -2-
REGN,2025-09-17,11:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Announces Positive Phase 3 Trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation"
REGN,2025-09-17,11:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: U.S. regulatory submission of garetosmab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation"
REGN,2025-09-17,11:00:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Pharmaceuticals Inc.: A Phase 3 trial of garetosmab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation"
REGN,2025-09-17,11:00:02,589803,Regeneron Pharmaceuticals Inc.,99,0.69,products-services,,"In 2017, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for garetosmab",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Announces Positive Phase -2-
REGN,2025-09-17,11:00:37,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Announces Positive Phase 3 Trial,NEWS-FLASH,Dow Jones Newswires,Regeneron Announces Positive Phase 3 Trial in Adults With Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva >REGN
REGN,2025-09-17,11:07:33,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,Regeneron Plans U.S. Regulatory Submission of Garetosmab,NEWS-FLASH,Dow Jones Newswires,Regeneron Plans U.S. Regulatory Submission of Garetosmab in Adults by End 2025 >REGN
REGN,2025-09-17,11:23:26,589803,Regeneron Pharmaceuticals Inc.,100,0.62,products-services,positive,Regeneron's Garetosmab Hits Main Endpoint in Phase 3 Study,FULL-ARTICLE,Dow Jones Newswires,Regeneron's Garetosmab Hits Main Endpoint in Phase 3 Study
REGN,2025-09-17,11:38:26,589803,Regeneron Pharmaceuticals Inc.,100,0.62,products-services,positive,Regeneron's Garetosmab Hits Main Endpoint in Phase 3 Study,FULL-ARTICLE,Dow Jones Newswires,Regeneron's Garetosmab Hits Main Endpoint in Phase 3 Study
REGN,2025-09-17,14:15:09,589803,Regeneron Pharmaceuticals Inc.,91,0.0,products-services,,Regeneron Pharmaceuticals said a mid-stage study of,FULL-ARTICLE,Dow Jones Newswires,Regeneron's Potential Obesity Treatment Could Preserve Muscle Mass
REGN,2025-09-17,14:30:09,589803,Regeneron Pharmaceuticals Inc.,91,0.0,products-services,,Regeneron Pharmaceuticals said a mid-stage study of,FULL-ARTICLE,Dow Jones Newswires,Regeneron's Potential Obesity Treatment Could Preserve Muscle Mass
REGN,2025-09-19,11:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.26,corporate-responsibility,,Regeneron Donates Ebola Treatment,PRESS-RELEASE,GlobeNewswire,Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
REGN,2025-09-19,11:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Inmazeb was approved by the FDA in 2020,PRESS-RELEASE,GlobeNewswire,Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
REGN,2025-09-19,11:00:00,589803,Regeneron Pharmaceuticals Inc.,100,0.26,corporate-responsibility,,Regeneron Donates Ebola Treatment,PRESS-RELEASE,GlobeNewswire,Regeneron Donates Ebola Treatment for Use in -2-
REGN,2025-09-19,11:00:01,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Inmazeb was approved by the FDA in 2020,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
REGN,2025-09-22,04:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,GlobeNewswire,Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
REGN,2025-09-22,04:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,GlobeNewswire,Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
REGN,2025-09-22,04:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
REGN,2025-09-22,04:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
REGN,2025-09-22,04:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
REGN,2025-09-22,04:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
REGN,2025-09-22,04:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Dupixent has received regulatory approvals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
REGN,2025-09-22,04:30:00,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Dupilumab is being jointly developed by Sanofi and Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
REGN,2025-09-26,11:01:46,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron: FDA Approves Evkeeza,NEWS-FLASH,Dow Jones Newswires,Regeneron: FDA Approves Evkeeza for Children Ages 1 to Less Than 5 Years Old With Homozygous Familial Hypercholesterolemia >REGN
REGN,2025-09-26,11:30:14,589803,Regeneron Pharmaceuticals Inc.,93,0.57,products-services,granted,Initially won FDA approval of Evkeeza,FULL-ARTICLE,Dow Jones Newswires,Regeneron: FDA Expands Evkeeza Approval to Children as Young as 1
REGN,2025-09-26,11:45:14,589803,Regeneron Pharmaceuticals Inc.,93,0.57,products-services,granted,Initially won FDA approval of Evkeeza,FULL-ARTICLE,Dow Jones Newswires,Regeneron: FDA Expands Evkeeza Approval to Children as Young as 1
REGN,2025-09-30,20:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron to Report Third Quarter 2025 Financial and Operating Results,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025"
REGN,2025-09-30,20:05:00,589803,Regeneron Pharmaceuticals Inc.,100,0.0,investor-relations,,Regeneron Pharmaceuticals Inc.: The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time,PRESS-RELEASE,GlobeNewswire,"Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025"
REGN,2025-10-02,04:30:17,589803,Regeneron Pharmaceuticals Inc.,97,0.46,legal,,"Regeneron Pharmaceuticals, Inc. (""Regeneron""), resolving all patent disputes",PRESS-RELEASE,DGAP News,EQS-News: Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
REGN,2025-10-02,04:30:17,589803,Regeneron Pharmaceuticals Inc.,97,-0.53,legal,,Regeneron initiated patent infringement proceedings against Formycon,PRESS-RELEASE,DGAP News,EQS-News: Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
REGN,2025-10-02,04:30:17,589803,Regeneron Pharmaceuticals Inc.,97,0.46,legal,,"Regeneron Pharmaceuticals, Inc. (""Regeneron""), resolving all patent disputes",PRESS-RELEASE,Dow Jones Newswires,EQS-News: Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
REGN,2025-10-02,04:30:17,589803,Regeneron Pharmaceuticals Inc.,97,-0.53,legal,,Regeneron initiated patent infringement proceedings against Formycon,PRESS-RELEASE,Dow Jones Newswires,EQS-News: Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
REGN,2025-10-06,11:28:01,589803,Regeneron Pharmaceuticals Inc.,100,-0.45,equity-actions,charge,Regeneron Pharma Sees 3Q Including Acquired In-Process R&D Charge of $83M,RNS-SEC8K,Dow Jones Newswires,Regeneron Pharma Sees 3Q Including Acquired In-Process R&D Charge of $83M on Pre-Tex Basis >REGN
REGN,2025-10-06,11:59:06,589803,Regeneron Pharmaceuticals Inc.,100,0.0,equity-actions,,Regeneron Sees $83 Million Charge,FULL-ARTICLE,Dow Jones Newswires,Regeneron Sees $83 Million Charge Hurting 3Q Results
REGN,2025-10-06,12:14:06,589803,Regeneron Pharmaceuticals Inc.,100,0.0,equity-actions,,Regeneron Sees $83 Million Charge,FULL-ARTICLE,Dow Jones Newswires,Regeneron Sees $83 Million Charge Hurting 3Q Results
REGN,2025-10-08,18:33:30,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron: Libtayo (cemiplimab-Rwlc) Gets FDA Approval for Adjuvant Treatment,NEWS-FLASH,Dow Jones Newswires,Regeneron: Libtayo (cemiplimab-Rwlc) Gets FDA Approval for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma With High Risk of Recurrence After Surgery and Radiation
REGN,2025-10-08,20:04:49,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Gets FDA Approval for Skin Cancer Treatment,FULL-ARTICLE,Dow Jones Newswires,Regeneron Pharmaceuticals Gets FDA Approval for Skin Cancer Treatment
REGN,2025-10-09,22:56:28,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Celltrion Receives U.S. FDA Approval For EYDENZELT(R) (aflibercept-boav), Biosimilar Referencing EYLEA(R) (aflibercept)",NEWS-FLASH,Dow Jones Newswires,"Celltrion Receives U.S. FDA Approval For EYDENZELT(R) (aflibercept-boav), Biosimilar Referencing EYLEA(R) (aflibercept) >068270.SE"
REGN,2025-10-09,22:56:28,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"The U.S. Food and Drug Administration (FDA) has approved EYDENZELT(R) (aflibercept-boav), biosimilar referencing EYLEA(R) (aflibercept), for the",PRESS-RELEASE,PR Newswire,"Celltrion receives U.S. FDA approval for EYDENZELT(R) (aflibercept-boav), biosimilar referencing EYLEA(R) (aflibercept)"
REGN,2025-10-09,22:56:32,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"The U.S. Food and Drug Administration (FDA) has approved EYDENZELT(R) (aflibercept-boav), biosimilar referencing EYLEA(R) (aflibercept), for the",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Celltrion receives U.S. FDA approval for EYDENZELT(R) (aflibercept-boav), biosimilar referencing EYLEA(R) (aflibercept)"
REGN,2025-10-10,17:34:55,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Morgan Stanley
REGN,2025-10-10,17:34:55,589803,Regeneron Pharmaceuticals Inc.,100,-0.17,price-targets,downgrade,Regeneron Pharma Price Target Cut to $756.00/Share From $761.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Cut to $756.00/Share From $761.00 by Morgan Stanley
REGN,2025-10-13,16:07:11,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Citigroup
REGN,2025-10-13,16:07:11,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $660.00/Share From $650.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $660.00/Share From $650.00 by Citigroup
REGN,2025-10-14,14:20:23,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Canaccord Genuity
REGN,2025-10-14,14:20:23,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,unchanged,Regeneron Pharma Price Target Maintained With a $850.00/Share by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Maintained With a $850.00/Share by Canaccord Genuity
REGN,2025-10-15,11:00:41,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Recently supported the FDA approval of Libtayo,PRESS-RELEASE,GlobeNewswire,"Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers"
REGN,2025-10-15,11:00:41,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Ubamatamab Randomized Phase 2 study of,PRESS-RELEASE,GlobeNewswire,"Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers"
REGN,2025-10-15,11:00:41,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The extensive clinical program for Libtayo,PRESS-RELEASE,GlobeNewswire,"Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers"
REGN,2025-10-15,11:00:45,589803,Regeneron Pharmaceuticals Inc.,99,0.57,products-services,granted,Recently supported the FDA approval of Libtayo,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers"
REGN,2025-10-15,11:00:45,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: Ubamatamab Randomized Phase 2 study of,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers"
REGN,2025-10-15,11:00:45,589803,Regeneron Pharmaceuticals Inc.,99,0.0,products-services,,Regeneron Pharmaceuticals Inc.: The extensive clinical program for Libtayo,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers"
REGN,2025-10-17,11:30:19,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Libtayo(R) (cemiplimab) Recommended for EU Approval,PRESS-RELEASE,GlobeNewswire,Libtayo(R) (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
REGN,2025-10-17,11:30:19,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Libtayo was approved by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,GlobeNewswire,Libtayo(R) (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
REGN,2025-10-17,11:30:23,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Libtayo(R) (cemiplimab) Recommended for EU Approval,PRESS-RELEASE,Dow Jones Newswires,Press Release: Libtayo(R) (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
REGN,2025-10-17,11:30:23,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Libtayo was approved by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Libtayo(R) (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
REGN,2025-10-17,11:31:10,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Libtayo Recommended for EU Approval,NEWS-FLASH,Dow Jones Newswires,"Regeneron: Libtayo Recommended for EU Approval by CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma With High Risk of Recurrence After Surgery, Radiation >REGN"
REGN,2025-10-22,11:00:50,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Dupixent(R) (dupilumab injection) approved in Canada,PRESS-RELEASE,Canadian News Wire,Dupixent(R) (dupilumab injection) approved in Canada for adults with inadequately controlled Chronic Obstructive Pulmonary Disease (COPD)
REGN,2025-10-23,13:13:54,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Canaccord Genuity
REGN,2025-10-23,13:13:54,589803,Regeneron Pharmaceuticals Inc.,100,0.0,price-targets,unchanged,Regeneron Pharma Price Target Maintained With a $850.00/Share by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Maintained With a $850.00/Share by Canaccord Genuity
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Third Quarter 2025 Financial Results,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Third quarter 2025 revenues increased 1% to $3.75 billion,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP EPS of $13.62,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: FDA approved Libtayo(R),PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: Positive Phase 3 results,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Fda approvals for Libtayo, Evkeeza",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,754 $ 3,721",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"September 2025, Japan's Ministry of Health, Labour and Welfare (MHLW) approved Libtayo",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: the Company announced five-year follow-up results,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,U.S. regulatory submission for DB-OTO is planned for the fourth quarter of 2025,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,U.S. regulatory submission for garetosmab is planned for the fourth quarter of 2025,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,"Regeneron Pharmaceuticals Inc.: In September 2025, the Company announced results from the Phase 3 trials",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,100,0.46,legal,,Regeneron Pharmaceuticals Inc.: the Company reached resolution of its patent infringement litigation,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,754 $ 3,720",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial -2-
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA HD increased in the third quarter of 2025,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial -2-
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the third quarter,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial -2-
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial -2-
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D expenses for the third quarter of 2025,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial -2-
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D expenses for the third quarter of 2024,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial -2-
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the third quarter of 2025, the Company repurchased shares of its common stock",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial -2-
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,dividends,,Regeneron Pharmaceuticals Inc.: the Company's board of directors declared a cash dividend of $0.88,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial -2-
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2025 Financial Guidance,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial -2-
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its third quarter 2025 financial and operating results on Tuesday, October 28, 2025, at 8:30 AM Eastern Time",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial -3-
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: September 30, December 31, 2025 2024 Assets",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial -4-
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial -4-
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Net income $1,460.0 $1,340.6",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial -4-
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 14.09 $ 12.40 $,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial -4-
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $1,460.0 $1,340.6",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial -5-
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,287.2 $1,462.4",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial -5-
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 12.42 $ 13.53 $,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial -5-
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,98,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total collaboration revenue,PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial -5-
REGN,2025-10-28,10:30:01,589803,Regeneron Pharmaceuticals Inc.,91,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Third Quarter 2025 Financial Results",PRESS-RELEASE,GlobeNewswire,Regeneron Reports Third Quarter 2025 Financial -6-
REGN,2025-10-28,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 3Q EPS $13.62,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q EPS $13.62 >REGN
REGN,2025-10-28,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 3Q Net $1.46B,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q Net $1.46B >REGN
REGN,2025-10-28,10:30:02,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,Regeneron Pharma 3Q Rev $3.75B >REGN,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q Rev $3.75B >REGN
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Third Quarter 2025 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,100,0.41,revenues,up,Regeneron Pharmaceuticals Inc.: Third quarter 2025 revenues increased 1% to $3.75 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: GAAP EPS of $13.62,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,Regeneron Pharmaceuticals Inc.: FDA approved Libtayo(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,100,0.84,products-services,positive,Regeneron Pharmaceuticals Inc.: Positive Phase 3 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"Fda approvals for Libtayo, Evkeeza",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,100,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,754 $ 3,721",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,100,0.57,products-services,granted,"September 2025, Japan's Ministry of Health, Labour and Welfare (MHLW) approved Libtayo",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,100,0.0,earnings,,Regeneron Pharmaceuticals Inc.: the Company announced five-year follow-up results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,U.S. regulatory submission for DB-OTO is planned for the fourth quarter of 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,U.S. regulatory submission for garetosmab is planned for the fourth quarter of 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,100,0.0,products-services,,"Regeneron Pharmaceuticals Inc.: In September 2025, the Company announced results from the Phase 3 trials",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,100,0.46,legal,,Regeneron Pharmaceuticals Inc.: the Company reached resolution of its patent infringement litigation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter 2025 Financial and Operating Results
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,"Regeneron Pharmaceuticals Inc.: Total revenues $ 3,754 $ 3,720",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,99,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Net product sales of EYLEA HD increased in the third quarter of 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,99,0.44,revenues,up,Regeneron Pharmaceuticals Inc.: Sanofi collaboration revenue increased in the third quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,99,0.0,equity-actions,,Regeneron Pharmaceuticals Inc.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D expenses for the third quarter of 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,99,0.62,acquisitions-mergers,,Regeneron Pharmaceuticals Inc.: Acquired IPR&D expenses for the third quarter of 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,99,0.59,equity-actions,,"Regeneron Pharmaceuticals Inc.: During the third quarter of 2025, the Company repurchased shares of its common stock",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,99,0.0,dividends,,Regeneron Pharmaceuticals Inc.: the Company's board of directors declared a cash dividend of $0.88,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: 2025 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -2-
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,99,0.0,investor-relations,,"Regeneron will host a conference call and simultaneous webcast to discuss its third quarter 2025 financial and operating results on Tuesday, October 28, 2025, at 8:30 AM Eastern Time",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -3-
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,99,0.0,assets,,"Regeneron Pharmaceuticals Inc.: September 30, December 31, 2025 2024 Assets",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,99,0.0,earnings,,Regeneron Pharmaceuticals Inc.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Net income $1,460.0 $1,340.6",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,99,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Net income per share - basic $ 14.09 $ 12.40 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -4-
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: GAAP net income $1,460.0 $1,340.6",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -5-
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,"Regeneron Pharmaceuticals Inc.: Non-GAAP net income $1,287.2 $1,462.4",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -5-
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,98,0.61,earnings,positive,Regeneron Pharmaceuticals Inc.: Non-GAAP net income per share - basic $ 12.42 $ 13.53 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -5-
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,98,0.0,revenues,,Regeneron Pharmaceuticals Inc.: Total collaboration revenue,PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -5-
REGN,2025-10-28,10:30:05,589803,Regeneron Pharmaceuticals Inc.,91,0.0,earnings,,"Regeneron Pharmaceuticals Inc.: Refer to ""Third Quarter 2025 Financial Results",PRESS-RELEASE,Dow Jones Newswires,Press Release: Regeneron Reports Third Quarter -6-
REGN,2025-10-28,10:31:28,589803,Regeneron Pharmaceuticals Inc.,100,0.44,revenues,up,"Regeneron Pharma: 3Q Dupixent Global Net Sales, Recorded by Sanofi, Rose 27%",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharma: 3Q Dupixent Global Net Sales, Recorded by Sanofi, Rose 27% to $4.86B >REGN"
REGN,2025-10-28,10:31:56,589803,Regeneron Pharmaceuticals Inc.,100,0.61,earnings,positive,Regeneron Pharma 3Q Adj EPS $11.83,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma 3Q Adj EPS $11.83 >REGN
REGN,2025-10-28,10:35:06,589803,Regeneron Pharmaceuticals Inc.,100,-0.46,revenues,down,"Regeneron Pharma 3Q Eylea HD, Eylea U.S. Net Sales Fell 28%",NEWS-FLASH,Dow Jones Newswires,"Regeneron Pharma 3Q Eylea HD, Eylea U.S. Net Sales Fell 28% to $1.11B >REGN"
REGN,2025-10-28,10:47:47,589803,Regeneron Pharmaceuticals Inc.,100,0.65,revenues,up,"Regeneron Pharmaceuticals 3Q Profit, Revenue Rise",FULL-ARTICLE,Dow Jones Newswires,"Regeneron Pharmaceuticals 3Q Profit, Revenue Rise"
REGN,2025-10-28,10:47:47,589803,Regeneron Pharmaceuticals Inc.,100,0.64,earnings,up,Regeneron Pharmaceuticals profit rose in the third quarter,FULL-ARTICLE,Dow Jones Newswires,"Regeneron Pharmaceuticals 3Q Profit, Revenue Rise"
REGN,2025-10-28,12:59:05,589803,Regeneron Pharmaceuticals Inc.,96,0.0,earnings,,Factset expected Regeneron Pharmaceuticals to earn $9.65 a share,FULL-ARTICLE,Dow Jones Newswires,"Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts -- IBD"
REGN,2025-10-28,12:59:05,589803,Regeneron Pharmaceuticals Inc.,96,0.61,earnings,positive,Regeneron earned $12.46 per share,FULL-ARTICLE,Dow Jones Newswires,"Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts -- IBD"
REGN,2025-10-29,12:00:05,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Modex Therapeutics Enters into Research Collaboration with Regeneron,PRESS-RELEASE,GlobeNewswire,OPKO Health's ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
REGN,2025-10-29,12:00:10,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,Modex Therapeutics Enters into Research Collaboration with Regeneron,PRESS-RELEASE,Dow Jones Newswires,Press Release: OPKO Health's ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
REGN,2025-10-29,12:02:07,589803,Regeneron Pharmaceuticals Inc.,100,0.49,partnerships,,"Opko Health Enters License, Collaboration Agreement With Regeneron Pharmaceuticals",NEWS-FLASH,Dow Jones Newswires,"OPKO Health Enters License, Collaboration Agreement With Regeneron Pharmaceuticals to Discover, Develop Multispecific Antibodies for Therapeutic Indications of Mutual Interest >OPK"
REGN,2025-10-29,12:16:58,589803,Regeneron Pharmaceuticals Inc.,100,-0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Underperform by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Underperform by B of A Securities
REGN,2025-10-29,12:16:58,589803,Regeneron Pharmaceuticals Inc.,100,0.78,price-targets,upgrade,Regeneron Pharma Price Target Raised to $627.00/Share From $543.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $627.00/Share From $543.00 by B of A Securities
REGN,2025-10-29,12:56:18,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Guggenheim
REGN,2025-10-29,12:56:18,589803,Regeneron Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Regeneron Pharma Price Target Raised to $865.00/Share From $815.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $865.00/Share From $815.00 by Guggenheim
REGN,2025-10-29,13:59:58,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Overweight by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Overweight by Cantor Fitzgerald
REGN,2025-10-29,13:59:58,589803,Regeneron Pharmaceuticals Inc.,100,0.74,price-targets,upgrade,Regeneron Pharma Price Target Raised to $740.00/Share From $678.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $740.00/Share From $678.00 by Cantor Fitzgerald
REGN,2025-10-29,14:25:58,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Equal-Weight by Wells Fargo
REGN,2025-10-29,14:25:58,589803,Regeneron Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Regeneron Pharma Price Target Raised to $615.00/Share From $580.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $615.00/Share From $580.00 by Wells Fargo
REGN,2025-10-29,17:04:28,589803,Regeneron Pharmaceuticals Inc.,100,0.0,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Sector Perform by RBC Capital
REGN,2025-10-29,17:04:28,589803,Regeneron Pharmaceuticals Inc.,100,0.3,price-targets,upgrade,Regeneron Pharma Price Target Raised to $708.00/Share From $704.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $708.00/Share From $704.00 by RBC Capital
REGN,2025-10-29,18:36:48,589803,Regeneron Pharmaceuticals Inc.,100,0.34,analyst-ratings,neutral,Regeneron Pharma Is Maintained at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Is Maintained at Buy by Citigroup
REGN,2025-10-29,18:36:48,589803,Regeneron Pharmaceuticals Inc.,100,0.62,price-targets,upgrade,Regeneron Pharma Price Target Raised to $700.00/Share From $660.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Regeneron Pharma Price Target Raised to $700.00/Share From $660.00 by Citigroup
REGN,2025-10-29,20:39:31,589803,Regeneron Pharmaceuticals Inc.,100,-0.48,insider-trading,,"Dir Poon Christine Registers 6,500 Of Regeneron Pharmaceuticals Inc >REGN",RNS-SEC144,Dow Jones Newswires,"Dir Poon Christine Registers 6,500 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2025-10-31,20:08:17,589803,Regeneron Pharmaceuticals Inc.,100,0.52,insider-trading,,"Vp Murphy Acquires 2,510 Of Regeneron Pharmaceuticals Inc >REGN",FULL-ARTICLE,Dow Jones Newswires,"VP Murphy Acquires 2,510 Of Regeneron Pharmaceuticals Inc >REGN"
REGN,2025-10-31,20:10:10,589803,Regeneron Pharmaceuticals Inc.,100,-0.49,insider-trading,,"Dir Poon Sells 6,500 Of Regeneron Pharmaceuticals Inc >REGN",FULL-ARTICLE,Dow Jones Newswires,"Dir Poon Sells 6,500 Of Regeneron Pharmaceuticals Inc >REGN"
